0001079973-23-001327.txt : 20230928 0001079973-23-001327.hdr.sgml : 20230928 20230928154553 ACCESSION NUMBER: 0001079973-23-001327 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230928 DATE AS OF CHANGE: 20230928 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BION ENVIRONMENTAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0000875729 STANDARD INDUSTRIAL CLASSIFICATION: AGRICULTURE CHEMICALS [2870] IRS NUMBER: 841176672 STATE OF INCORPORATION: CO FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19333 FILM NUMBER: 231289266 BUSINESS ADDRESS: STREET 1: PO BOX 323 CITY: OLD BETHPAGE STATE: NY ZIP: 11804 BUSINESS PHONE: (212) 758-6622 MAIL ADDRESS: STREET 1: PO BOX 323 CITY: OLD BETHPAGE STATE: NY ZIP: 11804 FORMER COMPANY: FORMER CONFORMED NAME: RSTS CORP DATE OF NAME CHANGE: 19930328 10-K 1 bion_10k-063023.htm FORM 10-K
0000875729 false FY 2023 0000875729 2022-07-01 2023-06-30 0000875729 2023-06-30 0000875729 2023-08-01 0000875729 2021-07-01 2022-06-30 0000875729 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-06-30 0000875729 us-gaap:CommonStockMember 2021-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-06-30 0000875729 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2022-06-30 0000875729 us-gaap:CommonStockMember 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:CommonStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-07-01 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-07-01 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-07-01 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-07-01 2023-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2022-07-01 2023-06-30 0000875729 us-gaap:CommonStockMember 2022-07-01 2023-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2023-06-30 0000875729 bnet:SubscriptionsReceivableMember 2022-07-01 2023-06-30 0000875729 us-gaap:RetainedEarningsMember 2022-07-01 2023-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-07-01 2023-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2023-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2023-06-30 0000875729 us-gaap:CommonStockMember 2023-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000875729 bnet:SubscriptionsReceivableMember 2023-06-30 0000875729 us-gaap:RetainedEarningsMember 2023-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2023-06-30 0000875729 bnet:JVAMember 2022-07-01 2023-06-30 0000875729 bnet:Gen3TechMember 2022-07-01 2023-06-30 0000875729 2022-01-27 2022-01-28 0000875729 2022-03-30 2022-03-31 0000875729 2023-01-16 2023-01-17 0000875729 2023-04-23 2023-04-24 0000875729 2023-07-25 2023-07-26 0000875729 2017-07-01 2018-06-30 0000875729 srt:MinimumMember 2023-06-30 0000875729 srt:MaximumMember 2023-06-30 0000875729 bnet:CenterpointMember 2023-06-30 0000875729 us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 us-gaap:WarrantMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2023-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2023-06-30 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2022-06-30 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2022-07-01 2023-06-30 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2021-07-01 2022-06-30 0000875729 bnet:PropertyPlantAndEquipmentOfPA1Member 2022-07-01 2023-06-30 0000875729 bnet:BassaniMember 2023-06-30 0000875729 bnet:SmithMember 2023-06-30 0000875729 bnet:BassaniMember 2022-06-30 0000875729 bnet:SmithMember 2022-06-30 0000875729 bnet:ConsultantsAndEmployeeMember 2023-06-30 0000875729 bnet:ConsultantsAndEmployeeMember 2022-06-30 0000875729 bnet:BassaniAndSmithMember 2023-06-30 0000875729 bnet:BillONeillMember 2023-06-30 0000875729 bnet:BillONeillMember 2022-06-30 0000875729 bnet:SmithMember 2023-06-30 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2022-07-01 2023-06-30 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2023-06-30 0000875729 2021-09-30 0000875729 2021-12-29 0000875729 bnet:YearsOneThroughFiveMember bnet:PennvestLoanMember 2022-07-01 2023-06-30 0000875729 bnet:YearsSixThroughMaturityMember bnet:PennvestLoanMember 2022-07-01 2023-06-30 0000875729 bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2020-07-01 2021-06-30 0000875729 bnet:PA1Member 2014-09-25 0000875729 bnet:PA1Member 2022-06-14 2022-06-15 0000875729 bnet:MarkASmithMember 2023-06-30 0000875729 bnet:DominicBassaniMember 2023-06-30 0000875729 bnet:EdSchaferMember 2023-06-30 0000875729 bnet:September2015ConvertibleNotesMember bnet:RestrictedCommonSharesMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:SmithMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:BassaniFamilyTrustsMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:SchaferMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:EdSchaferMember 2023-02-02 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-07-01 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember bnet:RestrictedCommonStockMember 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-07 2023-03-08 0000875729 bnet:AdjustedConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-30 2023-03-31 0000875729 bnet:AdjustedConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-06-01 2023-06-04 0000875729 bnet:ConvertibleObligations2020Member bnet:CommonSharesMember 2022-07-01 2023-06-30 0000875729 bnet:ConvertibleObligations2020Member bnet:WarrantsMember 2022-07-01 2023-06-30 0000875729 bnet:CommonSharesMember bnet:DirectOwnershipMember 2023-06-30 0000875729 bnet:WarrantsMember bnet:DirectOwnershipMember 2023-06-30 0000875729 bnet:CommonSharesMember bnet:IndirectOwnershipMember 2023-06-30 0000875729 bnet:WarrantsMember bnet:IndirectOwnershipMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember 2023-06-30 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember 2023-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2023-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-01-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-06-30 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-06-30 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-06-30 0000875729 bnet:The2020ConvertibleObligationsMember 2022-07-01 2023-06-30 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-06-30 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member bnet:CommonSharesMember 2022-07-01 2023-06-30 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member bnet:WarrantsMember 2022-07-01 2023-06-30 0000875729 bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-06-30 0000875729 bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member bnet:CommonSharesMember 2022-07-01 2023-06-30 0000875729 bnet:WarrantsMember bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-06-30 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member bnet:AfterAdjustmentMember 2022-07-01 2023-06-30 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member bnet:CommonSharesMember bnet:AfterAdjustmentMember 2022-07-01 2023-06-30 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member bnet:WarrantsMember bnet:AfterAdjustmentMember 2022-07-01 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-07-01 2022-06-30 0000875729 srt:PresidentMember bnet:SecuredPromissoryNoteMember 2023-06-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2023-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2022-03-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2022-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2022-03-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-07-01 2023-06-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-07-01 2022-06-30 0000875729 bnet:MarkASmithMember srt:ChiefOperatingOfficerMember 2023-06-30 0000875729 bnet:DominicBassaniMember srt:ChiefOperatingOfficerMember 2023-06-30 0000875729 bnet:EdSchaferMember srt:ChiefOperatingOfficerMember 2023-06-30 0000875729 bnet:MarkASmithMember 2023-03-31 0000875729 bnet:DominicBassaniMember 2023-03-31 0000875729 bnet:EdSchaferMember 2023-03-31 0000875729 bnet:September2015ConvertibleNotesMember bnet:RestrictedCommonSharesMember 2023-03-31 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-02 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-03 0000875729 us-gaap:SeriesBPreferredStockMember 2023-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2022-07-01 2023-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:RestrictedStockMember 2022-07-01 2023-06-30 0000875729 us-gaap:CommonStockMember 2023-01-02 2023-01-10 0000875729 us-gaap:CommonStockMember 2022-12-30 2022-12-31 0000875729 us-gaap:CommonStockMember 2022-07-01 2023-06-30 0000875729 bnet:RestrictedCommonStockMember 2022-07-01 2023-06-30 0000875729 bnet:RestrictedCommonStockMember 2023-06-30 0000875729 us-gaap:RestrictedStockMember 2023-06-30 0000875729 bnet:ConsultantServiceMember 2022-07-01 2023-06-30 0000875729 bnet:ConsultantServiceMember 2023-06-30 0000875729 bnet:ConsultantServiceOneMember 2022-07-01 2023-06-30 0000875729 bnet:ConsultantServiceOneMember 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember bnet:PrincipalMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 bnet:AccruedInterestMember us-gaap:WarrantMember bnet:The2020ConvertibleObligationsMember 2022-07-01 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember bnet:AccruedInterestMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 bnet:AccruedInterestMember bnet:The2020ConvertibleObligationsMember us-gaap:WarrantMember 2023-06-30 0000875729 us-gaap:WarrantMember 2023-06-30 0000875729 bnet:The2020OneConvertibleObligationsMember bnet:PrincipalMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 bnet:The2020OneConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 bnet:The2020OneConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2023-06-30 0000875729 us-gaap:WarrantMember bnet:The2020OneConvertibleObligationsMember 2023-06-30 0000875729 bnet:WarrantsMember 2023-06-30 0000875729 bnet:WarrantsMember 2022-07-01 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 us-gaap:ConvertibleDebtMember bnet:The2020ConvertibleObligationsMember us-gaap:WarrantMember 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-30 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-06-01 2023-06-04 0000875729 bnet:ThreeConsultantsMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 bnet:ThreeConsultantsMember us-gaap:WarrantMember srt:MinimumMember 2023-06-30 0000875729 bnet:ThreeConsultantsMember us-gaap:WarrantMember srt:MaximumMember 2023-06-30 0000875729 us-gaap:CommonStockMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2022-05-01 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2023-06-30 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 us-gaap:EmployeeStockOptionMember bnet:EquityIncentivePlanMember 2023-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2023-03-31 0000875729 bnet:Plan2006Member 2023-03-14 2023-03-15 0000875729 2023-02-06 2023-02-07 0000875729 bnet:NorthropMember 2023-02-06 2023-02-07 0000875729 bnet:BassaniMember 2023-02-06 2023-02-07 0000875729 bnet:SmithMember 2023-02-06 2023-02-07 0000875729 2023-05-08 2023-05-09 0000875729 bnet:BillONeillMember 2023-05-08 2023-05-09 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2023-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 us-gaap:OptionMember 2022-07-01 2023-06-30 0000875729 us-gaap:OptionMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember srt:WeightedAverageMember 2022-07-01 2023-06-30 0000875729 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2022-07-01 2023-06-30 0000875729 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2022-07-01 2023-06-30 0000875729 us-gaap:EmployeeStockOptionMember srt:WeightedAverageMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2021-07-01 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-06-30 0000875729 bnet:FormerEmployeeMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-06-30 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-06-30 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-06-30 0000875729 bnet:SmithsMember bnet:SecuredPromissoryNoteMember 2023-06-30 0000875729 bnet:FormerEmployeeMember bnet:SecuredPromissoryNoteMember 2023-06-30 0000875729 srt:PresidentMember 2016-10-01 2016-10-10 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2023-06-30 0000875729 2022-04-27 2022-05-02 0000875729 bnet:SmithMember 2022-07-01 2023-06-30 0000875729 bnet:SmithMember 2021-07-01 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2015-02-03 2015-02-10 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2016-10-31 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2017-04-27 0000875729 bnet:BassaniMember 2018-02-28 0000875729 bnet:BassaniMember 2018-07-28 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsExpiringOnDecember312025Member 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-07-01 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2021-07-01 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2022-07-01 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2023-06-30 0000875729 bnet:WilliamONeillMember 2022-07-01 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2021-07-01 2022-06-30 0000875729 2020-07-01 2021-06-30 0000875729 2023-05-02 0000875729 2023-04-27 2023-05-02 0000875729 2022-04-29 2022-04-30 0000875729 2022-03-22 2022-03-23 0000875729 2023-06-22 2023-06-23 0000875729 us-gaap:SubsequentEventMember 2023-07-01 2023-09-28 0000875729 us-gaap:SubsequentEventMember 2023-07-07 0000875729 us-gaap:SubsequentEventMember 2023-07-06 2023-07-07 0000875729 us-gaap:SubsequentEventMember 2023-07-20 2023-07-21 0000875729 us-gaap:SubsequentEventMember 2023-07-21 0000875729 us-gaap:SubsequentEventMember 2023-08-16 0000875729 us-gaap:SubsequentEventMember 2023-08-15 2023-08-16 0000875729 us-gaap:SubsequentEventMember 2023-08-27 2023-08-28 0000875729 us-gaap:SubsequentEventMember 2023-08-28 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure bnet:Decimal

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

  ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   

 

For the Fiscal Year Ended: June 30, 2023

     
    OR
     
  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   

 

For the transition period from: __________ to __________

 

 

Commission File No. 000-19333

 

BION ENVIRONMENTAL TECHNOLOGIES, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Colorado   84-1176672
(State or Other Jurisdiction of Incorporation or Organization)   (I.R.S. Employer Identification Number)

 

9 East Park Court

Old Bethpage, New York 11804

(Address of Principal Executive Offices, Including Zip Code)

 

Registrant’s Telephone Number, including area code: (516) 586-5643

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of Each Class   Name of Exchange on Which Registered
None   N/A

 

Securities Registered Pursuant to Section 12(g) of the Act:

 

Common Stock, No Par Value

(Title of Class)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

  YES   No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

  YES   No

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

  Yes   NO

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit).

  Yes   NO

 

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

 

 

 
 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   Accelerated filer
Non-accelerated filer   Smaller reporting company
Emerging growth company      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act)

  YES   No

 

The aggregate market value of the approximately 37,000,000 shares of voting stock held by non-affiliates of the Registrant as of June 30, 2023 approximated $46.5 million.  As of August 1, 2023, the Registrant had 49,408,214 shares of common stock issued and 48,703,905 shares of common stock outstanding.

 

 

DOCUMENTS INCORPORATED BY REFERENCE

 

None

 

 

 
 

 

FORWARD-LOOKING STATEMENTS

 

THE RISK FACTORS BELOW ARE FURTHER HEIGHTENED BY THE COVID-19 PANDEMIC AND RESULTING ECONOMIC DOWNTURN AND OTHER RELATED CRISES AS DISCUSSED BELOW.

 

This Annual Report on Form 10-K (and the documents incorporated herein by reference) contain forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "project," "predict," "plan," "believe," or "continue," or the negative thereof or variations thereon and/or references to goals, targets, projections or similar terminology. The expectations reflected in forward-looking statements may prove to be incorrect.

 

Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, the following (not set forth in any order that ranks priority or magnitude):

 

 

  · failure of the political, legal, regulatory and economic climate to support funding of environmental clean-up and enforcement of environmental rules and regulations;

 

  · changes in the public's perceptions of large scale livestock agriculture/CAFOs, consumption of meat and dairy, environmental protection and other related issues;

 

  · cybercrimes/hacking (actual and potential) of the Company’s online presence and limited operational computer systems; the Company’s <biontech.com domain was hacked/stolen during 2021 and the Company migrated to the bionenviro.com domain name. The Company initiated litigation seeking its recovery and other relief, recovered and subsequently sold the <biontech.com> domain. See Item 3 “Legal Proceedings” and Note 9 to Financial Statements, “Litigation”;

 

  · the Company's extremely limited financial and management resources which need to be augmented and the Company’s limited ability to raise additional needed funds and/or hire needed personnel;

 

  · Reactions to the wrap-up of the business activities of Bion PA-1 LLC (“PA1”) and/or resolution of PA-1’s negotiations with the Pennvest Infrastructure Authority (“Pennvest”) regarding PA1’s Pennvest Loan (presently in default) and the Kreider 1 System (see “Part I, Items 1 and Item 7 and “Notes to Financial Statements” below);

 

  · continued delays in (and/or failure of) development of markets (or other means of monetization) for nutrient reductions and other environmental benefits from agriculture and CAFOs and related waste treatment facilities; including failure of markets for nutrient (nitrogen and phosphorus) reductions to develop sufficient breadth and depth;

 

  · potential delays in constructing the Company’s Initial System, the initial beef Projects and other Gen3Tech system installations and/or further delays in the Kreider 2 project and other potential Projects (capitalized items defined in the Item 1 narrative below);

 

  · the ability of the Company to implement its business strategy;

 

  · the extent of the Company's success in the development of Gen3Tech joint ventures (“JVs”) and development/operation of Projects and retrofit/remediation of existing livestock facilities (“Retrofits”) and/or reaching the goals and targets set forth below, especially in light of the fact that at this date the Company has not yet developed its first Gen3Tech JV project and that the resources (CAPEX/personnel/expertise) required for development and operation of such projects will need to be sourced from outside the Company which has very limited resources in each listed category;

 

 

2 
 
  ·

dependence upon key personnel and the ability of the Company to keep its existing personnel and their accumulated expertise including the substantial risk of illness or death of one or more key personnel (most of whom are over 70 years of age and/or have existing health vulnerabilities that are exacerbated by the COVID-19 pandemic);

 

  · the need to obtain the services of additional personnel as employees and/or consultants as the Company’s business progresses;

  

  · engineering, mechanical or technological difficulties with operational equipment including potential mechanical failure or under-performance of equipment; operating variances from expectations;

 

  · the substantial capital expenditures required for the Company’s proposed JVs and development/construction of the Company's proposed Projects and facilities and the related need to fund such capital requirements through commercial banks and/or public or private securities markets;

 

  · the need to develop and re-develop technology and related applications over time;

  

  · operating hazards attendant to the environmental clean-up, CAFO and renewable energy production, fertilizer and/or food retailing and biofuel industries;

 

  · seasonal and climatic conditions;

 

  · decreased availability and increased cost of material and equipment (including those caused by the COVID-19 pandemic and supply chain challenges);

 

  · the strength and financial resources of the Company's potential competitors;

 

  · general economic, Covid-19 pandemic (see Item 7. “Management's Discussion and Analysis of Financial Condition and Results of Operations” and Note 1 to Financial Statements, “Covid-19 pandemic related matters”) and capital market conditions;

 

  · industry risks, including environmental related problems;

 

  · delays in anticipated permit approval and/or start-up dates;

 

  · the limited liquidity of the Company's equity securities; limited availability of capital on acceptable terms for small public companies like Bion in the current financial markets; and

 

  · the Company’s limited ability to comply with current and rapidly evolving ESG (environmental, social and governance) related items to date (which is due in large part to the Company’s small size and the fact that the Company has engaged in almost no new hiring ‘in house’ during the past decade combined with the Company’s limited financial capacity and the particular industry segments in which the Company is working) may inhibit the Company’s ability to raise capital and increase its shareholder base.

 

We do not undertake and specifically disclaim any obligation to publicly release the results of any revisions that may be made to any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

 

 

3 
 

 

PART I

 

 

 

ITEM 1.  BUSINESS.

 

GENERAL

 

Summary and Overview

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to create extraordinary value for our shareholders and employees (all of whom own securities in the Company) while delivering premium, sustainable meat products to our customers (and other stakeholders) through ventures developing profitable, transparent, and environmentally sustainable solutions for livestock agriculture.  Bion’s third generation technology-based platform (“Gen3Tech Platform” or “Platform”) provides comprehensive environmental treatment for large-scale livestock waste streams (and other organic waste streams), while simultaneously recovering resources that have traditionally been wasted or underutilized. Bion’s platform performs the dual benefits of improving profitability of production by upcycling those resources into value-added byproducts, while preventing their release to the environment, where they contribute to surface- and groundwater and air pollution, climate change, and other air quality issues.

Bion has identified three distinct market opportunities for the Gen3Tech platform and its core Ammonia Recovery System (“ARS”) technology that captures, stabilizes, and upcycles ammonia into low-carbon and/or organic pure nitrogen fertilizers. Bion intends to pursue: 1) a unique opportunity to ‘reimagine’ beef production ( within the existing industry supply chain) to produce premium and sustainable grain-finished beef, with minimal impacts to water, soil, and air, and better economics to its producers; 2) technology licensing and/or joint venture opportunities internationally and in the U.S. for post-anaerobic digester use of our ARS: a) dairy applications, and b) treatment of organic waste streams from food waste, food processing waste, biofuels, and other organic waste streams whose processes include anaerobic digestion to produce renewable energy; and 3) retrofit of existing large-scale livestock facilities, of which there are hundreds  of operations in the U.S. alone (if not thousands – the exact number is not reported).

 

Currently, Bion’s efforts are primarily focused on the sustainable beef production opportunity. We believe there is tremendous room for improvement in the beef production in this country. The beef industry today faces a wide range of challenges, from a fragmented commodity-producing industry with narrow margins to antiquated and inefficient production practices. Beef production and consumption is a primary target of the global ‘anti-meat’ messaging campaign from consumer, investor, and environmental advocacy groups (and the industry’s competitors in the alternative plant-based and cellular protein spaces). Bion intends to produce truly sustainable beef, certified by USDA, with dramatic, third-party verified reductions in the negative environmental effects by mitigating nutrient, greenhouse gas, and other environmental impacts. To accomplish Bion’s goal, we will partner with producers and other technology companies who provide solutions for different links of the beef value chain. Our joint venture/strategic partner-focused business model is designed to deliver a premium sustainable product to the consumer and increased profitability up and down the supply chain.

 

During September 2023, Bion successfully completed the initial startup of its patented Ammonia Recovery System (“ARS)” at its commercial-scale demonstration and optimization facility near Fair Oaks, Indiana. The facility has now commenced an operational ‘optimization’ phase during which modules will be tested/stressed to determine their operational characteristics and establish the best parameters (and related control systems) for long term operation. We have begun varying the ARS’s operating parameters with the goal of meeting and/or exceeding the results needed for Bion’s economic models for large-scale commercial projects. The Company expects the current optimization phase will continue during the next quarter (or longer) and provide data required to support final design/engineering for commercial project modules. We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects. The ARS is the core of the Gen3Tech platform. Once its operations have been optimized, Bion will be able to begin final design to support permitting, and financing of its first commercial beef project.

 

To Bion’s knowledge, there is no comprehensive treatment solution for beef manure waste other than our Gen3Tech Platform. Further, Bion’s business model, which addresses the entire supply chain, creates additional opportunities to improve on both environmental impacts and production efficiencies. Bion has 30 years of experience in livestock waste management and is building a world class team, focused on beef. We believe we have a significant advantage as the $66 billion U.S. beef industry contends with its environmental impacts, inherent inefficiencies, and a changing consumer demographic.

 

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our third generation technology (“Gen3Tech”) and business/technology platform in conjunction with other industry practices (“Gen3Tech Platform” or “Platform”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste stream ‘assets’ – including primarily nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate groundwater, pollute the air and exacerbate climate change.

 

4 
 

During the first half of 2022 Bion began pre-marketing our sustainable beef opportunity to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022, Bion announced a letter of intent (“Ribbonwire LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). During January 2023 Bion announced a letter of intent (“Olson LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Olson Feeders and TD Angus, near North Platte, Nebraska (with a provision to expand to 45,000 head or more) (“Olson Project”). During April 2023 Bion announced a letter of intent (“DVG LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with Dakota Valley Growers near Bathgate, North Dakota (“DVG Project”). Based on our experience to date, we believe we will not have great difficulty in securing participation from additional feeders/cattlemen in our Projects. The Olson, Dalhart and DVG Projects (and subsequent Projects) will be developed to produce blockchain-verified, sustainable beef in customized covered barns (resulting in reduced stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) with ongoing manure transfer (through slatted floors) to anaerobic digesters (AD) to capture nitrogen/ammonia from the manure stream before loss to the atmosphere and generate renewable natural gas (RNG) for sale while remediating the environmental/carbon impacts usually associated with cattle feedlots and CAFOs. Bion’s patented Gen3Tech platform will refine the waste stream into valuable coproducts that include clean water, RNG, photovoltaic solar electricity and fertilizer (‘climate smart’ and/or organic) products. We anticipate converting these LOIs into definitive JV agreements and creating related distribution agreements with key retailers and food service distributors during the current fiscal year and the balance of 2024.

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent one of the single largest enhanced revenue contributors provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the treatment process will be third-party verified, providing the basis for additional revenues, including renewable energy-related credits and, eventually, payment for ecosystem services, such as nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef JV projects over the next twenty-four (24) months while moving forward with the Initial Project (see below) and commencing development of one or more of the Dalhart/Olson/DVG Projects (“LOI Projects”)(and/or other Gen3Tech beef JV projects) while pursuing other opportunities in the livestock industry enabled by our Gen3Tech business model.  The LOI announcements have generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties) and has led to and assisted our discussions with many ‘major s’---large national and regional agriculture/livestock industry companies (including those involved with distribution and/or sales of meat products) in the country which are ongoing at this date. We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment at a rapid pace.

Based on our endeavors in executing multiple agreements and letters of intent related to the “Bion Beef Opportunity”, we intend to commence development of multiple sustainable beef JV projects over the next twelve-eighteen (12-18) months while moving forward with the Initial Project (see below) and one or more of the LOI Projects. Bion also intends to pursue other opportunities in the livestock industry enabled by our Gen3Tech business model. 

During the past nine months, the Company has constructed (construction is largely completed) our 3GTech Ammonia Recovery System (‘ARS’) at our Initial Project (our commercial scale demonstration facility) located near Fair Oaks, Indiana and begun operations of phase 1 of our Initial Project . We recently announced that the ARS has achieved and maintained controlled steady-state operations under a variety of conditions. When operated at steady state, the system produces an ammonium distillate solution, the base of Bion’s nitrogen fertilizer products. Bion has begun optimizing the ARS’s operating parameters with the goal of meeting and/or exceeding the results needed for Bion’s economic models for large-scale commercial projects. The Company expects the current optimization phase will continue during the next quarter (or longer) and provide data required to support final design/engineering for commercial project modules. We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below).

The patented ARS is the core of Bion’s Gen3Tech platform. The ARS recovers and upcycles problem ammonia contained in the effluent from anaerobic digestion (where methane is captured and more ammonia is released) of the livestock manure waste stream. The ARS captures the ammonia, minimizing its environmental impacts and creating low-carbon and/or organic nitrogen fertilizer products with it. Over during the next quarter, the Company intends to produce ammonium distillate at Fair Oaks in several concentrations and initiate the application process for organic certification for each concentration of liquid fertilizer product. Bion will also produce a solid/granular nitrogen fertilizer product at the Initial Project (when the crystalizer module is ready for operation during the next quarter) which we believe will be both ‘ClimateSmart’ and ‘Water-Smart’ – a pure nitrogen fertilizer with a low carbon footprint, that is water soluble and readily available to plants. Samples of the granular product will also be utilized to support organic certification applications. See Fertilizer: Organic and ‘ClimateSmart’ below.

 

 

5 
 

 

During the next three-six months , the Company intends to fully complete construction of the Initial Project’s phase 1 (including the crystalizer module) and continue the optimization operations. Bion expects the Initial Project data will document the effectiveness of our Gen3Tech in a commercial-scale setting during the current fiscal year and support development of the LOI Projects (and/or other Gen3Tech beef JV projects) commencing later this fiscal year.  We do not presently know the order in which these JV Projects will be developed as that decision will be made based on many factors not yet in place. We believe the Initial Project data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, food distributors and retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). 

 

Bion intends to focus primarily on: i) completion of development/construction and operation of the Initial Project, our initial commercial-scale Gen3Tech installation (see below and Notes to Financial Statements), and optimization of its operational parameters, ii) pre-development planning of the Dalhart, Olson and DVG Projects (and/or other Gen3Tech beef JV projects) including steps toward distribution agreements, iii) developing applications and markets for its low carbon ‘ClimateSmart’ and organic fertilizer products (including listings/certifications of multiple liquid and solid products) and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed herein) (and related Projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue : A) licensing opportunities and B) business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

At present, there is essentially no traceable and verifiable ‘sustainable beef’ available to the US market except for niche products. In response to consumer demand for transparency and sustainability, Bion expects the meat industry in general, and beef specifically, to evolve towards using new technologies to deliver these attributes in their products. While we anticipate a faster adoption of tracking, verification and sustainability technologies in other perishable food categories like produce and dairy due to their shorter product cycles (and related harvest and production techniques), meat industry leaders have also announced their willingness to move forward with initiatives in this area. Many companies have announced ‘sustainability’ initiatives but most appear to consist largely of ‘greenwashing’ marketing commitments rather than substantive undertakings at this date. Note, however, that Tyson’s Brazen beef initiative (which was announced during March 2023) may develop into a substantive competitive factor in the sustainable beef marketplace. Bion predicts that within approximately five years, consumers will be able to track and verify claims including sustainability on 25% (or more) of the products merchandised in the meat department. Bion believes that the retail market share of verifiably sustainable beef in the US will approach 7-10 % within three (3) years (end of 2026) and 25% in five (5) years (end of 2028) (approximately 6-7,000,000 cattle annually) (and more thereafter). If Bion can successfully execute on its sustainable beef business plan (which is subject to many contingencies), we believe that JV facilities utilizing Bion’s Gen3Tech platform will supply one-third (1/3) or more of that of the premium market segment (and a higher portion of meat that is actually traceable and verifiably sustainable). Our goal is to have multiple sustainable beef projects under development (within 3-5 distinct JVs) by the end of our 2025 fiscal year. Our first commercial project is likely to be one of our current LOI Projects but we anticipate commencing development of additional sustainable beef projects during the current fiscal year as well. Our current target is to have at least three (3) facility modules (15,000 head per module)(“Modules”) in development and/or under construction during 2024 in three (3) different JVs with the initial barns being populated with livestock during 2025. Further expansion in the number of distinct JVs is projected through 2026-7 aiming at 5-10 JVs in process --- each of which JVs will be pursuing development of multiple Modules with targets of 12-15 populated Modules by the end of 2026 (approximately 2%-3% of the US beef market) and 30-45 Modules constructed and being populated by 2029 (approximately 6%-8% of the US beef market) with further expansion thereafter. Bion’s current goal is that its Gen3Tech platform will be utilized to produce 33% of the verifiable “sustainable beef” category at the end of the period (which will equal approximately 2 million cattle annually)(45 Modules).

 

There is no assurance that the Company will reach or approach the goals/targets set forth above. Reaching such goals/targets will require access to very large amounts of capital (equity and debt) as each module is projected to cost in excess of $50 million to construct and require mobilization of substantial personnel, technical resources and management skills. The Company does not possess either the financial or personnel resources required internally and will need to source such resources from outside itself.

 

During this five (5) year period, the Company also anticipates having additional Gen3Tech projects underway in the pork/dairy/egg sectors of the US animal protein market.

 

In parallel with the business activities outlined above, during the current fiscal year the Company intends to proceed with adding to its senior management personnel, while strengthening its corporate governance (including environmental/social/governance steps (‘ESG’)) and seeking to ‘uplist’ its common stock on a national securities exchange improve both liquidity and ability to access capital markets.

 

 

 

6 
 

 

HISTORY, BACKGROUND AND CURRENT ACTIVITIES

 

Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.

From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product, while raising sustainable livestock.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market (despite the lack of verifiably sustainable attributes).

 

The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded conventional livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a production/marketing opportunity for Bion (but the former is far larger). Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon/organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.

 

During 2022-23, the Company entered into 3 LOIs setting forth the parties’ intention to negotiate joint venture agreement (“JVA”) and enter into joint ventures (“JV”) to develop and operate 15,000 head integrated, sustainable beef facilities (with future expansion under consideration) including:

 

  a) innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,

 

  b) ‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,

 

  c) a Bion Gen3Tech module (which will utilize the recycled CO2 to increase ammonia nitrogen/ammonium bicarbonate recovery) for the production of ammonia nitrogen fertilizer for use in organic and/or ‘ClimateSmart’ low carbon crop production (plus residual organic solids and clean water),

 

  d) which will produce verifiably sustainable beef products with USDA certified branding.

 

7 
 

 

The opportunity presented by the LOIs to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head operation a reality as soon as possible.

To place the LOI Projects in the context of Company’s business plan (and our prior public disclosure), if the contemplated ventures moves forward on the timelines currently contemplated, active development of the initial LOI Project will commence during 2024.

 

Prior to such activity, the Company has constructed and commenced operation of the initial phase of our previously discussed Gen3Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion Gen3Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the LOI Projects). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, is utilizing anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

During September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately 1,500 head). The facility is large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs (many pandemic associated)delayed delivery dates for core modules of the Bion system to the site until during January 2023. Construction has been substantially completed related to Phase 1 of the Initial Project, shakedown operations undertaken and the operation is now focused on optimization of operation parameters. See Note 3 “Property and Equipment” and Note 12 “Subsequent Events” (for activities since the start of the first quarter of the 2024 fiscal year).

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

 

8 
 

 

Specifically, the Initial Project was designed/developed to provide and/or accomplish the following:

 

i.   Proof of Gen3Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3Technology platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

ii.   Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

iii.   Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) in liquid and solid forms for commercial testing by potential joint venture partners and/or purchasers, for university growth trials and to provide samples (and related documentation) to support applications for organic and/or ‘ClimateSmart’ certifications.

 

iv.   Produce sustainable beef products for initial test marketing efforts.

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. Subsequent agreements were executed with engineering firms, contractors and other entities related to the construction of the Initial Project. The Company received progress billing in March 2022 and June 2022 for the second and third 25% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $533,100 which was paid on March 1, 2023 and on April 24, 2023 for $83,275 which was paid on May 2, 2023 bringing the aggregate payments to $2,615,500 as of the date of this filing. There remaining $50,000 open on the Purchase Order has been billed on July 26,2023. In addition to the Purchase Order, the Company has incurred additional costs of $4,182,260 on the Initial Project for capitalized interest and costs, non-cash compensation and consulting fees. $3,962,207 has been paid and $220,053 has been billed and not yet been paid.

 

The Initial Project will be carried out in stages with phase one focused largely on portions of items i. and iii. set forth above.

 

Upon completing the primary goals of phase 1 of the Initial Project (coupled with obtaining organic certifications(s) for our liquid and/or solid ammonium bicarbonate fertilizer product lines), Bion expects to be ready to move forward with its plans for development of much larger facilities such as the LOI Projects, by moving toward final design of its Gen3Tech modules. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 12-24 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the optimization operations of the Initial Project with a 2024 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.

 

After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the Company will determine whether to complete the entire Initial Project as originally designed at that location or the relocate the core modules to an alternative permanent location. The Company has engaged in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or other mutually agreed upon location) which facility would include innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long-term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company will also evaluate re-locating the core module of the Initial Project to Dalhart, Texas, where it might be integrated into the first phases of the Dalhart Project and/or to other locations. 

 

 

 

9 
 

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘Gen3Tech Kreider 2 Poultry Project below as an example) in the swine, dairy and poultry industries utilizing our Gen3Tech.

 

Gen3Tech Beef Business Model

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, enables the cleanup of the ‘dirtiest’ part of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/dairy/egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a large, but apparently limited, segment of consumers is choosing a seemingly sustainable offering, and are also willing to pay a premium for it. Tyson Foods, in the context of launching its Brazen beef initiative, recently said, “consumers would be willing to pay at least 24 percent more for environmentally friendly, sustainable options at retail.” Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary beef ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without support in empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy. Sustainability initiatives have been launched by large US livestock producers (including Tyson’s very recent ‘Brazen’ program), but it is not yet possible to determine the extent the attributes of such products will be substantive and verifiable rather than completely ‘modeled’ and largely public relations ‘greenwashing’.

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have also recently entered the plant protein space. However, while meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, have been heavily promoted (by themselves and the media) and enjoyed remarkable initial sales growth until recently, sales have flattened and/or declined over the past 18 months. It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint---and market growth rates have substantially slowed and may have already plateaued and/or peaked. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium verifiably sustainable beef products that address these consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or sustainable organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, while providing the superior taste and texture those consumers have grown to prefer.

 

While the beef industry has largely continued historic practices, the dairy industry has housed milk cows in barns and has been processing cow waste through anaerobic digesters (ADs) to generate energy for years. In recent years the renewable biogas (RNG) from the dairy ADs  has become increasingly lucrative due to related environmental credits .

 

 

10 
 

  

 

Bion‘s sustainable beef business model, based on our Gen3Tech platform, will develop and operate large scale facilities that: a) utilize custom designed barns (which enable a more controlled and monitored husbandry environment) and photovoltaic solar electricity generation utilizing the rooftops (where climate conditions permit), b) with continual manure transfer to anaerobic digesters (“ADs”), c) which produce RNG and related environmental revenues, and d) then channel the AD waste (including CO2 recovered from the RNG processing/cleanup) through a series of patented technologies to refine the waste into its various components. The diagram below depicts a simplified facility schematic/flow chart:

 

 

 

 

This overall business model unites several interrelated businesses driven by Bion’s technology and augments and aggregates multiple revenue streams as described below. See “Technology and Technology Platform” below for descriptions of the 4 major categories of products/revenue streams which Bion anticipates from its Gen3Tech beef facilities: a) premium ‘sustainable branded’ beef, b) renewable energy and energy/environmental/carbon-related credits, c) fertilizer products (organic and/or ‘ClimateSmart’) and d) nutrient credits.

 

Sustainable Beef

 

Bion’s goal is to be first (or at least early) to market with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at Bion facilities will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water and air, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.

 

A Bion sustainable beef facility (see diagram above) will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia volatilization and loss to the atmosphere, as well as odors, thereby improving animal health and human working conditions while preventing air/soil/water pollution. The manure will be collected and moved directly to customized anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in appropriate geographical locations) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.

 

Waste treatment and resource recovery will be provided by Bion’s Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

 

11 
 

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies, but a closer look finds that most consist largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance (excepting Tyson’s ‘Brazen’ announcement this past Spring which appears to have some substance).

 

 

At present, there is essentially no traceable and verifiable ‘sustainable beef’ available to the US market except for niche products. In response to consumer demand for transparency and sustainability, Bion expects the meat industry in general, and beef specifically, to evolve towards using new technologies to deliver these attributes in their products. While we anticipate a faster adoption of tracking, verification and sustainability technologies in other perishable food categories like produce and dairy due to their shorter product cycles (and related harvest and production techniques), meat industry leaders have also announced their willingness to move forward with initiatives in this area. Many companies have announced ‘sustainability’ initiatives but most appear to consist largely of ‘greenwashing’ marketing commitments rather than substantive undertakings at this date. Note, however, that Tyson’s Brazen beef initiative (which was announced during March 2023) may develop into a substantive competitive factor in the sustainable beef marketplace. Bion predicts that within approximately five years, consumers will be able to track and verify claims including sustainability on 25% (or more) of the products merchandised in the meat department. Bion believes that the retail market share of verifiably sustainable beef in the US will approach 7-10 % within three (3) years (end of 2026) and 25% in five (5) years (end of 2028) (approximately 6-7,000,000 cattle annually) (and more thereafter). If Bion can successfully execute on its sustainable beef business plan (which is subject to many contingencies), we believe that JV facilities utilizing Bion’s Gen3Tech platform will supply one-third (1/3) or more of that of the premium market segment (and a higher portion of meat that is actually traceable and verifiably sustainable). Our goal is to have multiple sustainable beef projects under development (within 3-5 distinct JVs) by the end of our 2025 fiscal year. Our first commercial project is likely to be one of our current LOI Projects but we anticipate commencing development of additional sustainable beef projects during the current fiscal year as well. Our current target is to have at least three (3) facility modules (15,000 head per module)(“Modules”) in development and/or under construction during 2024 in three (3) different JVs with the initial barns being populated with livestock during 2025. Further expansion in the number of distinct JVs is projected through 2026-7 aiming at 5-10 JVs in process --- each of which JVs will be pursuing development of multiple Modules with targets of 12-15 populated Modules by the end of 2026 (approximately 2%-3% of the US beef market) and 30-45 Modules constructed and being populated by 2029 (approximately 6%-8% of the US beef market) with further expansion thereafter. Bion’s current goal is that its Gen3Tech platform will be utilized to produce 33% of the verifiable “sustainable beef” category at the end of the period (which will equal approximately 2 million cattle annually)(45 Modules).

 

There is no assurance that the Company will reach or approach the goals/targets set forth above. Reaching such goals/targets will require access to very large amounts of capital (equity and debt) as each module is projected to cost in excess of $50 million to construct and require mobilization of substantial personnel, technical resources and management skills. The Company does not possess either the financial or personnel resources required internally and will need to source such resources from outside itself.

 

Some portion of which sustainable beef will likely be organic (see below).

 

Sustainable Organic Beef

 

Bion believes it has a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonia nitrogen fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and and also provide the tenderness and taste American consumers have come to expect from premium conventional American beef that has been missing in current organic beef products. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

 

 

12 
 

 

 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year. 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Fertilizer (Organic and ‘ClimateSmart’) Listing/Certification Process

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products. The Company’s low concentration ammonium bicarbonate liquid product successfully completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. During the next 3-4 months the Company intends to file applications with OMRI and the California Department of Food & Agriculture (“CDFA”) for a line of higher concentration liquid ammonium nitrogen products (ranging from 6% up to 16% (or higher)) based on production of liquid samples during operation of the Initial Project over the next 2 months. The Company anticipates applying for and obtaining one or more listings/certifications for higher concentration products in our liquid ammonium nitrogen fertilizer line well prior to operational dates for the Company’s initial large-scale JV Gen3Tech Sustainable Beef Projects. See Fertilizer: Organic and ‘ClimateSmart’ below.

 

Gen3Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) ('Kreider Renewable Energy Facility' or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company has commenced discussions with Kreider Farms regarding updating the JVA to reflect the capabilities of our Gen3Tech platform and anticipates executing an amended (or new) JVA during the current fiscal year. The Company anticipates that if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

 

13 
 

Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’. The Covid-19 pandemic has delayed legislative efforts in Pennsylvania needed to commence its development. However, the Company has had ongoing dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

Technology Deployment: Bion Gen3Tech

 

Widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products (approved for organic production and/or ‘ClimateSmart’ certified). All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic and/or ‘ClimateSmart’ certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand, and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage, and the Company has additional applications pending and/or planned.

 

Bion’s business model and technology platform can create the opportunity for joint ventures s (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent one of the largest enhanced revenue contributors provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits then can be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, are supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed other hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2024 calendar year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

14 
 

 

The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun - and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

15 
 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition - it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices relied on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

Nitrogen and ammonia are also global concerns, with a growing number of harmful algae blooms and recurring dead zones across the world. In the EU, a nitrogen cap has been established that has led to political and social unrest, especially in Ireland and the Netherlands, where farmers are faced with culling their dairy and swine herds by as much as 50 percent. The ability to capture and stabilize their ammonia, so that it can be easily transported away from regions where it is not wanted and then precision applied where and when needed, could have a profound impact on the agricultural economies of these countries that export the majority of the dairy and pork products they produce.

 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source-- before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture and treat. While not regulated yet, there have been ongoing discussions between the US EPA and the California Air Resources Board (CARB) what potential ammonia regulation might encompass. However, as above, California is moving forward with changes to how it deals with nitrates.

 

 

16 
 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

Chronic droughts in the west have also impacted the long-term sustainability of some beef herds. Relocation of some beef cattle feeding locations may be required. Access to clean water is an issue of concern that is rising in the world of risks on the ranch.

 

 For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

Technology and Technology Platform 

 

Bion has invested decades of work and substantial capital on the development of our technology and technology platform since 1989. The predecessor to Bion’s Gen3Tech platform, our patented second-generation technology (“2G Tech”), was proven at commercial scale and was reviewed and qualified for federal loan guarantees under USDA’s Technical Assessment program. Bion’s 2G Tech dairy project (“Kreider 1” or “KF1”), located at Kreider Farms in Pennsylvania (“PA”) received the first verified /measurable nutrient reduction credits from a non-point source livestock facility in the U.S. and its nutrient reductions were verified by the Pennsylvania Department of Environmental Protection (“DEP”) during 2012.

 

 

17 
 

 

A key attribute of Bion’s 2G Tech (now supplanted by our Gen3Tech) was that nutrient and other pollution reductions could be measured, providing a level of verification on par with a municipal wastewater treatment plant, which created the opportunity for the nutrient reductions to be used as “qualified offsets” to EPA-mandated requirements. While it was an engineering success, Kreider 1 has failed financially because the 2G Tech platform was almost wholly dependent for revenue from anticipated demand for nutrient credits, based on PA’s mandated nitrogen reductions under the Chesapeake Bay Strategy and their proposed nutrient trading program that did not materialize. Bion began development of its Gen3Tech platform when it became apparent there was significant opposition to the PA trading program (and private sector participation in clean water activities, generally) from entrenched clean water interests. The Company is no longer implementing Projects based on its 2G Tech and the Kreider 1 project has been shut down.

 

Bion’s Gen3Tech was developed to avoid the dependence of our 2G Tech systems on the sale of water quality trading credits in order to develop profitable projects. The Gen3Tech platform has been designed to maximize revenues from co-products, including biogas and fertilizer products, achieve premium pricing from USDA PVP-certified ‘environmentally sustainable’ retail branding of the animal protein products it supports, as well as generate verified credits for still-developing water quality trading programs. The first patent on the Gen3Tech was filed in 2015 for an ammonia recovery process that produces ammonium bicarbonate (a commercial fertilizer) without external chemical additives, thereby providing the basis for organic certification. A Notice of Allowance from the US Patent and Trademark Office (“USPTO”) was received during August 2018 related to this patent application and the patent was subsequently issued. Since July 2017 Bion has filed for extensions of this patent application to provide broadened protections and to cover improvements to the process developed in the interim. During August 2020 the Company received a Notice of Allowance’ for our third patent related to our Gen3Tech and additional related applications are pending and/or planned (See “Patents”.) The Gen3Tech platform incorporates Bion’s patented and proprietary technology which utilizes existing commercial evaporation and distillation process equipment (with decades of reliability and service history) that is customized for Bion’s specific applications.

 

Gen3Tech Platform 

 

Our Gen3Tech platform is the basis for a JV business model with four primary distinct revenue streams: 1) pipeline quality renewable natural gas and related carbon and other environmental credits, 2) premium fertilizer products: organic and ‘ClimateSmart’, 3) nutrient reduction credits, and 4) premium pricing/license fees for verifiably sustainable, USDA PVP-certified ‘Environmentally Sustainable’ branded meat at the retail level. Carbon and nutrient credit revenues will be supported by third-party verification of the waste treatment processes that simultaneously capture methane and nutrients, while producing renewable energy and fertilizer products from them with relatively limited incremental cost to Bion. The same verified data will also provide the backbone for the USDA PVP-certified sustainable brand, again with limited incremental cost.

 

1)Renewable energy- and carbon-related credits:

 

Bion’s Gen3Tech platform utilizes anaerobic digestion (“AD”) customized to maximize recovery of biogas (methane) (and ammonia nitrogen components) from the waste stream. At sufficient scale, methane produced from AD can be cost-effectively conditioned/cleaned, compressed and injected into a pipeline. The US Renewable Fuel Standard (“RFS”) program and state programs in California and elsewhere provide ongoing renewable energy credits for the production of biogas and its subsequent use as a renewable transportation fuel. The CO2 recovered in the gas cleaning process will be recycled for use in the production of organic fertilizer products along with the ammonia-rich digestate. Gen3Tech facilities will also generate photovoltaic (solar) electricity from modules placed on the roofs of the barns (approximately 12 acres of rooftop per 15,000 head of cattle module). Additional renewable energy-related credit programs are being developed that Bion believes will impact these revenues, including a Carbon Intensity (CI) score that measures the amount of carbon produced per unit of energy produced.

 

 

18 
 

 

 

2)Fertilizer: Organic and ‘ClimateSmart’:   The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products. The Company’s low concentration ammonium bicarbonate liquid product successfully completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. During the next 3-4 months the Company intends to file applications with OMRI and the California Department of Food & Agriculture (“CDFA”) for a line of higher concentration liquid ammonium nitrogen products (ranging from 6% up to 16% (or higher)) based on production of liquid samples during operation of the Initial Project over the next 2 months. The Company anticipates applying for and obtaining one or more listings/certifications for higher concentration products in our liquid ammonium nitrogen fertilizer line well prior to operational dates for the Company’s initial large-scale JV Gen3Tech Sustainable Beef Projects.

 

Additionally, the Company intends to explore the market potential for its fertilizer (in liquid and/or solid forms) to be a verifiably ‘ClimateSmart’ product (potentially a much larger market than the organic market) with focus on higher value specialty crops. This will require working with industry and academic entities to develop appropriate metrics and producing a ‘life cycle assessment’ (LCA) for Bion’s ammonium nitrogen fertilizer product which can be compared to conventional nitrogen fertilizer products. Bion’s processes will capture and utilize CO2 in the waste stream (including CO2 produced with the renewable natural gas (RNG) by anaerobic digestion that is usually vented to the atmosphere) as stabilizing agent thereby potentially creating carbon offsets compared to natural gas utilized as feedstock in chemical ammonia production which reduction will be reflected in the LCA. This LCA will assess environmental impacts associated with fertilizer production in support of the beef cattle supply chain for both the existing conventional approach (primarily fossil fuel-based Haber-Bosch production methods) and the largely decarbonized Bion production approach. We believe a series of coincident yet significant LCA benefits accrue from Bion’s patented fertilizer production approach including the reduced loss of ammonia to the environment via air (volatilized) and water (nitrate in groundwater) pathways, recycled/reused water, elimination of pathogens, the production of renewable natural gas, the production solar energy from photovoltaic panels on barn roofs, enhanced animal welfare practices and reduced animal husbandry risks from extreme weather events. Bion believes that current evaluations of the carbon impact from feedlot operations materially underestimate the negative impacts because existing models do not properly include significant ‘downstream’ carbon impacts of required energy intensive waste water treatment for re-deposited ammonia nitrogen. If the Company determines there is a significant ‘ClimateSmart’ opportunity for our fertilizer products, such an LCA can be completed (based in part on data from the Initial Project) and support marketing efforts well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.

Ammonium bicarbonate, manufactured using thermal and mechanical processes, has a long history of use as a fertilizer. In addition to liquid ammonium nitrogen fertilizer, Bion’s Gen3Tech is capable of recovering nitrogen in the form of solid ammonium bicarbonate products containing up to 18%-22% (or higher) nitrogen in a crystalline form that is easily transported (while producing liquids with various percentages of ammonium bicarbonate nitrogen during interim stages of the process). This solid product is water soluble and provides a readily available nitrogen source for crops. It will contain virtually none of the other salt, iron and mineral constituents of the livestock waste stream that often accompany other organic fertilizers. This product is being developed to fertilizer industry standards so that it that can be precision-applied to crops using existing equipment. Bion believes that this product will potentially have broad applications in the production of organic and/or ClimateSmart grains for livestock feed, row crops, horticulture, greenhouse and hydroponic production, and potentially retail lawn and garden products.

The ammonium bicarbonate products (liquid and solid) produced by Bion’s Gen3Tech platform will enjoy a dramatically lower carbon footprint than synthetic nitrogen fertilizers. Much of the reactive nitrogen captured and upcycled into our fertilizer products was going to be lost through volatilization and runoff, and that loss would generally need to be offset with a synthetic nitrogen fertilizer, such as anhydrous ammonia or urea. These synthetic nitrogen products are produced through the Haber-Bosch (and other) synthetic processes, which converts hydrogen and atmospheric nitrogen to ammonia, with methane from fossil fuels as the energy source. It is an extremely energy-intensive process with a carbon footprint that, while not yet fully understood, is widely accepted to by very large. While a complete Life Cycle Assessment (LCA) of carbon impacts from synthetic fertilizer production is not yet available, according to the Institute for Industrial Productivity, its production alone is responsible for approximately 1 percent of total global CO2 emissions. To the extent that Bion can capture and repurpose the nitrogen traditionally lost from livestock waste, that carbon cost will no longer need to be paid by the environment/climate.

Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line were filed with OMRI (filed during May 2021) and CDFA (filed during May 2022) without success to date. After an extended review processes (which was largely opaque), the OMRI application proceeded through multiple stages without receiving a positive result. We have initiated an informal dialogue with CDFA regarding the basis for and re-consideration of its initial negative determination and anticipate submitting additional supporting materials to CDFA during the next 30 days. The Company’s solid product line is novel (in the context of organic certification) in part due to the fact that no formal listing category currently in the organic space for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produces it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other organic fertilizer stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company intends to continue efforts to obtain listing/certification for its solid nitrogen fertilizer line over the course of this fiscal year.

 

 

 

 

19 
 

 

To provide a first level degree of clarity regarding organic approvals and the processes/procedures involved, Bion believes that the initial OMRI approval is of importance, because our other ammonium nitrogen organic products will produced by using the very same technology platform (our Gen3Tech). Note that there are different layers to the U.S. organic program and that fertilizers do not get ‘certified’ as organic, per se. Rather, they are evaluated to determine if they are acceptable for ‘use in organic production’.

The National Organic Program (“NOP”) was established by Congress in 2001 under the USDA’s Agricultural Marketing Service. The NOP develops and enforces uniform national standards for organically-produced agricultural end products – meat/dairy/milk, fruits, vegetables – sold in the United States. Operating as a public-private partnership, NOP accredits private companies and helps train their inspectors (USDA-accredited Certifiers) to certify that farms and businesses meet the national organic standards. For example, in a potential Midwest organic beef project, each element in the supply chain must provide their certifying agent’s certification that the specific product, such as organic corn, has been produced in accordance with their organic plan. The end product - the beef - would be USDA-certified as organic by an accredited Certifier after a review of ALL the farming practices and inputs (which would include Bion’s ammonium bicarbonate fertilizer).

OMRI enables a national listing thru one application versus the alternative of using certifiers to secure listings in individual states and regions. To those who wish to sell organic fertilizers into national distribution channels, an OMRI listing provides nearly uniform acceptance in the U.S. The OMRI listing Bion received in May was for our initial commercial product, a low-concentration liquid ammonia. It is valid ONLY for that particular product. For future Bion product offerings using the same technology platform, Bion will either need to file for specific state approval, or file for a national listing, or a combination of the two. Bion may elect to use an individual state listing initially to be followed by an OMRI application if and when the need for a regional or national listing arises.

The overarching standard of organic production, per NOP guidelines, is that a “product shall have been produced and handled without the use of synthetic chemicals…” That is rule Number One. At NOP, the term "synthetic" means “a substance that is formulated or manufactured by a chemical process or by a process that chemically changes a substance extracted from naturally occurring plant, animal, or mineral sources, except that such term shall not apply to substances created by naturally occurring biological processes.” In evaluating and approving Bion’s liquid ammonia for OMRI listing, Bion’s patented ammonia recovery system was not deemed synthetic. That is an important distinction for future Bion product filings based upon the same patented process.

The Company believes that organic approvals for its products will: a) provide access to substantially higher value markets compared to synthetic nitrogen products, and/or b) allow its products to be utilized in growing of organic feed grains to be consumed by livestock raised in JVs which will be sold as organic. Based on preliminary market surveys to date, we believe that existing competing organic fertilizer products in both liquid and granular form are being sold presently at price points significantly greater than Bion’s projected cost and projected pricing. We also believe that livestock products from animals raised with feed grains grown using Bion organic ammonium bicarbonate fertilizer products (and that otherwise qualify) will receive organic approvals. It is anticipated that the Company will continue to seek approvals for such products during the balance of the current fiscal year and will commence JVs that undertake initial production and marketing of such products during the 2024 calendar year.

 

 

20 
 

 

 

  3) Nutrient credits:

 

Bion believes that nutrient reduction (and other similar) credits and/or other methods of monetizing environmental benefits from the capture and re-purposing of the nutrients (largely nitrogen and phosphorus) from the livestock waste stream, will become available in multiple states over the next several years. The passage in the Pennsylvania (“PA”) Senate of key legislation – SB 575 – in June 2019 that would have established a competitively-bid market for nutrient credits in PA, is indicative of the trends. Despite the fact that the bill was not considered in the House, due to the Covid-19 pandemic (a re-introduced bill will have to be considered again in the current and/or future sessions, Bion anticipates that after passage of a similar bill in the future, PA will establish a competitively-bid market for nutrient credits within twelve months after legislative passage and being signed into law by the Governor. See “Policy Change is Coming” and “Kreider Poultry Joint Venture and Pennsylvania and Chesapeake Bay Initiatives” below for discussion of the history and status of matters in PA.

 

Note, however, that the Covid-19 pandemic and resultant social and economic crises and budgetary constraints have delayed policy initiatives related to these matters at both the state and federal levels. As a result, it is not currently possible to reasonably project a timetable for adoption of the policy changes discussed herein.

 

  4) Sustainable Branding:

 

Consumers have demonstrated a willingness to pay a premium for their safe and sustainable food choices. Based on Bion’s recognition of the potential opportunities created by such willingness, beginning in 2015, Bion worked with the USDA’s Process Verified Program (“PVP”) – the ‘gold standard’ in food verification and branding – to establish a USDA PVP-certified sustainable brand. Bion received conditional approval from the PVP related to its Kreider 1 project (utilizing 2G Tech). It is our intention to submit an application for the Gen3Tech platform when the initial Gen3Tech Project is operational and seek an approval for certification based on third-party-verified reductions in nutrient impacts, greenhouse gases and pathogens in the waste stream (and other attributes), based on our Gen3Tech platform. PVP certification incorporated as part of a recognizable brand (together with point-of-sale information) will provide consumers with products and brands that can be trusted. Bion believes that such a brand and livestock product line will command a pricing premium for Bion’s livestock JVs and their customers.

 

Food safety and sustainability are issues of growing importance in the U.S. and worldwide. Bion’s branding initiative reflects trends already underway in the livestock industry. Driven by growing consumer demand, large food retailers (such as Walmart and Costco) and restaurant chains (including Chipotle and McDonalds) are increasingly demanding greater responsibility and improved sustainability in food production practices from their suppliers. The Global Roundtable for Sustainable Beef (“Roundtable”) was created to advance a sustainable global beef value chain that is “environmentally sound, socially responsible and economically viable”. The Roundtable represents members from across the supply chain, including U.S., Canadian and Australian cattlemen’s associations, Cargill, JBS, Elanco, McDonalds and A&W.

 

Large institutional investors have begun to pressure the livestock industry. Ceres and several other large activist institutional investors have already expressed concerns about carbon footprint, water quality, antibiotic usage and animal welfare in letters to management of their investment holdings in the food production industry. The Collier Farm Animal Investment Risk & Return (“FAIRR”) Initiative was recently launched to highlight the environmental, social, and governance (“ESG”) risks associated with large-scale livestock production.

 

In past years, the UN FAO has issued several highly critical reports of the livestock industry, more recently focused on its impacts on climate change. While some of their early reports were based on incomplete data and faulty methodologies and have since been somewhat quietly ‘retracted’, a wide array of activist groups, including climate, animal rights, and anti-factory farming advocates, have seized on them to create a global “anti-meat” messaging campaign. Their messaging is predicated on the (incorrect) notion that agriculture, and the livestock sector specifically, is the largest contributor to climate change, greater than the energy and transportation sectors. While this fact has been publicly ‘debunked’, the anti-meat campaign has been joined and amplified by various other stakeholders, governments, and more recently, competitors in the alternative protein space, such as plant-based and cellular meats.

 

Over the last few years, most large meat and dairy product retailers have announced ‘sustainability’ initiatives, although the definition of sustainability is often unclear. Based on recent statements from the industry regarding sustainability policy, many that identify goals that are 10 to 30 years in the future, Bion believes that sustainability on the production side will look a lot like what the Company’s Gen3Tech platform can provide today. The Gen3Tech platform can deliver verifiable metrics that demonstrate meaningful improvements in sustainability for livestock production that are unmatched in the industry today, including a dramatically reduced carbon and nutrient footprint; lower negative impacts to water, soil and air; increased pathogen destruction; and other environmental and public health impacts. The Covid-19 pandemic has further heightened consumer awareness and concerns related to a) environmental sustainability, b) food safety, c) sourcing and traceability and d) humane treatment of both animals and workers.

 

 

21 
 

 

The more the livestock industry’s supply chain practices become transparent and known by consumers, the more consumers are seeking alternatives. Bion’s ‘Sustainable’ branding program is designed to address a wide array of consumer concerns including: a) ‘where does your food come from?’ (animal heritage information); b) climate change (carbon) and other key environmental impacts (air/water/soil); c) antibiotic use/ standards; d) animal welfare/ humane treatment; e) laborer welfare/ working conditions. These issues can be addressed with the consumer through general advertising and/or at the point of sale with a QR code on the packaging that links back to product-specific data. The verification processes that will be employed by Bion’s Gen3Tech platform support block chain traceability, providing accountability throughout that part of the supply chain addressed by Bion’s platform and enabling any quality issues to be quickly identified by lot and location, minimizing risk to its consumers. In essence, Bion’s comprehensive technology platform will enable its livestock JVs and other adopters to be not only the provider of the product the consumer wants, but also the businesses that shares their consumers’ values.

 

Technology Applications/Business Opportunities

 

For the past decade, Bion has been focused on developing its Gen3Tech platform and creating applications for its patented and proprietary waste management technology platform to pursue JVs and other business opportunities in three broad categories:

 

a)       Development of new state-of-the-art large scale waste treatment facilities (now utilizing our Gen3Tech) as JVs (or through other contractual arrangements and licensing), which may be developed in conjunction with new CAFOs in strategic locations (some of which were previously impracticable due to environmental impacts) and/or to treat the waste streams from one or more existing large livestock facilities (“Projects”). Some of these Projects may be either a) Integrated Projects as described below, b) ‘central processing facilities’ which receive the waste from multiple livestock facilities, c) Retrofit Projects or d) hybrids with elements of each of these types. Each version will be able to realize revenue from multiple revenue streams potentially generated by our Gen3Tech.

The “Sustainable Beef” and “Sustainable Organic Beef” opportunities (discussed both above and below) would be examples of this category. Bion anticipates that some of our Gen3Tech projects will involve swine and poultry. Some Projects may be international.

 

b)       Installation of Bion systems to retrofit and environmentally remediate existing large CAFOs (“Retrofits” and “Retrofit Projects”) in selected markets where:

 

a) government policy supports such efforts (such as the Chesapeake Bay watershed, Great Lakes Basin states, and/or other states and watersheds facing EPA ‘total maximum daily load’ (“TMDL”) issues), and/or

b) where CAFO’s need our technology to obtain permits to expand or develop without negative environmental consequences.

The Kreider Poultry JV project (“Kreider 2” or Kreider Poultry”) (discussed below) is an example of such a Retrofit Project.

 

c)    Technology licensing and/or joint venture opportunities internationally and in the U.S. for post-anaerobic digester: a) dairy applications, and b) treatment of organic waste streams from food waste, food processing waste, biofuels, and other organic waste streams whose processes include anaerobic digestion to produce renewable energy.

 

In each category (but especially in categories a) and b)) above, the Company intends to directly participate (whether by joint venture agreement or other contractual arrangements) in the revenues of the Retrofits and Projects.

 

The opportunities described in categories a) and b) above each require substantial political and regulatory (federal, state and local) efforts on the part of the Company and a substantial part of Bion’s efforts are focused on such political and regulatory matters. Bion currently intends to pursue the international opportunities primarily through the use of consultants with existing relationships in target countries.

 

At this time, our primary focus is on categories a) and b) above, using our Gen3Tech to develop new (or expanded) large-scale Projects with strategic partners (including the Kreider 2 Project) on a joint venture (or other participating contractual form) basis----but we have engaged in preliminary discussions concerning opportunities described in category c). Bion’s business model opens up the opportunity for JVs in various forms, based upon the revenue generated by our Gen3Tech platform from nutrient reductions, fertilizer co-products and renewable natural gas (which revenue streams will be secured through long term take-off agreements for each of these co-products) providing initial support for financing of required capital expenditures (whether equity or debt). We anticipate that these revenue streams will be supplemented by revenue realized from long-term premium pricing resulting from the sustainable branding opportunity. We believe that, over time, the branding opportunity may provide the single largest contribution to the overall economic opportunity enabled by Bion’s Gen3Tech platform and business model.

 

 

22 
 

 

Initial Project: Gen3Tech Demonstration Facility

 

During the 2021 fiscal year, Bion completed a series of core optimization trials of its Gen3Tech platform that were required to move forward with its initial commercial scale Gen3Tech project. See discussion of the Initial Project above.

 

Sustainable/Organic Corn-Finished Beef Opportunity

 

It is likely that one of the LOI Projects discussed above will be the first Bion Gen3Tech project in this category.

 

The U.S. is the largest producer of beef (and veal) in the world, accounting for 11.5 million tons out of 61.5 million tons produced worldwide in 2020. Per capita beef consumption in the U.S. was approximately 70 pounds in 2020, up from 55 pounds in 2011. Annual cash receipts for all U.S. ‘cattle and calves’ were lower at approximately $62 billion in 2020, with 2021 receipts anticipated to be higher (and back in line with recent years) at $66 billion. Retail sales of fresh beef in the U.S. in 2020 were $30.2 billion. In 2020, there were approximately 93.8 million cattle and calves in the U.S., with 14.7 million on feed. Of those cattle on feed, 81.4 percent were in feedlots with a capacity over 1,000 head.

 

Beef production is the most challenged sector of the livestock industry, due to its size and inability, as currently structured, to respond to growing consumer concerns related to sustainability and food safety. The beef industry is highly fragmented, and it is designed to produce multiple levels of commodity products (without any significant pricing premiums) that are graded based on marbling (fat) that determines taste and tenderness. Further, during its several decades of growth, the industry has avoided significant environmental regulation, and instead, has externalized its environmental costs by returning its waste to crop fields, where much of it is ‘flushed’ downstream. Today, however, consumer demand is shifting to products that are more sustainable, regarding carbon footprint, impacts to air and water, and other metrics. The result has been an opening for disruptive startups, including Beyond Meat and Impossible Foods, that are backed by large institutional investors and offer plant-based (in part) meat substitutes. The CEO of Impossible Foods has made bold claims that the $100B-plus (U.S. alone) meat industry will be obsolete in 15 years (before the ‘alt meat’ boom flattened). Bion disagrees --- but such competition provides and highlights opportunities for us.

 

The Company doesn’t think the consumer wants to ‘blow up’ the beef industry, which is responsible for the best and safest beef available in the world today (as well as the livelihoods of almost 800,000 farming, ranching and other families supported by the beef industry in the U.S). Nor do market studies bear out the concept that consumers want to replace the current supply chain. Rather, the studies indicate that consumers want the supply chain to be more sustainable---and still taste good. Bion believes that strong demand exists for a verified sustainable beef product that is real meat, with the taste and texture of traditional corn-fed beef, but which addresses consumers’ sustainability concerns. Bion’s technology platform is designed to produce such an environmentally sustainable beef (and other meat) product. Bion previously achieved conditional approval (for its 2G Tech pending resubmission and final inspections) for USDA brand certification that would initially include verified reductions in carbon, nutrients, and pathogens. The Company is confident that its Gen3Tech will support a PVP brand for products of sustainable and organic beef JVs.

 

Market studies indicate there is potentially a large, currently unserved, market for sustainable/organic corn-finished beef; and further, that this is a long term and growing trend. Bion believes its 30 years of experience and expertise in livestock waste management, coupled with its state-of-the-art Gen3Tech platform and first-mover advantage, put the Company and its selected JV partners in a unique position to develop the most environmentally and economically sustainable animal protein production facilities possible today. The Company is unaware of any other technology and/or business model that can offer the same level of comprehensive treatment of livestock waste, produce high value coproducts, and deliver a sustainable brand that can provide an industry response to counter today’s anti-meat messaging, along with the inroads in the animal protein market being made by alternative protein competitors.

 

‘Sustainable’ and ‘organic’ are two separate and distinct designations and represent different markets and consumers. While the markets and consumer demographics may overlap, it is assumed for purposes of Bion’s analysis and planning that the market for sustainable beef will be substantially larger but command a smaller pricing premium; while the market for organic will be smaller but command a substantially larger premium and be costlier to produce. Note that in the sustainable and organic markets targeted by Bion, ‘corn-finished’ is a constant. Bion believes, and the market has demonstrated, that delivering the same taste and texture that consumers expect in American beef and other meat products is a key to successful market acceptance, within both the sustainable and sustainable organic markets. The success of grass-fed/organic ground beef vs that of grass-fed/organic steaks demonstrates that palatability, as well as price, is a key criterion in whether a consumer chooses sustainability. Bion’s Gen3Tech platform supports production of beef products that check all the boxes: sustainable, expected taste/texture, and affordable.

 

 

 

23 
 

 

Bion believes there is an opportunity, without the need to ‘reinvent’ the beef production supply chain, to provide at least a premium segment of the market with an affordable product that satisfies consumers’ sustainability concerns. Further, we believe that the opportunity is large in scope and of sufficient duration and potential economic upside to warrant the investment of significant capital and resources. Our anticipated project development timeline can potentially allow us and our JV partners to be first to market with a sustainable/organic beef product at scale. The ability to deliver a large supply of a consistent product will be critical to the large retail distribution partners Bion will seek to include in its JVs. Our first/early-mover advantage should allow us to capture a significant portion of the early adopters in what market studies indicate is a potentially large, and essentially unserved, market.

 

In parallel with the beef demonstration project described above, we continue to move forward with preliminary pre-development work on a JV to build a large-scale state-of-the-art beef cattle feeding operations in the Midwest U.S. Such projects will be developed to produce a supply of corn-fed beef that is a mixture of both USDA PVP-certified sustainable and sustainable-organic brands. One of the three LOIs (Ribbonwire/Olson/DVG )(discussed above), representing the first fruition of this initiative, will most likely be our first large scale sustainable beef JV with development commencing during the 2024 calendar year.

 

Bion intends to pursue its ‘beef opportunity’ in a series of large-scale JV projects, which will be based on construction of modules housing approximately 15,000 head each, for differing aggregate totals depending on multiple geographic and economic factors. Bion anticipates that these JVs would be comprised of parties that could include a) Bion, b) capital market/financing providers, and c) strategic industry partners who would be equity participants and/or offtake customers for the products of the ventures. The supply chain for each JV would vary and might include participating a) organic corn producers, b) cow-calf operators, c) cattle feedlot operators, d) slaughter/processing plants, and e) retail distribution partners--- each subject to negotiated standards and controls. Bion’s model will potentially enable segment of the supply chain to generate greater profitability as part of an integrated program, rather than the present fragmented industry model, for essentially performing the same basic services. One example of such synergies/integration might involve providing an organic corn producer with sufficient ammonium bicarbonate fertilizer to support a higher yield per acre, in return for a share of the excess yield value and a production purchase commitment.

 

At present, there is essentially no traceable and verifiable ‘sustainable beef’ available to the US market except for niche products. In response to consumer demand for transparency and sustainability, Bion expects the meat industry in general, and beef specifically, to evolve towards using new technologies to deliver these attributes in their products. While we anticipate a faster adoption of tracking, verification and sustainability technologies in other perishable food categories like produce and dairy due to their shorter product cycles (and related harvest and production techniques), meat industry leaders have also announced their willingness to move forward with initiatives in this area. Many companies have announced ‘sustainability’ initiatives but most appear to consist largely of ‘greenwashing’ marketing commitments rather than substantive undertakings at this date. Note, however, that Tyson’s Brazen beef initiative (which was announced during March 2023) may develop into a substantive competitive factor in the sustainable beef marketplace. Bion predicts that within approximately five years, consumers will be able to track and verify claims including sustainability on 25% (or more) of the products merchandised in the meat department. Bion believes that the retail market share of verifiably sustainable beef in the US will approach 7-10 % within three (3) years (end of 2026) and 25% in five (5) years (end of 2028) (approximately 6-7,000,000 cattle annually) (and more thereafter). If Bion can successfully execute on its sustainable beef business plan (which is subject to many contingencies), we believe that JV facilities utilizing Bion’s Gen3Tech platform will supply one-third (1/3) or more of that of the premium market segment (and a higher portion of meat that is actually traceable and verifiably sustainable). Our goal is to have multiple sustainable beef projects under development (within 3-5 distinct JVs) by the end of our 2025 fiscal year. Our first commercial project is likely to be one of our current LOI Projects but we anticipate commencing development of additional sustainable beef projects during the current fiscal year as well. Our current target is to have at least three (3) facility modules (15,000 head per module)(“Modules”) in development and/or under construction during 2024 in three (3) different JVs with the initial barns being populated with livestock during 2025. Further expansion in the number of distinct JVs is projected through 2026-7 aiming at 5-10 JVs in process --- each of which JVs will be pursuing development of multiple Modules with targets of 12-15 populated Modules by the end of 2026 (approximately 2%-3% of the US beef market) and 30-45 Modules constructed and being populated by 2029 (approximately 6%-8% of the US beef market) with further expansion thereafter. Bion’s current goal is that its Gen3Tech platform will be utilized to produce 33% of the verifiable “sustainable beef” category at the end of the period (which will equal approximately 2 million cattle annually)(45 Modules).

 

There is no assurance that the Company will reach or approach the goals/targets set forth above. Reaching such goals/targets will require access to very large amounts of capital (equity and debt) as each module is projected to cost in excess of $50 million to construct and require mobilization of substantial personnel, technical resources and management skills. The Company does not possess either the financial or personnel resources required internally and will need to source such resources from outside itself.

 

Retrofit Gen3Tech Project: Kreider Poultry JV (“Kreider 2”)

 

The JV Kreider 2 Gen3Tech project is intended to treat the waste from Kreider Farms’ approximately six million egg layer chickens (with capacity for an additional three million layers)(and potentially 1,600 dairy cows). The Project will be designed for an initial capacity of 450 tons per day of waste and will remove nitrogen and phosphorus from the waste stream that will be converted into high-value coproducts instead of polluting local and downstream waters. The Project is planned to be built in multiple phases and may be expanded to include a ‘central processing facility’ with modules that will accept transported waste from the region on a fee basis.

 

 

24 
 

 

Bion has a long-standing relationship with Kreider Farms, including a 2016 joint venture agreement related to these potential facilities. Kreider has already made a significant investment in upgrading its poultry facilities to maximize the treatment and recovery efficiencies that can be achieved with Bion’s technology. Note, however, that the Kreider 2 project is dependent, in part, on development of a substantial competitively-bid market for long-term commercial sale of the nutrient reduction credits produced at Kreider 2 (or another form of payment for ecosystem services). If/when a viable competitive procurement program for nutrient credits or similar program is implemented in PA, we intend to move forward on the development of the initial portions of the Kreider 2 Project during the subsequent year. Certain matters related to Kreider 2 are discussed at “Kreider Poultry Joint Venture and Pennsylvania and Chesapeake Bay Initiatives”.

 

Policy Change is Coming

 

Because Bion believes that policy change is coming, we continue to work with an array of stakeholders, including national representatives of the livestock industry, to support establishing new market driven strategies to allow the private sector, including the livestock industry, to provide low-cost large-scale verifiable solutions to our Nation’s clean water challenges. There are many states that face similar (or worse) to Pennsylvania’s livestock waste-related pollution issues, and they will be forced to adopt new strategies, as well. In the face of a growing problem that will only be exacerbated by climate change, it will be necessary to go beyond status quo solutions or risk losing the ecosystems that comprise many of our watersheds and estuaries.

 

When competitively-bid markets for nutrient reductions (and/or other forms of payment for ecosystem services that will allow us to monetize environmental benefits) become fully established, Bion anticipates a robust opportunity to use its Gen3Tech-based platforms to retrofit both existing CAFOs and equip new large-scale livestock facilities (“Projects”) which will generate the supplemental revenue needed to profitably afford technology implementation from sales of verified nutrient reduction credits.

 

Bion's Gen3Tech can provide a solution to a significant portion of the livestock problem discussed above, because it upcycles the nutrients, providing a pathway to export and precision apply them when and where needed, which prevents the uncontrolled release to the environment of most of the nutrients from the CAFO waste stream. Treatment costs are offset by recovering a substantial portion of those nutrients for value-added commercial utilization.

 

Our technology platform largely eliminates ammonia emissions, other substantial greenhouse gas emissions, odors and other harmful air pollutants. Additionally, the platform destroys virtually all pathogens in the waste stream that have been linked to foodborne illnesses and growing antibiotic resistance. Similar to point-source treatment, such as provided by an industrial or municipal wastewater treatment plant, the performance of Bion’s technology platform can be precisely monitored, measured and quantified (in contrast to the modeled, in-exact - and so far, disappointing - results from modeled BMPs). Third-party data from our facilities can provide the basis for verified environmental credits, and related revenues, as well as sustainable branding claims.

 

In contrast, the current clean water strategy being utilized in the U.S. is clearly failing, because it doesn’t adequately address waste from agriculture. A lot of U.S. crops are now fertilized with raw, untreated manure. However, approximately 80 percent of the nitrogen in that manure is not utilized by the plants being fertilized but rather ‘escapes’ to contaminate the environment through various pathways. Because livestock waste is one of the largest contributors to nutrient problems in certain watersheds, livestock waste treatment can be the source of the low-cost solution for such problems – if the waste is treated upstream at (or close to) the source of production. Manure control technologies, applied to large scale facilities where concentration and scale enable cost-effective cleanup, can potentially offer the lowest cost nutrient solutions available in most watersheds today. More than 80 percent of U.S. livestock production takes place on large-scale facilities, where cost-effective treatment can be implemented. There is no longer any real question regarding whether such facilities need to be cleaned up. The actual question for public policy concerns is developing sources of new revenues which will enable the livestock industry to offset the implementation costs for the cleanup.

 

Despite trends toward concentration in segments over the last several decades, the U.S. animal-protein industry, particularly beef, remains (in large part) a fragmented, low-margin commodity business without effective integrated efforts toward either environmentally or economically sustainable production. Cleaning it up will have to be orderly and contain a path to sustainability that does not cause U.S. food costs to spike or bankrupt the industry. This will require treatment sufficient to remove the volume of nutrients in excess of crop requirements. Because the global export market represents a significant part of the U.S. livestock production industry, direct increases in federal regulation without offsetting revenues would likely create costs that could not be absorbed by the industry in a manner that would allow it to remain competitive in international markets. Selective state regulation would have a similar chilling effect within the U.S., since regulated producers in one state would be unable to compete with unregulated producers in adjoining states. Subsidies and/or new revenue sources are required.

 

Bion believes that reallocating some part of the approximately $110 billion in existing U.S. taxpayer-funded clean water spending to lower-cost alternative solutions in agriculture (including competitively-bid nutrient reduction procurement) is inevitable. It will provide the taxpayer with accelerated and substantially lower-cost (and verified) air and water quality solutions compared to current strategies. If Bion’s technology is implemented in appropriate situations, it will provide the livestock industry with the recurring revenues that are needed to offset the costs of technology adoption without major disruption to the industry. To date, a wide range of entrenched interests have opposed and fought policy change that might reallocate clean water spending to more cost-effective alternatives; but this common-sense approach is being accepted by a widening group of stakeholders.

 

 

25 
 

 

 

NOTE, THAT THE COVID-19 PANDEMIC AND RESULTANT ECONOMIC CRISES AND BUDGETARY CONSTRAINTS APPEAR TO HAVE DELAYED POLICY INITIATIVES RELATED TO THESE MATTERS AT BOTH THE STATE AND FEDERAL LEVELS. AS A RESULT, IT IS NOT CURRENTLY POSSIBLE TO REASONABLY PROJECT A TIMETABLE FOR ADOPTION OF THE POLICY CHANGES DISCUSSED HEREIN.

 

However, Bion believes that some opportunity exists at the federal level in the projected infrastructure spending to create funding for climate and environmental initiatives. For example, the recently passed Inflation Reduction Act includes provisions that may provide up to a 30% federal tax credit to partially offset costs of adoption of environmental technologies such as AD and Bion’s Gen3Tech waste treatment technology. Such an incentive, if available (of which there is no assurance), would materially impact JV project economics (including the Dalhart Project and the Kreider 2 project). Further, we believe that AD projects will ultimately be required to utilize ammonia control technologies, since ammonia emissions are an area of increasing concern, and AD exacerbates the release of ammonia from the organic waste stream.

 

Note that a bipartisan 2013 Pennsylvania legislative study projected that creating a competitive bidding program to procure verified nitrogen reductions to meet federal Chesapeake Bay mandates, regardless of source, could reduce the state’s tax- and ratepayer-funded compliance costs by up to 80 percent (approximately $1.5B annually). The legislative study was updated in 2018 to reflect new policies. The updated report projected savings of up to 90 percent. As discussed in the original study, much of the savings were due to low-cost high-impact manure control projects (Bion’s technology figured prominently in the report).  Senate Bill 575, which was supported by legislative leadership, national livestock interests and other key stakeholders (and is consistent with US EPA policies), which would have established a competitive procurement program and unlock some of these opportunities in PA was passed during June 2019 by the Pennsylvania Senate voted 33 to 17 but one effect of the Covid-19 pandemic crisis has been that PA funding for new initiatives is largely ‘on hold’ at the present time. Bion anticipates that after passage of a similar bill in the future (of which there is no assurance), PA will establish a competitively-bid market for nutrient credits within twelve months after legislative passage and being signed into law by the Governor. See “Pre-Gen3Tech: Chesapeake Bay Watershed: Kreider Farms Projects/Pennsylvania Initiatives” below for discussion of the history and status of matters in PA.

 

In a 2017 Letter of Expectation to PA’s Department of Environmental Protection, US EPA demonstrated its support of a procurement strategy to engage the private sector - as long as the Credits are verified. It is noteworthy that US EPA and national livestock industry representatives agree on this strategy. Such a procurement strategy is also consistent with USDA and EPA support of ‘Private Partnerships’ and OMB’s guidance that supports acquiring verified results vs. financing projects with uncertain outcomes and taxpayer risks. Not surprisingly, the primary opponents of this strategy are the entrenched interests of the clean water status quo, although how much longer they can avoid accountability for a failing strategy remains to be seen.

 

We believe that such strategies that may be developed in Pennsylvania and the Chesapeake Bay, if implemented, are likely to serve as a model for the 40 other states now seeking solutions to similar water quality problems. Today, most states face a similar issue---unfunded federal clean water mandates. Pennsylvania’s proposed competitive bidding program provides an opportunity to significantly reduce the cost to PA (and a model for other states to utilize in the future) in meeting such mandates.

 

Going Concern:

 

The Company’s audited financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and incurred a net income of $8,291,000 for the year ended June 30, 2022 and a net loss of approximately $3,189,000 during the year ended June 30, 2023. The net income for the year ended June 30, 2022 was largely due to a one-time, non-cash event of the dissolution of PA-1 resulting in a gain of approximately $10,235,000 as well as a one-time gain of $902,000 from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period. At June 30, 2023, the Company has a working deficit and a stockholders’ equity of approximately $968,000 and $4,194,000, respectively. During the year ended June 30, 2023 the Company had debt modifications that resulted in a reduction of debt of $3,522,000 and an increase in equity in the same amount. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern.

PRINCIPAL PRODUCTS AND SERVICES

 

The Company’s primary focus is on implementing its Gen3Tech in JVs (as described above). Therefore, the category ‘PRINCIPAL PRODUCTS AND SERVICES’ is not fully appropriate for the Company’s business. While the Company may implement some Gen3Tech systems on a contractual basis, our business does not primarily involve sale of our systems or long term direct operations/management of our systems. The discussion below should be read in the context this business focus (described in detail above and below).

 

Bion has invested over $100 million in its business since 1989, much of which has been expended development of its technologies and technology platform, policy change initiatives and other activities. Our 2G Tech (now supplanted by our Gen3Tech) was proven at commercial scale and has been reviewed and qualified for federal loan guarantees under USDA’s Technical Assessment program. The 2G Tech platform (as will our Gen3Tech going forward) provided verified nutrient credits from wet livestock waste (dairy, beef, and swine) that can be used to offset US EPA-mandated TMDL requirements. The Company intends to implement its first Gen3Tech systems during the current fiscal year. Our Gen3Tech and Gen3Tech platform provide the basis for our planned JVs and Projects and therefore constitute our ‘principal products’.

 

 

26 
 

 

Each Bion system (whether prior 2G Tech or current Gen3Tech) is comprised of several process units combined in a ‘process train’, much like a municipal wastewater treatment plant. The platform utilizes a combination of mechanical, biological, and thermal processes and can be configured in a variety of ways, based on the needs and economics of the location, to provide the level of environmental treatment required, while separating and aggregating the various components of the waste stream for processing and recovery. A key attribute of the Bion platform is that the performance of the systems can be measured, quantified and verified through a proprietary data collection system, providing a level of oversight and verification similar to waste water treatment facilities. In addition to providing third-party verification of reductions for regulatory/credit purposes, the same data can also be used to support the claims of a USDA-certified sustainable branding.

 

Bion’s waste treatment solutions are scalable, proven in commercial operations (2G Tech) and the verified results have been accepted by EPA (for use as a “qualified offset”), USDA and other regulatory agencies. Bion’s core processes are protected by five United States patents. Additionally, Bion has two United States patent applications pending and has three international patent applications currently pending. We do not know of any other cost-effective technology that provides Bion Gen3Tech platform’s system’s level of treatment of livestock waste (dairy, beef, poultry and swine) or which can provide the full set of ‘sustainability benefits’ anticipated to be provided by the Company’s JVs. Note that while revenues from Bion’s 2G platform were 90 percent dependent on developing markets for nutrient reductions, our Gen3Tech platform will generate revenues from multiple co-product streams to supplement revenues from nutrient reductions.

  

Bion’s Gen3Tech platform has been developed over the past six years to maximize co-product recovery values from large scale facilities (or multiple modular facilities) while maintaining/improving the level of environmental remediation produced by our 2G systems. The 3G systems will recover nitrogen from the CAFO waste stream for production of nitrogen-rich products that Bion believes will qualify for certification for use as fertilizer in growing organic crops (the first approval was received during the 2020 fiscal year) for livestock and human consumption and/or for other uses. Further, the Gen3Tech platform will recover methane that can be conditioned/cleaned to pipeline quality gas (with the CO2 recovered from the cleaning process re-cycled and utilized in the fertilizer production process) and will qualify for various credits and subsidies as clean, renewable natural gas.  These two revenue streams will supplement revenues from the sale of USDA PVP-certified, verifiably sustainable branded meat products.  In some locations, revenues may also be realized from nutrient credits and other environmental services.

 

Building upon our 2G Tech and Bion's over 20 years of experience providing waste treatment services to the livestock industry, commencing with our first generation technology applications, the Company is also pursuing the Retrofit opportunities related to environmental remediation of existing CAFOs in appropriate situations (see discussion of Kreider Poultry venture herein).  Our technology has evolved and been upgraded over the decades to meet changing standards and requirements. Bion's Gen3Tech platform creates potentially profitable business opportunities to provide waste treatment services and systems and/or renewable energy production capability to existing large livestock operations (of which there are many), and potentially to smaller facilities through aggregation of waste streams. However, this is not our primary focus. Candidates for these solutions include individual CAFO facilities that face impending regulatory action, CAFOs that wish to expand or relocate, and operations located in regions that suffer severe and immediate environmental issues, such as the Chesapeake Bay watershed, Great Lakes region and/or the San Joaquin Valley, where financial incentives (such as nutrient reduction credit trading programs) are (or may become) available that encourage voluntary reductions of nutrient releases and/or atmospheric emissions from agricultural sources.

 

See ‘HISTORY, BACKGROUND AND CURRENT ACTIVITIES’ above.

 

Sustainable/Organic Corn-Fed Beef Opportunity

 

The Company believes that one of its major opportunities will be in JVs to pursue the Sustainable Beef Opportunity and the Sustainable/Organic Corn-Fed Beef Opportunity in the Midwest as discussed at some length above. It is the Company’s current intention to initiate several JVs pursuing this opportunity as developer of, technology provider to, and direct participant. See discussion above.

 

While it is not possible at this time to firmly predict where the initial JVs and/or Project will be developed or the order in which JVs and Projects will be developed, the Dalhart Project (see discussion above) will most likely be the Company’s first large scale Gen3Tech commercial project. All potential JVs and/or Projects are in very early pre-development stages and may never progress to actual development or may be developed after other JVs and/or Projects not yet under active consideration.

 

The Company's successful accomplishment of its business activities is dependent upon many factors (see 'Forward-Looking Statements' above) including without limitation the following, none of which can be assured at this date:

 

  Successful development and completion of the Initial Project (at least phase 1) and the first large scale Gen3Tech commercial Project(s) to demonstrate the commercial economics of its Gen3Tech platform;

 

  Successful development of the first Integrated Project to demonstrate the operation of a fully-integrated, environmentally-compliant Integrated Project at a profitable level;

 

  Establishment of a substantial and liquid market for nutrient reductions and other environmental attributes generated from the Company’s future facilities;

 

 

27 
 

 

  Establishment of marketing relationships needed for realization of full value from the saleable co-products including sustainable and organic meat products and organic nitrogen fertilizer products;

 

  Successful completion of organic certifications and USDA PVP-certified sustainable brand;

 

  Our ability to raise sufficient funds to allow us to finance our activities, JVs, and Projects; and

 

  Regulatory and enforcement policies at the Federal, State and local levels.

 

 

Kreider Poultry Joint Venture and Pennsylvania and Chesapeake Bay Initiatives

 

Bion’s activities in Pennsylvania (“PA”) commenced with the Kreider 1 2G Tech dairy system in the Chesapeake Bay watershed. This retrofit installation was designed and intended primarily to reduce nitrogen and phosphorus releases and ammonia emissions from the dairy waste streams to generate tradable nutrient reduction credits as part of a nutrient credit trading program through the PA Department of Environmental Protection (‘PADEP’). While this project was not a commercial success (due to PA’s failure to implement a viable long-term credit trading market), it demonstrated that Bion’s manure treatment technology can generate low-cost verified credits and provided the basis of a 2013 PA Legislative Budget and Finance Committee report (updated in 2018) that supports the use of manure technologies to provide low-cost alternatives to meet Bay mandates.

 

It is possible that the Kreider 2 poultry waste treatment Project, which is in its early development and pre-permitting phase, will be one of our first large scale JV Projects if a workable market for nutrient reduction credits develops in PA, of which there is no assurance. See “Retrofit Gen3Tech Project: Kreider Poultry JV (“Kreider 2”)” above. The Kreider 2 Project will utilize our Gen3Tech platform to treat the waste stream from Kreider Farm’s large poultry operations (possibly together with waste from other nearby poultry operations and/or other waste streams) (and the dairy waste stream previously treated in the Kreider 1 system) to generate renewable energy, marketable nutrient reduction credits and co-products (including nitrogen in organic and/or non-organic forms). It is targeted to treat the waste stream from approximately 9 million birds, in modules, when fully developed. Estimated capital costs (‘capex’) are currently estimated in the $60 million range (with the caveat that no site has yet been chosen, technology development is not complete and the final design work has not yet begun) and has the potential to generate gross revenues of up to $50 million annually from the multiple revenue streams based on current projected yields and prices, none of which are assured. Note that tech and system design work is continuing and the Company anticipates reduce reductions of both capex and operating costs.

 

To date the market for long-term nutrient reduction Credits in Pennsylvania has been very slow to develop and the Company’s activities have been negatively affected by such lack of development.  However, Bion is confident that if and when these markets are established, the Credits it produces will be competitive in the credit trading markets, based on its cost to remove nitrogen from the livestock waste stream, compared to the cost to remove nitrogen through various other treatment activities.

 

Several independent studies have calculated the average cost to remove nitrogen through various sector practices. Reports prepared for the PA Senate (2008), Chesapeake Bay Commission (2012) and PA legislature (2013; described below), as well as the Maryland Chesapeake Bay Financing Strategy Report (2015), demonstrate that the cost to remove nitrogen (per pound on average) from agriculture is $44 to $54, municipal wastewater: $28 to $43, and storm water: $386 to $633. Pursuant to the PA legislative study, by replacing sector allocation (for all sectors) with competitive bidding, up to 80 percent savings could be achieved in PA’s Chesapeake Bay compliance costs ($1.5 billion annually) by 2025. If the legislative study had focused on the cost differentials of competitive bidding compared only with storm water, the relative savings would be substantially greater.

 

Since these studies were completed, most of the larger (Tier 1) municipal wastewater treatment plants in PA have been upgraded, at a cost of approximately $2.5 billion (vs initial 2004 PA DEP cost estimates of $376 million). US EPA is now focused on PA’s storm water allocation (3.5 million pounds) and has this sector on ‘backstop level actions’, the highest level of EPA-oversight and the final step before sanctions. In the same 2004 PA DEP cost estimate that led to the more than a $2 billion underestimate/miscalculation in municipal wastewater plant upgrade costs, the estimate for storm water cost was $5.6 billion. In April 2017, US EPA sent a Letter of Expectation to PA DEP, expressing the agency’s support for the use of nutrient credit trading and competitive bidding to engage the private-sector to lower costs. The letter specifically encouraged the use of credit trading to offset the state’s looming storm water obligations.

 

Bion anticipates that it will be able to profitably develop the Kreider 2 project if it is able sell nutrient credits generated at the Kreider 2 facilities (and subsequent projects) at prices are in the range of $6-$12 (or higher) per lb. of nitrogen reduction under long-term contracts, of which there is no assurance. Bion further believes that with the studies and information now available to other states that are (or will shortly be) facing these same decisions, a cost-benefit analysis will make it clear from the outset that competitive bidding for nutrient reduction credits from alternative approaches can provide dramatically lower-cost solutions than traditional strategies.

 

The Kreider 2 poultry waste treatment facility in PA may be one of our initial Gen3Tech Projects outside of the sustainable beef segment. However, Bion intends that it will select a site for the Kreider 2 Project and/or its initial Integrated Project (and possibly additional Projects) only after PA adopts a competitively-bid nutrient reduction Credit purchase program (see discussion above and below).

 

 

28 
 

 

CORPORATE BACKGROUND

 

The Company is a Colorado corporation organized on December 31, 1987. Our principal executive offices are located in the home offices of our senior executives. Our primary administrative office is now located at the residence of our Office Manager at 9 East Park Court, Old Bethpage, New York 11804, at which location most of the Company’s physical records and central computer reside. Our primary telephone number is 516-586-5643. We have no additional offices at this time as all employees and primary consultants work from their home offices.

 

HISTORY AND DEVELOPMENT OF OUR BUSINESS

 

Substantially all of our business and operations to date has been conducted through wholly-owned subsidiaries, Bion Technologies, Inc. (a Colorado corporation organized September 20, 1989), Bion Integrated Projects Group, Inc. ("Projects Group") (formerly Bion Dairy Corporation through August 2008 and originally Bion Municipal, Inc., a Colorado corporation organized July 23, 1999) and Bion Services Group, Inc. ("Services Group") (formerly Bion International, Inc., a Colorado corporation organized July 23, 1999) and BionSoil, Inc. (a currently inactive Colorado corporation organized June 3, 1996).  Bion is also the parent of Bion PA 2 LLC (a Colorado entity organized June 24, 2010) (“PA2”) and Bion 3G-1, LLC (a Colorado entity organized on September 23, 2021). In January 2002, Bion entered into a series of transactions whereby the Company became a 57.7% (now 58.9%) owner of Centerpoint Corporation (a Delaware corporation organized August 9, 1995) ("Centerpoint"). Bion was formerly the parent of Bion PA 1 LLC (a Colorado entity organized August 14, 2008) (“PA1”) which was dissolved on December 29, 2021 (See “Pennvest Loan and Bion PA1 LLC Dissolution” herein).

 

Although we have been conducting business since 1989, we determined that we needed to redefine how we could best utilize our technology during 2003 and again in 2015.  From 2003 through early 2008, we primarily worked on technology improvements and applications and in furtherance of our business model of Integrated Project development.  During 2008 we re-commenced pursuing active commercial transactions involving installation of our 2G Tech for CAFO waste treatment and related environmental remediation and initiation of pre-development modeling and pre-development work to prepare for our initial Integrated Projects. Commencing during 2015, the Company focused its efforts largely on the development of our Gen3Tech platform which was largely completed during 2021. We are now focused primarily on development of JVs and Projects based on implementation of our Gen3Tech platform (and business model) in the industry segments discussed above.

 

Our original systems were wastewater treatment systems for dairy farms and food processing plants.  The basic design was modified in late 1994 to create Nutrient Management Systems ("NMS") that produced organic soil products as a byproduct of remediation of the waste stream when installed on large dairy or swine farms.  Through June 30, 2002, we sold and subsequently installed, in the aggregate, approximately 30 of these first iteration of Bion’s systems in 7 states, of which we believe a few may still in operation in 3 states.  We discontinued marketing of our first-generation NMS systems during fiscal year 2002 and turned control and ownership of the first-generation systems over to the farms on which they were installed over the following two years.  We were unable to produce a business model based on the first-generation systems that would generate sufficient revenues to create a profitable business.  While continuing to market and operate the first-generation systems, during the second half of calendar year 2000, we began to focus our activities on developing the next generation of the Bion technology. We no longer operate or own any of the first-generation NMS systems.

 

As a result of our research and development efforts, the core of our current technology was re-developed during fiscal years 2001-2004.  We designed and tested Systems that used state-of-the-art, computerized, real-time monitoring and system control with the potential to be remotely accessed for both reporting requirements and control functions.  These Systems were smaller and faster than our first-generation NMS systems.  The initial versions of our second generation of Bion Systems were designed to harvest solids used to produce organic fertilizer and soil amendments or additives (the "BionSoil(R) products") in a few weeks as compared to six to twelve months with our first-generation systems.

 

During 2003-4 we designed, installed and began testing a commercial scale, second generation Bion System as a temporary modification or retrofit to a waste lagoon on a 1,250-milking cow dairy farm in Texas, known as the DeVries Dairy.  In December 2004, Bion published an independently peer-reviewed report, a copy of which may be found on our website, www.biontech.com, with data from the DeVries project demonstrating a reduction in nutrients (nitrogen and phosphorus) of approximately 75% and air emissions of approximately 95%.  More specifically, those published results indicated that the Bion System produced a 74% reduction of nitrogen and a 79% reduction of phosphorus.  The air results show that the Bion System limited emissions from the waste stream as follows: (in pounds per 1,400-pound dairy cow per year):

 

Ammonia 0.20  
Hydrogen Sulfide  0.56  
Volatile Organic Compounds    0.08  
Nitrogen Oxides 0.17  

 

These emissions represented a reduction from published baselines of 95%-99%.

 

 

29 
 

 

Through 2007 the demonstration project at the DeVries Dairy in Texas also provided Bion with the opportunity to explore mechanisms to best separate the processed manure into streams of coarse and fine solids, with the coarse cellulosic solids/biomass supporting generation of renewable energy and the fine solids potentially becoming the basis of organic fertilizer products and/or a high-protein animal feed ingredients. On-going research was also carried out on various aspects of nutrient releases and atmospheric emissions.

 

Bion discontinued operation of the DeVries demonstration research system during 2008.

 

During the 2005-2008 period, Bion focused on completing development of its 2G Tech platform and business model.  As such, we did not pursue near term sales and revenue opportunities, such as retrofitting existing CAFO's with interim versions of our waste management solutions, because such efforts would have diverted scarce management and financial resources and negatively impacted our ability to complete development of an integrated technology platform in support of large-scale sustainable Projects.

 

From 2009 through 2015 (when development of our Gen3Tech platform began), Bion  actively pursued business opportunities in three broad areas 1) Bion systems to retrofit of existing CAFO’s (some of which may  generate verified nutrient credits and revenues from the production of renewable energy and byproducts) (“Retrofits”), and 2) development of new state-of-the-art large scale waste treatment facilities, potentially in conjunction with new CAFOs developed in strategic locations that were not previously possible due to environmental constraints in strategic locations (“Projects”) (some of these may be “closed loop’ Integrated Projects that were not previously possible due to environmental constraints as described below), and 3) licensing and/or joint venturing of Bion’s technology (primarily) outside North America. Bion is now primarily pursuing JVs related to these opportunities within the United States and internationally based on our Gen3Tech as described above.

 

Pre-Gen3Tech: Chesapeake Bay Watershed: Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution/Kreider Farms Projects/Pennsylvania Initiatives

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheets. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheets in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s consolidated balance sheets. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheets as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

 

30 
 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who  arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period between May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. The remaining unsold assets will be transferred to Kreider Farms during the next quarter in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form 10-K Annual Reports for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

Chesapeake Bay Watershed: Kreider Farms Projects/Pennsylvania Initiatives

 

The urgency and priority of the need to clean up nutrient (primarily nitrogen and phosphorus) pollution to the Chesapeake Bay was clearly demonstrated with promulgation of President Obama's 2009 Executive Order concerning clean-up of the Chesapeake Bay and the EPA’s publication and issuance during December 2010 of the Chesapeake Bay Total Maximum Daily Load (TMDL) standard (http://www.epa.gov/reg3wapd/tmdl/ChesapeakeBay/tmdlexec.html) for nutrient pollution in Chesapeake Bay tributaries. In May 2010, the EPA published their overall strategy for remediating the Chesapeake Bay, and they have committed to reducing nitrogen and phosphorus flows to the Bay sufficiently to enable 60% of the Bay watershed segments to meet water quality standards by 2025.  At that time, 89 of the 92 Bay and tidal watershed segments were not in compliance with water quality standards (97% were out of compliance).  The EPA and associated state agencies also committed to short-term 3-year compliance milestones to enhance accountability and corrective actions, along with a host of definable and measurable goals, enhanced partnerships, and major environmental initiatives.  Based on these actions, greater compliance has been required commencing with the 2016 ‘water year’.  EPA documents defined the overall mission as requiring an approximately 65-million-pound annual reduction from existing nitrogen (N) loading to the Chesapeake Bay by 2025, of which 35 million pounds was allocated to Pennsylvania. Importantly, the 3-year compliance milestones were established as a part of the compliance program to add both short- and long-term accountability to state actions associated with reduced nutrient and sediment flows to the Chesapeake Bay. According to the EPA’s Interim Evaluation of Pennsylvania’s Milestone Progress published in June 2015, PA was 14.6 million pounds behind its 2014-2015 milestone commitments for nitrogen, a remarkably large deficit given the previously stated 2-million-pound deficit from the 2012-2013 water year.  EPA has placed PA’s agriculture and urban/suburban sectors under a “Backstop Actions Level”, the highest level of EPA oversight.  EPA has also stated that if load reductions remain off track, EPA may consider seeking additional (and expensive) pollutant reductions from the wastewater sector.  

 

In an effort to get back on track and hold off federal intervention, PA unveiled a purported “comprehensive strategy” to "reboot" the state's efforts to improve water quality in January 2016.  The reboot strategy relied upon a mix of enhanced farm compliance and enforcement activities along with the promotion of additional best management practices (BMP).  This proposed strategy has been met with skepticism about its efficacy/practicality and resistance within the agricultural community. While many of these reboot efforts are continuing today, the PADEP Secretary resigned in May 2016 and PA appears to have slowed implementation efforts recently while seeking alternative approaches to reduce PA’s nitrogen pollution to the Chesapeake Bay. The EPA has continued to reject PA’s proposed plans related to the Chesapeake Bay clean-up mandate as inadequate. Recent reports indicate that PA is in need of 32 million pounds of nitrogen reductions to meet its requirements. Litigation has been initiated against PA and the EPA by neighboring states to compel performance by PA and enforcement by the EPA. The recent PA budget spending package that was passed by the PA legislature in 2022 includes allocation of some PA’s remaining pandemic relief funding for clean water related to either the Chesapeake Bay compliance mandates or state water quality. However, it appears that the funds will likely be expended on existing unsuccessful programs and clean-up strategies.

 

 

31 
 

 

As a result of PA’s default of its Bay mandates, and the host of upcoming both short and long-term specific commitments and compliance deadlines, Bion believes that its long-term opportunity related to the Chesapeake Bay clean-up has potentially been significantly expanded and accelerated.

 

During 2008, Bion executed an agreement to install a Bion System at the Kreider Farms (“KF”) in Lancaster County, Pennsylvania to reduce nitrogen (including ammonia emissions which are re-deposited as nitrogen from the atmosphere) and phosphorus in the farm's effluent. Bion undertook this project (through PA1) due, in large part, to Pennsylvania's nutrient credit trading program, which was established to provide cost-effective reductions of the excess flow of nutrients (nitrogen and phosphorus) into the Chesapeake Bay watershed. Bion worked extensively with the Pennsylvania Department of Environmental Protection ('PADEP') over several years to establish nutrient credit calculation/ verification methodologies that were appropriate to Bion's 2G Tech and recognizes its 'multi-media' (both water and atmospheric) approach to nutrient reductions.  Pennsylvania's nutrient credit trading program allows for voluntary credit trading between a 'non-point source' (such as a dairy or other agricultural sources) and a 'point source' polluter, such as a municipal waste water treatment plant or a housing development. However, the market for long term Credits in PA has failed to develop any significant breadth or depth and no Credits were sold by PA1 from the Kreider 1 system.

 

The original Kreider agreements also provided for Bion to develop a waste treatment/renewable energy production facility to treat the waste from Kreider's approximately 6+ million chickens (planned to expand to approximately 9-10 million)(and potentially other poultry operations and/or other waste streams)('Kreider Renewable Energy Facility' or ' Kreider 2 Project'). On May 5, 2016, the Company executed a stand-alone joint venture agreement (‘JVA’) with Kreider Farms covering all matters related to development and operation of a system to treat the waste streams from Kreider's poultry facilities in Bion PA2 LLC ("PA2"). Bion anticipates that it will execute an updated JVA with Kreider Farms during the current fiscal year which will include utilization of Bion’s Gen3Tech and other matters. The Company continues its pre-development work related to the details of the Kreider 2 Project. For more information regarding the history and background of the Kreider 2 Project, please review our Forms 10-K for the years from 2008 through 2021.

 

The Company believes that Pennsylvania is potentially ‘ground zero’ in the long-standing clean water battle between agriculture and the further regulation of agriculture relative to nutrient impacts. The ability of Bion and other technology providers to achieve verified reductions from agricultural non-point sources can resolve the current stalemate and enable implementation of constructive solutions that benefit all stakeholders, providing a mechanism that ensures that taxpayer funds will be used to achieve the most beneficial result at the lowest cost, regardless of source. All sources, point and non-point, rural and urban, will be able to compete for tax payer-funded nitrogen reductions in a fair and transparent process; and since payment from the tax and rate payers would now be performance-based, these providers will be held financially accountable.

 

See the extended additional discussion regarding these matters in our Annual Reports on Form 10-K for the year ended June 30, 2021 and prior years.

 

RECENT FINANCINGS

 

Sales of Common Stock during 2023 and 2022 Fiscal Years

 

During the year ended June 30, 2023 the Company entered into subscription agreements to sell units for $1.00 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $1.25 per share with an expiry date of 12/31/2023, and pursuant thereto, the Company issued 346,230 units for total proceeds of $346,230.

 

During the year ended June 30, 2023 the Company entered into subscription agreements to sell shares for $1.00 per share and pursuant thereto, the Company issued 2,000,000 of the Company’s restricted common stock for total proceeds of $2,000,000.

 

During the year ended June 30, 2023 the Company entered into subscription agreements to sell units for $1.60 per unit, with each unit consisting of one share of the Company’s restricted common stock and one-half warrant to purchase shares of the Company’s restricted common stock for $2.40 per share with an expiry date of 6/30/2024 and pursuant thereto, the Company issued 975,000 units for total proceeds of $1,560,000, net proceeds of $1,473,600 after commissions of $86,400.

 

During the year ended June 30, 2023, 175,114 warrants were exercised to purchase 175,114 shares of the Company’s common stock at $0.75 per share for total proceeds of $131,335.

 

During the year ended June 30, 2023 Mark Smith elected to convert $50,000 of his 2020 Convertible Obligation into 100,000 units at $0.50 per unit (pursuant to the 2006 Consolidated Incentive Plan) with each unit consisting of one share of common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until 12/31/2024.

 


During the year ended June 30, 2023 Mark Smith elected to convert $99,889 of his Adjusted 2020 Convertible Obligation into 1,055,906 units at $0.0946 per unit (pursuant to the 2006 Consolidated Incentive Plan) with each unit consisting of one share of common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until March 2026.

 

 

32 
 

 


During the year ended June 30, 2023 Mark Smith elected to convert $36,573 of his Adjusted 2020 Convertible Obligation into 386,608  units at $0.0946 per unit (pursuant to the 2006 Consolidated Incentive Plan) with each unit consisting of one share of common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until March 2026.

 

During the year ended June 30, 2023 the Company issued 82,259 shares for services of $130,000.

 

During the year ended June 30, 2022, 2,315,550 warrants were exercised to purchase 2,315,550 shares of the Company’s common stock at $0.75 per share for total proceeds of $1,736,662, net proceeds of $1,718,061 after commissions of $18,601.

 

During the year ended June 30, 2022, Smith elected to convert accounts payable of $17,711 into an aggregate of 35,424 units at $0.50 per unit (pursuant to the 2006 Consolidated Incentive Plan) with each unit consisting of one share of the common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2022, the Company issued 25,000 units at $1.10 per until for services of $27,500.

 

COMPETITION:

  

There are a significant number of potential competitors in the industries in which Bion is working, including livestock waste treatment, renewable energy production, and the production of sustainable beef products.

 

There are a host of competitors working in the livestock waste treatment space. One efficient way to assess competition in these spaces is to review the Newtrient, LLC catalogue which is produced by an organization created by the dairy industry to help farmers, technology providers, manure-based product developers and other stakeholders assess manure related challenges and opportunities. Many of the technologies reviewed by and organized by Newtrient in their catalog, such as Bion, address manure streams in addition to dairy. The potential competition has increased with the growing governmental and public concern focused on pollution due to CAFO wastes.  Waste treatment lagoons which depend on anaerobic microorganisms ("anaerobic lagoons" or “ADs”) are the most common traditional treatment process for animal waste on large farms within the swine and dairy industries.  Additionally, many beef feedlots, poultry facilities and dairy farms simply scrape and accumulate manure for later field application. Both lagoon and scrape/pile manure storage approaches are coming under increasing regulatory pressure due to associated odor, nutrient management and water quality issues and are facing possible phase-out in some states.

 

Although we believe that Bion’s comprehensive solution is the most economically and technologically viable solution for the current problems, other alternative (though partial) solutions do exist, including, for example, synthetic lagoon covers (which are placed on the top of the water in the lagoon to trap the gases), stand-alone ADs (a tank which uses anaerobic microorganisms to break down the waste to produce methane), multistage and solids separators (processes which separate large solids from fine solids), as well as various thermal waste-to-energy technologies.  Additionally, many efforts are underway to develop and test new technologies.

 

There is a growing industry associated with the production of fertilizer products produced from nutrients captured in CAFO manure streams. Many technology firms, including Bion, have figured out how to generate nonsynthetic products which are certified for organic production, which enables a higher valuation. Bion and its competitors are working hard to improve the production efficiency of these products while reducing production costs. Bion, as documented in its patents, has invented a non-synthetic process to produce ammonium nitrogen fertilizer in solid and liquid forms. To our understanding, no other manure nutrient technology firm has figured out a way to match our development of a solid ammonium nitrogen fertilizer.

 

Competition in the renewable energy generation space is growing in the agricultural sector, predominantly from the growth in anaerobic digestion (AD) projects designed to reduce odors and generate revenues from captured energy and reduced carbon footprints. AD projects are primarily associated with the dairy sector as the manure is mostly already captured and therefore there are minimal infrastructure projects required to add on AD technology. We intend to evaluate the use of our technology as a ‘bolt-on’ behind dairy ADs once we have complete date from our Initial Project. Therefore, such ‘competitors may be turned into customers for Bion. W We are predominantly focused on generating AD projects at beef cattle finishing operations, an area in which very few ADs have been implemented. There is not much competition in that space as most current beef feedlots do not engage in the type of efficient manure collection which is a required prerequisite for AD economics. Bion has also engaged with solar photovoltaic (PV) developers to install PV panels on barn roofs, and there is some competition in that space, but again not much in the beef cattle finishing sector.

 

Third there is competition in the space of production of sustainable beef products. A number of ranches and beef producers are working with various third-party certification organizations to document the sustainable practices that are being implemented. Bion is working in a similar manner. All investments in this area are subject to competition and decisions made by consumers---including ‘how much will a consumer pay for truly sustainable beef products vs. standard conventional feedlot produced beef?’

 

Our ability to compete is dependent upon favorable regulatory conditions, our ability to obtain required approvals and permits from regulatory and other authorities and upon our ability to introduce and market our Systems in the appropriate industry and geographic segments.

 

There are many companies that are already selling products to satisfy demand in the sectors of these markets we are trying to enter.  Many of these companies have established marketing and sales organizations and customer commitments, are supporting their products with advertising, sometimes on a national basis, and have developed brand name recognition and customer loyalty in many cases.

 

Because Bion systems offer a comprehensive waste treatment solution that is designed to produce/augment up to four separate and distinct revenue streams, the Company believes that it has the ability to be competitive in each of the sectors from which it derives revenue.

 

 

33 
 

 

DEPENDENCE ON ONE OR A FEW MAJOR CUSTOMERS

 

In our JVs/Projects (including Integrated Projects) business segment, we will most likely be dependent upon one or a few major customers/partners/joint venturers since a relatively limited number of JVs and/or Projects (including Integrated Projects) will be developed by the Company. We anticipate initially developing, owning interests in, and operating only one or a small number of Projects commencing during 2023 and, thereafter, developing a limited number of Projects at a time. Thus, at least for the near future, our revenues will be dependent on a relatively small number of major Projects, participants and/or customers.

  

PATENTS

 

We are the sole owner of five United States patents. Additionally, Bion has two United States patent applications pending and has three International patent applications currently pending.

 

Patent Numbers and date of issue:

 

United States Currently Issued:

 

(1)   8,287,734:  Method for Treating Nitrogen in Waste Streams: (OCN) Jere Northrop & James W. Morris (Exp 3/20/31)

 

(2)   10,106,447: Process to Recover Ammonium Bicarbonate from Wastewater: Morton Orentlicher & Mark M. Simon. (Exp. 9/14/2035)

 

(3)   10,604,432: Process to Recover Ammonium Bicarbonate from Wastewater; Dominic Bassani, Steve Pagano, Morton Orentlicher & Mark M. Simon. (Exp 6/29/2037)

 

(4)   10,793,458: Process to Recover Ammonium Bicarbonate from Wastewater; Dominic Bassani, Steve Pagano, Morton Orentlicher & Mark M. Simon. (Exp 9/14/2035)

 

(5)   11,254,581: Process to Recover Ammonium Bicarbonate from Wastewater; Dominic Bassani, Morton Orentlicher, Mark M. Simon & Steve Pagano. (Exp 9/14/2035)

 

We are also the sole owner of, or possess the contractual right to acquire exclusive patent rights to, a pending United States provisional patent application, a pending United States utility patent application and three international applications as set forth below:

 

United States Currently Pending:

 

(1)   63/512,361 (provisional): Methods For Recovering Ammonium Compounds From A Waste Stream; Dominic Bassani & Steve Pagano. (Exp 7/07/2024)

 

(2)   17/589,037: Process to Recover Ammonium Bicarbonate from Wastewater; Dominic Bassani, Steve Pagano, Morton Orentlicher & Mark M. Simon.

 

International Applications Currently Pending:

 

(1)   EP 18943551.4: Process to recover ammonium bicarbonate from wastewater; Dominic Bassani, Steve Pagano, Morton Orentlicher & Mark M. Simon.

 

(2)   CA3123802A1: Process to recover ammonium bicarbonate from wastewater; Dominic Bassani, Steve Pagano, Morton Orentlicher & Mark M. Simon.

 

(3)   MX/a/2021/007358: Process to recover ammonium bicarbonate from wastewater; Dominic Bassani, Steve Pagano, Morton Orentlicher & Mark M. Simon.

 

In addition to such factors as innovation, technological expertise and experienced personnel, we believe that a strong patent position is increasingly important to compete effectively in the businesses on which we are focused.  It is likely that we will file applications for additional patents in the future. There is, however, no assurance that any such patents will be granted.

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

It may become necessary or desirable in the future for us to obtain patent and technology licenses from other companies relating to technologies that may be employed in future products or processes.  To date, we have not received notices of claimed infringement of patents based on our existing processes or products, but due to the nature of the industry, we may receive such claims in the future.

 

We generally require all of our employees and consultants, including our management, to sign a non-disclosure and invention assignment agreements upon employment with us.

 

 

34 
 

 

It may become necessary or desirable in the future for us to obtain patent and technology licenses from other companies relating to technologies that may be employed in future products or processes.  To date, we have not received notices of claimed infringement of patents based on our existing processes or products, but due to the nature of the industry, we may receive such claims in the future.

 

We generally require all of our employees and consultants, including our management, to sign a non-disclosure and invention assignment agreements upon employment with us.

 

RESEARCH AND DEVELOPMENT

 

Current research and development work is focused on completion of the development and ongoing improvement of our Gen3Tech (the initial version of which is ready for implementation in an appropriate Project) with emphasis on increased recovery of valuable by-products (including nutrients in organic and/or non-organic forms, production of renewable energy from by-products together with related renewable energy and/or environmental credits). Bion believes its Gen3Tech will produce significantly greater value from the CAFO waste stream through the recovery of a concentrated natural nitrogen fertilizer and pipeline-quality natural gas. See discussion of Initial Project above.

 

During the years ended June 30, 2023 and June 30, 2022, respectively, we expended approximately $79,000 and $178,000 (excluding non-cash stock-based compensation) on research and development activities related to our technology platform applications in support of large-scale, economically and environmentally sustainable Projects and Retrofits. Since the 2018 fiscal year, Bion’s research and development has been primarily focused on development work to complete and further refine development of our Gen3Tech which will have the capacity to process dry, poultry CAFO waste streams in addition to wet dairy/beef/swine CAFO waste streams and increase our ability to recover marketable by-products from the waste stream remediation including renewable natural gas and nitrogen products (organic and non-organic). Some work  has also involved modifying and adding unit processes to our Gen3Tech platform with the objective of reducing capital costs and operating costs, while generating commercial equivalent by-products (and therefore, potential revenue streams) and significantly increasing environmental efficiency. As a result of these efforts (including their continuation during the current period), Bion made new (and supplemental) patent filing(s) during the 2019-2021 fiscal years related to our Gen3Tech. The Company anticipates completion of its pilot system and pre-commercial testing for its Gen3Tech by end of the current calendar year to support design finalization for our initial Gen3Tech systems. Our technology focus is to separate and aggregate the various “assets” in the waste stream and then to re-assemble them to maximize their economic value. Our current research and development efforts have been focused on developments that will minimize water removal requirements thereby significantly reducing the associated energy costs. In addition, current efforts are focused on fertilizer and soil amendment products (organic and inorganic), water reuse, environmental and reduction credits (including but not limited to nutrient, carbon, sediment, water and pathogen reduction) while reducing capital costs and operating costs. Bion continues to focus on “normalizing” its technology platform for use on multiple species. This effort has required significant work and resource allocation on research regarding balancing the activities of each unit process so that its output enables the subsequent unit processes to maximize efficiency and discharge to the subsequent unit process in order to produce a feedstock cost effectively. The by-products of this series of unit processes (which include certain Bion proprietary elements) are then “reassembled” into products to maximize their economic value. To date, research and development results have supported our objectives.

  

Environmental Protection/Regulation and Public Policy

 

In regards to Retrofits and development of Projects, we will be subject to extensive environmental (and other) regulations related to CAFO's, biofuel production and end product (e.g. fertilizer) producers.  To the extent that we are a provider of systems and services to others that result in the reduction of pollution, we are not under direct enforcement or regulatory pressure.  However, we are involved in the business of CAFO waste treatment and are impacted by environmental regulations in at least four different ways:

 

•     Our marketing and sales success depends, to a substantial degree, on the pollution clean-up requirements of various governmental agencies, from the Environmental Protection Agency (EPA) at the federal level to state and local agencies;

•     Our System design and performance criteria must be responsive to the changes in federal, state and local environmental agencies' effluent and emission standards and other requirements;

•     Our System installations and operations require governmental permits and/or other approvals in many jurisdictions; and

•     To the extent we own or operate Projects (including Integrated Projects with CAFO facilities and ethanol plants), those facilities will be subject to environmental regulations.

 

Additionally, our activities are affected by many public policies and regulations (federal, state and local) related to other industries such as agriculture, food, energy, municipal waste and storm water treatment, watershed-wide mandates, and others. For example, the existing differences in the regulatory requirements for agriculture versus municipal wastewater clean-up currently in place have negatively impaired the development of viable markets for nutrient reduction credits.

 

 

35 
 

 

Bion system installations and operations may require verification and compliance with an assortment of voluntary regulatory programs, such as the USDA Organic and USDA Process Verified branding programs. Each of these programs has a series of compliance verification steps that need to be met in order to maintain proper standing for use of the USDA shield on packaging.

 

EMPLOYEES

 

As of September 1, 2023, we had 8 employees and primary consultants, all of whom are performing services for the Company on a full-time basis. The Company utilizes other consultants and professionals on an ‘as needed’ basis. Our future success depends in significant part on the continued service of our key personnel and the ability to hire additional qualified personnel. The competition for highly qualified personnel is intense, and there can be no assurance that we will be able to retain our key managerial and technical employees or that we will be able to attract and retain additional highly qualified technical and managerial personnel in the future. None of our employees is represented by a labor union, and we consider our relations with our employees to be good. None of our employees is covered by "key person" life insurance.

 

ITEM 1A. RISK FACTORS.

 

Not applicable.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS.

 

Not applicable.

 

ITEM 2. PROPERTIES.

 

The Company maintains its corporate offices at 9 East Park Court, Old Bethpage, New York 11804, the home of its office manager/bookkeeper, and its main corporate telephone number is (516) 586-5643.

 

We are the sole owner of five United States patents. Additionally, Bion has two United States patent applications pending and has three international patent applications currently pending. (See Item 1, “Patents” above).

 

ITEM 3. LEGAL PROCEEDINGS.

 

The Company is currently involved in no litigation matters except:

 

A: Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

 On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subject disruption and expenses were incurred related to the matter including legal fees.

 

 The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

 

36 
 

 

B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheets. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheets in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheets. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheets as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021. The Company is of the understanding that the liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period between May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. The remaining unsold assets will be transferred to Kreider Farms during the next quarter in order to complete the winding up of the Kreider 1 project.

 

 

37 
 

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

The Company currently is not involved in any other material litigation or similar events.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

None.

 

 

PART II

 

ITEM 5.  MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.

 

(a)  Market Information

 

Our common stock is quoted on the Over-The-Counter Electronic Bulletin Board under the symbol "BNET."  The following quotations reflect inter dealer prices, without retail mark up, markdown or commissions and may not represent actual transactions.

 

    2023     2022  
Fiscal Year Ended June 30,   High     Low     High     Low  
                         
First Fiscal Quarter   $ 1.68     $ 0.93     $ 1.80     $ 1.15  
Second Fiscal Quarter   $ 1.36     $ 0.85     $ 1.66     $ 0.81  
Third Fiscal Quarter   $ 2.20     $ 1.25     $ 1.40     $ 0.80  
Fourth Fiscal Quarter   $ 1.64     $ 1.125     $ 1.27     $ 0.80  
                                 
(b) Holders                                
                      1.40          

  

The number of holders of record of our common stock at September 1, 2023 was approximately 1,300. Many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, so we are unable to estimate the number of stockholders represented by these record holders.

 

The transfer agent for our common stock is Equiniti, 3200 Cherry Creek Drive South, Suite 430, Denver, Colorado 80209.

 

(c) Dividends

 

We have never paid any cash dividends on our common stock. Our board of directors does not intend to declare any cash dividends in the foreseeable future, but instead intends to retain earnings, if any, for use in our business operations. The payment of dividends, if any, in the future is within the discretion of the board of directors and will depend on our future earnings, if any, our capital requirements and financial condition, and other relevant factors.

 

No preferred shares are outstanding at this time. During fiscal year 2023 the Company paid an aggregate dividend of $0 cash, respectively, on shares of Series B Preferred Stock and Series C Preferred Stock which were outstanding during the year. A dividend of $1,000 was accrued on Series B Preferred Stock during the 2022 fiscal year. From July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock was mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares have reached their maturity date and the Company approved the redemption of the Series B preferred stock during the quarter ended December 31, 2021 and the final 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

38 
 

 

 

(d)  Securities Authorized for Issuance Under Equity Compensation Plans

 

In June 2006 the Company adopted its 2006 Consolidated Incentive Plan, as amended ("Plan"), which terminated all prior plans and merged them into the Plan.  The Plan was ratified by the Company's shareholders in October 2006 (and has been amended multiple times since initial ratification).  Under the Plan, Directors may grant Shares, Options, Stand Alone Stock Appreciation Rights ("SAR's"), shares of Restricted Stock, shares of Phantom Stock and Stock Bonuses and other items with respect to a number of Common Shares that in the aggregate does not exceed 36,000,000 shares. The maximum number of Common Shares for which Incentive Awards, including Incentive Stock Options, may be granted to any one Participant shall not exceed 2,000,000 shares in any one calendar year; and the total of all cash payments to any one participant pursuant to the Plan in any calendar year shall not exceed $1,500,000. As of June 30, 2023 12,006,600 options have been granted and outstanding under the Plan (as amended), including all options granted under prior merged plans, and were merged into the 2021 Equity Incentive Plan.  As of June 30, 2023, the Company had no outstanding contingent Stock Bonuses. 

 

In December 2021 the Company adopted its 2021 Equity Incentive Plan, as amended ("2021 Equity Plan").  The 2021 Equity Plan was ratified by the Company's shareholders in April 2022.  Under the 2021 Equity Plan, Directors may grant Shares, Options, Stand Alone Stock Appreciation Rights ("SAR's"), shares of Restricted Stock, shares of Phantom Stock and Stock Bonuses and other items with respect to a number of Common Shares that in the aggregate does not exceed 30,000,000 shares. The maximum number of Common Shares for which Incentive Awards, including Incentive Stock Options, may be granted to any one Participant shall not exceed 2,500,000 shares in any one calendar year. As of June 30, 2022 nil options have been granted and outstanding under the 2021 Equity Plan.  As of June 30, 2023, the Company had no outstanding contingent Stock Bonuses. 

 

Equity Compensation Plan Information

 

The following table summarizes share and exercise price information about the Company’s 2006 equity compensation plans as of June 30, 2023:

 

2006 Equity Compensation Plan table

                   
Plan category  

Number of securities to be issued upon the exercise of outstanding options, warrants

and rights 

    Weighted average exercise price of outstanding options, warrants and rights     Number of Securities remaining available for future issuance under equity compensation plans  
                   
Equity compensation plans
approved by security holders
    29,078,033       0.58       6,921,967  
                         
Equity compensation plans not
approved by security holders
    —         —         —    
                         
Total     29,078,033       0.58       6,921,967  

 

(e) Recent Sales of Unregister Securities

 

During the year ended June 30, 2023 the Company entered into subscription agreements to sell units for $1.00 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase on share of the Company’s restricted common stock for $1.25 per share with an expiry date of 12/31/2023, and pursuant thereto, the Company issued 346,230 units for total proceeds of $346,230.

 

During the year ended June 30, 2023 the Company entered into subscription agreements to sell shares for $1.00 per share and pursuant thereto, the Company issued 2,000,000 of the Company’s restricted common stock for total proceeds of $2,000,000.

 

During the year ended June 30, 2023 the Company entered into subscription agreements to sell units for $1.60 per unit, with each unit consisting of one share of the Company’s restricted common stock and one-half warrant to purchase shares of the Company’s restricted common stock for $2.40 per share with an expiry date of 6/30/2024 and pursuant thereto, the Company issued 975,000 units for total proceeds of $1,560,000, net proceeds of $1,473,600 after commissions of $86,400.

 

 

39 
 

During the year ended June 30, 2023, 175,114 warrants wee exercised to purchase 175,114 shares of the Company’s common stock at $0.75 per share for total proceeds of $131,335.

 

During the year ended June 30, 2023 Mark Smith elected to convert $50,000 of his 2020 Convertible Obligation into 100,000 units at $0.50 per unit (pursuant to the 2006 Consolidated Incentive Plan) with each unit consisting of one share of common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until 12/31/2024.

 


During the year ended June 30, 2023 Mark Smith elected to convert $99,889 of his Adjusted 2020 Convertible Obligation into 1,055,906 units at $0.0946 per unit (pursuant to the 2006 Consolidated Incentive Plan) with each unit consisting of one share of common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until March 2026.

 


During the year ended June 30, 2023 Mark Smith elected to convert $36,573 of his Adjusted 2020 Convertible Obligation into 386,608  units at $0.0946 per unit (pursuant to the 2006 Consolidated Incentive Plan) with each unit consisting of one share of common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until March 2026.

 

During the year ended June 30, 2023 the Company issued 82,259 shares for services of $130,000.

 

During the year ended June 30, 2022, 2,315,550 warrants were exercised to purchase 2,315,550 shares of the Company’s common stock at $0.75 per share for total proceeds of $1,736,662, net proceeds of $1,718,061 after commissions of $18,601.

 

During the year ended June 30, 2022, Smith elected to convert accounts payable of $17,711 into an aggregate of 35,424 units at $0.50 per unit (pursuant to the 2006 Consolidated Incentive Plan) with each unit consisting of one share of the common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2022, the Company issued 25,000 units at $1.10 per until for services of $27,500.

 

During the year ended June 30, 2021, the Company entered into subscription agreements, under three different offerings, to sell units for $0.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2021 and pursuant thereto, the Company issued 3,720,000 units for total proceeds of $1,860,000, net proceeds of $1,699,000 after commissions of $161,000.

 

During the year ended June 30, 2021 300,000 shares of the Company’s restricted company stock were sold to an investor for $300,000. 

 

During the year ended June 30, 2021, 129,364 shares of its unregistered common stock were issued as commissions.

 

During the year ended June 30, 2021, the company issued 1,186,824 units to various employees/consultants upon the conversion of debt  pursuant to the 2006 Consolidated Incentive Plan with each unit consisting of one share of the common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until June 30, 2023.

 

During the year ended June 30, 2021, Mark Smith elected to convert deferred compensation, accrued interest and accounts payable of $124,698, $3,342 and $52,360 respectively into an aggregate of 360,805 units at $0.50 per unit, pursuant to the 2006 Consolidated Incentive Plan with each unit consisting of one share of the common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2021, the Company issued 144,000 units to Mr. Smith for salary of $72,000, pursuant to the 2006 Consolidated Incentive Plan with each unit consisting of one share of the common stock and one warrant to purchase one share of the Company’s stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2021, 4,065,988 warrants were exercised to purchase 4,065,988 shares of the Company’s common stock at $0.75 per share for total proceeds of $3,049,491.

             

 

40 
 

TEM 6. SELECTED FINANCIAL DATA.

 

N/A

 

ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

This Annual Report on Form 10-K (and the documents incorporated herein by reference) contain forward-looking statements, within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that involve substantial risks and uncertainties. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expect," "intend," "estimate," "anticipate," "project," "predict," "plan," "believe," or "continue," or the negative thereof or variations thereon and/or references to “goals”, “targets”, “projections” or similar terminology. The expectations reflected in forward-looking statements may prove to be incorrect. The Company's actual results of operations, most of which are beyond the Company's control, could differ materially. We wish to caution readers not to place undue reliance on any such forward looking statements, which speak only as of the date made. Any forward-looking statements represent management's best judgment as to what may occur in the future. However, forward looking statements are subject to risks, uncertainties and important factors beyond our control that could cause actual results and events to differ materially from historical results of operations and events and those presently anticipated or projected.

 

These factors include adverse economic conditions, entry of new and stronger competitors, inadequate capital and limited ability to obtain financing, needed personnel (including entire team related to project development and project operations in coming years) and equipment, unexpected costs, failure (or delay) to gain product certifications and/or regulatory approvals in the United States (or particular states) or foreign countries, loss (permanently or for any extended period of time) of the services of members of the Company’s small core management team (many of whom are age 70 or older) and failure to capitalize upon access to new markets. Additional risks and uncertainties that may affect forward looking statements about Bion's business and prospects include: i) the possibility that markets for nutrient reduction credits (discussed below) and/or other ways to monetize nutrient reductions and other environmental benefits will be slow to develop (or not develop at all), ii) PA1’s dissolution and its effect on how the Company is viewed, (if any), iii) the possibility that competitors will develop more comprehensive and/or less expensive environmental solutions, iv) delays in market awareness of Bion and our Systems, v) uncertainties and costs increases related to research and development efforts to update and improve Bion’s technologies and applications thereof, and/or vi) delays and/or costs exceeding expectations relating to Bion's development of the Initial Project, JVs and/or Projects and vii) failure of marketing strategies, each of which could have both immediate and long term material adverse effects by placing us behind our competitors and requiring expenditures of our limited resources.

 

THESE RISKS, UNCERTAINTIES AND FACTORS BEYOND OUR CONTROL ARE MAGNIFIED DURING THE CURRENT UNCERTAIN PERIOD RELATED TO THE COVID-19 PANDEMIC AND THE UNIQUE ECONOMIC, FINANCIAL, GOVERNMENTAL AND HEALTH-RELATED CONDITIONS IN WHICH THE COMPANY, THE ENTIRE COUNTRY AND THE ENTIRE WORLD NOW RESIDE.  TO DATE THE COMPANY HAS EXPERIENCED DIRECT IMPACTS  IN VARIOUS AREAS INCLUDING WITHOUT LIMITATION: I) GOVERNMENT-ORDERED  SHUTDOWNS WHICH HAVE SLOWED THE COMPANY’S RESEARCH AND DEVELOPMENT PROJECTS AND OTHER INITIATIVES, II) SHIFTED FOCUS OF STATE AND FEDERAL GOVERNMENT WHICH IS LIKELY TO NEGATIVELY IMPACT THE COMPANY’S LEGISLATIVE INITIATIVES IN PENNSYLVANIA AND WASHINGTON DC, III) STRAINS AND UNCERTAINTIES IN BOTH THE EQUITY AND DEBT MARKETS HAVE MADE DISCUSSION AND PLANNING OF FUNDING OF THE COMPANY AND ITS INITIATIVES AND PROJECTS WITH INVESTMENT BANKERS, BANKS AND POTENTIAL STRATEGIC PARTNERS MORE TENUOUS, IV) STRAINS AND UNCERTAINTIES IN THE AGRICULTURAL SECTOR AND MARKETS HAVE MADE DISCUSSION AND PLANNING OF FUNDING OF THE COMPANY AND ITS INITIATIVES AND PROJECTS MORE DIFFICULT AS FUTURE INDUSTRY CONDITIONS ARE NOW MORE DIFFICULT TO ASSESS/PREDICT, V) CONSTRAINTS DUE TO PROBLEMS EXPERIENCED IN THE GLOBAL INDUSTRIAL SUPPLY CHAIN WHICH HAVE INCREASED ANTICIPATED PROJECT DEVELOPMENT COSTS, VI) DUE TO THE AGE AND HEALTH OF OUR CORE MANAGEMENT TEAM, MOST OF WHOM ARE AGE 70 OR OLDER AND HAVE HAD ONE OR MORE EXISTING HEALTH ISSUES, THE COVID-19 PANDEMIC PLACES THE COMPANY AT GREATER RISK THAN WAS PREVIOUSLY THE CASE (TO A HIGHER DEGREE THAN WOULD BE THE CASE IF THE COMPANY HAD A LARGER, DEEPER AND/OR YOUNGER CORE MANAGEMENT TEAM), AND VII) THERE ALMOST CERTAINLY WILL BE OTHER UNANTICIPATED CONSEQUENCES FOR THE COMPANY AS A RESULT OF THE CURRENT PANDEMIC EMERGENCY AND ITS AFTERMATH.

 

 

41 
 

 

Bion disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

 

The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements and Notes to Consolidated Financial Statements filed with this Report. 

 

BUSINESS OVERVIEW AND PLAN

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to make livestock production more sustainable, profitable and transparent. We intend to accomplish this by deploying our Gen3Tech platform/business model (discussed below) in ventures focused on the ‘feeder’ space of the livestock production/value chain to provide the consumer with verifiably sustainable premium meat products (together with environmentally friendly, sustainable and/or organic co-products from the production process).  Bion believes this approach can create extraordinary value for our shareholders and employees (all of whom own securities in the Company) and for livestock/agriculture industry ‘partners’ who join us in our ventures. We anticipate pursuing the opportunity created by our third generation technology (“Gen3Tech”) and business/technology platform in conjunction with other industry practices (“Gen3Tech Platform” or “Platform”).

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our Gen3Tech can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate surface groundwater, and exacerbate climate change.

 

We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent one of the largest enhanced revenue contributors provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the animal raising and waste treatment process will be third-party verified, providing the basis for additional revenues, including carbon and/or renewable energy-related credits and, eventually, payment for a range of ecosystem services, including nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

 

42 
 

 

 During the first half of 2022 Bion began pre-marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022, Bion announced a letter of intent (“Ribbonwire LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). During January 2023 Bion announced a letter of intent (“Olson LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Olson Feeders and TD Angus, near North Platte, Nebraska (with a provision to expand to 45,000 head or more) (“Olson Project”). During April 2023 Bion announced a letter of intent (“DVG LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with Dakota Valley Growers near Bathgate, North Dakota (“DVG Project”). Based on our experience to date, we believe we will not have difficulty in securing participation in our Projects from additional feeders/cattlemen. The Olson, Dalhart and DVG Projects (and subsequent Projects) will be developed to produce blockchain-verified, sustainable beef in customized covered barns (resulting in reduced stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) with ongoing manure transfer (through slatted floors) to anaerobic digesters (AD) to capture nitrogen from the manure stream before loss to the atmosphere and generate renewable natural gas (RNG) for sale while remediating the environmental/carbon impacts usually associated with cattle feedlots and CAFOs. Bion’s patented Gen3Tech platform will refine the waste stream into valuable coproducts that include clean water, RNG, photovoltaic solar electricity and fertilizer (‘climate smart’ and/or organic) products. We anticipate converting these LOIs into definitive JV agreements and creating related distribution agreements with key retailers and food service distributors during the current fiscal year.

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long-term value for Bion.. To accomplish Bion’s goals, we anticipate the we will ‘partner’ with other technology companies who provide solutions for different links of the beef (and other livestock) value chain and with strategic partners up and down the supply chain.In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent one of the single largest enhanced revenue contributor provided by Bion to the JVs (and, in some cases, Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

During the next three to six months, the Company intends to fully complete construction of the Initial Project’s phase 1 (including the crystalizer module) and continue the optimization operations. Bion expects the Initial Project data will document the effectiveness of our Gen3Tech in a commercial-scale setting during the current fiscal year and support development of the LOI Projects (and/or other Gen3Tech beef JV projects) commencing later this fiscal year.  We do not presently know the order in which these JV Projects will be developed as that decision will be made based on many factors not yet in place. We believe the Initial Project data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, food distributors and retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). 

Bion is now focused primarily on: i) completion of development/construction and operation of the Initial Project, our initial commercial-scale Gen3Tech installation, and optimization of its operational parameters, ii) pre-development planning of the LOI Projects (and/or other Gen3Tech beef JV projects) including steps toward distribution agreements, iii) developing applications and markets for its low carbon ‘ClimateSmart’ and organic fertilizer products (including listings/certifications of multiple liquid and solid products) and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed herein) (and related Projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

At present, there is essentially no traceable and verifiable ‘sustainable beef’ available to the US market except for niche products. In response to consumer demand for transparency and sustainability, Bion expects the meat industry in general, and beef specifically, to evolve towards using new technologies to deliver these attributes in their products. While we anticipate a faster adoption of tracking, verification and sustainability technologies in other perishable food categories like produce and dairy due to their shorter product cycles (and related harvest and production techniques), meat industry leaders have also announced their willingness to move forward with initiatives in this area. Many companies have announced ‘sustainability’ initiatives but most appear to consist largely of ‘greenwashing’ marketing commitments rather than substantive undertakings at this date. Note, however, that Tyson’s Brazen beef initiative (which was announced during March 2023) may develop into a substantive competitive factor in the sustainable beef marketplace. Bion predicts that within approximately five years, consumers will be able to track and verify claims including sustainability on 25% (or more) of the products merchandised in the meat department. Bion believes that the retail market share of verifiably sustainable beef in the US will approach 7-10 % within three (3) years (end of 2026) and 25% in five (5) years (end of 2028) (approximately 6-7,000,000 cattle annually) (and more thereafter). If Bion can successfully execute on its sustainable beef business plan (which is subject to many contingencies), we believe that JV facilities utilizing Bion’s Gen3Tech platform will supply one-third (1/3) or more of that of the premium market segment (and a higher portion of meat that is actually traceable and verifiably sustainable). Our goal is to have multiple sustainable beef projects under development (within 3-5 distinct JVs) by the end of our 2025 fiscal year. Our first commercial project is likely to be one of our current LOI Projects but we anticipate commencing development of additional sustainable beef projects during the current fiscal year as well. Our current target is to have at least three (3) facility modules (15,000 head per module)(“Modules”) in development and/or under construction during 2024 in three (3) different JVs with the initial barns being populated with livestock during 2025. Further expansion in the number of distinct JVs is projected through 2026-7 aiming at 5-10 JVs in process --- each of which JVs will be pursuing development of multiple Modules with targets of 12-15 populated Modules by the end of 2026 (approximately 2%-3% of the US beef market) and 30-45 Modules constructed and being populated by 2029 (approximately 6%-8% of the US beef market) with further expansion thereafter. Bion’s current goal is that its Gen3Tech platform will be utilized to produce 33% of the verifiable “sustainable beef” category at the end of the period (which will equal approximately 2 million cattle annually)(45 Modules).

 

 

43 
 

 

During this five (5) year period, the Company also anticipates having additional Gen3Tech projects underway in the pork/dairy/egg sectors of the US animal protein market.

 

There is no assurance that the Company will reach or approach the goals/targets set forth above. Reaching such goals/targets will require access to very large amounts of capital (equity and debt) as each module is projected to cost in excess of $50 million (debt/equity/grants) to construct and require mobilization of substantial personnel, technical resources and management skills. The Company does not possess either the financial or personnel resources required internally and will need to source such resources from outside itself.

For additional information regarding our ‘HISTORY, BACKGROUND AND CURRENT ACTIVITIES’, see discussion in Part I, Item 1 above and Notes to the Financial Statements (particularly Notes 1, 3, 5 and 9) included in this report .

 

COVID-19 PANDEMIC RELATED MATTERS:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

 

44 
 

 

CRITICAL ACCOUNTING POLICIES

 

Revenue Recognition

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of Accounting Standards Codification (“ASC”) 606 “Revenue from Contracts with Customers”.

Stock-based compensation

 

The Company follows the provisions of ASC 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of income based upon their grant date fair values.

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. As of March 31, 2023 and 2022, there are no derivative financial instruments.

 

Options:

 

The Company has issued options to employees and consultants under its 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease. 

 

45 
 

 

YEAR ENDED JUNE 30, 2023 COMPARED TO THE YEAR ENDED JUNE 30, 2022

Revenue

Total revenues were nil for both the years ended June 30, 2023 and 2022.

General and Administrative

Total general and administrative expenses were $3,072,000 and $2,348,000 for the year ended June 30, 2023 and 2022, respectively.

Salaries and related payroll tax expenses were $730,000 and $340,000 for the years ended June 30, 2023 and 2022, respectively, representing a $390,000 increase. The increase is largely due to the addition of Bill O’Neill (and administrative initiatives he has commenced), pay increases, and lower percentage of total salaries capitalized to the Initial Project. Consulting costs were $485,000 and $561,000 for the years ended June 30, 2023 and 2022, respectively. The $76,000 decrease in consulting costs is due to the capitalization of a larger portion of Brightcap’s consulting expense to the Initial Project in fiscal year 2023. Investor relations expenses were $697,000 and $395,000 for the years ended June 30, 2023 and 2022, respectively, and the $302,000 increase is due to a new contract with an investor relations firm and increased activity during the year ended June 30, 2023 due to the resumption of investor conferences and other matters. Legal costs were $83,000 and $291,000 for the years ended June 30, 2023 and 2022, respectively, and the $208,000 decrease is due to less outside legal activities in the year 2023 compared to the year 2022 in which legal fees surrounding the hack and theft of the Company’s domain name and the dissolution of PA-1 were incurred.

Stock-based compensation for the years ended June 30, 2023 and 2022 were $442,000 and $269,000, respectively.

Depreciation

Total depreciation expense was $1,645 and $1,161 for the year ended June 30, 2023 and 2022, respectively.

Research and Development

Total research and development expenses were $83,000 and $201,000 for the years ended June 30, 2023 and 2022, respectively, representing a $118,000 decrease due to less legal and salary expense allocated to research and development and greater allocation to the Initial Project.

Salaries and related payroll tax expenses were $9,000 and $32,000 for the years ended June 30, 2023 and 2022, respectively, as more salary expense was allocated to administrative expense than research and development expense for the year ended June 30, 2023. Consulting costs were $43,000 and $80,000 for the years ended June 30, 2023 and 2022, respectively. The Company also incurred $14,000 and $55,000 for the years ended June 30, 2023 and 2022, respectively in legal costs related to patent applications and renewals.

Stock-based compensation allocated to research and development for the years ended June 30, 2023 and 2022 were $4,000 and $22,000, respectively.

Loss from Operations

As a result of the factors described above, the loss from operations was $3,157,000 and $2,550,000 for the years ended June 30, 2023 and 2022 respectively.

 

Other Income/(Expense)

Other income/(expense) was $(33,000) and $10,841,000 for the years ended June 30, 2023 and 2022, respectively. The difference was due to the gains recognized in 2022 consisting of $10,200,000 on the dissolution of PA1 and $902,000 from the sale of a domain name.

 

Interest expense related to deferred compensation, loan payable and convertible notes for the year ended June 30, 2023 was $218,000 prior to capitalization of $180,000. Interest expense related to deferred compensation, loan payable and convertible notes for the year ended June 30, 2022 was $334,000 prior to capitalization of $32,000. The decrease is due to more interest being capitalized to the 3G1 project.

 

Net Loss Attributable to the Noncontrolling Interest

The net loss attributable to the noncontrolling interest was nil and $1,500 for the years ended June 30, 2023 and 2022, respectively.

Net Income/(Loss) Attributable to Bion’s Common Stockholders

As a result of the factors described above, the net income/loss attributable to Bion’s stockholders was $(3,189,000) and $8,292,000 for the years ended June 30, 2023 and 2022, respectively, and the net income/(loss) per basic common share was $(.07) and $.20 for the years ended June 30, 2023 and 2022, respectively.

 

46 
 

LIQUIDITY AND CAPITAL RESOURCES

 

The Company's consolidated financial statements for the year ended June 30, 2023 have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The Report of our Independent Registered Public Accounting Firm on the Company's consolidated financial statements as of and for the year ended June 30, 2023 includes a "going concern" explanatory paragraph which means that the auditors stated that conditions exist that raise substantial doubt about the Company's ability to continue as a going concern.

 

Operating Activities

 

As of June 30, 2023, the Company had cash of approximately $626,000. During the year ended June 30, 2023, net cash used in operating activities was $2,929,000, primarily consisting of cash operating expenses related to salaries and benefits, and other general and administrative costs such as insurance, legal, accounting, consulting and investor relations expenses as well as the purchase of property and equipment. Cash expenditures were offset by proceeds from financing activities, primarily the exercise of warrants and sale of common shares. As previously noted, the Company is currently not generating significant revenue and accordingly has not generated cash flows from operations. The Company does not anticipate generating sufficient revenues to offset operating and capital costs for a minimum of two to five years. While there are no assurances that the Company will be successful in its efforts to develop and construct its Projects and market its Systems, it is certain that the Company will require substantial funding from external sources. Given the unsettled state of the current credit and capital markets for companies such as Bion, there is no assurance the Company will be able to raise the funds it needs on reasonable terms.

 

Investing Activities

 

During the year ended June 30, 2023, the Company invested $3,557,000 in the purchase of property and equipment, primarily related to the Initial Project construction in process.

 

Financing Activities

 

During the year ended June 30, 2023, the Company received gross cash proceeds of $131,335 from the exercise of 175,114 warrants into shares of the Company’s common stock.

During the year ended June 30, 2023, the Company entered into subscription agreements to sell units for $1.00 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 346,230 units for total proceeds of $346,230.

 

During the year ended June 30, 2023, the Company entered into a subscription agreement to sell 2,000,000 shares of restricted common stock of which 1,800,000 shares were purchased on January 10, 2023 (the other 200,000 shares were purchased on December 31, 2022) for total proceeds during year ending June 30, 2023 of $2,000,000.

 

During the year ended June 30, 2023, the Company entered into subscription agreements to sell 575,000 units at a price of $1.60, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $2.40 per share with an expiry date of June 30, 2024, and, pursuant thereto, the Company issued 575,000 units for total proceeds of $920,000, in aggregate. The Company paid commissions of $86,000 on the sale of units.

 

As of June 30, 2023, the Company has debt obligations consisting of: a) deferred compensation of $865,000 and b) convertible notes payable – affiliates of $1,716,000.

 

47 
 

 

Plan of Operations and Outlook

 

As of June 30, 2023, the Company had cash of approximately $626,000.

 

The Company continues to explore sources of additional financing to satisfy its current operating requirements as it is not currently generating any significant revenues.

 

During fiscal years 2023 and 2022, the Company faced less difficulty in raising equity funding (but was subject to substantial equity dilution from the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. However, this positive trend did not continue during the last quarter of the 2023 fiscal year and first quarter of the current fiscal year (to date). The Company raised only raised very limited equity funds during such periods to meet its some of its immediate needs, therefore, the Company needs to raise additional funds in the upcoming periods. The Company currently faces substantial increases in demand for capital and operating expenditures for the fiscal year 2024 to date (and we anticipate such increased demands will continue during the remainder of the 2024 fiscal year and periods thereafter) as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management issues due to limited capital resources and working capital constraints which had only recently begun to be alleviated. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring most of their cash compensation and/or are accepting compensation in the form of securities of the Company (Notes 5 and 7 to Financial Statements) and members of the Company's senior management have from time to time made loans to the Company and may need to do so in future periods. Note that, to deal with earlier capital constraints, during the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. As set forth in detail elsewhere herein, during the year ended June 30, 2023 senior management (and family members) who held convertible obligations of the Company adjusted the terms of their outstanding notes and agreed to debt modifications that reduced of the Company’s debt by $3,522,000 and increased shareholders equity by the same amount. The constraints on available resources have had, and continue to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and/or curtailment of ongoing activities including research and development activities.

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop the Initial Project, JVs, Projects and CAFO Retrofit waste remediation systems (potentially including the Kreider 2 facility. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more (debt and equity) during the next twelve months. However, as discussed above, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

 

The Company is not currently generating any significant revenues. Further, the Company’s anticipated revenues, if any, from existing projects, JVs and proposed projects will not be sufficient to meet the Company’s anticipated operational and capital expenditure needs for many years. During the year ended June 30, 2023 the Company raised gross proceeds of approximately $4,038,000 through the sale of its securities and paid commissions of approximately $86,000. During the year ended June 30, 2022 the Company raised gross proceeds for approximately $1,737,000 and paid commissions of approximately $19,000. The Company anticipates raising additional funds from such sales and transactions in the coming periods. However, there is no guarantee that we will be able to raise sufficient funds or further capital for the operations planned in the near future.

 

Because the Company is not currently generating significant revenues, the Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop the Initial Project and subsequent Projects.

 

As indicated above, the Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more (from debt, equity, joint venture, strategic partnering, etc.) during the next twelve months, some of which may be in the context of joint ventures for the development of one or more large scale projects. We reiterate that there is no assurance, especially in the extremely unsettled capital markets that presently exist for companies such as Bion, that the Company will be able to obtain the funds that it needs to stay in business, finance its Projects and other activities, continue its technology development and/or to successfully develop its business.

 

48 
 

See Item 2 below and Note 5 (“Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution”) to the Financial Statements included in this report and the Company’s Forms 10-K for the year ended June 30, 2022 (and the years 2009-2021) for discussion and more details related to the dissolution of PA1, the Pennvest Loan and the

Kreider 1 project.

 

There is extremely limited likelihood that funds required during the next twelve months or in the periods immediately thereafter will be generated from operations and there is no assurance that those funds will be available from external sources such as debt or equity financings or other potential sources. The lack of additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company's existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for companies such as Bion.

 

Covid-19 pandemic related matters:

 

The Company faces risks and uncertainties and factors beyond our control that are magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

49 
 

 

 

CONTRACTUAL OBLIGATIONS

 

We have the following material contractual obligations (in addition to employment and consulting agreements with management and employees):

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of June 30, 2023:

 

Year ended June 30, 2023 to June 2024  $75,000 
Year ended June 30, 2024 to December 2024   37,500 
Undiscounted cash flow   112,500 
Less imputed interest   (8,432)
Total  $104,068 
  Less current portion   (75,000)
Long tern lease liability   29,068 

 

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of June 30, 2023 were 1.58 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

OFF-BALANCE SHEET ARRANGEMENTS

 

The Company does not have any off-balance sheet arrangements (as that term is defined in Item 303 of Regulation S-K) that are reasonably likely to have a current or future material effect on our financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable.

 

Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTAL DATA

 

The consolidated financial statements are set forth on pages F-1 through F-41 hereto.

 

 

50 
 

 

Item 9A. Controls and Procedures.

 

Disclosure Controls and Procedures

 

As of June 30, 2023, under the supervision and with the participation of the Company’s President and Principal Financial Officer (the same person), management has evaluated the effectiveness of the design and operations of the Company’s disclosure controls and procedures. Based on that evaluation, the President and Principal Financial Office concluded that the Company’s disclosure controls and procedures were not effective as of June 30, 2023 as a result of the material weakness in internal control over financial reporting discussed below.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in internal control over financial reporting that occurred during the last fiscal quarter covered by this report that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

Management’s Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in the Securities Exchange Act of 1934 Rule 13a-15(f). Our Chief Executive Officer and Principal Financial Officer (the same person) conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control – Integrated Framework, issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO Framework”) and the related guidance provided in Internal Control Over Financial Reporting – Guidance for Smaller Public Companies, also issued by the Committee of Sponsoring Organizations.

 

Based on this evaluation, management has concluded that our internal control over financial reporting was not effective as of June 30, 2022. Our President and Principal Financial Officer concluded we have a material weakness due to our control environment, and one condition caused by this is an inadequate of segregation of duties as well as a lack of timely review and approval of related party transactions and a second condition is the a lack of timely review and approval of capitalized internal costs and interest. Our size has prevented us from being able to employ sufficient resources to enable us to have an adequate level of supervision and segregation of duties within our internal control system. There is one person involved in the processing of the Company's accounting and banking transactions and a single person with overall supervision and review of the cash disbursements and receipts and the overall accounting process. Therefore, while there are some compensating controls in place, it is difficult to ensure effective segregation of accounting duties. While we strive to segregate duties as much as practicable, there is an insufficient volume of transactions to justify additional full time staff. As a result of this material weakness, we have implemented remediation procedures whereby in May 2006 we engaged an outside accounting and consulting firm with SEC and US GAAP experience to assist us with the preparation of our financial statements, evaluation of complex accounting issues and the implementation of systems to improve controls and review procedures over all financial statement and account balances. In December of 2021, there was a change made to a new outside accounting and consulting firm. We believe that this outside consultant's review improved our disclosure controls and procedures. If this review is effective throughout a period of time, we believe it will help remediate the segregation of duties material weakness. However, we may not be able to fully remediate the material weakness unless we hire more staff. We will continue to monitor and assess the costs and benefits of additional staffing.

This annual report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s independent registered public accounting firm pursuant to rules of the SEC that permit the Company to provide only management’s report on internal control in this annual report.

 

 

51 
 

 

 

Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subject disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

Bank account hacking

On June 23, 2023, an officer of the Company with personal accounts with Signature Bank was hacked and $75,000 was transferred from the Company’s accounts at Signature Bank to the officer’s personal accounts. The bank was notified and all Company accounts were placed on hold. Subsequently, the funds were released and transferred back to the Company prior to June 30, 2023 the end of the fiscal year and there were no losses incurred.

The Company has reviewed the authorized individuals on all accounts and further limited access to its bank accounts after the hacking incident.  

 

ITEM 9B. OTHER INFORMATION

 

None.

 

 

52 
 

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.

 

Our directors, executive officers and significant employees/consultants, along with their respective ages and positions are as follows:

 

Name   Age     Position
           
Directors and Officers:            
             
Mark A. Smith     73     Executive Chairman, President, General Counsel, Chief Financial Officer and Director
Jon Northrop     80     Secretary and Director
William O’Neill     64     Chief Executive Officer
Dominic Bassani     76     Chief Operating Officer
William Rupp     62      Director
Salvatore Zizza     77      Director
Edward T. Schafer     77      Director

 

Mark A. Smith (73) currently serves Bion Environmental Technologies, Inc. as Executive Chairman, President, General Counsel, Chief Financial Officer and a director and has continually served in senior positions since late March 2003. Since that time, he has also served as sole director, President and General Counsel of Bion’s wholly-owned subsidiaries including Project Group and Services Group. Since mid-February 2003, Mr. Smith has served as sole director and President and General Counsel of Bion’s majority-owned subsidiary, Centerpoint Corporation. Mr. Smith also serves as Manager of Bion PA1, LLC and Bion PA2, LLC. Previously, from May 21, 1999 through January 31, 2002, Mr. Smith served as a director of Bion. From July 23, 1999, when he became President of Bion, until mid-2001 when he ceased to be Chairman, Mr. Smith served in senior positions with Bion on a consulting basis. Additionally, Mr. Smith was the president of RSTS Corporation prior to its acquisition of Bion Technologies, Inc. in 1992. Mr. Smith received a Juris Doctor Degree from the University of Colorado School of Law, Boulder, Colorado (1980) and a BS from Amherst College, Amherst, Massachusetts (1971). Mr. Smith has engaged in the private practice of law in Colorado since 1980. In addition, Mr. Smith has been active in running private family companies, Stonehenge Corporation (until 1994), LoTayLingKyur, Inc. (1994-2002) and LoTayLingKyur, LLC (2007-present). Until returning to Bion during March 2003, Mr. Smith had been in retirement with focus on charitable work and spiritual retreat. From July 2018 to March 2020 Mr. Smith served as a senior executive and director at Grow-Ray Technologies, Inc., a private LED lighting company based in Boulder, Colorado, on a consulting basis.

 

Jon Northrop (80) has served as our Secretary and a Director since March of 2003. Since September 2001 he has been self employed as a consultant with a practice focused on business buyer advocacy. Mr. Northrop is one of our founders and served as our Chief Executive Officer and a Director from our inception in September 1989 until August 2001. Before founding Bion Technologies, Inc., he served in a wide variety of managerial and executive positions. He was the Executive Director of Davis, Graham & Stubbs, one of Denver’s largest law firms, from 1981 to 1989. Prior to his law firm experience, Mr. Northrop worked at Samsonite Corporation’s Luggage Division in Denver, Colorado, for over 12 years. His experience was in all aspects of manufacturing, systems design and implementation, and planning and finance, ending with three years as the Division’s Vice President, Finance. Mr. Northrop has a bachelor’s degree in Physics from Amherst College, Amherst, Massachusetts (1965), an MBA in Finance from the University of Chicago, Chicago, Illinois (1969), and spent several years conducting post graduate research in low energy particle physics at Case Institute of Technology, Cleveland.

 

 

53 
 

 

William O’Neill (64) has served as Chief Executive officer since May 1, 2022 (he previously held the same position for the period from November 2010 through May 2011). Mr. O’Neill currently also serves as a director of Wise Up Food, LLC, a privately-held company that provides a transparent supply chain and real sustainability information for food retailers (including restaurants) enabling consumers to make informed purchase decisions. He founded Wise Up Food during 2020 and served as its President until May 1, 2022 when his wife assumed that position. From February 2018 through May 2020 he was employed as Vice President Retail & Value-Added Business Teys, USA, as subsidiary of Teys, a large Australian beef packer. From April 2015 through February 2018 Mr. O’Neill served as Vice President Retail of Colorado Premium Foods. From 1990 through 2015 he held marketing and executive positions with a varity of companies in the agriculture and food service businesses with an emphasis on developing/marketing products in the meat industry. Mr. O’Neill graduated from Gettysburg College in 1981 with a B.A. in economics.

 

Dominic Bassani (76) has served as Chief Operating Officer of Bion Environmental Technologies, Inc. since May 1, 2022 and served as Chief Executive Officer from April 2011. Previously he was a full-time consultant to the Company and served as the General Manager of Bion's Projects Group subsidiary from April 2003 through September 2006. From September 15, 2008 he has served as Director-Special Projects and Strategic Planning of the Company and our Projects Group subsidiary. He has been an investor in and consultant to Bion since December 1999. He is an independent investor and since 1990 has owned and operated Brightcap, a management consulting company that provides management services to early stage technology companies. He was a founding investor in 1993 in Initial Acquisition Corp. that subsequently merged in 1995 with Hollis Eden Corp. (HEPH), a biotech company specializing in immune response drugs. From early 1998 until June 1999 he was a consultant to Internet Commerce Corp. (re-named EasyLink Services International Corporation) (ESIC), a leader in business-to-business transactions using the Internet. He is presently an investor in numerous private and public companies primarily in technology related businesses. From 1980 until 1986, Mr. Bassani focused primarily on providing management reorganization services to manufacturing companies and in particular to generic pharmaceutical manufacturers and their financial sponsors.

 

William (Bill) Rupp (62) has served as a director of the company since ___, 2023.He is a ‘meat industry leader’ who served as President of JBS Beef from 2010-2016 with responsilibity for the leadership of JBS’s North American Beef business. He was CEO of Meyer Natural Foods from 2009-2010. Mr. Rupp served in various management roles for Cargill Beef from 1983 until 2009 where he was President from 1998-2008 with responsibility for Cargill’s global beef business with operations in US, Canada, Argentina, and Australia. He graduated from the University of South Dakota with a B.S. in Business Administration in 1983. Mr Rupp salso serves on the boards of Sustainable Beef, DecisionNext, Superior Lamb and Lumachain.

 

Salvatore J. Zizza (77) Salvatore Zizza has served as a director of Bion since 2023. He is presently President of Zizza & Associates Corp. a private holding company which invests in various industries and retired Chairman of BAM (Bethlehem Advanced Materials), which designs and manufactures high-temperature furnaces for sale and for its own use in the processing of specialty carbon, graphite and ceramic materials for semiconductor and aerospace applications, and Chairman of Bergen Cove Realty Inc., with substantial holdings in residential real estate. Mr. Zizza serves as Director & Chairman of Trans-Lux Corporation, a full service provider of integrated multimedia systems for today’s communications environments (since 2018) and served on board since 2009. Mr. Zizza bought NICO Construction Company, Inc., in 1978 and was President and CFO until 1985 when NICO merged with The LVI Group Inc., a (NYSE), listed company. Prior to joining The LVI Group Inc., Mr. Zizza was an independent financial consultant and had been a lending officer of Chemical Bank. Mr. Zizza is also an investor in numerous private companies and real estate holdings. Mr. Zizza currently holds directorship positions at nineteen (19) Gabelli/GAMCO funds and trusts. He has been associated with this family of investment funds for over thirty (30) years. He received a Baccalaureate/Political Science, St. John’s University (1967) and a Master of Business Administration, St. John’s University (1972). In 2007 Mr. Zizza received a Doctor of Commercial Sciences (Honorary) from St. John’s University.

 

Edward T. Schafer (77) Edward Schafer previously served the Company’s senior management team as Executive Vice Chairman and has been a member of the Company’s Board of Directors since January 1, 2011. Mr. Schafer had served as a consultant to Bion since July 2010. Mr. Schafer served as a director of Continental Resources (NYSE-CLR) 2011-2016. He also chairs the Board of Directors of Dynamic Food Ingredients. In addition he has served on the Board of Governors of Amity Technology LLP since 2009. Mr. Schafer served as a trustee of the Investors Real Estate Trust (NASDAQGS-IRET) from September 2009 to October 2011. He also served as a trustee of the IRET from September 2006 through December 2007, when he resigned from the IRET’s Board to serve as Secretary of the U.S. Department of Agriculture under President George W. Bush.  Mr. Schafer, a private investor, is a two-term former Governor of North Dakota. He served as Chief Executive Officer of Extend America, a telecommunications company, from 2001 to 2006, and he has been a member of the Boards of RDO Equipment Co., a privately-owned agricultural and construction equipment company (August 2001 to July 2003) and the University of North Dakota Foundation (June 2005 to December 2007). Since 2019 Mr. Schafer has served on the Board of Directors of Cellular Biomedicine Group (NASDAQ: CBMG) and is Chairman of its Audit Committee. Mr. Schafer serves as a board member of the Center for Innovation at the University of North Dakota and is an adjunct professor at North Dakota State University. Mr. Schafer is a past chair of the Republican Governors Association, the Midwestern Governors’ Association, the Interstate Oil and Gas Compact, the Western Governors’ Association and served as the 29th United States Secretary of Agricultural from 2008 to 2009. Mr. Schafer holds a Master’s degree in Business Administration from the University of Denver. Mr. Schafer brings the following experience, qualifications, attributes and skills to the Company: general business management, budgeting and strategic planning experience from his service as Chief Executive Officer of Extend America and extensive government, regulatory, strategic planning, budgeting administrative and public affairs experience from his service as Governor of North Dakota and Secretary of the US Department of Agriculture.

 

 

54 
 

Family Relationships

 

There are currently no family relationships among our Directors and Executive Officers.

 

Compliance with Section 16(a) of the Exchange Act

 

Section 16(a) of the Exchange Act requires our officers and directors, and stockholders owning more than ten percent of a registered class of our equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission. The Company is not aware of any persons who failed to timely file reports under this section.

 

Involvement in Legal Proceedings

 

To the best of our knowledge, during the past five years, none of the following occurred with respect to our directors or executive officers:

 

(1)   any bankruptcy petition filed by or against any business of which one of them was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;

 

(2)   any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);

 

(3)   being subject to any order, judgment or decree of any court of competent jurisdiction, permanently or temporarily inquiring, barring, suspending or otherwise limiting involvement in any type of business, securities or banking activities; and

 

(4)   being found by a court of competent jurisdiction, the SEC or the CFTC to have violated Federal or state securities or commodities laws.

 

Audit Committee

 

The Company has no audit committee and is not now required to have one, or an audit committee financial expert.

 

Code of Ethics

 

To date, the Company has not adopted a code of business conduct and ethics applicable to its officers, directors or accounting officer.

 

 

55 
 

 

Advisory Group

 

The Company, which has only 7 full-time employees/consultants (all of whom are effectively ‘department heads’), has utilized many outside parties as consultants and contract workers for various roles to augment our management capabilities and expertise. Over the last year the Company has begun to establish a more formal ‘advisory’ relationship with some of these people to insure their availability for consultation by our senior management (separate from specific consulting engagements). At present, a) William Rupp (meat and beef industry), b) Matthew Lamb (agriculture/animal husbandry/dairy), c) Stanley Rapp (government affairs), d) Dennis Tristao (agricultural tech, engineering and agricultural/environmental policy) and e) Dennis Bracht (organic seed, corn/feed grain cultivation and related matters) have accepted roles as members of our Advisory Group. The Company anticipates that additional persons will be added to this group over time.

 

ITEM 11. EXECUTIVE COMPENSATION.

 

The Company does not have a compensation committee due to its small size and limited resources. The Board of Directors directly reviews and authorizes all compensation matters.

 

SUMMARY COMPENSATION TABLE

 

The following table sets forth the compensation paid to, or accrued for, each of our current executive officers during each of our last two fiscal years.

 

                                  Non-Equity     Nonqualified              
                                  Incentive     Deferred              
                            Option     Plan     Compen-     Other        
Name and Principal   Fiscal     Salary           Stock     Awards     Compen-     sation     Compen-        
Position   Year     (1)     Bonus     Awards     (2)     sation     Earnings     sation     Total  
                                                       
Mark A. Smith (3)     2023     $ 300,000     $ —       $ —         —         —         —         —       $ 300,000  
President and Chief     2022     $ 230,000     $ —       $ —         115,200       —         —         —       $ 345,200  
Financial Officer Since March 25, 2003,                                                                        
Director                                                                        
                                                                         
Brightcap/Dominic Bassani (4)     2023     $ 372,000     $ —       $ —         —         —         —         —       $ 372,000  
VP - Special Projects & Strategic     2022     $ 372,000     $ —       $ —         115,200       —         —         —       $ 487,200  
Planning and Chief Operating Officer                                                                        
                                                                         
William O'Neill     2023     $ 270,000     $ —       $ —         191,500       —         —         —       $ 461,500  
Chief Executive Officer (5)     2022     $ 45,000     $ —       $ —         —         —         —         —       $ 45,000  

 

     
  (1)   Includes compensation paid by Bion Environmental Technologies, Inc. and our wholly owned subsidiaries.
       
  (2)   Reflects the dollar amount expensed by the Company during the applicable fiscal year for financial statement reporting purposes pursuant to ASC 718.
       
  (3)   Since October 2016, the Company approved a month-to-month contract extension with Smith which included a monthly deferred salary of $18,000 and the right to convert up to $300,000 of deferred compensation, at his sole election, at $0.75 per share until December 31, 2022 (which date was extended to July 1, 2024).   Smith also has the right to convert his deferred compensation in whole or in part, at this sole election, at any time in an amount at "market" or into securities sold in the Company's most current/recent private offering.  During fiscal year 2021 the Company paid Smith $13,460 for payroll taxes on his deferred compensation conversions which was treated as salary.
       
  (4)   On February 10, 2015, Mr. Bassani agreed to an extension to continue his employment through December 31, 2017 at an annual salary of $372,000 effective January 1, 2015.  During October 2016, Bassani was granted  the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share which was expanded on April 27, 2017 to the right to convert up to $300,000).  During February 2018, the Company agreed to the material terms of a binding two-year extension agreement.  Bassani's annual salary will remain at $372,000 and the Company granted Bassani 2,000,000 fully vested options at $0.75 per share with an expiry date of December 31, 2024 which contain a 90% exercise price adjustment and the options may be extended for an additional 5 years at $0.01 per share per extension year.
       
  (5)   On May 1, 2022 William O'Neill joined the Company with an annual salary of $420,000 which includes $10,000 monthly deferred compensation to be paid at the discretion of the Board.  There is an additional $1,500 per month health insurance allowance.  Terms of the contract are thirty-seven months.  William O'Neill was previously paid as a contractor through Identifoods. Total payments for the years ended June 30, 2023 and June 2022, respectively were $318,000 and $165,000.
       

 

 

56 
 

 

Employment Agreements:

 

Mark A. Smith (“Smith”) has held the positions of Executive Chairman, Director, President and General Counsel of Company and its subsidiaries under various agreements and terms since March 2003 (details regard earlier years and periods between 2003 and 2011 may be found in the Company’s prior Forms 10-K and other SEC filings). During July 2011, the Company entered into an extension agreement pursuant to which Smith continued to hold his current positions in the Company through a date no later than December 31, 2012. Commencing January 1, 2012, Smith’s monthly salary was $20,000, which has been accrued and deferred. In addition, Smith has been issued 90,000 shares of the Company’s common stock in two tranches of 45,000 shares on each of January 15, 2013 and 2014, respectively. As part of the extension agreement, Smith was also granted 200,000 options, which vested immediately, to purchase common shares of the Company at a price of $3.00 per share and which options were originally to expire on December 31, 2019. Effective July 15, 2012, the Company entered into an extension agreement pursuant to which Smith will continue to hold his current positions in the Company through a date no later than June 30, 2014. Effective September 2012, Smith’s monthly salary became $21,000 (which is currently being deferred). In addition, Smith was issued 150,000 shares of the Company’s common stock in two tranches of 75,000 shares on each of January 15, 2014 and 2015, which shares vested immediately. As part of the extension agreement, Smith was also granted a bonus of $25,000 paid in warrants, which vested immediately, to purchase 250,000 shares of the Company’s common stock at a price of $2.10 per share and which warrants expire on December 31, 2018 and a contingent stock bonus of 100,000 shares payable on the date on which the Company’s stock price first reaches $10.00 per share (regardless of whether Smith is still providing services to the Company on such date). Mr. Smith has voluntarily reduced his monthly deferred salary accrual to $14,000 due to the Company’s financial situation. During September 2014, Smith agreed to continue his employment agreement through April 15, 2015 and also agreed to continue to defer his temporarily reduced salary of $14,000 per month.  On February 10, 2015, the Company executed an Extension Agreement with Smith pursuant to which Smith extended his employment with the Company to December 31, 2015 (with the Company having an option to extend his employment an additional six months).  As part of the Extension Agreement, the balance of Smith’s existing convertible note payable of $854,316 as of December 31, 2014, adjusted for conversions subsequent to that date, was replaced with a new convertible note with an initial principal amount of $760,519 with terms that i) materially reduced the interest rate by 50% (from 8% to 4%), ii) increased the conversion price by 11% (from $0.45 to $0.50), iii) set the conversion price at a fixed price so there can be no further reductions, iv) reduced the number of warrants received on conversion by 75% (from 1 warrant per unit to 1/4 per unit) and v) extended the maturity date to December 31, 2017 (which maturity date was subsequently extended to July 1, 2019).  Additionally, pursuant to the Extension Agreement, Smith: i) continued to defer his cash compensation ($18,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation,  ii) cancelled 150,000 contingent stock bonuses previously granted to him by the Company, iii) was granted 150,000 new options which vested immediately and iv) outstanding options and warrants owned by Smith (and his donees) were extended and had the exercise prices reduced to $1.50 (if above that price). Due to expiration of his most recent extension, Mr. Smith is currently serving the Company on a month-to –month basis. On April 29, 2022, Smith’s monthly salary was increased to $25,000, of which $5,000 is deferred each month.

 

 

57 
 

 

  

Dominic Bassani (“Bassani”) has served in senior management positions with the Company (as a full-time consultant) since 2001 (see prior Forms 10-K for earlier years and other filings with the SEC). Since March 31, 2005, the Company has had various agreements with Brightcap, Bassani’s family consulting company, through which the services of Bassani were provided through 2011. On September 30, 2009 the Company entered into an extension agreement with Brightcap pursuant to which Bassani provided services to the Company through September 30, 2012 for $312,000 annually (currently deferred). The Board appointed Bassani as the Company's CEO effective May 13, 2011 in which position he served until May 2022. On July 15, 2011, Bassani, Brightcap and the Company agreed to an extension/amendment of the existing agreement with Brightcap which provided that Bassani serve as CEO through June 30, 2013 and would continue to provide full-time services to the Company in other capacities through June 30, 2014 at a salary of $26,000 per month. In addition Bassani was to be issued 300,000 shares of the Company’s common stock issuable in three tranches of 100,000 shares on each of January 15, 2015, 2016 and 2017, respectively. Bassani was also granted 725,000 options, which vested immediately, to purchase shares of the Company’s common stock at $3.00 per share which options expired on December 31, 2019. Effective July 15, 2012, Bassani, Brightcap and the Company agreed to a further extension/amendment of the existing agreement with Brightcap which provided that Bassani would continue to provide the services of CEO through June 30, 2014. Bassani continued to provide full-time services to the Company at a cash salary of $26,000 per month (which has been deferred) and Bassani would be issued 300,000 shares of the Company’s common stock issuable in two tranches of 150,000 shares on each of January 15, 2015 and 2016, respectively, which shares would be immediately vested upon issuance. As part of the extension agreement, Bassani was also granted a bonus of $5,000 paid in warrants, which vested immediately, to purchase 50,000 shares of the Company’s common stock at a price of $2.10 per share and which warrants expired on December 31, 2018. During September 2014, Bassani agreed to extend his employment agreement until April 15, 2015 and that previously issued and expensed share grants of 100,000 and 150,000 shares that were to be issued on January 15, 2015, would be deferred until January 15, 2016.  On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017, (with the Company having an option to extend the term an additional six months.)  As part of the agreement, the Company’s existing loan payable, deferred compensation and convertible note payable to Bassani, were restructured into two promissory notes as follows: a) The of sum of the cash loaned by Bassani to the Company of $279,000 together with $116,277 of unreimbursed expenses through December 31, 2014 were placed into a new promissory note with initial principal of $395,277 which was due and payable on December 31, 2015.  In connection with these sums and the new promissory note, Bassani was issued warrants to purchase 592,916 shares of the Company’s common stock at a price of $1.00 until December 31, 2020; and b) the remaining balances of the Company’s accrued obligations to Bassani ($1,464,545) were replaced with a new convertible promissory note with terms that compared with the largest prior convertible note obligation to Bassani:  i) materially reduced the interest rate by 50% (from 8% to 4%), ii) increased the conversion price by 11% (from $0.45 to $0.50), iii) set the conversion price at a fixed price so there can be no further reductions, iv) reduced the number of warrants received on conversion by 75% (from 1 warrant per unit to 1/4 per unit) and v) extended the maturity date to December 31, 2017 (See Notes to Financial Statements) (which maturity date was subsequently extended to July 1, 2019.  Additionally,  pursuant to the Extension Agreement, Bassani i) will continue to defer his cash compensation ($31,000 per month) until the Board of Directors re-instates cash payments to all employees and consultants who are deferring their compensation, ii) cancelled 250,000 contingent stock bonuses previously granted to him by the Company, iii) was granted 450,000 new options which vested immediately and iv) outstanding options and warrants owned by Bassani (and his donees) have been extended and had the exercise prices were reduced to $1.50 (if above that price). On May 5, 2013, the Board of Directors approved agreements with Bassani and Smith, with effective date of May 15, 2013, in which Bassani and Smith agreed to continue to defer their respective cash compensation through April 30, 2014 (unless the Board of Directors elected to re-commence cash payment on an earlier date) and extended the due dates of their respective deferred cash compensation until January 15, 2015. The Company provided Bassani and Smith with convertible promissory notes which reflected all the terms of these agreements to which future accruals were added as additional principal. These convertible promissory notes were altered as set forth in the paragraphs below. As part of the agreements, Bassani and Smith also forgave any possible obligations that Bion may have owed each of them in relation to unused vacation time for periods (over 10 years) prior to June 30, 2012. In consideration of these agreements, Bassani and Smith: a) have been granted 50% ‘execution/exercise’ price adjustment (subsequently increased to 75%) to be effective upon future exercise of outstanding (or subsequently acquired) options and warrants owned by Bassani and Smith (and their respective donees) and in relation to contingent stock bonuses; b) their warrants and options, if due to expire prior to December 31, 2018, were extended to that date (and later further extended); and c) other modifications were made. Currently Bassani receives $25,000 per month in cash and $6,000 per month of deferred compensation.

 

 

58 
 

 

 

William O’Neill (“O’Neill”) joined as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, has assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s Gen3Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill have entered into a thirty-seven (37) month employment agreement (subject to Board renewal for the final two (2) years during the 13th month) with compensation of $25,000 cash and $10,000 deferred compensation per month. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants were cancellable until O’Neill’s agreement was re-affirmed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise price adjustment if the terms set forth therein are met.  As set forth in the Employment Agreement, the Company and Wise Up Foods LLC (an entity founded by O’Neill with which he continues to serve as a Director and of which O’Neill and his family members are majority owners) sets forth the intent to form “… a strategic alliance and committed to collaborate on projects each company has in their respective pipelines.  WUF and Bion will work together to use/create technology that will deliver the consumer verified sustainable results produced by Bion’s technology and technology platform.  The key to the strategic relationship is each company’s commitment to deliver real and verified results to the consumer – free of marketing hype and greenwashing…”.

 

Bassani, Smith and Schafer have each agreed (multiple times) to extend the maturity date of the outstanding 2020 Convertible Obligations and 2015 Convertible Notes (“CVObligations”) set forth in the paragraphs above from December 31, 2017 (initial maturity date) to July 1, 2024 (current maturity date) which is also the maturity date of all CV Obligations after adjustment. 

 

Effective May 4, 2020 the Company agreed that all options and warrants owned (or subsequently acquired by conversion of CvObligations) by its officers, directors and key employees and consultants (including Jon Northrop (director), Bassani, Smith and Schafer) and their donees be amended to: a) lower the exercise price to $0.75 for any options/warrants with higher exercise prices and b) extend the expiration dates to December 31, 2024. Subsequently, it was agreed that if any of the CVObligations are converted, the warrants in units received will be exercisable through a date 3 years after conversion date with exercise price adjustment provision effective two years after the date on which the converted portion of the CVObligations (as adjusted, if applicable) was accrued.

Other Agreements

The Company has declared contingent deferred stock bonuses to its key employees and consultants at various times throughout the years. The stock bonuses were contingent upon the Company’s stock price exceeding a certain target price per share, and the grantees still being employed by or providing services to the Company at the time the target prices are reached. During the year ended June 30, 2017, pursuant to agreement with the employees and a consultant who had been granted the outstanding contingent stock bonuses, the Company cancelled all 117,500 outstanding contingent stock bonuses. In consideration for the cancellations, the Company granted 109,500 fully vested options to these employees and a consultant to purchase common stock of the Company at $1.00 per share until December 31, 2024 (including recent extensions).

 

 

59 
 

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END

 

The following table sets forth the number of shares of common stock covered by outstanding stock option awards that are exercisable and unexercisable, and the number of shares of common stock covered by unvested restricted stock awards for each of our named executive officers as of June 30, 2023.

 

Outstanding Equity Awards at Fiscal Year-End
 
      Option Awards       Stock Awards  
                                                                         
Name    

Number of

Securities

Underlying Unexercised

Options (#) Exercisable

     

Number of

Securities

Underlying

Unexercised

Options (#)Unexercisable

     

Equity

Incentive Plan

Awards:

Number of

Securities

Underlying

Unexercised

Unearned

Options (#)

     

Option

Exercise

 Price ($)

     

Option

Expiration

Date

     

Number of

Shares or

Units of

Stock That

Have Not

Vested (#)

     

Market

Value of

Shares or

Units of

Stock That

Have Not

Vested

     

Equity

Incentive Plan

Awards:

Number of

Unearned Shares,

Units or Other

Rights That Have

Not Vested

     

Equity

Incentive Plan

Awards:

Market or

Payout Value of

Unearned Shares,

Units or Other

Rights That Have

Not Vested

 
Mark A. Smith (1)     100,000       —         —         0.60       2024       —         —         —         —    
Mark A. Smith (1)     1,675,000       —         —         0.75       2024       —         —         —         —    
Mark A. Smith (2)     200,000       —         —         0.75       2024       —         —         —         —    
Mark A. Smith (1)     250,000       —         —         1.20       2026       —         —         —         —    
Mark A. Smith (1)     200,000       —         —         1.00       2025       —         —         —         —    
 Brightcap/ Dominic Bassani (1)     1,675,000       —         —         0.75       2024       —         —         —         —    
Brightcap/ Dominic Bassani (2)     2,000,000       —         —         0.75       2024       —         —         —         —    
Brightcap/ Dominic Bassani (1)     250,000       —         —         1.20       2026       —         —         —         —    
Brightcap/ Dominic Bassani (1)     200,000       —         —         1.00       2025       —         —         —         —    
Edward Schafer (3)     25,000       —         —         0.60       2024       —         —         —         —    
Edward Schafer (3)     300,000       —         —         0.75       2024       —         —         —         —    
Edward Schafer (1)     600,000       —         —         0.75       2024       —         —         —         —    
Edward Schafer (2)     190,000       —         —         0.75       2024       —         —         —         —    
Edward Schafer (1)     50,000       —         —         1.20       2026       —         —         —         —    
Edward Schafer (1)     50,000       —         —         1.00       2025       —         —         —         —    
William O’Neill (3)     250,000       —         —         1.60       2026       250,000       95,750                  
William O’Neill (3)     250,000       —         —         1.60       2026       250,000       95,750                  

 

 

(1)   Options are subject to a 75% execution/exercise price adjustment upon notice of intent to exercise under certain conditions.

 

(2)   Options are subject to a 90% execution/exercise price adjustment upon notice of intent to exercise under certain conditions.

 

(3)   Options are subject to a 50% execution/exercise price adjustment upon notice of intent to exercise under certain conditions.

 

 

60 
 

 

 

Director Compensation

 

Members of the Board of Directors do not currently receive any cash compensation for their services as Directors, but are entitled to be reimbursed for their reasonable expenses in attending meetings of the Board. However, it is the Company's intention to begin to pay cash compensation to Board members at some future date (probably during the current fiscal year).

 

DIRECTOR COMPENSATION

 

The following table sets forth certain information regarding the compensation paid to directors during the fiscal year ended June 30, 2023:

 

Director Compensation
                                                         
Name     Fees earned or paid in Cash ($)       Stock Awards ($)       Option Awards ($)(1)       Non-equity incentive plan compensation ($)      

Nonqualified deferred

 compensation earnings ($)

      All other compensation ($)       Total ($)  
                                                         
Jon Northrop     —         —         19,550       —         —         —         19,500  
Edward Schafer     —         —         —         —         —         —         —    
William Rupp     —          —         39,100         —          —          —         39,100   
Salvatore Zizza      —         —         39,100         —          —          —         39,100   

 

  (1) Reflects the dollar amount expensed by the Company during the applicable fiscal year for financial statement reporting purposes pursuant to ASC 718.

 

ITEM 12.  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

As of August 1, 2023, the Registrant had 49,408,214 shares of common stock issued and 48,703,905 shares of common stock outstanding. (balance of 704,309 shares are owned by Centerpoint, the Company's majority-owned subsidiary).

 

The following table sets forth certain information regarding the beneficial ownership of our common stock as of August 1, 2022 by:

 

  each person that is known by us to beneficially own more than 5% of our common stock;

 

  each of our directors;

 

  each of our executive officers and significant employees; and

 

  all our executive officers, directors and significant employees as a group.

 

Under the rules of the Securities and Exchange Commission, beneficial ownership includes voting or investment power with respect to securities and includes the shares issuable under stock options, warrants and convertible securities that are exercisable/convertible within sixty (60) days of August 1, 2023.  Those shares issuable under stock options, warrants and/or convertible securities are deemed outstanding for computing the percentage of each person holding options, warrants and/or convertible securities but are not deemed outstanding for computing the percentage of any other person.  The percentage of beneficial ownership schedule ‘Entitled to Vote’ is based upon 48,703,905 shares outstanding as of August 1, 2023.  The address for those individuals for which an address is not otherwise provided is c/o Bion Environmental Technologies, c/o PO Box 323, Old Bethpage, NY 11804.  To our knowledge, except as indicated in the footnotes to this table and pursuant to applicable community property laws, the persons named in the table have sole voting power and investment power with respect to all shares of common stock listed as owned by them.

 

 

61 
 

 

Name and Address  Number   Percent of Class Outstanding   Entitled
To Vote
 
             

Centerpoint Corporation(1)

c/o PO Box 323

Old Bethpage, NY 11604

   704,309    1.4%   —   
                

Dominic Bassani (2)

64 Village Hills Drive

Dix Hills, NY 11746

   15,242,691    24.3%   24.6%
                

Mark A. Smith(3)

401 N. Riverside Beach #408

Pompano Beach, FL 33062

   8,401,433    14.9%   15.1%
                

Christopher B. Parlow(4)

23 Longbow Drive

Commack, NY 11725

   8,754,807    15.2%   15.4%
                
Danielle Lominy(5)
c/o Dominic Bassani
64 Village Hill Drive
Dix Hills, NY 11746
   8,744,803    15.3%   15.5%
                
Edward Schafer (6)
c/o PO Box 323
Old Bethpage, NY 11804
   3,039,138    5.8%   5.9%
                

Anthony Orphanos(7)

c/o Blacksmith Advisors, LLC

320 Park Avenue 18th Floor

New York, NY 10022

   2,285,618    4.4%   4.6%
                
William O’Neill (8)
107 12th Street E
St. Petersburg, FL 3371
   1,560,888    3.1%   3.1%
                
Craig Scott (9)
3131 North Daffodil Dr.
Billings, MT 59102
   2,663,652    5.2%   5.2%
                
Jon Northrop (10)
59 Chestnut Street
Westfield, NY 14787
   636,135    1.3%   1.3%
                

Salvatore Zizza (11)

641 Lexington Avenue, 20th Floor

New York, NY 10022

   155,112    0.3%   0.3%
                

William Rupp (12)

PO Box 536

Loveland, CO 80539

   125,000    0.3%   0.3%
                
All executive officers and directors as a group (8 persons)   31,824,049    41.5%   41.6%

 

(1)   Centerpoint Corporation is currently majority owned by the Company. Under Colorado law, Centerpoint Corporation is not entitled to vote these shares unless otherwise ordered by a court. These shares of common stock may be distributed to the shareholders of Centerpoint Corporation at a future date pursuant to a dividend declared during July 2004. The shares distributed to Bion, if any, will be cancelled immediately upon receipt.

 

 

62 
 

 

(2)   Includes 70,577 shares, 3,025,000 shares underlying options and 965,000 shares underlying warrants held directly by Mr. Bassani; 464,644 shares and 250,000 shares underlying warrants held by Mr. Bassani’s wife; and 909,747 shares held in IRA accounts of Mr. Bassani and his wife. Also included are the shares set forth below owned (directly and indirectly) by Mr. Bassani’s daughter, Danielle Lominy (formerly Danielle Bassani) who resides within his residence and are included in Mr. Bassani’s beneficial ownership for purposes of the calculation including: a) 570,000 shares directly b) 646,458 shares underlying warrants owned directly; and c) Danielle Lominy is the 50% beneficiary of the Dominic Bassani 2019 Irrevocable Trust (“2019Trust”) which owns: i) 3,000,000 warrants and 1,000,000 options to purchase shares of the Company’s common stock and, as a result, Danielle Lominy is the beneficial owner of 1,500,000 shares underlying warrants and 500,000 shares underlying options and ii) $459,277.02 principal amount of the Company’s Adjusted 2020 Convertible Obligation (“CVObligation”) which is convertible @ $.0953 into 4,819,277 shares and 3,214,458 warrants and, as a result, Danielle Lominy is the beneficial owner of 2,409,639 shares underlying conversion of the Adjusted CVObligation and 1,607,229 shares underlying the warrants issuable on conversion of the Adjusted CVObligation. The total also includes: a) 724,754 shares of common stock and 483,411 underlying warrants that could be issued on the conversion (at the election of Bassani) by Mr. Bassani of a convertible note in the amount of $362,376, (convertible @ $0.50 price) and b) 265,693 shares of common stock that could be issued on the conversion (at the election of Bassani) by Mr. Bassani of a convertible note in the amount of $159,416 (convertible @ $0.60 price) and c) 222,962 shares of common stock that could be issued on the conversion (at the election of Bassani) of Adjusted Convertible Note in the amount of $25,641 (convertible @$.115 price) and d) 627,577 shares of common stock that could be issued on the conversion (at the election of Bassani) of deferred compensation in the amount of $548,057. Mr. Bassani disclaims ownership of 1,511,477 shares underlying warrants held by the Danielle Christine Bassani Trust, which is separately itemized herein. Mr. Bassani’s adult daughter Danielle Lominy (formerly Danielle Bassani), who resides within his residence, is the beneficiary of the Danielle Christine Bassani Trust and Mr. Bassani is not one of the trustees of the trust. Mr. Bassani further disclaims beneficial ownership of shares and warrants owned by various other family members (including Christopher Parlow who is itemized separately), none of whom live with him or are his dependents, and such shares are not included in this calculation.

  

(3)   Includes 752,268 shares, 2,425,000 shares underlying options, 1,806,987 warrants held directly by Mr. Smith, and 62,535 shares held by Mr. Smith in an IRA. Also includes 575,000 shares and 370,948 underlying warrants held by Mr. Smith’s wife and 53,756 shares held in his wife’s IRA. Also includes 12,681 shares of common stock held by held by LoTayLingKyur Foundation and 100,001 shares of common stock and 100,001 underlying warrants held by LoTayLingKyur LLC which is controlled by Mr. Smith and his wife. Also includes 971,492 shares and 971,492 warrants underlying units that could be issued on the conversion (at the election of Mr. Smith) by Mr. Smith of his Adjusted 2020 Convertible Obligation in the aggregate amount of $91,903.05. Mr. Smith has the option to convert this amount into units with each unit consisting of 1 share of common stock and 1 warrant exercisable at $0.75 per share. The conversion price will be $.0946 per unit. Also includes 72,858 shares and 72,858 warrants underlying units that could be issued on the conversion (at the election of Mr. Smith) by Mr. Smith of his 2020 Convertible Obligation in the aggregate amount of $36,428.77. Mr. Smith has the option to convert this amount into units with each unit consisting of 1 share of common stock and 1 warrant exercisable at $0.75 per share. The conversion price will be $.50 per unit. Also includes 53,556 shares of common stock that could be issued on the conversion (at the election of Mr. Smith) of deferred compensation in the amount of $40,167. Does not include shares and warrants owned by various other family members of which Mr. Smith disclaims beneficial ownership. Mr. Smith is also the President of Centerpoint, although shares owned by Centerpoint are not entitled to a vote while held by Centerpoint

 

63 
 

 

(4)   Includes 2,005 shares held directly by Christopher Parlow, 65,000 shares held jointly with wife, 250,000 shares owned by the Christopher Parlow Trust and 50,000 shares owned by Christopher Parlow’s minor daughters. Also includes 1,614,000 shares underlying warrants held by the Christopher Parlow Trust, 147,154 shares underlying warrants held jointly with wife, 150,000 warrants held directly by Mr. Parlow and 459,780 shares underlying warrants held by Mr. Parlow’s minor daughters. In addition, Christopher is the 50% beneficial owner of the Dominic Bassani 2019 Irrevocable Trust (“2019 Trust”) which owns 3,000,000 warrants to purchase shares of the Company’s common stock and 1,000,000 options and as a result, Christopher Parlow is the beneficial owner of 1,500,000 shares underlying exercise of the warrants and 500,000 shares underlying exercise of the options. Additionally, the 2019 Trust owns $459,277.02 principal amount of the Company’s Adjusted 2020 Convertible Obligations (“CVObligation”) which is convertible @$.0953 into 4,819,277 shares and 3,214,458 warrants. As a result, Christopher Parlow is the beneficial owner of 2,409,639 shares underlying conversion of the CVObligation and 1,607,229 shares underlying the warrants issuable on conversion of the CVObligation.

 

(5)   Includes 170,000 shares held directly by Danielle Lominy (formerly Danielle Bassani), 1,511,477 shares underlying warrants held by The Danielle Christine Bassani Trust, 400,000 shares owned by the Danielle Bassani Trust, 311,458 shares underlying warrants, 105,000 shares underlying warrants owned jointly with husband and 230,000 shares underlying warrants owned by Danielle Lominy’s daughter. In addition, Danielle is the 50% beneficial owner of the Dominic Bassani 2019 Irrevocable Trust (“2019 Trust”) which owns 3,000,000 warrants to purchase shares of the Company’s common stock and 1,000,000 options and, as a result Danielle Lominy is the beneficial owner of 1,500,000 shares underlying exercise of the warrants and 500,000 shares underlying exercise of the options. Additionally, the 2019 Trust owns $459,277.02 principal amount of the Company’s Adjusted 2020 Convertible Obligation (“CVObligation”) which is convertible @ $.0953 into 4,819,277 shares and 3,214,458 warrants. As a result, Danielle Lominy is the beneficial owner of 2,409,639 shares underlying conversion of the CVObligation and 1,607,229 shares underlying the warrants issuable on conversion of the CVObligation.

 

(6)   Includes 158,254 shares held directly by Mr. Schafer, options to purchase 1,215,000 shares and warrants to purchase 23,934 shares. Also includes 1,070,021 shares and 535,011 warrants underlying units that could be issued on the conversion by Mr. Schafer of his Adjusted Convertible Obligation in the amount of $101,973. Mr. Schafer has the option to convert this amount into units with each unit consisting of 1 share of common stock and ½ warrant exercisable at $0.75 per share until December 31, 2024. The conversion price is $.0953 per unit. Also includes 36,918 shares of common stock that could be issued on the conversion (at the election of Mr. Schafer) by Mr. Schafer of his Adjusted September 2015 convertible note in the amount of $4,245.47. The conversion price will be $.115 per share.

 

(7)   Includes 94,927 shares held directly by Mr. Orphanos; 156,750 shares underlying warrants held directly by Mr. Orphanos; 945 shares held jointly with his wife; 1,262,774 shares held in IRA accounts; and 770,222 shares of common stock that could be issued on conversion of $462,133 convertible notes ($.60 conversion price). Not included are 1,021,303 common shares owned by certain clients of Blacksmith Advisors, over which Mr. Orphanos exercises discretionary authority (which shares include: 68,000 shares owned by Danielle Lominy (formerly Danielle Bassani). Mr. Orphanos disclaims beneficial ownership of the shares listed in the preceding sentences because he has no pecuniary interest in the shares.

 

 

64 
 

 

 
(8)   Includes 50,000 underlying warrants held directly by Mr. O’Neill, 500,000 shares underlying options held directly by Mr. O’Neill and 10,888 shares held by Mr. O’Neill’s wife, and 1,000,000 shares underlying warrants held by Identifoods, LLC which is owned by Mr. O’Neill and his wife.

 

(9)   Includes 504,894 shares, 1,545,000 shares underlying options and 573,747 shares underlying warrants held directly by Mr. Scott. The total also includes 40,011 shares of common stock that could be issued on the conversion (at the election of Mr. Scott) of deferred compensation in the amount of $43,612.11.

 

(10)   Includes 120,635 shares held directly by Mr. Northrop and options to purchase 515,500 shares held by Mr. Northrop. Does not include shares or options owned by the adult children of Mr. Northrop nor his former wife.

 

(11)   Includes 105,112 shares of common stock and 50,000 shares of common stock underlying options held directly by Mr. Zizza.

 

(12)   Includes 50,000 shares of common stock underlying options and 75,000 shares of common stock underlying warrants held directly by Mr. Rupp.

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

 

Other than the employment/consulting agreements, deferred compensation arrangements and conversions of debt described above in Item 1 Business and Item 11 Executive Compensation, there are no related party transactions.

 

Four directors of the Company (Jon Northrop, Ed Schaefer, Salvatore Zizza and William Rupp) are considered to be independent directors.

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.

 

Audit Fees

In January 2017 the Company engaged Eide Bailly LLP as its independent registered public accounting firm. The aggregate fees billed for the fiscal year ended June 30, 2022 and June 30, 2023 by Eide Bailly LLP for professional services rendered for the audit of the Company's annual financial statements and reviews of interim financial statements included in the Company's quarterly reports on Form 10-Q (and related matters) were $10,600 and $54,325, respectively.

 

In December 2022 the Company engaged Haynie & Company as its independent registered public accounting firm. The aggregate fees billed for the fiscal year ended June 30, 2023 by Haynie & Company for professional services rendered for the audit of the Company’s annual financial statements and reviews of the interim financial statements included in the Company’s quarterly reports on Form 10-Q (and related matters) were $71, 000.

 

Audit Related Fees

There were no fees billed by Eide Bailly LLP for audit-related fees in each of the last two fiscal years ended June 30, 2022 and June 30, 2021.

 

There were no fees billed by Haynie & Company for audit-related fees in the last fiscal year ended June 30, 2023.

 

Tax Fees

The aggregate fees billed for tax services rendered by Eide Bailly LLP for tax compliance and related services for the two fiscal years ended June 30, 2023 and June 30, 2022 were nil and nil, respectively.

 

The aggregate fees billed for tax services rendered by Haynie & Company for tax compliance and related services for the year ended June 30, 2023 were nil.

 

All Other Fees

None.

 

Audit Committee Pre-Approval Policy

Under provisions of the Sarbanes-Oxley Act of 2002, the Company's principal accountant may not be engaged to provide non-audit services that are prohibited by law or regulation to be provided by it, and the Board of directors (which serves as the Company's audit committee) must pre-approve the engagement of the Company's principal accountant to provide audit and permissible non-audit services. The Company's Board has not established any policies or procedures other than those required by applicable laws and regulations.

 

 

65 
 

 

 

PART IV

 

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.

 

(a) Exhibits 

 

Exhibit
Number
Description and Location
   
3.1 Amended and Restated Articles of Incorporation of Bion Environmental Technologies, Inc., filed with the Secretary of State of the State of Colorado on April 11, 2022. (Incorporated by reference to Exhibit 3.1 filed with Form 8-K filed on April 12, 2022).
3.2 Amended and Restated Bylaws. (Incorporated by reference to Exhibit 3.2 filed with Form 8-K filed on January 4, 2022).
10.1 Subscription Agreement dated January 10, 2002 between Bion Environmental Technologies, Inc. and Centerpoint Corporation regarding issuance of stock in exchange for cash and claims regarding Aprilia (Incorporated by reference to Exhibit 10.1 filed with Form 10SB12G on November 14, 2006).
10.2 Agreement dated March 15, 2002 and effective January 15, 2002 between Bion Environmental Technologies, Inc. and Centerpoint Corporation regarding purchase of warrant and management agreement (Incorporated by reference to Exhibit 10.2 filed with Form 10SB12G on November 14, 2006).
10.3 Agreement dated February 12, 2003 between Bion Environmental Technologies, Inc. and Centerpoint Corporation canceling provisions of the Subscription Agreement by and between Bion Environmental Technologies, Inc. and Centerpoint Corporation (Incorporated by reference to Exhibit 10.3 filed with Form 10SB12G on November 14, 2006).
10.4 Promissory Note and Security Agreement between Bion Environmental Technologies, Inc. and Bright Capital, LLC (Incorporated by reference to Exhibit 10.4 filed with Form 10SB12G on November 14, 2006).
10.5 Letter Agreement with Bright Capital, Ltd. (Incorporated by reference to Exhibit 10.8 filed with Form 10SB12G on November 14, 2006).
10.6 Amended Agreement with Centerpoint Corporation dated April 23, 2003  (Incorporated by reference to Exhibit 10.10 filed with Form 10SB12G on November 14, 2006).
10.7 Promissory Note and Conversion Agreement between Bion Environmental Technologies, Inc. and Mark A. Smith related to deferred compensation (Incorporated by reference to Exhibit 10.21 filed with Form 10SB12G on November 14, 2006).
10.8 Promissory Note and Conversion Agreement between Bion Environmental Technologies, Inc. and Bright Capital, Ltd. related to deferred compensation (Incorporated by reference to Exhibit 10.22 filed with Form 10SB12G on November 14, 2006).
10.9 Employment agreement with Mark A. Smith (Incorporated by reference to Exhibit 10.23 filed with Form 10SB12G on November 14, 2006).
10.10 Employment agreement with Bright Capital, Ltd. (Incorporated by reference to Exhibit 10.25 filed with Form 10SB12G on November 14, 2006).
10.11 Employment agreement with Jeff Kapell (Incorporated by reference to Exhibit 10.26 filed with Form 10SB12G on November 14, 2006).
10.12 Employment agreement with Jeremy Rowland (Incorporated by reference to Exhibit 10.27 filed with Form 10SB12G on November 14, 2006).
10.13 Office lease at 641 Lexington Avenue, 17th Floor, New York (Incorporated by reference to Exhibit 10.28 filed with Form 10SB12G on November 14, 2006).
10.14 2006 Consolidated Incentive Plan (Incorporated by reference to Exhibit 10.29 filed with Form 10SB12G on November 14, 2006).
10.15 Memo to Dominic Bassani & Bright Capital, Ltd. dated October 16, 2006 regarding Change in Title/Status of DB/Amendment to Brightcap Agreement (Incorporated by reference to Exhibit 10.30 filed with Form 10SB12G on November 14, 2006).
10.16 Promissory Note and Conversion Agreement for Mark Smith, dated January 1, 2007 (Incorporated by reference to Exhibit 10.31 filed with Form 10SB12G/A on February 1, 2007).
10.17 Promissory Note and Conversion Agreement for Bright Capital, Ltd., dated January 1, 2007 (Incorporated by reference to Exhibit 10.35 filed with Form 10SB12G/A on February 1, 2007).
10.18 Extension Agreement dated March 31, 2007 between the Company and Mark A Smith (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on April 3, 2007)
10.19 Form of Note dated March 31, 2007 in the amount of $151,645.89 in favor of Mark A. Smith (Incorporated by reference to Exhibit 10. 2 filed with Form 8-K filed on April 3, 2007)
10.20 Form of Note dated March 31, 2007 in the amount of $455.486.30 in favor of Bright Capital, Ltd. (Incorporated by reference to Exhibit 10.4 filed with Form 8-K filed on April 3, 2007)
10.21 Memorandum of Understanding with Kreider Farms (Incorporated by reference to Exhibit 99.1 filed with Form 8-K filed on February 27, 2008)
10.22 Subscription Agreement from Bright Capital, Ltd. (Incorporated by reference to Exhibit 99.1 filed with Form 8-K filed on June 3, 2008)

 

 

66 
 

 

 

 

   
10.23 Amendment to 2006 Consolidated Incentive Plan (Incorporated by reference to Exhibit 99.2 filed with Form 8-K filed on June 3, 2008)
10.24 Agreement between the Company and Mark A. Smith dated May 31, 2008 (Incorporated by reference to Exhibit 99.3 filed with Form 8-K filed on June 3, 2008).
10.25 2007 Series AB Convertible Promissory Note (Incorporated by reference to Exhibit 99.1 filed with Form 8-K filed on June 19, 2008).
10.26 Promissory Note between Bion Environmental Technologies, Inc. and Dominic Bassani (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on September 30, 2008).
10.27 Promissory Note between Anthony Orphanos and Bion dated October 30, 2008, Guaranteed by Dominic Bassani (Incorporated by reference to Exhibit 10.3 filed with Form 8-K filed on November 13, 2008).
10.28 Addendum to Settlement Agreement and Release Stipulation from Bion, Bion Dairy and Mark Smith dated October 31, 2008 (Incorporated by reference to Exhibit 10.4 filed with Form 8-K filed on November 13, 2008).
10.29 Kreider Farms Agreement (September 25, 2008): REDACTED (Incorporated by reference to Exhibit 10.1 filed with Form 10-Q filed on November 14, 2008).
10.30 Amendment #3 to 2006 Consolidated Incentive Plan (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on January 6, 2009).
10.31 Agreement between Bright Capital, Ltd. and Dominic Bassani and Bion effective January 11, 2009 (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on January 15, 2009).
10.32 Agreement between Mark A. Smith and Bion effective January 12, 2009 (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on January 15, 2009).
10.33 Orphanos Extension Agreement dated January 13, 2009 (Incorporated by reference to Exhibit 10.3 filed with Form 8-K filed on January 15, 2009).
10.34 Lease Agreement between Ronald Kreider and Kreider Farms and Bion PA 1 LLC dated June 26, 2009 (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on July 2, 2009).
10.35 Capitalization Agreement between Bion Companies and Bion PA 1 LLC dated June 30, 2009 (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on July 2, 2009).
10.36 Extension Agreement with Mark A. Smith. (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on August 18, 2010).
10.37 Agreement with Edward Schafer (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on August 18, 2010).
10.38 Accepted Funding Offer (base loan agreement) (without exhibits) with PENNVEST for Kreider Farms Project Loan -- effective November 3, 2010 (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on November 3, 2010).
10.39 Short Form Agreement (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on November 22, 2010).
10.40 Resume of William O’Neill. (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on November 22, 2010).
10.41 Loan & Security Agreement with Milestone Bank (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on December 6, 2010).
10.42 O'Neill Employment Agreement (dated December 22, 2010) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on December 6, 2010).
10.43 Schafer Employment Agreement (dated December 21, 2010) (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on December 6, 2010).
10.44 Biography of Edward T. Schafer (Incorporated by reference to Exhibit 10.3 filed with Form 8-K filed on December 6, 2010).
10.45 Kreider Farms Clarification Agreement (Incorporated by reference to Exhibit 10.3 filed with Form 8-K filed on March 16, 2011).
10.46 Resignation of William O’Neill (effective May 13, 2011) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on May 13, 2011).
10.47 PADEP Certification of Kreider Poultry Credits (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on June 1, 2011).
10.48 Bassani/Bright Capital Extension Agreement (executed August 31, 2011) (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on September 2, 2011).
10.49 Smith Extension Agreement (executed August 31, 2011) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on September 2, 2011).
10.50 Bloom Employment Agreement (executed September 30, 2011) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on October 4, 2011).

 

 

67 
 

 

 

 

 

 

10.51 Extension/Conversion Agreement with Smith and Bassani (dated March 31, 2012) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on April 4, 2012).
10.52 Memorialization of extension of Maturity of Bassani convertible deferred compensation (dated July 31, 2012) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on August 3, 2012).
10.53 Memorialization of Smith Extension Agreement (dated August 14, 2012) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on August 21, 2012).
10.54 Memorialization of Bassani Extension Agreement (dated August 14, 2012) (Incorporated by reference to Exhibit 10.2 filed with Form 8-K filed on August 21, 2012).
10.55 Memorialization of Schafer Agreement (dated August 21, 2012) (Incorporated by reference to Exhibit 10.3 filed with Form 8-K filed on August 21, 2012).
10.56 Board Ratification dated May 5, 2013 (Incorporated by reference to Exhibit 10.1 filed with Form 10-Q filed on May 14, 2013).
10.57 Demand Promissory Note dated May 13, 2013 (Incorporated by reference to Exhibit 10.2 filed with Form 10-Q filed on May 14, 2013).
10.58 Pennvest Demand Letter (dated September 25, 2014) (Incorporated by reference to Exhibit 10.92 filed with Form 10-K filed on September 26, 2014).
10.59 Extension Agreement with Mark A. Smith (w/o exhibits) (February 10, 2015) (Incorporated by reference to Exhibit 10.1 filed with Form 10-Q filed on February 11, 2015).
10.60 Extension Agreement with Dominic Bassani (w/o exhibits) (February 10, 2015) (Incorporated by reference to Exhibit 10.2 filed with Form 10-Q filed on February 11, 2015).
10.61 Agreement with Edward Schafer (w/o exhibits) (February 10, 2015) (Incorporated by reference to Exhibit 10.3 filed with Form 10-Q filed on February 11, 2015).
10.62 Convertible Promissory Note between the Company and Dominic Bassani dated September 8, 2015 (Incorporated by reference to Exhibit 10.96 filed with Form 10-K filed on September 22, 2015).
10.63 Convertible Promissory Note between the Company and Edward Schafer dated September 8, 2015 (Incorporated by reference to Exhibit 10.97 filed with Form 10-K filed on September 22, 2015).
10.64 Convertible Promissory Note between the Company and Anthony Orphanos dated September 8, 2015 (Incorporated by reference to Exhibit 10.98 filed with Form 10-K filed on September 22, 2015).
10.65 Kreider Poultry Joint Venture Agreement (May 5, 2016) (Incorporated by reference to Exhibit 10.1 filed with Form 10-Q filed on May 9, 2016).
10.66 Bassani Warrant Purchase effective August 1, 2018 (Incorporated by reference to Exhibit 10.100 filed with Form 10-K filed on September 24, 2019).
10.67 Smith Warrant Purchase effective August 1, 2018 (Incorporated by reference to Exhibit 10.101 filed with Form 10-K filed on September 24, 2019).
10.68 Amendment #9 to 2006 Consolidated Incentive Plan, as amended (Incorporated by reference to Exhibit 10.102 filed with Form 10-K filed on September 24, 2019).
10.69 Lease (executed September 23, 2021) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on September 29, 2021).
10.70 Subsidiaries of the Registrant (Incorporated by reference to Exhibit 21 filed with Form 10SB12G on November 14, 2006).
10.71 Buflovak/Hebeler Purchase Order (January 28, 2022)(without Technical Details and Standard Terms and Conditions) (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on February 1, 2022)
10.72 Agreement with BioNTech SE re sale/purchase of domain name <biontech.com> (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on March 25, 2022)
10.73 Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan. (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on January 4, 2022).
10.74 William O’Neill Employment Agreement (effective May 1, 2022) (without exhibits). (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on May 3, 2022).
10.75

Letter of Intent with Ribbonwire Ranch (July 20, 2022). (Incorporated by reference to Exhibit 10.1 filed with Form 8-K filed on July 27, 2022). 

31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 - Filed herewith electronically.
31.2 Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 - Filed herewith electronically.
32.1 Certification of Chief Executive Officer Pursuant to Section 18 U.S.C. Section 1350. Furnished*
32.2 Certification of Principal Financial Officer Pursuant to Section 18 U.S.C. Section 1350. Furnished*
101.INS Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

*This exhibit is being furnished rather than filed and shall not be deemed incorporated by reference into any filing, in accordance with Item 601 of Regulation S-K.

 

68 
 

 

 

 

 

 

   
 Report of Independent Registered Public Accounting Firm (Haynie & Company, PCAOB ID: 457)  F-2
   
Report of Independent Registered Public Accounting Firm (Eide Baily LLP; Denver, CO, PCAOB ID:  286)  F-4
   
Consolidated balance sheets     F-6
   
Consolidated statements of operations     F-7
   
Consolidated statements of changes in stockholders’ equity (deficit)  F-8
   
Consolidated statements of cash flows  F-9
   
Notes to consolidated financial statements  F-10 - F-42

 

 

 

F-1 
 

 

 

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

To the Board of Directors and
Stockholders of Bion Environmental Technologies, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheet of Bion Environmental Technologies, Inc. (the Company) as of June 30, 2023 and the related consolidated statements of operations, changes in stockholders’ equity (deficit), and cash flow for the year then ended June 30, 2023, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2023 and the results of its operations and its cash flow for the year then ended June 30, 2023, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has yet to generate any revenue and has suffered recurring losses from operations. These factors raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also discussed in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

 

 

F-2 
 

 

Critical Audit Matters

 

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

Equity Transactions

As discussed in Note 6 and Note 7 to the financial statements, the Company has numerous equity-based agreements, including stock options and warrants issued for services and debt convertible into units (which include common stock and warrants). These agreements require management to estimate the value of options and warrants issued for services on the measurement date or include complicated calculations when debt is converted to equity. During the year ended June 30, 2023, the Company recorded stock-based compensation expense of $249,744, warrants issued for services of $62,563, warrant modifications of $154,932, and a $186,462 of debt converted to common stock.

Our audit procedures required a significant amount of time performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. Those procedures included gaining an overall understanding of the Company’s process for estimating fair value and the related calculations. We read the related equity-based agreements verifying the terms of each agreement to the Company’s calculations and ensuring the mathematical accuracy. We evaluated the assumptions used by management to develop their estimates and considered the relevant accounting guidance.

 

 

 

/s/ Haynie & Company

   
We have served as the Company’s auditor since 2023.
   
Salt Lake City, Utah
September 28, 2023  
   
   

 

 

 

F-3 
 

 

 

 

 

 

 

Report of Independent Registered Public Accounting Firm

 

 

To the Board of Directors and Stockholders
Bion Environmental Technologies, Inc.

Old Bethpage, New York

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Bion Environmental Technologies, Inc. (the “Company”) as of June 30, 2022, and the related consolidated statements of operations, changes in stockholders’ equity (deficit), and cash flows, for the year then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of Bion Environmental Technologies, Inc. as of June 30, 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has not generated significant revenue and has suffered recurring losses from operations. These factors raise substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also discussed in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control over financial reporting. Accordingly, we express no such opinion.

 

 

 

F-4 
 

 

 

Our audit included performing procedures to assess the risk of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

Critical Audit Matter

The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

 

Equity Transactions

 

As discussed in Note 7 to the financial statements, the Company has entered into various equity-based compensation agreements. These agreements include transactions, including the original issuance and subsequent modifications of warrants and stock options, that are required to be measured and accounted for at estimated fair value. These transactions resulted in recording of stock-based compensation expense of $419,370, modification of options of $-0-, warrant issuances of $30,000, and warrant modifications of $8,337 for the year ended June 30, 2022.

 

The Company’s determination of the estimated fair values involves the identification of related financial instruments and a clear understanding of the terms of the agreements. Auditing management’s estimates of fair value requires a high degree of auditor judgment and an increased extent of effort, including the need to carefully examine to understand the true nature of the related agreements.

 

The primary procedures we performed to address this critical audit matter included:

 

·We gained an understanding of management's process and methodology to develop the estimates
·We examined agreements and agreed terms utilized in calculations
·We evaluated the reasonableness of the inputs and assumptions used by management in developing the estimates
·We recalculated the amounts and compared to management’s calculation
·We evaluated the adequacy of the disclosures related to these fair value measurements.

 

  

We have served as Bion Environmental Technologies, Inc. auditor since 2017.

 

Denver, Colorado

September 27, 2022

 

 

F-5 
 

 

 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

         
   June 30,   June 30, 
   2023   2022 
         
ASSETS          
           
 Current assets:          
 Cash  $625,964   $3,160,442 
 Prepaid expenses   16,785    157,550 
 Deposits and other assets   6,000    1,000 
           
 Total current assets   648,749    3,318,992 
           
 Operating lease right-of-use asset   93,875    145,787 
 Property and equipment, net (Note 3)   6,851,009    2,895,558 
           
 Total assets  $7,593,633   $6,360,337 
           
 LIABILITIES AND EQUITY (DEFICIT)          
           
Current liabilities:          
Accounts payable and accrued expenses  $677,137   $1,360,644 
Deferred compensation (Note 4)   864,781    594,798 
Operating lease liability, current (Note 9)   75,000       
           
 Total current liabilities   1,616,916    1,955,442 
           
 Operating lease liability, long term (Note 9)   29,068    128,864 
 Convertible notes payable - affiliates (Note 6)   1,715,970    5,170,610 
           
 Total liabilities   3,361,954    7,254,916 
           
           
 Equity (deficit):          
Common stock, no par value, 250,000,000 shares authorized, 48,044,790 and 43,758,820 shares issued, respectively; 47,340,480 and 43,054,511 shares outstanding, respectively            
Additional paid-in capital   131,935,418    123,620,046 
Subscription receivable - affiliates (Note 8)   (504,650)   (504,650)
Accumulated deficit   (127,236,663)   (124,047,548)
           
Total Bion's stockholders’ equity (deficit)   4,194,105    (932,152)
           
Noncontrolling interest   37,573    37,573 
           
Total equity (deficit)   4,231,678    (894,579)
           
Total liabilities and deficit  $7,593,633   $6,360,337 

 

 

See notes to consolidated financial statements

 

 

 

F-6 
 

 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

YEARS ENDED JUNE 30, 2023 AND 2022

 

         
   2023   2022 
         
Revenue  $    $  
         
Operating expenses:          
General and administrative (including stock-based compensation)   3,072,163    2,348,324 
Depreciation   1,645    1,161 
Research and development (including stock-based compensation)   82,759    200,691 
           
Total operating expenses   3,156,567    2,550,176 
           
Loss from operations   (3,156,567)   (2,550,176)
           
Other (income) expense:          
Interest income   (5,836)   (5,625)
Interest expense   38,384    301,659 
Gain on sale of domain         (902,490)
Gain on legal dissolution of subsidiary         (10,234,501)
           
Total other expense   32,548    (10,840,957)
           
Net income (loss)   (3,189,115)   8,290,781 
           
Net loss attributable to the noncontrolling interest         1,544 
           
Net income (loss) applicable to Bion's common stockholders  $(3,189,115)  $8,292,325 
           
Net income (loss) applicable to Bion's common stockholders          
per basic and diluted common share  $(0.07)  $0.20 
           
Weighted-average number of common shares outstanding:          
Basic and diluted   45,038,479    41,962,302 

 

 

See notes to consolidated financial statements

 

 

F-7 
 

 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) 

YEARS ENDED JUNE 30, 2022 AND 2021

 

 

                                                                                         
    Bion's Stockholders'              
    Series A Preferred Stock     Series C Preferred Stock     Common Stock     Additional paid-in    

Subscription Rec-

-eivables for

    Accumulated     Noncontrolling     Total  
    Shares     Amount     Shares     Amount     Shares     Amount     capital     Shares     deficit     interest     equity/(deficit)  
Balances, July 1, 2021            $                 $          41,315,986     $          121,399,067     $ (504,650 )   $ (132,339,873 )   $ 39,117     $ (11,406,339 )
Warrants exercised for common shares     —                  —                  2,315,550                1,736,662                                  1,736,662  
Commissions on warrant exercises     —                  —                  66,860                (18,601 )                                (18,601 )
Conversion of debt and liabilities     —                  —                  35,424                17,711                                  17,711  
Issuance of units for services     —                  —                  25,000                27,500                                  27,500  
Modification of warrants     —                  —                  —                  8,337                                  8,337  
Issuance of warrants     —                  —                  —                  30,000                                  30,000  
Vesting of options for services     —                  —                  —                  419,370                                  419,370  
Net income (loss)     —                  —                  —                                    8,292,325       (1,544 )     8,290,781  
Balances, June 30, 2022            $                 $          43,758,820     $        $ 123,620,046     $ (504,650 )   $ (124,047,548 )   $ 37,573     $ (894,579 )
Sale of units     —                  —                  1,321,530                1,906,230                                  1,906,230  
Sales of common stock     —                  —                  2,000,000                2,000,000                                  2,000,000  
Warrants exercised for common shares     —                  —                  175,114                131,335                                  131,335  
Issuance of units for services     —                  —                  82,259                130,000                                  130,000  
Issuance of warrants for services     —                  —                  —                  62,563                                  62,563  
Conversion of debt and liabilities     —                  —                  1,542,514                186,462                                  186,462  
Vesting of options for employees and services     —                  —                                   249,744                                  249,744  
Commissions on sale of units     —                  —                  —                  (86,400 )                                (86,400 )
Modification of warrants - non-cash comp     —                  —                  —                  154,932                                  154,932  
Modification of warrants - interest     —                  —                  —                  72,589                                  72,589  
Debt modification     —                  —                  —                  3,507,917                                  3,507,917  
Net loss     —                  —                  —                                    (3,189,115 )              (3,189,115 )
Balances, June 30, 2023            $                 $          48,880,237     $        $ 131,935,418     $ (504,650 )   $ (127,236,663 )   $ 37,573     $ 4,231,678  

 

 

See notes to consolidated financial statements

 

 

F-8 
 

 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

YEARS ENDED JUNE 30, 2023 AND 2022

 

         
   2023   2022 
CASH FLOWS FROM OPERATING ACTIVITIES          
Net income (loss)  $(3,189,115)  $8,290,781 
Adjustments to reconcile net loss to net cash used in operating activities:          
Gain on legal dissolution of subsidiary         (10,234,501)
Depreciation expense   1,645    1,161 
Accrued interest on loans payable, deferred compensation and other   38,384    319,523 
Stock- based compensation   249,744    346,846 
Stock-based compensation for services   130,000       
Modification of warrants   154,932       
Warrants issued for compensation for services   62,563       
Decrease (increase) in prepaid expenses   140,765    (33,501)
Increase (decrease) in deposits in other assets   (5,000)      
Increase (decrease) in accounts payable and accrued expenses   (879,618)   366,629 
Decrease (increase) in operating lease assets and liabilities   27,116    (16,923)
Increase in deferred compensation   340,000    289,200 
           
Net cash used in operating activities   (2,928,584)   (670,785)
           
CASH FLOWS FROM INVESTING ACTIVITIES          
Purchase of property and equipment   (3,557,059)   (2,062,155)
           
Net cash used in investing activities   (3,557,059)   (2,062,155)
           
CASH FLOWS FROM FINANCING ACTIVITIES          
Proceeds from sale of units   3,906,230       
Proceeds from sale of warrants   131,335    1,736,662 
Commissions on sale of warrants   (86,400)   (18,601)
Commissions on sale of units            
Redemption of Preferred Series B shares and interest         (41,000)
           
Net cash provided by financing activities   3,951,165    1,677,061 
           
Net increase (decrease) in cash   (2,534,478)   (1,055,879)
           
Cash at beginning of year   3,160,442    4,216,321 
           
Cash at end of year  $625,964   $3,160,442 
           
Supplemental disclosure of cash flow information:          
Cash paid for interest  $     $   
           
Non-cash investing and financing transactions:          
Adjustment for debt modification  $3,507,917   $   
Conversion of debt and liabilities into common units  $186,462   $17,711 
Conversion of debt and liabilities into notes payable  $23,943   $   
Conversion of deferred compensation to notes payable  $90,000   $190,000 
Capitalized interest in property and equipment  $179,984   $32,000 
Shares issued for warrant exercise commissions  $     $50,145 
Purchase of property and equipment for accounts payable  $220,052   $666,375 

 

See notes to consolidated financial statements

 

 

F-9 
 

 

 

BION ENVIRONMENTAL TECHNOLOGIES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

YEARS ENDED JUNE 30, 2023 AND 2022

 

1.ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

 

Organization and nature of business:

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to make livestock production more sustainable, profitable and transparent. We intend to accomplish this by deploying our Gen3Tech platform/business model (discussed below) in ventures focused on the ‘feeder’ space of the livestock production/value chain to provide the consumer with verifiably sustainable premium meat products (together with environmentally friendly, sustainable and/or organic co-products from the production process).  Bion believes this approach can create extraordinary value for our shareholders and employees (all of whom own securities in the Company) and for livestock/agriculture industry ‘partners’ who join us in our ventures. We anticipate pursuing the opportunity created by our third generation technology (“Gen3Tech”) and business/technology platform in conjunction with other industry practices (“Gen3Tech Platform” or “Platform”) utilizing a joint venture/strategic partner model. We believe our approach will improve the well-being of farmers, ranchers, feeders, etc. we work with and create value for our shareholders while improving the environment.  

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate surface groundwater, and exacerbate climate change.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). To accomplish Bion’s goals, we anticipate the we will ‘partner’ with other technology companies who provide solutions for different links of the beef (and other livestock) value chain and with strategic partners up and down the supply chain.

We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent one of the largest enhanced revenue contributors provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the animal raising and waste treatment process will be third-party verified, providing the basis for additional revenues, including carbon and/or renewable energy-related credits and, eventually, payment for a range of ecosystem services, including nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

 During the first half of 2022 Bion began pre-marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022, Bion announced a letter of intent (“Ribbonwire LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). During January 2023 Bion announced a letter of intent (“Olson LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Olson Feeders and TD Angus, near North Platte, Nebraska (with a provision to expand to 45,000 head or more) (“Olson Project”). During April 2023 Bion announced a letter of intent (“DVG LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with Dakota Valley Growers near Bathgate, North Dakota (“DVG Project”). Based on our experience to date, we believe we will not have difficulty in securing participation in our Projects from additional feeders/cattlemen. The Olson, Dalhart and DVG Projects (and subsequent Projects) will be developed to produce blockchain-verified, sustainable beef in customized covered barns (resulting in reduced stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) with ongoing manure transfer (through slatted floors) to anaerobic digesters (AD) to capture nitrogen from the manure stream before loss to the atmosphere and generate renewable natural gas (RNG) for sale while remediating the environmental/carbon impacts usually associated with cattle feedlots and CAFOs. Bion’s patented Gen3Tech platform will refine the waste stream into valuable coproducts that include clean water, RNG, photovoltaic solar electricity and fertilizer (‘climate smart’ and/or organic) products. We anticipate converting these LOIs into definitive JV agreements and creating related distribution agreements with key retailers and food service distributors during the current fiscal year.

 

F-10 
 

 

 

Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef JV projects over the next twenty-four (24) months while moving forward with the Initial Project (see below) and commencing development of one or more of the Dalhart/Olson/DVG Projects (“LOI Projects”)(and/or other Gen3Tech beef JV projects) while pursuing other opportunities in the livestock industry enabled by our Gen3Tech business model.  The LOI announcements have generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties) and has led to and assisted our discussions with many major of the larger agriculture/livestock industry companies (including those involved with distribution and/or sales of meat products) in the country which are ongoing at this date. We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment at a rapid pace.

During the past nine months, the Company has constructed (construction is largely completed) our 3GTech Ammonia Recovery System (‘ARS’) located near Fair Oaks, Indiana and begun operations of phase 1 of our Initial Project (our commercial scale demonstration facility) located near Fair Oaks, Indiana. We recently announced that announced the ARS has achieved and maintained controlled steady-state operations under a variety of conditions. When operated at steady state, the system produces an ammonium distillate (solution), the base of Bion’s nitrogen fertilizer products. Bion has begun optimizing the ARS’s operating parameters with the goal of meeting and/or exceeding the results needed for Bion’s economic models for large-scale commercial projects. The Company expects the current optimization phase will continue during the next quarter (or longer) and provide data required to support final design/engineering for commercial project modules. We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below).

 

The patented ARS is the core of Bion’s Gen3Tech platform. It recovers and upcycles problem ammonia contained in the effluent from anaerobic digestion (where methane is captured and more ammonia is released) of the livestock manure waste stream. The ARS captures the ammonia, minimizing its environmental impacts and creating low-carbon and/or organic nitrogen fertilizer products with it. Over during the next quarter, the Company intends to produce ammonium distillate at Fair Oaks in several concentrations and initiate the application process for organic certification for each concentration of liquid fertilizer product. Bion will produce a solid/granular nitrogen fertilizer product at the Initial Project (when the crystalizer module is ready for operation) which we believe will be both ‘Climate-Smart’ and ‘Water-Smart’ – a pure nitrogen fertilizer with a low carbon footprint, that is water soluble and readily available to plants. Samples of the granular product will also be utilized to support organic certification applications. See Fertilizer---Organic and ‘ClimateSmart’ below.

 

During the next three - six/ months, the Company intends to fully complete construction of the Initial Project’s phase 1, including the crystalizer module, and continue the optimization operations. Bion expects the Initial Project data will document the effectiveness of our Gen3Tech in a commercial-scale setting during the current fiscal year and support development of the LOI Projects (and/or other Gen3Tech beef JV projects) commencing later this fiscal year.  We do not presently know the order in which these JV Projects will be developed as that decision will be made based on many factors not yet in place. We believe the Initial Project data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, food distributors and retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). 

 

Bion is now focused primarily on: i) completion of development/construction and operation of the Initial Project, our initial commercial-scale Gen3Tech installation, and optimization of its operational parameters, ii) pre-development plan of the LOI Projects (and/or other Gen3Tech beef JV projects) including steps toward distribution agreements, iii) developing applications and markets for its low carbon ‘ClimateSmart’ and organic fertilizer products (including listings/certifications of multiple liquid and solid products) and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed herein) (and related Projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

 

F-11 
 

 

HISTORY, BACKGROUND AND CURRENT ACTIVITIES

 

Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.

From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product, while raising sustainable livestock.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market (despite the lack of verifiably sustainable attributes).

 

The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded conventional livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a production/marketing opportunity for Bion (but the former is far larger). Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon/organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.

 

During 2022-23, the Company entered into 3 LOIs setting forth the parties’ intention to negotiate joint venture agreement (“JVA”) and enter into joint ventures (“JV”) to develop and operate 15,000 head integrated, sustainable beef facilities (with future expansion under consideration) including:

 

  a) innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,

 

  b) ‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,

 

  c) a Bion Gen3Tech module (which will utilize the recycled CO2 to increase ammonia nitrogen/ammonium bicarbonate recovery) for the production of ammonia nitrogen fertilizer for use in organic and/or ‘ClimateSmart’ low carbon crop production (plus residual organic solids and clean water),

 

  d) which will produce verifiably sustainable beef products with USDA certified branding.

 

F-12 
 

 

 

The opportunity presented by the LOIs to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head operation a reality as soon as possible.

To place the LOI Projects in the context of Company’s business plan (and our prior public disclosure), if the contemplated ventures moves forward on the timelines currently contemplated, active development of the the initial LOI Project will commence during 2024.

 

Prior to such activity, the Company has constructed and commenced operate of the initial phase of our previously discussed Gen3Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion Gen3Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the LOIProjects). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, is utilizing anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

During late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately 1,500 head). The facility is large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs (many pandemic-associated) delayed delivery dates for core modules of the Bion system to the site until during January 2023. Construction has been substantially completed related to Phase 1 of the Initial Project, shakedown operations undertaken and the operation is now focused on optimization of operation parameters. See Note 3 “Property and Equipment” and Note 12 “Subsequent Events” (for activities since the start of the first quarter of the 2024 fiscal year).

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

 

F-13 
 

 

Specifically, the Initial Project was designed/developed to provide and/or accomplish the following:

 

i.   Proof of Gen3Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3Technology platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

ii.   Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

iii.   Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) in liquid and solid forms for commercial testing by potential joint venture partners and/or purchasers, for university growth trials and to provide samples (and related documentation) to support applications for organic and/or ‘ClimateSmart’ certifications.

 

iv.   Produce sustainable beef products for initial test marketing efforts.

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. Subsequent agreements were executed with engineering firms, contractors and other entities related to the construction of the Initial Project. The Company received progress billing in March 2022 and June 2022 for the second and third 25% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $533,100 which was paid on March 1, 2023 and on April 24,203 for $83,275 which was paid on May 2, 2023 bringing the aggregate payments to $2,615,500 as of the date of this filing. There remaining $50,000 open on the Purchase Order has been billed on July 26,2023. In addition to the Purchase Order, the Company has incurred additional costs of $4,182,260 on the Initial Project for capitalized interest and costs, non-cash compensation and consulting fees. $3,962,207 has been paid and $220,053 has been billed and not yet been paid.

 

The Initial Project will be carried out in stages with phase one focused largely on portions of items i. and iii. set forth above.

 

Upon completing the primary goals of phase 1 of the Initial Project (coupled with obtaining organic certifications(s) for our liquid and/or solid ammonium bicarbonate fertilizer product lines), Bion expects to be ready to move forward with its plans for development of much larger facilities including the LOI Projects, including final design of its Gen3Tech modules. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 12-24 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the optimization operations of the Initial Project with a 2024 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.

 

After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the Company will determine whether to complete the entire Initial Project as originally designed at that location or the relocate the core modules to an alternative permanent location. The Company has engaged in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or other mutually agreed upon location) which facility would include innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long-term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company will also evaluate re-locating the core module of the Initial Project to Dalhart, Texas, where it might be integrated into the first phases of the Dalhart Project and/or other locations. 

 

 

F-14 
 

The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. Applications for our first solid ammonium bicarbonate product line have been filed with OMRI, the California Department of Food & Agriculture (“CDFA”) and the Iowa Organic Program (“IOP”) and are in the review processes (which is likely to require an extended period of time and multiple procedural steps, in part due to the novel nature of our Gen3Tech in the context of organic certifications). See “Fertilizer– Organic and ‘ClimateSmart’” below.

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘Gen3Tech Kreider 2 Poultry Project’ below as an example) in the swine, dairy and poultry industries utilizing our Gen3Tech.

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/dairy/egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a large, but apparently limited, segment of consumers is choosing seemingly sustainable offering, and are also willing to pay a premium for it. Tyson Foods, in the context of launching its Brazen beef initiative, recently said, “consumers would be willing to pay at least 24 percent more for environmentally friendly, sustainable options at retail.” Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, will enable the cleanup of one of the ‘dirtiest’ parts of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef was 63% more expensive in 2021, while pork and chicken, which are now primarily raised in covered barns at CAFOs with highly integrated supply chains, were 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have also recently entered the plant protein space. While meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, have been heavily promoted (by themselves and the media) and enjoyed remarkable initial sales growth, recently, sales have flattened and/or declined over the past 18 months. It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint---and market growth rates have substantially slowed and may have already plateaued and/or peaked. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.

 

In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary beef ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy. Sustainability initiatives have been launched by large US livestock producers (including Tyson’s very recent ‘Brazen’ program), but it is not yet possible to determine the extent the attributes of such products will be substantive and verifiable rather than completely ‘modeled’ and largely public relations ‘greenwashing’.

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.

 

F-15 
 

 

 

Sustainable Beef

 

Bion’s goal is to be one of the ‘first to market’ with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at Bion facilities will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.

 

A Bion sustainable beef facility will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia and greenhouse gas volatilization and loss, as well as odors, thereby improving animal health and human working conditions while preventing air/soil pollution. The manure will be collected and moved directly to anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in geographical locations with adequate sunshine and appropriate ‘tariffs’) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.

 

 

Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass-fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies (including Tyson’s very recent ‘Brazen’ program), but a closer look finds that many have consisted largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.

 

Sustainable Organic Beef

 

Bion also believes it may also have a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

 

 

F-16 
 

 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.

 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Fertilizer: Organic and ‘Climate Smart’

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products. The Company’s low concentration ammonium bicarbonate liquid product successfully completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. During the next 3-4 months the Company intends to file applications with OMRI and the California Department of Food & Agriculture (“CDFA”) for a line of higher concentration liquid ammonium nitrogen products ( ranging from 6% up to 16% (or higher)) based on production of liquid samples during operation of the Initial Project over the next 2 months. The Company anticipates applying for and obtaining one or more listings/certifications for higher concentration products in our liquid ammonium nitrogen fertilizer line well prior to operational dates for the Company’s initial large scale JV Gen3Tech Sustainable Beef Projects.

 

Additionally, the Company intends to explore the market potential for its fertilizer (in liquid and/or solid forms) to be a verifiably ‘ClimateSmart’ product (potentially a much larger market than the organic market) with focus on higher value specialty crops. This will require working with industry and academic entities to develop appropriate metrics and producing a ‘life cycle assessment’ (LCA) for Bion’s ammonium nitrogen fertilizer product which can be compared to conventional nitrogen fertilizer products. Bion’s processes will capture and utilize CO2 in the waste stream (including CO2 produced with the renewable natural gas (RNG) by anaerobic digestion that is usually vented to the atmosphere) as stabilizing agent thereby potentially creating carbon offsets compared to natural gas utilized as feedstock in chemical ammonia production which reduction will be reflected in the LCA. This LCA will assess environmental impacts associated with fertilizer production in support of the beef cattle supply chain for both the existing conventional approach (primarily fossil fuel-based Haber-Bosch production methods) and the largely decarbonized Bion production approach. We believe a series of coincident yet significant LCA benefits accrue from Bion’s patented fertilizer production approach including the reduced loss of ammonia to the environment via air (volatilized) and water (nitrate in groundwater) pathways, recycled/reused water, elimination of pathogens, the production of renewable natural gas, the production solar energy from photovoltaic panels on barn roofs, enhanced animal welfare practices and reduced animal husbandry risks from extreme weather events. Bion believes that current evaluations of the carbon impact from feedlot operations materially underestimate the negative impacts because existing models do not properly include significant ‘downstream’ carbon impacts of required energy intensive waste water treatment for re-deposited ammonia nitrogen. If the Company determines there is a significant ‘ClimateSmart’ opportunity for our fertilizer products, such an LCA can be completed (based in part on data from the Initial Project) and support marketing efforts well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.

 

 

F-17 
 

 

Ammonium bicarbonate, manufactured using thermal and mechanical processes, has a long history of use as a fertilizer. In addition to liquid ammonium nitrogen fertilizer, Bion’s Gen3Tech is capable of recovering nitrogen in the form of solid ammonium bicarbonate products containing up to 18%-22% (or higher) nitrogen in a crystalline form that is easily transported (while producing liquids with various percentages of ammonium bicarbonate nitrogen during interim stages of the process). This solid product is water soluble and provides a readily available nitrogen source for crops. It will contain virtually none of the other salt, iron and mineral constituents of the livestock waste stream that often accompany other organic fertilizers. This product is being developed to fertilizer industry standards so that it that can be precision-applied to crops using existing equipment. Bion believes that this product will potentially have broad applications in the production of organic and/or ClimateSmart grains for livestock feed, row crops, horticulture, greenhouse and hydroponic production, and potentially retail lawn and garden products.

 

The ammonium bicarbonate products (liquid and solid) produced by Bion’s Gen3Tech platform will enjoy a dramatically lower carbon footprint than synthetic nitrogen fertilizers. Much of the reactive nitrogen captured and upcycled into our fertilizer products was going to be lost through volatilization and runoff, and that loss would generally need to be offset with a synthetic nitrogen fertilizer, such as anhydrous ammonia or urea. These synthetic nitrogen products are produced through the Haber-Bosch (and other) synthetic processes, which converts hydrogen and atmospheric nitrogen to ammonia, with methane from fossil fuels as the energy source. It is an extremely energy-intensive process with a carbon footprint that, while not yet fully understood, is widely accepted to by very large. While a complete Life Cycle Assessment (LCA) of carbon impacts from synthetic fertilizer production is not yet available, according to the Institute for Industrial Productivity, its production alone is responsible for approximately 1 percent of total global CO2 emissions. To the extent that Bion can capture and repurpose the nitrogen traditionally lost from livestock waste, that carbon cost will no longer need to be paid by the environment/climate.

 

Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line were filed with OMRI (filed during May 2021) and CDFA (filed during May 2022) without success to date. After an extended review processes (which was largely opaque), the OMRI application proceeded through multiple stages without receiving a positive result. We have initiated an informal dialogue with CDFA regarding the basis for and re-consideration of its initial determination and anticipate submitting additional supporting materials to CDFA during the next 30 days. The Company’s solid product line is novel (in the context of organic certification) in part due to the fact that no formal listing category currently in the organic space for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produces it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other organic fertilizer stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company intends to continue efforts to obtain listing/certification for its solid nitrogen fertilizer line over the course of this fiscal year.

 

F-18 
 

 

 

Gen3Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

Technology Deployment: Bion Gen3Tech

 

In the absence of firm regulatory mandates, widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production and/or certified as ‘ClimateSmart’. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion above and below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage. The Company has additional applications pending and/or planned.

 

 

F-19 
 

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2024 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun — and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition — it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

 

F-20 
 

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source—before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.

 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

 

F-21 
 

 

Going concern and management’s plans:

 

The Company’s audited financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and generated/incurred a net income of $8,292,000 for the year ended June 30, 2022 and a net loss of approximately $3,189,000 during the year ended June 30, 2023. The net income for the year ended June 30, 2022 was largely due to a one-time, non-cash event of the dissolution of PA-1 resulting in a gain of approximately $10,235,000 as well as a one-time gain of $902,000 from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period. At June 30, 2023, the Company has a working deficit and a stockholders’ equity of approximately $968,000 and $4,194,000, respectively. During the year ended June 30, 2023 the Company had debt modifications that resulted in a reduction of debt of $3,522,000 and an increase in equity in the same amount. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

 

The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

 

During the years ended June 30, 2023 and 2022, the Company received gross proceeds of approximately $4,038,000 and $1,737,000, respectively, from the sale of its debt and equity securities. The company paid commissions on the exercise of warrants in the amount of $86,000 and $19,000 in 2023 and 2022, respectively.

 

During fiscal years 2023 and 2022, the Company faced less difficulty in raising equity funding (but was subject to substantial equity dilution from the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. However, this positive trend did not continue during the last quarter of the 2023 fiscal year and first quarter of the current fiscal year (to date). The Company raised only raised very limited equity funds during such periods to meet its some of its immediate needs, therefore, the Company needs to raise additional funds in the upcoming periods. The Company currently faces substantial increases in demand for capital and operating expenditures for the fiscal year 2024 to date (and we anticipate such increased demands will continue during the remainder of the 2024 fiscal year and periods thereafter) as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management issues due to limited capital resources and working capital constraints which had only recently begun to be alleviated. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring most of their cash compensation and/or are accepting compensation in the form of securities of the Company (Notes 5 and 7 to Financial Statements) and members of the Company's senior management have from time to time made loans to the Company and may need to do so in future periods. Note that, to deal with earlier capital constraints, during the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. As set forth in detail elsewhere herein, during the year ended June 30, 2023 senior management (and family members) who held convertible obligations of the Company adjusted the terms of their outstanding notes and agreed to debt modifications that reduced of the Company’s debt by $3,522,000 and increased shareholders equity by the same amount. The constraints on available resources have had, and continue to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and/or curtailment of ongoing activities including research and development activities.

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including operations at the Initial Project, JV Projects (including the Dalhart/Olson/DVG Projects), and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and/or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

 

F-22 
 

 

 

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

 

Covid-19 pandemic related matters:

 

The Company faces many risks and uncertainties and factors beyond our control that have been magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

2.       SIGNIFICANT ACCOUNTING POLICIES

 

Principles of consolidation:

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

 

 

F-23 
 

 

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of June 30, 2023 and June 30, 2022 there are no cash equivalents.

 

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

 

F-24 
 

 

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

 

F-25 
 

 

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income (Loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the years ended June 30, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

 

          
   June 30,
2023
   June 30,
2022
 
Warrants   22,543,765    20,778,635 
Options   12,006,600    11,201,600 
Convertible debt   9,922,769    10,686,065 
Convertible preferred stock            

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the years ended June 30, 2023 and 2022:

 

           
   Year
ended
June 30,
2023
   Year
ended
June 30,
2022
 
Shares issued – beginning of period   43,758,820    41,315,986 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)
Shares outstanding – beginning of period   43,054,511    40,611,677 
Weighted average shares issued
    during the period
   1,983,968    1,350,625 
Diluted weighted average shares –
    end of period
   45,038,479    41,962,302 

 

 

Use of estimates:

 

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

 

F-26 
 

 

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.

 

3.  PROPERTY AND EQUIPMENT:

 

Property and equipment consist of the following:

 

          
   June 30,
2023
   June 30,
2022
 
Computers and office equipment   15,156    13,598 
Initial Project: construction in process   6,847,760    2,892,222 
Property and equipment, gross   6,862,916    2,905,820 
Less accumulated depreciation   (11,907)   (10,262)
 Property and equipment, net  $6,851,009   $2,895,558 

 

The 3G1 project (“Initial Project”) began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for the Initial Project construction in process includes $211,984 for capitalized interest and $135,648 in non-cash compensation as of June 30, 2023.

 

Management has reviewed the remaining property and equipment for impairment as of June 30, 2023 and believes that no impairment exists.

 

Depreciation expense was $1,645 and $1,161 for the years ended June 30, 2023 and 2022, respectively.

 

4.       DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling $864,781 and $594,798 as of June 30, 2023 and 2022, respectively. Included in the deferred compensation balances as of June 30, 2023, are $527,058 and $20,167 owed Dominic Bassani (“Bassani”), the Company’s Chief Operating Officer (who was Chief Executive Officer until through April 30, 2022), and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at 4% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of June 30, 2022 was $437,508 and $10,000, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $105,056 and $74,790 as of June 30, 2023 and 2022, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at 0% to 3% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing. Bassani and Smith have each been granted the right to convert up to $300,000 of deferred compensation balances at a price of $0.75 per share until June 30, 2024 into common shares (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election but such right is no longer in force.

Bill O’Neill has a balance of $140,000 and $20,000 at June 30, 2023 and 2022, respectively. There is no interest or conversions on the deferred balance. During the year ended June 30, 2023, Smith elected to add $90,000 of deferred compensation to his 2020 Convertible Note.

The Company recorded interest expense of $19,983 ($17,716 with related parties) and $16,390 ($15,537 with related parties) for the years ended June 30, 2023 and 2022, respectively.

  

F-27 
 

 

5.       LOANS PAYABLE:

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436). The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

 

F-28 
 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

6.       CONVERTIBLE NOTES PAYABLE - AFFILIATES:

 

Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes --- see below) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate –See Note 7 below, ‘Debt Modification to Additional Paid in Capital’) while equitably maintaining existing conversion rights.  The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.

 

Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and the adjusted portion of the September 2015 Convertible Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units (consisting of 1 share and from one half (1/2) to one (1) warrant) at prices of $.0946, $.0953, and $.0953, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The adjusted conversion prices slightly reduce the securities to be issued on conversion of each instrument from the amount receivable under the unadjusted instruments. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). After the adjustment, the Company owed Smith, Bassani (and trust) and Schafer $262,154, $434,016 and $96,364, respectively, of Adjusted 2020 Convertible Obligations and Bassani and Schafer, respectively, $24,230 and $4,012 of Adjusted September 2015 Convertible Notes.

 

 

F-29 
 

 

 

During the year ended June 30, 2023, Smith elected to convert $136,462, in aggregate, of his Adjusted 2020 Convertible Obligation into 1,442,514 units at $0.0946 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until March 2026. In more detail, effective: a) March 8, 2023, Smith converted $70,000 of his Adjusted 2020 Convertible Obligation into 739,958 Units (each Unit consisting one share and one warrant); b) March 31, 2023, Smith converted $29,888 of his Adjusted Convertible Obligation into 315,948 Units (each Unit consisting one share of common stock and one warrant); and c) June 4, 2023, Smith converted $36,573 of his Adjusted Convertible Obligation into 386,608 Units (each Unit consisting one share of common stock and one warrant). Smith donated to charitable organizations and/or gifted to family members and others a large portion of these securities (700,000 common shares and 955,000 warrants, in aggregate) while retaining direct ownership of 292,514 common shares and 116,566 warrants and indirect ownership of 450,000 common shares and 370,948 warrants (owned by his wife). The warrants are exercisable for three years from conversion dates. Subsequent to June 30, 2023, Smith converted additional portions of his Adjusted Convertible Obligation. See Note 12.

 

As of June 30 2023, the Adjusted 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer were $441,446, $130,180 and $98,014, respectively.

 

As of June 30, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $24,645 and $4,081, respectively.

 

2020 Convertible Obligations

 

The 2020 Convertible Obligations (which combined/replaced prior convertible instruments dating to 2017 (or earlier), which accrue interest at either 4% per annum or 4% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until July 1, 2024. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”. Effective February 1, 2023, a large portion of the 2020 Convertible Obligations were adjusted as set forth herein.

 

 

F-30 
 

 

 

As of June 30, 2023, the remaining unadjusted portion of the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees) and Smith, were $361,321 and $36,432, respectively. As of June 30, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $2,597,329, $1,328,040 and $499,274, respectively.

 

During the year ended June 30, 2023 (on dates prior to the adjustment on February 1, 2023), Smith elected to add $90,000 of his accrued unpaid compensation/un-reimbursed expenses to his 2020 Convertible Obligations.

 

During the year ended June 30, 2023 (on dates prior to the adjustment on February 1, 2023), Smith elected to convert $30,000 in principal of the 2020 Convertible Obligation to 60,000 units (60,000 common shares and 60,000 warrants), and $20,000 of accrued interest of the 2020 Convertible Obligation to 40,000 units (40,000 common shares and 40,000 warrants). The warrants are exercisable for three years from conversion date.

 

During the year ended June 30, 2023 (on dates after the adjustment on February 1, 2023), Smith elected to convert $136,462 in principal of the Adjusted 2020 Convertible Obligation to 1,442,514 units (1,442,514 common shares and 1,442,514 warrants). The warrants are exercisable for three years from conversion dates.

 

The Company recorded interest expense of $102,478 and $131,718 for the year ended June 30, 2023 and 2022, respectively. The Company capitalized $179,981 and $32,000 related to the Initial Project for the year ended June 30, 2023 and 2022, respectively.

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long-term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights. Because the modifications where with affiliates that are related parties, the debt modification was treated as an equity transaction. The Company recorded a deemed dividend for the reductions.

 

Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations (see above and Note 7.). The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.

 

September 2015 Convertible Notes

 

During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at 4% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.

 

The balances of the September 2015 Convertible Notes as of June 30, 2023, including accrued interest owed Bassani, Schafer and Shareholder, are $183,628, $4,081 and $460,873, respectively. The balances of the September 2015 Convertible Notes as of June 30, 2022, including accrued interest, were $279,366, $20,845 and $445,756, respectively.

 

The Company recorded interest expense of $23,318 and $23,796 for the year ended June 30, 2023 and 2022, respectively.

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including the September 2015 Convertible Notes owned by Bassani and Schafer) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.52 million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President), Dominic Bassani (the Company’s Chief Operating Officer)(and a family Trust) and Ed Schafer (Director), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the were renamed Adjusted September 2015 Convertible Notes. The Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. As of June 30, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $24,645 and $4,081, respectively. The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties. See above.

 

 

F-31 
 

  

 

7.       STOCKHOLDERS' EQUITY:

 

Debt Modification to Additional paid in capital

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes --- see below) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights. Because the modifications where with affiliates that are related parties, the debt modification was treated as an equity transaction. The Company recorded a deemed dividend for the reductions.

 

Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and the adjusted portion of the September 2015 Convertible Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units at prices of $.0946, $0953, and $.0953, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The adjusted conversion prices slightly reduce the securities to be issued on conversion of each instrument from the amount receivable under the unadjusted instruments. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). After the adjustment, the Company owed Smith, Bassani (and trust) and Schafer $262,154, $434,016 and $96,364, respectively, of Adjusted 2020 Convertible Obligations and Bassani and Schafer, respectively, $24,230 and $4,012 of Adjusted September 2015 Convertible Notes. The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.

 

The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). The Company treated this as an equity transaction and recorded the reduction of debt through additional paid in capital at the net present value of the modified debt agreements. This resulted in an increase to Additional Paid in Capital of $3,522,000 at the modification date and a reduction of additional paid in capital of $14,051 for the year ended June 30, 2023 for the adjustment to the net present value of the modified debt agreements.

 

Series B Preferred stock:

 

Since July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. The 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

During the years ended June 30, 2023, and 2022, the Company declared dividends of nil and $1,000 respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements. There is no liability at June 30, 2023.

 

Common stock:

 

Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.

 

Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

 

 

F-32 
 

 

 

During the year ended June 30, 2023, the Company entered into a subscription agreement to sell 2,000,000 shares of restricted and legended common stock of which 1,800,000 shares were purchased on January 10, 2023 and the other 200,000 shares were purchased on December 31, 2022 for total proceeds during the year ended June 30, 2023 $2,000,000.

 

During the year ended June 30, 2023, the Company entered into subscription agreements to sell 975,000 units at a price of $1.60, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $2.40 per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued 975,000 units for total proceeds of $1,560,000, in aggregate. The Company paid commissions of $86,400 on the sale of units.

 

During the year ended June 30, 2023, 175,114 warrants were exercised to purchase 175,114 shares of the Company’s common stock at $0.75 per share for total proceeds of $131,335.

During the year ended June 30, 2023, the Company entered into subscription agreements to sell units for $1.00 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 346,230 units for total proceeds of $346,230.

 

During the year ended June 30, 2023, the Company issued 50,000 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.60 per share for a total value of $80,000.

During the year ended June 30, 2023, the Company issued 32,259 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.55 per share for a total value of $50,000.

During the year ended June 30, 2023, Smith elected to convert $30,000 in principal and $20,000 in accrued interest from the 2020 Convertible Obligation to 100,000 units at $.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2023, Smith elected to convert $136,462 in principal of his Adjusted 2020 Convertible Obligation into 1,442,514 units at $0.0946 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until March 2026. See above and Note 6 for more detail.

 

 

F-33 
 

 

Warrants:

 

As of June 30, 2023, the Company had approximately 22.5 million warrants outstanding, with exercise prices from $0.60 to $2.40 and expiring on various dates through November 9, 2026.

 

The weighted-average exercise price for the outstanding warrants is $0.80, and the weighted-average remaining contractual life as of March 31, 2023 is 1.6 years.

 

During the year ended June 30, 2023, Smith elected to convert $30,000 in principal and $20,000 in accrued interest from the 2020 Convertible Obligation to 100,000 units at $.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until three years after the date of conversion.

 

During the year ended June 30, 2023, Smith elected to convert $136,462, in aggregate, of his Adjusted 2020 Convertible Obligation into 1,442,514 units at $0.0946 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until March 2026. In more detail: a) effective March 8, 2023, Smith converted $70,000 of his Adjusted 2020 Convertible Obligation into 739,958 Units (each Unit consisting one share and one warrant); b) effective March 31, 2023, Smith converted $29,888 of his Adjusted Convertible Obligation into 315,948 Units (each Unit consisting one share of common stock and one warrant); and c) effective June 4, 2023, Smith converted $36,573 of his Adjusted Convertible Obligation into 386,608 Units (each Unit consisting one share of common stock and one warrant). Smith donated to charitable organizations and/or gifted to family members and others a large portion of these securities (700,000 common shares and 955,000 warrants, in aggregate) while retaining direct ownership of 292,514 common shares and 116,566 warrants and indirect ownership of 450,000 common shares and 370,948 warrants (owned by his wife). The warrants are exercisable for three years from conversion dates. Subsequent to June 30, 2023, Smith converted additional portions of his Adjusted Convertible Obligation. See Note 12.

 

During the twelve months ended June 30, 2023, the Company approved the issuance of 210,000 warrants, in aggregate, to three new members of its Advisory Group for advisory and/or consulting services of $21,000, in aggregate. The warrants are exercisable at $1.50 to $1.60 and expire in August 2025.

During the twelve months ended June 30, 2023, the Company approved the modification of existing warrants held by one former consultant and investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $154,932 and interest expenses of $72,589.

During the twelve months ended June 30, 2023, 175,114 warrants were exercised to purchase 175,114 shares of the Company’s common stock at $0.75 per share for total proceeds of $131,335.

 

Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise price adjustment provision if the terms set forth therein are met. 700,000 of the warrants are vesting through May 1, 2023 and 2024. The vesting resulted in non-cash compensation of $41,653 during the year ended June 30, 2023.

 

Stock options:

 

On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “Equity Plan”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to 30,000,000 shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.

 

 

F-34 
 

 

 

The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to 36,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms,

 

On March 15, 2023, the Company granted 30,000 options under the 2006 Plan to two consultants. The options vest equally in thirds on March 20, 2023, June 20, 2023 and September 30, 2023.

 

On February 7, 2023, the Company granted an aggregate of 275,000 options under the 2006 Plan to five employees/consultants/directors including: i) 25,000 options to Jon Northrop for service as director, ii) 100,000 to two consultants and iii) 150,000 to employees.

 

On May 9, 2023, the Company granted 500,000 options under the 2006 Plan to Bill O’Neill. 250,000 of these options vest on June 1, 2024 and 250,000 options vest on June 1, 2025; all options expire on June 30, 2026.

 

The Company recorded compensation expense related to employee stock options of $249,744 and $419,370 for the years ended June 30, 2023 and 2022, respectively. The Company granted 805,000 and 730,000 options for the year ended June 30, 2023 and 2022, respectively.

 

The fair value of the options granted during the years ended June 30, 2023 and 2022 were estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:

                
   Weighted
Average,
June 30,
2023
   Range,
June 30,
2023
   Weighted
Average,
June 30,
2022
   Range,
June 30,
2022
 
Volatility   65%   64% -66%   65%   65%-69%
Dividend yield                        
Risk-free interest rate   3.83%   3.67% – 4.11    2.99%   1.71%-3.01 
Expected term (years)   3.44    2.84 to 3.95%   3.71    3.04 to 3.72%

 

The expected volatility was based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

A summary of option activity under the 2006 Plan for year ended June 30, 2023 is as follows:

                                   
      Options     Weighted-
Average
Exercise
Price
    Weighted-
Average
Remaining
Contractual
Life
    Aggregate
Intrinsic
Value
 
  Outstanding at July 1, 2022       11,201,600     $ 0.80       2.7     $ 4,429,263  
    Granted       805,000                           
    Exercised                                    
    Forfeited                                    
    Expired                                    
  Outstanding at June 30, 2023       12,006,600     $ 0.85       1.83     $ 5,085,659  

 

The total fair value of stock options that vested during both the year ended June 30, 2023 and 2022 was $249,744 and $419,370, respectively. As of June 30, 2023, the Company had no unrecognized compensation cost related to stock options.

 

8.       SUBSCRIPTION RECEIVABLE - AFFILIATES:

 

As of June 30, 2023, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $428,250 ($517,553, including interest) from Bassani which were received as consideration for purchases of warrants to purchase 5,565,000 shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $0.75 (with a 75% exercise price adjustment provision) and have expiry dates ranging from December 31, 2024 to December 31, 2025 (subject to extension rights) secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.

 

 As of June 30, 2023, the Company has an interest bearing, secured promissory note for $30,000 ($35,884 including interest) from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60(with a 75% exercise price adjustment provision) and have expiry dates of December 31, 2024 (subject to extension rights) The promissory note bears interest at 4% per annum, and is secured by $30,000 ($35,885 including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.

 

 

F-35 
 

 

As of June 30, 2023 the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $46,400 ($56,860 including interest) from two employee/consultants as consideration to acquire warrants to purchase 928,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.75 (with a 90% exercise price adjustment provision) and have expiry dates of December 31, 2024. (The promissory notes bear interest at 4% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.

These secured promissory notes are recorded as “Subscription receivable—affiliates” on the Company’s balance sheet pending payment.

9.       COMMITMENTS AND CONTINGENCIES:

 

Employment and consulting agreements:

 

Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month-to-month contract extension with Smith which included provisions for i) a monthly salary of $18,000 ( deferred until the Board of Directors re-instated cash payments to all employees and consultants who are deferring compensation), ii) the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until December 31, 2024, and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $25,000 per month of which $5,000 per month is deferred. Currently Smith is deferring all but $5000 of his monthly compensation to help the Company conserve cash. For the years ended June 30, 2023 and 2022, Smith was paid $200,000 and $130,000, respectively, of cash compensation.

 

Since March 31, 2005, the Company has had various agreements with Bassani (and/or Brightcap which provided his services during some of the years), now the Company’s Chief Operating Officer (‘COO’) and formerly the Company’s Chief Executive Officer (‘CEO’)(any reference to Brightcap or Bassani for all purposes are referring to the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017 (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($31,000 per month) until the Board of Directors re-instated cash payments to all employees and consultants who were deferring their compensation. During October 2016 Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until June 30, 2024 (including extensions). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $31,000 per month, which will continue to be accrued in part during periods when the Board determines there is not adequate cash available. Additionally, the Company agreed to pay or accrue $2,000 per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of June 30, 2023, the principal and accrued interest was $361,321. Currently Bassani is deferring all but $5000 of his monthly compensation to help the Company conserve cash. For the years ended June 30, 2023 and 2022, Brightcap was paid $300,000 and $250,000, respectively, of cash compensation.

 

William O’Neill (“O’Neill”) was hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s Gen3 Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill entered into a thirty-seven (37) month employment agreement with compensation of $25,000 cash and $10,000 deferred compensation per month. The cash payment is paid $12,500 to O’Neill and $12,500 to an entity affiliated with O’Neill. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share ( a 75% exercise price adjustment provision if the terms set forth therein are met) until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. Currently O’Neill is deferring all but $5000 of his monthly compensation to help the Company conserve cash. For the years ended June 30, 2023 and 2022, O’Neill and the entity affiliated with O’Neill was paid $150,000 and $25,000, respectively, of cash compensation.

 

 

F-36 
 

 

 

Exercise Price Adjustments/Extension Rights:

 

As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise price adjustment provision (exercise bonus in the context of options) which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the adjustment shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock adjustments, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods were reduced to $.01 per option or warrant. These exercise adjustments were subsequently increased to 75%.

 

During the year ended June 30, 2021, the Company added a 75% exercise price adjustment to the terms of 3,000,000 warrants held by a trust owned by Bassani.

 

As of June 30, 2023, exercise price adjustment provisions ranging from 50-90% were applicable to 11,771,600 of the Company’s outstanding options and 18,438,339 of the Company’s outstanding warrants.

 

Effective May 1, 2022, an entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants were cancellable if O’Neill was not renewed at 13 months (renewal has happened) and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise price adjustments if the terms set forth therein are met.

 

Initial Project:

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. The Company received progress billing in March 2022 and June 2022 for the second and third 25% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $533,100 which was paid on March 1, 2023 and on April 24, 2023 the Company received an invoice from Buflovak for $83,275 which was paid on May 2, 2023 bringing the aggregate payments to $2,615,500 as of the date of this filing. There remains $50,000 open on the Purchase Order has been billed on July 26, 2023. In addition to the Purchase Order, through June 30, 2023 the Company has incurred additional costs of $4,182,260 on the Initial Project for capitalized interest and costs, non-cash compensation and consulting fees. $3,962,207 has been paid and $220,053 has been billed and not yet paid. See Note 12 “Subsequent Events” for expenditure after June 30, 2023.

 

 

F-37 
 

 

Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete, fabrication and delivery of equipment from Bufflovak from the Purchase Order Agreement has been largely completed and assembly/construction is in process.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, utilities, etc.) for work related to the Initial Project. The Company has incurred costs of $6,103,693 on the Initial Project, not including capitalized labor and interest.

 

Litigation:

 

A: Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

 On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subjected to disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s consolidated balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

 

F-38 
 

 

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

 

F-39 
 

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

Bank Account Hacking

 

On June 23, 2023, an officer of the Company with personal accounts with Signature Bank was hacked and $75,000 was transferred from the Company’s accounts at Signature Bank to the officer’s personal accounts. The bank was notified and all Company accounts were placed on hold. Subsequently, the funds were released and transferred back to the Company prior to June 30, 2023 the end of the fiscal year and there were no losses incurred.  The Company has reviewed the authorized individuals on all accounts and further limited access after the hacking incident.  

 

The Company currently is not involved in any other material litigation or similar events.

 

Lease:

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of June 30, 2023:

 

Schedule Of Future Minimum Lease Payment      
Year ended June 30, 2023 to June 2024   $ 75,000  
Year ended June 30, 2024 to December 2024     37,500  
Undiscounted cash flow     112,500  
Less imputed interest     (8,432 )
Total   $ 104,068  
   Less current portion     (75,000 )
Long term lease liability     29,068  

 

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of June 30, 2023 were 1.58 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

 

F-40 
 

 

 

10.       INCOME TAXES

 

The reconciliation between the expected federal income tax benefit computed by applying the Federal statutory rate to loss before income taxes and the actual benefit for taxes on loss for the years ended June 30, 2023 and 2022 is as follows:

          
   2023   2022 
Expected income tax benefit at statutory rate  $(670,000)  $1,741,000 
State taxes, net of federal benefit   (117,000)   303,000 
Permanent differences and other   9,000    8,000 
Expiration of net operating allowances   733,000    1,229,000 
Change in valuation allowance   (45,000)   (3,281,000)
Income tax benefit  $     $   

 

The Company has net operating loss carry-forwards (“NOLs”) for tax purposes of approximately $39,500,000 as of June 30, 2023. These NOLs expire on various dates through 2042.

 

The utilization of the NOLs may be limited under Section 382 of the Internal Revenue Code.

The Company’s deferred tax assets for the years ended June 30, 2023 and 2022 are estimated as follows:

          
   2023   2022 
NOL carryforwards (Federal and State)  $8,299,000   $8,274,000 
Stock-based compensation   5,459,000    5,436,000 
Impairment   1,340,000    1,340,000 
Business interest   338,000    339,000 
Deferred compensation   1,054,000    1,054,000 
Capitalized research and development   66,000       
Gross deferred tax assets   16,148,000    16,443,000 
Valuation allowance   (16,148,000)   (16,443,000)
Net deferred tax assets  $     $   

 

The Company has provided a valuation allowance of 100% of its net deferred tax asset due to the uncertainty of generating future profits that would allow for the realization of such deferred tax assets.

 

 

F-41 
 

 

 

11.       401(k) PLAN:

 

The Company has adopted the Bion Technologies, Inc. 401(k) Profit Sharing Plan and Trust (the “401(k) Plan”), a defined contribution retirement plan for the benefit of its employees. The 401(k) Plan is currently a salary deferral only plan and at this time the Company does not match employee contributions. The 401(k) is open to all employees over 21 years of age and no service requirement is necessary.

 

 

12.        SUBSEQUENT EVENTS:

 

The Company has evaluated events that occurred subsequent to June 30, 2023 for recognition and disclosure in the financial statements and notes to the financial statements.

 

From July 1, 2023 through September 28, 2023, the Company has incurred costs of $583,870 for an aggregate of $7,431,630 for the Initial Project. 

 

From July 1, 2023 through September 28, 2023, 38,000 warrants were exercised to purchase 38,000 shares of the Company’s common stock at $0.75 per share for total proceeds of $28,500.

 

On July 7, 2023, the Company issued 7,500 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.20 per share for a total value of $9,000.

On July 21, 2023, Mr. Smith converted $49,048 of principal from his Adjusted 2020 Convertible note into 518,477 Units at a conversion rate of $.0946; each unit consisting of one share and one warrant with the exercise price of $.75 until 7/21/2026. Each of these warrants carry an exercise price adjustment provision of 75%.

 

On August 16, 2023, the Company issued 10,753 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.55 per share for a total value of $16,667.

On August 28, 2023, the Company sold 28,589 units at a price of $1.60 for a total of $45,742.  

 

 

 

 

 

F-42 
 

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunder duly authorized.

 

  BION ENVIRONMENTAL TECHNOLOGIES, INC.
   
Dated:  September 28, 2023 By: /s/ Mark A. Smith
      Mark A. Smith, President and Chief
      Financial Officer (Principal Financial
      and Accounting Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:

 

SIGNATURE   TITLE   DATE
         
         
/s/ Mark A. Smith   Executive Chairman,   September 28, 2023
Mark A. Smith  

President, Chief Financial Officer

and Director

   
         
         
/s/ William O’Neill   Chief Executive Officer   September 28, 2023
William O’Neill        
         
         
/s/ Jon Northrop   Secretary and Director   September 28, 2023
Jon Northrop        
         
         
/s/ Edward Schafer       September 28, 2023
Edward Schafer   Director    
         
         
/s/ William Rupp   Director   September 28, 2023
William Rupp        
         
         
/s/ Salvatore Zizza   Director   September 28, 2023
Salvatore Zizza        

 

 

 

 69

 

 

 

 

 

 

 

 

EX-31.1 2 bion_ex31x1.htm EXHIBIT 31.1 Certification

Exhibit 31.1

 


SECTION 302 CERTIFICATION

 


I, William O’Neill, certify that:

 


1.   I have reviewed this annual report on Form 10-K of Bion Environmental Technologies, Inc.;

 


2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 


3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;

 


4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 


(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 


(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 


(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 


(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 


5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 


(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 


(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 


Date:  September 28, 2023

 



/s/ William O’Neill

William O’Neill

Chief Executive Officer





EX-31.2 3 bion_ex31x2.htm EXHIBIT 31.2 Certification


Exhibit 31.2


SECTION 302 CERTIFICATION


I, Mark A. Smith, certify that:


1.   I have reviewed this annual report on Form 10-K of Bion Environmental Technologies, Inc.;


2.   Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


3.   Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the of the registrant as of, and for, the periods presented in this report;


4.   The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)  Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)  Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)  Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)  Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


5.   The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


(a)  All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


(b)  Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


Date:  September 28, 2023




/s/ Mark A. Smith

Mark A. Smith

Executive Chairman, President and Chief Financial Officer




EX-32.1 4 bion_ex32x1.htm EXHIBIT 32.1 Certification


Exhibit 32.1

 


CERTIFICATION OF CEO PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Form 10-K of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the fiscal year ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"),William O’Neill, Chief Executive Officer of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

September 28, 2023 /s/ William O’Neill  
 

William O’Neill

Chief Executive Officer

 

 




This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 


A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



EX-32.2 5 bion_ex32x2.htm EXHIBIT 32.2 Certification


Exhibit 32.2

 


CERTIFICATION OF CFO PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 


In connection with the Form 10-K of Bion Environmental Technologies, Inc., a company duly formed under the laws of Colorado (the "Company"), for the fiscal year ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Mark A. Smith, President (Executive Chairman) and Chief Financial Officer (Principal Financial and  Accounting Officer) of the Company, hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:

 

(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

       
Date: September 28, 2023   /s/ Mark A. Smith  
   

Mark A. Smith

Executive Chairman, President and

Chief Financial Officer

 
       

 

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

 

A signed original of this written statement required by Section 906 has been provided to Bion Environmental Technologies, Inc. and will be retained by Bion Environmental Technologies, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

 

GRAPHIC 6 image_001.jpg GRAPHIC begin 644 image_001.jpg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image_002.jpg GRAPHIC begin 644 image_002.jpg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image_003.jpg GRAPHIC begin 644 image_003.jpg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end EX-101.SCH 9 bnet-20230630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - DEFERRED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - LOANS PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - STOCKHOLDERS' EQUITY: link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES: link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - 401(k) PLAN: link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUBSEQUENT EVENTS: link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - STOCKHOLDERS' EQUITY: (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - DEFERRED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - LOANS PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - STOCKHOLDERS' EQUITY - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - STOCKHOLDERS' EQUITY: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - INCOME TAXES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - SUBSEQUENT EVENTS: (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 bnet-20230630_cal.xml XBRL CALCULATION FILE EX-101.DEF 11 bnet-20230630_def.xml XBRL DEFINITION FILE EX-101.LAB 12 bnet-20230630_lab.xml XBRL LABEL FILE Class of Stock [Axis] Series A Preferred Stock [Member] Series C Preferred Stock [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Subscriptions Receivable [Member] Retained Earnings [Member] Noncontrolling Interest [Member] Counterparty Name [Axis] J V A [Member] Gen 3 Tech [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Ownership [Axis] Centerpoint [Member] Antidilutive Securities [Axis] Warrant [Member] Share-Based Payment Arrangement, Option [Member] Convertible Debt Securities [Member] Convertible Preferred Stock Antidilutive Securities [Member] Long-Lived Tangible Asset [Axis] Property Plant And Equipment Of P A 1 [Member] Title of Individual [Axis] Bassani [Member] Smith [Member] Consultants And Employee [Member] Bassani And Smith [Member] Bill O Neill [Member] Nature of Expense [Axis] Interest Expense On Deferred Compensation Obligation [Member] Debt Instrument [Axis] Pennvest Loan [Member] Scenario [Axis] Years One Through Five [Member] Years Six Through Maturity [Member] Legal Entity [Axis] P A 1 [Member] Mark A Smith [Member] Dominic Bassani [Member] Ed Schafer [Member] September 2015 Convertible Notes [Member] Award Type [Axis] Restricted Common Shares [Member] Chief Executive Officer [Member] The 2020 Convertible Obligations [Member] Related Party Transaction [Axis] Bassani Family Trusts [Member] Schafer [Member] Long-Term Debt, Type [Axis] Convertible Debt [Member] Restricted Common Stock [Member] Adjusted Convertible Obligations [Member] Convertible Obligations 2020 [Member] Common Shares [Member] Warrants [Member] Direct Ownership [Member] Indirect Ownership [Member] President [Member] Executive Vice Chairman [Member] Principal [Member] Accrued Interest [Member] After Adjustment [Member] Receivable Type [Axis] Secured Promissory Note [Member] Shareholder [Member] Consultants [Member] Chief Operating Officer [Member] Series B Preferred Stock [Member] Restricted Stock [Member] Consultant Service [Member] Consultant Service One [Member] The 2020 One Convertible Obligations [Member] Three Consultants [Member] Plan Name [Axis] Equity Incentive Plan [Member] Plan 2006 [Member] Northrop [Member] Financial Instrument [Axis] Options Held [Member] Weighted Average [Member] Class of Warrant or Right [Axis] Warrants Issused Subscription Receivable [Member] Former Employee [Member] Smiths [Member] Warrants Issued In Connection With Sale Of Units In Exchange For Salary [Member] Extension Bonus [Member] Fy 2016 Extension Agreement [Member] Warrants Expiring On December 312025 [Member] Secured Promissory Note Consideration For Warrants Expiring On December 312025 [Member] William O Neill [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Document financial statement error correction Auditor Firm ID Auditor Name Auditor Location Statement of Financial Position [Abstract] ASSETS  Current assets:  Cash  Prepaid expenses  Deposits and other assets  Total current assets  Operating lease right-of-use asset  Property and equipment, net (Note 3)  Total assets  LIABILITIES AND EQUITY (DEFICIT) Current liabilities: Accounts payable and accrued expenses Deferred compensation (Note 4) Operating lease liability, current (Note 9)  Total current liabilities  Operating lease liability, long term (Note 9)  Convertible notes payable - affiliates (Note 6)  Total liabilities  Equity (deficit): Common stock, no par value, 250,000,000 shares authorized, 48,044,790 and 43,758,820 shares issued, respectively; 47,340,480 and 43,054,511 shares outstanding, respectively Additional paid-in capital Subscription receivable - affiliates (Note 8) Accumulated deficit Total Bion's stockholders’ equity (deficit) Noncontrolling interest Total equity (deficit) Total liabilities and deficit Common stock, par value Common stock, authorized (in shares) Common Stock, Shares Issued Common Stock, Shares Outstanding Income Statement [Abstract] Revenue Operating expenses: General and administrative (including stock-based compensation) Depreciation Research and development (including stock-based compensation) Total operating expenses Loss from operations Other (income) expense: Interest income Interest expense Gain on sale of domain Gain on legal dissolution of subsidiary Total other expense Net income (loss) Net loss attributable to the noncontrolling interest Net income (loss) applicable to Bion's common stockholders Weighted-average number of common shares outstanding: per basic common share per Diluted common share Weighted-average number of common shares outstanding, basic Weighted-average number of common shares outstanding, diluted Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Sale of units Sale of units, shares Sales of common stock Sales of common stock, shares Warrants exercised for common shares Warrants exercised for common shares , shares Issuance of warrants for services Commissions on warrant exercises Commissions on warrant exercises , shares Conversion of debt and liabilities Conversion of debt and liabilities, shares Issuance of units for services Issuance of units for services, shares Modification of warrants Issuance of warrants Vesting of options for services Vesting of options for employees and services Commissions on sale of units Modification of warrants - non-cash comp Modification of warrants - interest Debt modification Net loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Net income (loss) Adjustments to reconcile net loss to net cash used in operating activities: Gain on legal dissolution of subsidiary Depreciation expense Accrued interest on loans payable, deferred compensation and other Stock- based compensation Stock-based compensation for services Modification of warrants Warrants issued for compensation for services Decrease (increase) in prepaid expenses Increase (decrease) in deposits in other assets Increase (decrease) in accounts payable and accrued expenses Decrease (increase) in operating lease assets and liabilities Increase in deferred compensation Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from sale of units Proceeds from sale of warrants Commissions on sale of warrants Commissions on sale of units Redemption of Preferred Series B shares and interest Net cash provided by financing activities Net increase (decrease) in cash Cash at beginning of year Cash at end of year Supplemental disclosure of cash flow information: Cash paid for interest Non-cash investing and financing transactions: Adjustment for debt modification Conversion of debt and liabilities into common units Conversion of debt and liabilities into notes payable Conversion of deferred compensation to notes payable Capitalized interest in property and equipment Shares issued for warrant exercise commissions Purchase of property and equipment for accounts payable Organization, Consolidation and Presentation of Financial Statements [Abstract] ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Property, Plant and Equipment [Abstract] PROPERTY AND EQUIPMENT Share-Based Payment Arrangement [Abstract] DEFERRED COMPENSATION Debt Disclosure [Abstract] LOANS PAYABLE Convertible Notes Payable - Affiliates CONVERTIBLE NOTES PAYABLE - AFFILIATES Equity [Abstract] STOCKHOLDERS' EQUITY: Subscription Receivable - Affiliates SUBSCRIPTION RECEIVABLE - AFFILIATES Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES: Income Tax Disclosure [Abstract] INCOME TAXES Retirement Benefits [Abstract] 401(k) PLAN: Subsequent Events [Abstract] SUBSEQUENT EVENTS: Principles of consolidation Cash and cash equivalents Property and equipment Patents Stock-based compensation Derivative Financial Instruments Options Warrants Concentrations of credit risk Noncontrolling interests Fair value measurements Lease Accounting Revenue Recognition Income (Loss) per share Use of estimates Recent Accounting Pronouncements Schedule of anti dilutive securities Schedule of earnings per share, basic and diluted Schedule of property and equipment Schedule of assumptions Schedule of option activity Schedule Of Future Minimum Lease Payment Schedule of effective income tax rate reconciliation Schedule of deferred tax assets and liabilities Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Tech wastage Cattle per head Debt instrument paid amount Debt Instrument, Interest Rate During Period Principal, interest Aggregate payment Purchase order Capitalized labor and interest costs Capitalized labor and interest costs paid Capitalized labor and interest costs yet to pay Percentage of sustainable Description of kreider 2 poultry project Net Income (loss) Net income Gain on sale of domain Working Capital Reduction of debt Proceeds from Issuance or Sale of Equity Exercise of warrants Deferred Compensation Liability, Amount Cancelled Capital Required for Capital Adequacy Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities Shares issued – beginning of period Shares held by subsidiaries (Note 7) Shares outstanding – beginning of period Weighted average shares issued     during the period Diluted weighted average shares –     end of period Noncontrolling interest, ownership percentage by parent Cash equivalents Computers and office equipment Initial Project: construction in process Property and equipment, gross Less accumulated depreciation  Property and equipment, net Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Capitalized interest Non cash compensation Impairment of Long-Lived Assets Held-for-use Depreciation expense Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Deferred compensation liability Interest Rate on Deferred Compensation Deferred Compensation Consecutive Trading Days (Day) Former employee compensation Deferred Compensation, Convertible to Common Stock Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share) Deferred compensation interest Interest Expense Interest Expense, Related Party Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Construction Loan Accrued Interest and Late Charges Payable Total assets Total liabilities Accounts payable and accrued liabilities Accounts payable Accrued Liabilities, Current Gain on legal dissolution of subsidiary Line of Credit Facility, Maximum Borrowing Capacity Debt Instrument, Annual Principal Payment Long-Term Debt, Maturity, Year Two Long-Term Debt, Maturity, Year Three Long-Term Debt, Maturity, Year Four Interest Expense, Debt Loans as a liability Debt Instrument, Debt Default, Amount Realized from the asset sale Convertible notes payable Principal amount Conversion price per unit Convertible Notes Payable Conversion of shares, value Conversion of shares, shares Sell units Convertible stock shares issued, warrants Shares issued, warrants Convertible Notes Payable, Noncurrent Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage, Quarterly Original conversion price Salary paid Debt conversion value Debt conversion shares, warrants Capitalized amount Financing receivable interest rate stated percentage Convertible note Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Volatility Dividend yield Risk-free interest rate Expected term (years) Options outstanding, beginning (in shares) Options outstanding, beginning weighted-average exercise price Outstanding, weighted-average remaining contractual life (Year) Outstanding, aggregate intrinsic value beginning Granted, options (in shares) Granted, weighted-average exercise price Exercised, options (in shares) Exercised, weighted-average exercise price Forfeited, options (in shares) Forfeited, weighted-average exercise price Expired, options (in shares) Expired, weighted-average exercise price Options outstanding, ending (in shares) Options outstanding, ending weighted-average exercise price Outstanding, aggregate intrinsic value ending Schedule of Stock by Class [Table] Class of Stock [Line Items] Convertible Notes Payable, Current Debt Instrument, Face Amount Conversion Price Per Unit (in dollars per share) Increase to additional paid in capital Reduction of additional paid in capital Preferred Stock, Shares Outstanding, Ending Balance (in shares) Par value Preferred Stock, Convertible Option Per Share Preferred Stock, Redemption Price Per Share Redemption of convertible Preferred stock Dividends Payable Dividends, Preferred Stock Shares Held by Subsidiaries Sale of stock, shares Shares purchased, shares Shares purchased, value Sale of units Share price Number of shares issued Sale of common shares Commissions paid Class of Warrant or Right, Exercised During Period Common Stock Shares Issued upon Exercise of Warrants Warrants exercisable per share Warrant Exercised for Common Stock Shares issued for consultant services Share price Total value of consultant services Debt conversion shares Conversion price per share Warrant outstanding Weighted average exercise price Remaining contractual life Number of shares issued Issuance of warrants Share-based Payment Arrangement, Plan Modification, Incremental Cost Interest expenses Cancellation of warrants Exercise bonus Vesting period Non cash compensation Stock options, authorized (in shares) Number of shares granted Share-based Compensation, Granted Share-based Compensation, Granted Share-based Payment Arrangement, Expense Financing Receivable, after Allowance for Credit Loss, Total Notes receivable interest Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) Financing Receivable, Principal Amount Financing Receivable, Interest Rate, Stated Percentage Year ended June 30, 2023 to June 2024 Year ended June 30, 2024 to December 2024 Undiscounted cash flow Less imputed interest Total    Less current portion Long term lease liability Loss Contingencies [Table] Loss Contingencies [Line Items] Monthly Officers Cash Compensation Compensation increased Cash compensation paid Cash compensation paid Deferred Compensation, Maximum Convertible Amount Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share) Salaries and wages Additional paid amount Interest bearing secured promissory note Repayments of Long-term Debt, Total Payment for cash Exercise price adjustment provision Percentage Warrants held by trust owned Warrants and Rights Outstanding Paid invoice amount Capitalized labor and interest costs Sale of domain, description Accrued interest Gain on legal dissolution of subsidiary Bank account hacked amount Weighted average remaining lease term Discounted rate Expected income tax benefit at statutory rate State taxes, net of federal benefit Permanent differences and other Expiration of net operating allowances Change in valuation allowance Income tax benefit NOL carryforwards (Federal and State) Stock-based compensation Impairment Business interest Deferred compensation Capitalized research and development Gross deferred tax assets Valuation allowance Net deferred tax assets Operating Loss Carryforwards, Total Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Subsequent Event [Table] Subsequent Event [Line Items] Cost incurred Aggregate cost Number of shares exercised Number of shares exercised Warrants exercised Total proceeds Number of shares warrants outstanding Total value of consultant services Unreimbursed expenses Number of shares converted Conversion price per unit Warrant exercise price Warrants exercise price percentage Slae of shares Slae of share price Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit). Amount of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expiration of net operating allowance. Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from business interest. Assets, Current Liabilities, Current Common Stock, Share Subscribed but Unissued, Subscriptions Receivable Equity, Attributable to Parent Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Expenses Operating Income (Loss) Interest Income, Operating GainOnSaleOfDomains GainOnLegalDissolutionOfSubsidiary Other Nonoperating Income (Expense) Net Income (Loss) Attributable to Noncontrolling Interest Net Income (Loss) Available to Common Stockholders, Basic Shares, Outstanding GainOnLegalDissolutionsOfSubsidiary ModificationOfWarrants Increase (Decrease) in Prepaid Expense Increase (Decrease) in Other Operating Assets Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Payments for Repurchase of Warrants CommissionsOnSaleOfUnits Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Property, Plant and Equipment, Gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, Plant and Equipment, Other, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value SaleOfUnitPricePerUnit Adjustments to Additional Paid in Capital, Warrant Issued Share-Based Payment Arrangement, Expense Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross FinanceLeasesLiabilityCurrent InterestsCostsIncurredCapitalized Extinguishment of Debt, Gain (Loss), Net of Tax Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Deferred Tax Assets, Valuation Allowance TotalValueOfConsultantServices ConversionPricePerUnits EX-101.PRE 13 bnet-20230630_pre.xml XBRL PRESENTATION FILE XML 14 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - USD ($)
$ in Millions
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Aug. 01, 2023
Cover [Abstract]      
Document Type 10-K    
Amendment Flag false    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Jun. 30, 2023    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2023    
Current Fiscal Year End Date --06-30    
Entity File Number 000-19333    
Entity Registrant Name BION ENVIRONMENTAL TECHNOLOGIES, INC.    
Entity Central Index Key 0000875729    
Entity Tax Identification Number 84-1176672    
Entity Incorporation, State or Country Code CO    
Entity Address, Address Line One 9 East Park Court    
Entity Address, City or Town Old Bethpage    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 11804    
City Area Code (516)    
Local Phone Number 586-5643    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float $ 46.5    
Entity Common Stock, Shares Outstanding     48,703,905
Document financial statement error correction false    
Auditor Firm ID 457 286  
Auditor Name Haynie & Company Eide Baily LLP  
Auditor Location Salt Lake City, Utah Denver, Colorado  
XML 15 R2.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2023
Jun. 30, 2022
 Current assets:    
 Cash $ 625,964 $ 3,160,442
 Prepaid expenses 16,785 157,550
 Deposits and other assets 6,000 1,000
 Total current assets 648,749 3,318,992
 Operating lease right-of-use asset 93,875 145,787
 Property and equipment, net (Note 3) 6,851,009 2,895,558
 Total assets 7,593,633 6,360,337
Current liabilities:    
Accounts payable and accrued expenses 677,137 1,360,644
Deferred compensation (Note 4) 864,781 594,798
Operating lease liability, current (Note 9) 75,000
 Total current liabilities 1,616,916 1,955,442
 Operating lease liability, long term (Note 9) 29,068 128,864
 Convertible notes payable - affiliates (Note 6) 1,715,970 5,170,610
 Total liabilities 3,361,954 7,254,916
 Equity (deficit):    
Common stock, no par value, 250,000,000 shares authorized, 48,044,790 and 43,758,820 shares issued, respectively; 47,340,480 and 43,054,511 shares outstanding, respectively
Additional paid-in capital 131,935,418 123,620,046
Subscription receivable - affiliates (Note 8) (504,650) (504,650)
Accumulated deficit (127,236,663) (124,047,548)
Total Bion's stockholders’ equity (deficit) 4,194,105 (932,152)
Noncontrolling interest 37,573 37,573
Total equity (deficit) 4,231,678 (894,579)
Total liabilities and deficit $ 7,593,633 $ 6,360,337
XML 16 R3.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2023
Jun. 30, 2022
Statement of Financial Position [Abstract]    
Common stock, par value $ 0 $ 0
Common stock, authorized (in shares) 250,000,000 250,000,000
Common Stock, Shares Issued 48,044,790 43,758,820
Common Stock, Shares Outstanding 47,340,480 43,054,511
XML 17 R4.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Revenue
Operating expenses:    
General and administrative (including stock-based compensation) 3,072,163 2,348,324
Depreciation 1,645 1,161
Research and development (including stock-based compensation) 82,759 200,691
Total operating expenses 3,156,567 2,550,176
Loss from operations (3,156,567) (2,550,176)
Other (income) expense:    
Interest income (5,836) (5,625)
Interest expense 38,384 301,659
Gain on sale of domain (902,490)
Gain on legal dissolution of subsidiary (10,234,501)
Total other expense 32,548 (10,840,957)
Net income (loss) (3,189,115) 8,290,781
Net loss attributable to the noncontrolling interest 1,544
Net income (loss) applicable to Bion's common stockholders $ (3,189,115) $ 8,292,325
XML 18 R5.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) - $ / shares
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
per basic common share $ (0.07) $ 0.20
per Diluted common share $ (0.07) $ 0.20
Weighted-average number of common shares outstanding, basic 45,038,479 41,962,302
Weighted-average number of common shares outstanding, diluted 45,038,479 41,962,302
XML 19 R6.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Series A Preferred Stock [Member]
Series C Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Subscriptions Receivable [Member]
Retained Earnings [Member]
Noncontrolling Interest [Member]
Total
Beginning balance, value at Jun. 30, 2021 $ 121,399,067 $ (504,650) $ (132,339,873) $ 39,117 $ (11,406,339)
Beginning balance, shares at Jun. 30, 2021 41,315,986          
Warrants exercised for common shares 1,736,662 1,736,662
Warrants exercised for common shares , shares     2,315,550          
Commissions on warrant exercises (18,601) (18,601)
Commissions on warrant exercises , shares     66,860          
Conversion of debt and liabilities 17,711 17,711
Conversion of debt and liabilities, shares     35,424          
Issuance of units for services 27,500 27,500
Issuance of units for services, shares     25,000          
Modification of warrants 8,337 8,337
Issuance of warrants 30,000 30,000
Vesting of options for services 419,370 419,370
Net loss 8,292,325 (1,544) 8,290,781
Ending balance, value at Jun. 30, 2022 123,620,046 (504,650) (124,047,548) 37,573 (894,579)
Ending balance, shares at Jun. 30, 2022 43,758,820          
Sale of units 1,906,230 1,906,230
Sale of units, shares     1,321,530          
Sales of common stock 2,000,000 $ 2,000,000
Sales of common stock, shares     2,000,000         346,230
Warrants exercised for common shares 131,335 $ 131,335
Warrants exercised for common shares , shares     175,114          
Issuance of warrants for services 62,563 62,563
Conversion of debt and liabilities 186,462 186,462
Conversion of debt and liabilities, shares     1,542,514          
Issuance of units for services 130,000 130,000
Issuance of units for services, shares     82,259          
Vesting of options for employees and services 249,744 249,744
Commissions on sale of units (86,400) (86,400)
Modification of warrants - non-cash comp 154,932 154,932
Modification of warrants - interest 72,589 72,589
Debt modification 3,507,917 3,507,917
Net loss (3,189,115) (3,189,115)
Ending balance, value at Jun. 30, 2023 $ 131,935,418 $ (504,650) $ (127,236,663) $ 37,573 $ 4,231,678
Ending balance, shares at Jun. 30, 2023 48,880,237          
XML 20 R7.htm IDEA: XBRL DOCUMENT v3.23.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES    
Net income (loss) $ (3,189,115) $ 8,290,781
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on legal dissolution of subsidiary (10,234,501)
Depreciation expense 1,645 1,161
Accrued interest on loans payable, deferred compensation and other 38,384 319,523
Stock- based compensation 249,744 346,846
Stock-based compensation for services 130,000
Modification of warrants 154,932
Warrants issued for compensation for services 62,563
Decrease (increase) in prepaid expenses 140,765 (33,501)
Increase (decrease) in deposits in other assets (5,000)
Increase (decrease) in accounts payable and accrued expenses (879,618) 366,629
Decrease (increase) in operating lease assets and liabilities 27,116 (16,923)
Increase in deferred compensation 340,000 289,200
Net cash used in operating activities (2,928,584) (670,785)
CASH FLOWS FROM INVESTING ACTIVITIES    
Purchase of property and equipment (3,557,059) (2,062,155)
Net cash used in investing activities (3,557,059) (2,062,155)
CASH FLOWS FROM FINANCING ACTIVITIES    
Proceeds from sale of units 3,906,230
Proceeds from sale of warrants 131,335 1,736,662
Commissions on sale of warrants (86,400) (18,601)
Commissions on sale of units
Redemption of Preferred Series B shares and interest (41,000)
Net cash provided by financing activities 3,951,165 1,677,061
Net increase (decrease) in cash (2,534,478) (1,055,879)
Cash at beginning of year 3,160,442 4,216,321
Cash at end of year 625,964 3,160,442
Supplemental disclosure of cash flow information:    
Cash paid for interest
Non-cash investing and financing transactions:    
Adjustment for debt modification 3,507,917
Conversion of debt and liabilities into common units 186,462 17,711
Conversion of debt and liabilities into notes payable 23,943
Conversion of deferred compensation to notes payable 90,000 190,000
Capitalized interest in property and equipment 179,984 32,000
Shares issued for warrant exercise commissions 50,145
Purchase of property and equipment for accounts payable $ 220,052 $ 666,375
XML 21 R8.htm IDEA: XBRL DOCUMENT v3.23.3
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS
12 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS

 

1.ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS:

 

Organization and nature of business:

 

Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to make livestock production more sustainable, profitable and transparent. We intend to accomplish this by deploying our Gen3Tech platform/business model (discussed below) in ventures focused on the ‘feeder’ space of the livestock production/value chain to provide the consumer with verifiably sustainable premium meat products (together with environmentally friendly, sustainable and/or organic co-products from the production process).  Bion believes this approach can create extraordinary value for our shareholders and employees (all of whom own securities in the Company) and for livestock/agriculture industry ‘partners’ who join us in our ventures. We anticipate pursuing the opportunity created by our third generation technology (“Gen3Tech”) and business/technology platform in conjunction with other industry practices (“Gen3Tech Platform” or “Platform”) utilizing a joint venture/strategic partner model. We believe our approach will improve the well-being of farmers, ranchers, feeders, etc. we work with and create value for our shareholders while improving the environment.  

Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate surface groundwater, and exacerbate climate change.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). To accomplish Bion’s goals, we anticipate the we will ‘partner’ with other technology companies who provide solutions for different links of the beef (and other livestock) value chain and with strategic partners up and down the supply chain.

We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent one of the largest enhanced revenue contributors provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the animal raising and waste treatment process will be third-party verified, providing the basis for additional revenues, including carbon and/or renewable energy-related credits and, eventually, payment for a range of ecosystem services, including nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.

 

 During the first half of 2022 Bion began pre-marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022, Bion announced a letter of intent (“Ribbonwire LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). During January 2023 Bion announced a letter of intent (“Olson LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Olson Feeders and TD Angus, near North Platte, Nebraska (with a provision to expand to 45,000 head or more) (“Olson Project”). During April 2023 Bion announced a letter of intent (“DVG LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with Dakota Valley Growers near Bathgate, North Dakota (“DVG Project”). Based on our experience to date, we believe we will not have difficulty in securing participation in our Projects from additional feeders/cattlemen. The Olson, Dalhart and DVG Projects (and subsequent Projects) will be developed to produce blockchain-verified, sustainable beef in customized covered barns (resulting in reduced stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) with ongoing manure transfer (through slatted floors) to anaerobic digesters (AD) to capture nitrogen from the manure stream before loss to the atmosphere and generate renewable natural gas (RNG) for sale while remediating the environmental/carbon impacts usually associated with cattle feedlots and CAFOs. Bion’s patented Gen3Tech platform will refine the waste stream into valuable coproducts that include clean water, RNG, photovoltaic solar electricity and fertilizer (‘climate smart’ and/or organic) products. We anticipate converting these LOIs into definitive JV agreements and creating related distribution agreements with key retailers and food service distributors during the current fiscal year.

Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef JV projects over the next twenty-four (24) months while moving forward with the Initial Project (see below) and commencing development of one or more of the Dalhart/Olson/DVG Projects (“LOI Projects”)(and/or other Gen3Tech beef JV projects) while pursuing other opportunities in the livestock industry enabled by our Gen3Tech business model.  The LOI announcements have generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties) and has led to and assisted our discussions with many major of the larger agriculture/livestock industry companies (including those involved with distribution and/or sales of meat products) in the country which are ongoing at this date. We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment at a rapid pace.

During the past nine months, the Company has constructed (construction is largely completed) our 3GTech Ammonia Recovery System (‘ARS’) located near Fair Oaks, Indiana and begun operations of phase 1 of our Initial Project (our commercial scale demonstration facility) located near Fair Oaks, Indiana. We recently announced that announced the ARS has achieved and maintained controlled steady-state operations under a variety of conditions. When operated at steady state, the system produces an ammonium distillate (solution), the base of Bion’s nitrogen fertilizer products. Bion has begun optimizing the ARS’s operating parameters with the goal of meeting and/or exceeding the results needed for Bion’s economic models for large-scale commercial projects. The Company expects the current optimization phase will continue during the next quarter (or longer) and provide data required to support final design/engineering for commercial project modules. We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below).

 

The patented ARS is the core of Bion’s Gen3Tech platform. It recovers and upcycles problem ammonia contained in the effluent from anaerobic digestion (where methane is captured and more ammonia is released) of the livestock manure waste stream. The ARS captures the ammonia, minimizing its environmental impacts and creating low-carbon and/or organic nitrogen fertilizer products with it. Over during the next quarter, the Company intends to produce ammonium distillate at Fair Oaks in several concentrations and initiate the application process for organic certification for each concentration of liquid fertilizer product. Bion will produce a solid/granular nitrogen fertilizer product at the Initial Project (when the crystalizer module is ready for operation) which we believe will be both ‘Climate-Smart’ and ‘Water-Smart’ – a pure nitrogen fertilizer with a low carbon footprint, that is water soluble and readily available to plants. Samples of the granular product will also be utilized to support organic certification applications. See Fertilizer---Organic and ‘ClimateSmart’ below.

 

During the next three - six/ months, the Company intends to fully complete construction of the Initial Project’s phase 1, including the crystalizer module, and continue the optimization operations. Bion expects the Initial Project data will document the effectiveness of our Gen3Tech in a commercial-scale setting during the current fiscal year and support development of the LOI Projects (and/or other Gen3Tech beef JV projects) commencing later this fiscal year.  We do not presently know the order in which these JV Projects will be developed as that decision will be made based on many factors not yet in place. We believe the Initial Project data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, food distributors and retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). 

 

Bion is now focused primarily on: i) completion of development/construction and operation of the Initial Project, our initial commercial-scale Gen3Tech installation, and optimization of its operational parameters, ii) pre-development plan of the LOI Projects (and/or other Gen3Tech beef JV projects) including steps toward distribution agreements, iii) developing applications and markets for its low carbon ‘ClimateSmart’ and organic fertilizer products (including listings/certifications of multiple liquid and solid products) and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed herein) (and related Projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&D activities.

 

HISTORY, BACKGROUND AND CURRENT ACTIVITIES

 

Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.

From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product, while raising sustainable livestock.

 

The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market (despite the lack of verifiably sustainable attributes).

 

The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded conventional livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a production/marketing opportunity for Bion (but the former is far larger). Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon/organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.

 

During 2022-23, the Company entered into 3 LOIs setting forth the parties’ intention to negotiate joint venture agreement (“JVA”) and enter into joint ventures (“JV”) to develop and operate 15,000 head integrated, sustainable beef facilities (with future expansion under consideration) including:

 

  a) innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,

 

  b) ‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,

 

  c) a Bion Gen3Tech module (which will utilize the recycled CO2 to increase ammonia nitrogen/ammonium bicarbonate recovery) for the production of ammonia nitrogen fertilizer for use in organic and/or ‘ClimateSmart’ low carbon crop production (plus residual organic solids and clean water),

 

  d) which will produce verifiably sustainable beef products with USDA certified branding.

 

The opportunity presented by the LOIs to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial 15,000 head operation a reality as soon as possible.

To place the LOI Projects in the context of Company’s business plan (and our prior public disclosure), if the contemplated ventures moves forward on the timelines currently contemplated, active development of the the initial LOI Project will commence during 2024.

 

Prior to such activity, the Company has constructed and commenced operate of the initial phase of our previously discussed Gen3Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion Gen3Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the LOIProjects). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, is utilizing anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

During late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately 300 head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately 1,500 head). The facility is large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs (many pandemic-associated) delayed delivery dates for core modules of the Bion system to the site until during January 2023. Construction has been substantially completed related to Phase 1 of the Initial Project, shakedown operations undertaken and the operation is now focused on optimization of operation parameters. See Note 3 “Property and Equipment” and Note 12 “Subsequent Events” (for activities since the start of the first quarter of the 2024 fiscal year).

 

The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.

 

Specifically, the Initial Project was designed/developed to provide and/or accomplish the following:

 

i.   Proof of Gen3Tech platform scalability

 

  - Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3Technology platform.

 

  - Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.

 

ii.   Use Bion’s data collection system to support 3rd party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.

 

iii.   Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) in liquid and solid forms for commercial testing by potential joint venture partners and/or purchasers, for university growth trials and to provide samples (and related documentation) to support applications for organic and/or ‘ClimateSmart’ certifications.

 

iv.   Produce sustainable beef products for initial test marketing efforts.

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. Subsequent agreements were executed with engineering firms, contractors and other entities related to the construction of the Initial Project. The Company received progress billing in March 2022 and June 2022 for the second and third 25% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $533,100 which was paid on March 1, 2023 and on April 24,203 for $83,275 which was paid on May 2, 2023 bringing the aggregate payments to $2,615,500 as of the date of this filing. There remaining $50,000 open on the Purchase Order has been billed on July 26,2023. In addition to the Purchase Order, the Company has incurred additional costs of $4,182,260 on the Initial Project for capitalized interest and costs, non-cash compensation and consulting fees. $3,962,207 has been paid and $220,053 has been billed and not yet been paid.

 

The Initial Project will be carried out in stages with phase one focused largely on portions of items i. and iii. set forth above.

 

Upon completing the primary goals of phase 1 of the Initial Project (coupled with obtaining organic certifications(s) for our liquid and/or solid ammonium bicarbonate fertilizer product lines), Bion expects to be ready to move forward with its plans for development of much larger facilities including the LOI Projects, including final design of its Gen3Tech modules. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 12-24 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the optimization operations of the Initial Project with a 2024 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.

 

After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the Company will determine whether to complete the entire Initial Project as originally designed at that location or the relocate the core modules to an alternative permanent location. The Company has engaged in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or other mutually agreed upon location) which facility would include innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long-term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company will also evaluate re-locating the core module of the Initial Project to Dalhart, Texas, where it might be integrated into the first phases of the Dalhart Project and/or other locations. 

 

The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. Applications for our first solid ammonium bicarbonate product line have been filed with OMRI, the California Department of Food & Agriculture (“CDFA”) and the Iowa Organic Program (“IOP”) and are in the review processes (which is likely to require an extended period of time and multiple procedural steps, in part due to the novel nature of our Gen3Tech in the context of organic certifications). See “Fertilizer– Organic and ‘ClimateSmart’” below.

 

Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘Gen3Tech Kreider 2 Poultry Project’ below as an example) in the swine, dairy and poultry industries utilizing our Gen3Tech.

 

Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/dairy/egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a large, but apparently limited, segment of consumers is choosing seemingly sustainable offering, and are also willing to pay a premium for it. Tyson Foods, in the context of launching its Brazen beef initiative, recently said, “consumers would be willing to pay at least 24 percent more for environmentally friendly, sustainable options at retail.” Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is 29.5 percent on average.

 

As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, will enable the cleanup of one of the ‘dirtiest’ parts of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.

 

Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef was 63% more expensive in 2021, while pork and chicken, which are now primarily raised in covered barns at CAFOs with highly integrated supply chains, were 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.

 

Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have also recently entered the plant protein space. While meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, have been heavily promoted (by themselves and the media) and enjoyed remarkable initial sales growth, recently, sales have flattened and/or declined over the past 18 months. It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint---and market growth rates have substantially slowed and may have already plateaued and/or peaked. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.

 

In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary beef ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy. Sustainability initiatives have been launched by large US livestock producers (including Tyson’s very recent ‘Brazen’ program), but it is not yet possible to determine the extent the attributes of such products will be substantive and verifiable rather than completely ‘modeled’ and largely public relations ‘greenwashing’.

 

Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.

 

Sustainable Beef

 

Bion’s goal is to be one of the ‘first to market’ with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at Bion facilities will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.

 

A Bion sustainable beef facility will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia and greenhouse gas volatilization and loss, as well as odors, thereby improving animal health and human working conditions while preventing air/soil pollution. The manure will be collected and moved directly to anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in geographical locations with adequate sunshine and appropriate ‘tariffs’) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.

 

 

Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.

 

Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass-fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies (including Tyson’s very recent ‘Brazen’ program), but a closer look finds that many have consisted largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.

 

Sustainable Organic Beef

 

Bion also believes it may also have a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.

 

Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.

 

The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.

 

Fertilizer: Organic and ‘Climate Smart’

 

The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products. The Company’s low concentration ammonium bicarbonate liquid product successfully completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. During the next 3-4 months the Company intends to file applications with OMRI and the California Department of Food & Agriculture (“CDFA”) for a line of higher concentration liquid ammonium nitrogen products ( ranging from 6% up to 16% (or higher)) based on production of liquid samples during operation of the Initial Project over the next 2 months. The Company anticipates applying for and obtaining one or more listings/certifications for higher concentration products in our liquid ammonium nitrogen fertilizer line well prior to operational dates for the Company’s initial large scale JV Gen3Tech Sustainable Beef Projects.

 

Additionally, the Company intends to explore the market potential for its fertilizer (in liquid and/or solid forms) to be a verifiably ‘ClimateSmart’ product (potentially a much larger market than the organic market) with focus on higher value specialty crops. This will require working with industry and academic entities to develop appropriate metrics and producing a ‘life cycle assessment’ (LCA) for Bion’s ammonium nitrogen fertilizer product which can be compared to conventional nitrogen fertilizer products. Bion’s processes will capture and utilize CO2 in the waste stream (including CO2 produced with the renewable natural gas (RNG) by anaerobic digestion that is usually vented to the atmosphere) as stabilizing agent thereby potentially creating carbon offsets compared to natural gas utilized as feedstock in chemical ammonia production which reduction will be reflected in the LCA. This LCA will assess environmental impacts associated with fertilizer production in support of the beef cattle supply chain for both the existing conventional approach (primarily fossil fuel-based Haber-Bosch production methods) and the largely decarbonized Bion production approach. We believe a series of coincident yet significant LCA benefits accrue from Bion’s patented fertilizer production approach including the reduced loss of ammonia to the environment via air (volatilized) and water (nitrate in groundwater) pathways, recycled/reused water, elimination of pathogens, the production of renewable natural gas, the production solar energy from photovoltaic panels on barn roofs, enhanced animal welfare practices and reduced animal husbandry risks from extreme weather events. Bion believes that current evaluations of the carbon impact from feedlot operations materially underestimate the negative impacts because existing models do not properly include significant ‘downstream’ carbon impacts of required energy intensive waste water treatment for re-deposited ammonia nitrogen. If the Company determines there is a significant ‘ClimateSmart’ opportunity for our fertilizer products, such an LCA can be completed (based in part on data from the Initial Project) and support marketing efforts well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.

 

Ammonium bicarbonate, manufactured using thermal and mechanical processes, has a long history of use as a fertilizer. In addition to liquid ammonium nitrogen fertilizer, Bion’s Gen3Tech is capable of recovering nitrogen in the form of solid ammonium bicarbonate products containing up to 18%-22% (or higher) nitrogen in a crystalline form that is easily transported (while producing liquids with various percentages of ammonium bicarbonate nitrogen during interim stages of the process). This solid product is water soluble and provides a readily available nitrogen source for crops. It will contain virtually none of the other salt, iron and mineral constituents of the livestock waste stream that often accompany other organic fertilizers. This product is being developed to fertilizer industry standards so that it that can be precision-applied to crops using existing equipment. Bion believes that this product will potentially have broad applications in the production of organic and/or ClimateSmart grains for livestock feed, row crops, horticulture, greenhouse and hydroponic production, and potentially retail lawn and garden products.

 

The ammonium bicarbonate products (liquid and solid) produced by Bion’s Gen3Tech platform will enjoy a dramatically lower carbon footprint than synthetic nitrogen fertilizers. Much of the reactive nitrogen captured and upcycled into our fertilizer products was going to be lost through volatilization and runoff, and that loss would generally need to be offset with a synthetic nitrogen fertilizer, such as anhydrous ammonia or urea. These synthetic nitrogen products are produced through the Haber-Bosch (and other) synthetic processes, which converts hydrogen and atmospheric nitrogen to ammonia, with methane from fossil fuels as the energy source. It is an extremely energy-intensive process with a carbon footprint that, while not yet fully understood, is widely accepted to by very large. While a complete Life Cycle Assessment (LCA) of carbon impacts from synthetic fertilizer production is not yet available, according to the Institute for Industrial Productivity, its production alone is responsible for approximately 1 percent of total global CO2 emissions. To the extent that Bion can capture and repurpose the nitrogen traditionally lost from livestock waste, that carbon cost will no longer need to be paid by the environment/climate.

 

Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line were filed with OMRI (filed during May 2021) and CDFA (filed during May 2022) without success to date. After an extended review processes (which was largely opaque), the OMRI application proceeded through multiple stages without receiving a positive result. We have initiated an informal dialogue with CDFA regarding the basis for and re-consideration of its initial determination and anticipate submitting additional supporting materials to CDFA during the next 30 days. The Company’s solid product line is novel (in the context of organic certification) in part due to the fact that no formal listing category currently in the organic space for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produces it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other organic fertilizer stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company intends to continue efforts to obtain listing/certification for its solid nitrogen fertilizer line over the course of this fiscal year.

 

Gen3Tech Kreider 2 Poultry Project

 

Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.

 

Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.

 

Technology Deployment: Bion Gen3Tech

 

In the absence of firm regulatory mandates, widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production and/or certified as ‘ClimateSmart’. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion above and below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage. The Company has additional applications pending and/or planned.

 

Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.

 

In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).

 

The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2024 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.

 

The Livestock Problem

 

The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun — and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21st Century consumer demands for meaningful sustainability.

 

In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.

 

Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.

 

More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition — it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.

 

Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.

 

Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.

 

Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source—before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.

 

High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.

 

The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.

 

For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.

 

Going concern and management’s plans:

 

The Company’s audited financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and generated/incurred a net income of $8,292,000 for the year ended June 30, 2022 and a net loss of approximately $3,189,000 during the year ended June 30, 2023. The net income for the year ended June 30, 2022 was largely due to a one-time, non-cash event of the dissolution of PA-1 resulting in a gain of approximately $10,235,000 as well as a one-time gain of $902,000 from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period. At June 30, 2023, the Company has a working deficit and a stockholders’ equity of approximately $968,000 and $4,194,000, respectively. During the year ended June 30, 2023 the Company had debt modifications that resulted in a reduction of debt of $3,522,000 and an increase in equity in the same amount. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.

 

The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.

 

During the years ended June 30, 2023 and 2022, the Company received gross proceeds of approximately $4,038,000 and $1,737,000, respectively, from the sale of its debt and equity securities. The company paid commissions on the exercise of warrants in the amount of $86,000 and $19,000 in 2023 and 2022, respectively.

 

During fiscal years 2023 and 2022, the Company faced less difficulty in raising equity funding (but was subject to substantial equity dilution from the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. However, this positive trend did not continue during the last quarter of the 2023 fiscal year and first quarter of the current fiscal year (to date). The Company raised only raised very limited equity funds during such periods to meet its some of its immediate needs, therefore, the Company needs to raise additional funds in the upcoming periods. The Company currently faces substantial increases in demand for capital and operating expenditures for the fiscal year 2024 to date (and we anticipate such increased demands will continue during the remainder of the 2024 fiscal year and periods thereafter) as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management issues due to limited capital resources and working capital constraints which had only recently begun to be alleviated. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring most of their cash compensation and/or are accepting compensation in the form of securities of the Company (Notes 5 and 7 to Financial Statements) and members of the Company's senior management have from time to time made loans to the Company and may need to do so in future periods. Note that, to deal with earlier capital constraints, during the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $2,404,000. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. As set forth in detail elsewhere herein, during the year ended June 30, 2023 senior management (and family members) who held convertible obligations of the Company adjusted the terms of their outstanding notes and agreed to debt modifications that reduced of the Company’s debt by $3,522,000 and increased shareholders equity by the same amount. The constraints on available resources have had, and continue to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and/or curtailment of ongoing activities including research and development activities.

 

The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including operations at the Initial Project, JV Projects (including the Dalhart/Olson/DVG Projects), and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $20,000,000 to $80,000,000 or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and/or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.

 

There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.

 

Covid-19 pandemic related matters:

 

The Company faces many risks and uncertainties and factors beyond our control that have been magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.

 

XML 22 R9.htm IDEA: XBRL DOCUMENT v3.23.3
SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES

2.       SIGNIFICANT ACCOUNTING POLICIES

 

Principles of consolidation:

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

 

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of June 30, 2023 and June 30, 2022 there are no cash equivalents.

 

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income (Loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the years ended June 30, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

 

          
   June 30,
2023
   June 30,
2022
 
Warrants   22,543,765    20,778,635 
Options   12,006,600    11,201,600 
Convertible debt   9,922,769    10,686,065 
Convertible preferred stock            

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the years ended June 30, 2023 and 2022:

 

           
   Year
ended
June 30,
2023
   Year
ended
June 30,
2022
 
Shares issued – beginning of period   43,758,820    41,315,986 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)
Shares outstanding – beginning of period   43,054,511    40,611,677 
Weighted average shares issued
    during the period
   1,983,968    1,350,625 
Diluted weighted average shares –
    end of period
   45,038,479    41,962,302 

 

 

Use of estimates:

 

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.

 

XML 23 R10.htm IDEA: XBRL DOCUMENT v3.23.3
PROPERTY AND EQUIPMENT
12 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT

3.  PROPERTY AND EQUIPMENT:

 

Property and equipment consist of the following:

 

          
   June 30,
2023
   June 30,
2022
 
Computers and office equipment   15,156    13,598 
Initial Project: construction in process   6,847,760    2,892,222 
Property and equipment, gross   6,862,916    2,905,820 
Less accumulated depreciation   (11,907)   (10,262)
 Property and equipment, net  $6,851,009   $2,895,558 

 

The 3G1 project (“Initial Project”) began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for the Initial Project construction in process includes $211,984 for capitalized interest and $135,648 in non-cash compensation as of June 30, 2023.

 

Management has reviewed the remaining property and equipment for impairment as of June 30, 2023 and believes that no impairment exists.

 

Depreciation expense was $1,645 and $1,161 for the years ended June 30, 2023 and 2022, respectively.

 

XML 24 R11.htm IDEA: XBRL DOCUMENT v3.23.3
DEFERRED COMPENSATION
12 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
DEFERRED COMPENSATION

4.       DEFERRED COMPENSATION:

The Company owes deferred compensation to various employees, former employees and consultants totaling $864,781 and $594,798 as of June 30, 2023 and 2022, respectively. Included in the deferred compensation balances as of June 30, 2023, are $527,058 and $20,167 owed Dominic Bassani (“Bassani”), the Company’s Chief Operating Officer (who was Chief Executive Officer until through April 30, 2022), and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at 4% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last 10 trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of June 30, 2022 was $437,508 and $10,000, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $105,056 and $74,790 as of June 30, 2023 and 2022, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at 0% to 3% per annum. The Company also owes a former employee $72,500, which is not convertible and is non-interest bearing. Bassani and Smith have each been granted the right to convert up to $300,000 of deferred compensation balances at a price of $0.75 per share until June 30, 2024 into common shares (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election but such right is no longer in force.

Bill O’Neill has a balance of $140,000 and $20,000 at June 30, 2023 and 2022, respectively. There is no interest or conversions on the deferred balance. During the year ended June 30, 2023, Smith elected to add $90,000 of deferred compensation to his 2020 Convertible Note.

The Company recorded interest expense of $19,983 ($17,716 with related parties) and $16,390 ($15,537 with related parties) for the years ended June 30, 2023 and 2022, respectively.

XML 25 R12.htm IDEA: XBRL DOCUMENT v3.23.3
LOANS PAYABLE
12 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
LOANS PAYABLE

5.       LOANS PAYABLE:

 

Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436). The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

XML 26 R13.htm IDEA: XBRL DOCUMENT v3.23.3
CONVERTIBLE NOTES PAYABLE - AFFILIATES
12 Months Ended
Jun. 30, 2023
Convertible Notes Payable - Affiliates  
CONVERTIBLE NOTES PAYABLE - AFFILIATES

6.       CONVERTIBLE NOTES PAYABLE - AFFILIATES:

 

Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes --- see below) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate –See Note 7 below, ‘Debt Modification to Additional Paid in Capital’) while equitably maintaining existing conversion rights.  The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.

 

Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and the adjusted portion of the September 2015 Convertible Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units (consisting of 1 share and from one half (1/2) to one (1) warrant) at prices of $.0946, $.0953, and $.0953, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The adjusted conversion prices slightly reduce the securities to be issued on conversion of each instrument from the amount receivable under the unadjusted instruments. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). After the adjustment, the Company owed Smith, Bassani (and trust) and Schafer $262,154, $434,016 and $96,364, respectively, of Adjusted 2020 Convertible Obligations and Bassani and Schafer, respectively, $24,230 and $4,012 of Adjusted September 2015 Convertible Notes.

 

During the year ended June 30, 2023, Smith elected to convert $136,462, in aggregate, of his Adjusted 2020 Convertible Obligation into 1,442,514 units at $0.0946 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until March 2026. In more detail, effective: a) March 8, 2023, Smith converted $70,000 of his Adjusted 2020 Convertible Obligation into 739,958 Units (each Unit consisting one share and one warrant); b) March 31, 2023, Smith converted $29,888 of his Adjusted Convertible Obligation into 315,948 Units (each Unit consisting one share of common stock and one warrant); and c) June 4, 2023, Smith converted $36,573 of his Adjusted Convertible Obligation into 386,608 Units (each Unit consisting one share of common stock and one warrant). Smith donated to charitable organizations and/or gifted to family members and others a large portion of these securities (700,000 common shares and 955,000 warrants, in aggregate) while retaining direct ownership of 292,514 common shares and 116,566 warrants and indirect ownership of 450,000 common shares and 370,948 warrants (owned by his wife). The warrants are exercisable for three years from conversion dates. Subsequent to June 30, 2023, Smith converted additional portions of his Adjusted Convertible Obligation. See Note 12.

 

As of June 30 2023, the Adjusted 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer were $441,446, $130,180 and $98,014, respectively.

 

As of June 30, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $24,645 and $4,081, respectively.

 

2020 Convertible Obligations

 

The 2020 Convertible Obligations (which combined/replaced prior convertible instruments dating to 2017 (or earlier), which accrue interest at either 4% per annum or 4% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $0.50 per Unit until July 1, 2024. The original conversion price of $0.50 per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”. Effective February 1, 2023, a large portion of the 2020 Convertible Obligations were adjusted as set forth herein.

 

As of June 30, 2023, the remaining unadjusted portion of the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees) and Smith, were $361,321 and $36,432, respectively. As of June 30, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $2,597,329, $1,328,040 and $499,274, respectively.

 

During the year ended June 30, 2023 (on dates prior to the adjustment on February 1, 2023), Smith elected to add $90,000 of his accrued unpaid compensation/un-reimbursed expenses to his 2020 Convertible Obligations.

 

During the year ended June 30, 2023 (on dates prior to the adjustment on February 1, 2023), Smith elected to convert $30,000 in principal of the 2020 Convertible Obligation to 60,000 units (60,000 common shares and 60,000 warrants), and $20,000 of accrued interest of the 2020 Convertible Obligation to 40,000 units (40,000 common shares and 40,000 warrants). The warrants are exercisable for three years from conversion date.

 

During the year ended June 30, 2023 (on dates after the adjustment on February 1, 2023), Smith elected to convert $136,462 in principal of the Adjusted 2020 Convertible Obligation to 1,442,514 units (1,442,514 common shares and 1,442,514 warrants). The warrants are exercisable for three years from conversion dates.

 

The Company recorded interest expense of $102,478 and $131,718 for the year ended June 30, 2023 and 2022, respectively. The Company capitalized $179,981 and $32,000 related to the Initial Project for the year ended June 30, 2023 and 2022, respectively.

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long-term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights. Because the modifications where with affiliates that are related parties, the debt modification was treated as an equity transaction. The Company recorded a deemed dividend for the reductions.

 

Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations (see above and Note 7.). The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.

 

September 2015 Convertible Notes

 

During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at 4% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.60 per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.

 

The balances of the September 2015 Convertible Notes as of June 30, 2023, including accrued interest owed Bassani, Schafer and Shareholder, are $183,628, $4,081 and $460,873, respectively. The balances of the September 2015 Convertible Notes as of June 30, 2022, including accrued interest, were $279,366, $20,845 and $445,756, respectively.

 

The Company recorded interest expense of $23,318 and $23,796 for the year ended June 30, 2023 and 2022, respectively.

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including the September 2015 Convertible Notes owned by Bassani and Schafer) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.52 million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President), Dominic Bassani (the Company’s Chief Operating Officer)(and a family Trust) and Ed Schafer (Director), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the were renamed Adjusted September 2015 Convertible Notes. The Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. As of June 30, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $24,645 and $4,081, respectively. The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties. See above.

 

XML 27 R14.htm IDEA: XBRL DOCUMENT v3.23.3
STOCKHOLDERS' EQUITY:
12 Months Ended
Jun. 30, 2023
Equity [Abstract]  
STOCKHOLDERS' EQUITY:

7.       STOCKHOLDERS' EQUITY:

 

Debt Modification to Additional paid in capital

 

Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes --- see below) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $3.47 million, in aggregate) while equitably maintaining existing conversion rights. Because the modifications where with affiliates that are related parties, the debt modification was treated as an equity transaction. The Company recorded a deemed dividend for the reductions.

 

Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $1,109,649, $1,939,670 and $424,873, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and the adjusted portion of the September 2015 Convertible Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units at prices of $.0946, $0953, and $.0953, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $0.115 per share. The adjusted conversion prices slightly reduce the securities to be issued on conversion of each instrument from the amount receivable under the unadjusted instruments. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). After the adjustment, the Company owed Smith, Bassani (and trust) and Schafer $262,154, $434,016 and $96,364, respectively, of Adjusted 2020 Convertible Obligations and Bassani and Schafer, respectively, $24,230 and $4,012 of Adjusted September 2015 Convertible Notes. The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.

 

The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). The Company treated this as an equity transaction and recorded the reduction of debt through additional paid in capital at the net present value of the modified debt agreements. This resulted in an increase to Additional Paid in Capital of $3,522,000 at the modification date and a reduction of additional paid in capital of $14,051 for the year ended June 30, 2023 for the adjustment to the net present value of the modified debt agreements.

 

Series B Preferred stock:

 

Since July 1, 2014, the Company had 200 shares of Series B redeemable convertible Preferred stock outstanding with a par value of $0.01 per share, convertible at the option of the holder at $2.00 per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $100 per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. The 200 shares of Series B redeemable convertible Preferred stock were redeemed for $41,000, which included the $21,000 in accrued dividend payable.

 

During the years ended June 30, 2023, and 2022, the Company declared dividends of nil and $1,000 respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements. There is no liability at June 30, 2023.

 

Common stock:

 

Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.

 

Centerpoint holds 704,309 shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.

 

During the year ended June 30, 2023, the Company entered into a subscription agreement to sell 2,000,000 shares of restricted and legended common stock of which 1,800,000 shares were purchased on January 10, 2023 and the other 200,000 shares were purchased on December 31, 2022 for total proceeds during the year ended June 30, 2023 $2,000,000.

 

During the year ended June 30, 2023, the Company entered into subscription agreements to sell 975,000 units at a price of $1.60, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $2.40 per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued 975,000 units for total proceeds of $1,560,000, in aggregate. The Company paid commissions of $86,400 on the sale of units.

 

During the year ended June 30, 2023, 175,114 warrants were exercised to purchase 175,114 shares of the Company’s common stock at $0.75 per share for total proceeds of $131,335.

During the year ended June 30, 2023, the Company entered into subscription agreements to sell units for $1.00 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued 346,230 units for total proceeds of $346,230.

 

During the year ended June 30, 2023, the Company issued 50,000 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.60 per share for a total value of $80,000.

During the year ended June 30, 2023, the Company issued 32,259 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.55 per share for a total value of $50,000.

During the year ended June 30, 2023, Smith elected to convert $30,000 in principal and $20,000 in accrued interest from the 2020 Convertible Obligation to 100,000 units at $.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until December 31, 2024.

 

During the year ended June 30, 2023, Smith elected to convert $136,462 in principal of his Adjusted 2020 Convertible Obligation into 1,442,514 units at $0.0946 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until March 2026. See above and Note 6 for more detail.

 

Warrants:

 

As of June 30, 2023, the Company had approximately 22.5 million warrants outstanding, with exercise prices from $0.60 to $2.40 and expiring on various dates through November 9, 2026.

 

The weighted-average exercise price for the outstanding warrants is $0.80, and the weighted-average remaining contractual life as of March 31, 2023 is 1.6 years.

 

During the year ended June 30, 2023, Smith elected to convert $30,000 in principal and $20,000 in accrued interest from the 2020 Convertible Obligation to 100,000 units at $.50 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until three years after the date of conversion.

 

During the year ended June 30, 2023, Smith elected to convert $136,462, in aggregate, of his Adjusted 2020 Convertible Obligation into 1,442,514 units at $0.0946 per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $0.75 per share until March 2026. In more detail: a) effective March 8, 2023, Smith converted $70,000 of his Adjusted 2020 Convertible Obligation into 739,958 Units (each Unit consisting one share and one warrant); b) effective March 31, 2023, Smith converted $29,888 of his Adjusted Convertible Obligation into 315,948 Units (each Unit consisting one share of common stock and one warrant); and c) effective June 4, 2023, Smith converted $36,573 of his Adjusted Convertible Obligation into 386,608 Units (each Unit consisting one share of common stock and one warrant). Smith donated to charitable organizations and/or gifted to family members and others a large portion of these securities (700,000 common shares and 955,000 warrants, in aggregate) while retaining direct ownership of 292,514 common shares and 116,566 warrants and indirect ownership of 450,000 common shares and 370,948 warrants (owned by his wife). The warrants are exercisable for three years from conversion dates. Subsequent to June 30, 2023, Smith converted additional portions of his Adjusted Convertible Obligation. See Note 12.

 

During the twelve months ended June 30, 2023, the Company approved the issuance of 210,000 warrants, in aggregate, to three new members of its Advisory Group for advisory and/or consulting services of $21,000, in aggregate. The warrants are exercisable at $1.50 to $1.60 and expire in August 2025.

During the twelve months ended June 30, 2023, the Company approved the modification of existing warrants held by one former consultant and investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $154,932 and interest expenses of $72,589.

During the twelve months ended June 30, 2023, 175,114 warrants were exercised to purchase 175,114 shares of the Company’s common stock at $0.75 per share for total proceeds of $131,335.

 

Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise price adjustment provision if the terms set forth therein are met. 700,000 of the warrants are vesting through May 1, 2023 and 2024. The vesting resulted in non-cash compensation of $41,653 during the year ended June 30, 2023.

 

Stock options:

 

On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “Equity Plan”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to 30,000,000 shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.

 

The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to 36,000,000 shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms,

 

On March 15, 2023, the Company granted 30,000 options under the 2006 Plan to two consultants. The options vest equally in thirds on March 20, 2023, June 20, 2023 and September 30, 2023.

 

On February 7, 2023, the Company granted an aggregate of 275,000 options under the 2006 Plan to five employees/consultants/directors including: i) 25,000 options to Jon Northrop for service as director, ii) 100,000 to two consultants and iii) 150,000 to employees.

 

On May 9, 2023, the Company granted 500,000 options under the 2006 Plan to Bill O’Neill. 250,000 of these options vest on June 1, 2024 and 250,000 options vest on June 1, 2025; all options expire on June 30, 2026.

 

The Company recorded compensation expense related to employee stock options of $249,744 and $419,370 for the years ended June 30, 2023 and 2022, respectively. The Company granted 805,000 and 730,000 options for the year ended June 30, 2023 and 2022, respectively.

 

The fair value of the options granted during the years ended June 30, 2023 and 2022 were estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:

                
   Weighted
Average,
June 30,
2023
   Range,
June 30,
2023
   Weighted
Average,
June 30,
2022
   Range,
June 30,
2022
 
Volatility   65%   64% -66%   65%   65%-69%
Dividend yield                        
Risk-free interest rate   3.83%   3.67% – 4.11    2.99%   1.71%-3.01 
Expected term (years)   3.44    2.84 to 3.95%   3.71    3.04 to 3.72%

 

The expected volatility was based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

A summary of option activity under the 2006 Plan for year ended June 30, 2023 is as follows:

                                   
      Options     Weighted-
Average
Exercise
Price
    Weighted-
Average
Remaining
Contractual
Life
    Aggregate
Intrinsic
Value
 
  Outstanding at July 1, 2022       11,201,600     $ 0.80       2.7     $ 4,429,263  
    Granted       805,000                           
    Exercised                                    
    Forfeited                                    
    Expired                                    
  Outstanding at June 30, 2023       12,006,600     $ 0.85       1.83     $ 5,085,659  

 

The total fair value of stock options that vested during both the year ended June 30, 2023 and 2022 was $249,744 and $419,370, respectively. As of June 30, 2023, the Company had no unrecognized compensation cost related to stock options.

 

XML 28 R15.htm IDEA: XBRL DOCUMENT v3.23.3
SUBSCRIPTION RECEIVABLE - AFFILIATES
12 Months Ended
Jun. 30, 2023
Subscription Receivable - Affiliates  
SUBSCRIPTION RECEIVABLE - AFFILIATES

8.       SUBSCRIPTION RECEIVABLE - AFFILIATES:

 

As of June 30, 2023, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $428,250 ($517,553, including interest) from Bassani which were received as consideration for purchases of warrants to purchase 5,565,000 shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $0.75 (with a 75% exercise price adjustment provision) and have expiry dates ranging from December 31, 2024 to December 31, 2025 (subject to extension rights) secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.

 

 As of June 30, 2023, the Company has an interest bearing, secured promissory note for $30,000 ($35,884 including interest) from Smith as consideration to purchase warrants to purchase 300,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60(with a 75% exercise price adjustment provision) and have expiry dates of December 31, 2024 (subject to extension rights) The promissory note bears interest at 4% per annum, and is secured by $30,000 ($35,885 including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.

 

As of June 30, 2023 the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $46,400 ($56,860 including interest) from two employee/consultants as consideration to acquire warrants to purchase 928,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.75 (with a 90% exercise price adjustment provision) and have expiry dates of December 31, 2024. (The promissory notes bear interest at 4% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.

These secured promissory notes are recorded as “Subscription receivable—affiliates” on the Company’s balance sheet pending payment.

XML 29 R16.htm IDEA: XBRL DOCUMENT v3.23.3
COMMITMENTS AND CONTINGENCIES:
12 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES:

9.       COMMITMENTS AND CONTINGENCIES:

 

Employment and consulting agreements:

 

Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month-to-month contract extension with Smith which included provisions for i) a monthly salary of $18,000 ( deferred until the Board of Directors re-instated cash payments to all employees and consultants who are deferring compensation), ii) the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until December 31, 2024, and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $25,000 per month of which $5,000 per month is deferred. Currently Smith is deferring all but $5000 of his monthly compensation to help the Company conserve cash. For the years ended June 30, 2023 and 2022, Smith was paid $200,000 and $130,000, respectively, of cash compensation.

 

Since March 31, 2005, the Company has had various agreements with Bassani (and/or Brightcap which provided his services during some of the years), now the Company’s Chief Operating Officer (‘COO’) and formerly the Company’s Chief Executive Officer (‘CEO’)(any reference to Brightcap or Bassani for all purposes are referring to the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017 (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($31,000 per month) until the Board of Directors re-instated cash payments to all employees and consultants who were deferring their compensation. During October 2016 Bassani was granted the right to convert up to $125,000 of his deferred compensation, at his sole election, at $0.75 per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $300,000 of his deferred compensation, at his sole election, at $0.75 per share, until June 30, 2024 (including extensions). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $31,000 per month, which will continue to be accrued in part during periods when the Board determines there is not adequate cash available. Additionally, the Company agreed to pay or accrue $2,000 per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $300,000 from Bassani as consideration to purchase warrants to purchase 3,000,000 shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of June 30, 2023, the principal and accrued interest was $361,321. Currently Bassani is deferring all but $5000 of his monthly compensation to help the Company conserve cash. For the years ended June 30, 2023 and 2022, Brightcap was paid $300,000 and $250,000, respectively, of cash compensation.

 

William O’Neill (“O’Neill”) was hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s Gen3 Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill entered into a thirty-seven (37) month employment agreement with compensation of $25,000 cash and $10,000 deferred compensation per month. The cash payment is paid $12,500 to O’Neill and $12,500 to an entity affiliated with O’Neill. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share ( a 75% exercise price adjustment provision if the terms set forth therein are met) until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. Currently O’Neill is deferring all but $5000 of his monthly compensation to help the Company conserve cash. For the years ended June 30, 2023 and 2022, O’Neill and the entity affiliated with O’Neill was paid $150,000 and $25,000, respectively, of cash compensation.

 

Exercise Price Adjustments/Extension Rights:

 

As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise price adjustment provision (exercise bonus in the context of options) which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the adjustment shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock adjustments, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods were reduced to $.01 per option or warrant. These exercise adjustments were subsequently increased to 75%.

 

During the year ended June 30, 2021, the Company added a 75% exercise price adjustment to the terms of 3,000,000 warrants held by a trust owned by Bassani.

 

As of June 30, 2023, exercise price adjustment provisions ranging from 50-90% were applicable to 11,771,600 of the Company’s outstanding options and 18,438,339 of the Company’s outstanding warrants.

 

Effective May 1, 2022, an entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share until April 30, 2026 of which up to 700,000 Incentive Warrants were cancellable if O’Neill was not renewed at 13 months (renewal has happened) and/or fails to serve the entire contract term thereafter. These warrants each have a 75% exercise price adjustments if the terms set forth therein are met.

 

Initial Project:

 

On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $2,665,500 (and made the initial 25% payment ($666,375) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. The Company received progress billing in March 2022 and June 2022 for the second and third 25% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $533,100 which was paid on March 1, 2023 and on April 24, 2023 the Company received an invoice from Buflovak for $83,275 which was paid on May 2, 2023 bringing the aggregate payments to $2,615,500 as of the date of this filing. There remains $50,000 open on the Purchase Order has been billed on July 26, 2023. In addition to the Purchase Order, through June 30, 2023 the Company has incurred additional costs of $4,182,260 on the Initial Project for capitalized interest and costs, non-cash compensation and consulting fees. $3,962,207 has been paid and $220,053 has been billed and not yet paid. See Note 12 “Subsequent Events” for expenditure after June 30, 2023.

 

Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete, fabrication and delivery of equipment from Bufflovak from the Purchase Order Agreement has been largely completed and assembly/construction is in process.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, utilities, etc.) for work related to the Initial Project. The Company has incurred costs of $6,103,693 on the Initial Project, not including capitalized labor and interest.

 

Litigation:

 

A: Website: Domain Sale/Resolved Litigation/Hacking/Theft

 

 On March 23, 2022 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name <biontech.com> no longer represented a core asset of the Company.

 

As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the <biontech.com> domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.

 

On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name <biontech.com> ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and <biontech.com>, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name <biontech.com> to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).

 

No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subjected to disruption and expenses were incurred related to the matter including legal fees.

 

The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.

 

B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)

 

PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $2,255,802 as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $297 and its total liabilities were $10,154,334 (including the Pennvest Loan in the aggregate amount of $9,939,148, accounts payable of $214,235 and accrued liabilities of $950) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s consolidated balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $10,234,501 (including the Pennvest Loan in the aggregate amount of $10,009,802, accounts payable of $212,263 and accrued liabilities of $12,436. The net amount of $10,234,501 was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.

 

 

As background, the terms of the Pennvest Loan provided for funding of up to $7,754,000 which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at 2.547% per annum for years 1 through 5 and 3.184% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $5,886,000 in fiscal years 2013 through 2021, and $846,000 in fiscal year 2022, $873,000 in fiscal year 2023 and $149,000 in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $123,444 and $246,887 for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.

 

During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $9,868,495 despite the fact that the obligation (if any) was solely an obligation of PA1

 

On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $8,137,117 (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. 

 

On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.

 

PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $104,725 was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.

 

Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.

 

PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.

 

For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.

 

Bank Account Hacking

 

On June 23, 2023, an officer of the Company with personal accounts with Signature Bank was hacked and $75,000 was transferred from the Company’s accounts at Signature Bank to the officer’s personal accounts. The bank was notified and all Company accounts were placed on hold. Subsequently, the funds were released and transferred back to the Company prior to June 30, 2023 the end of the fiscal year and there were no losses incurred.  The Company has reviewed the authorized individuals on all accounts and further limited access after the hacking incident.  

 

The Company currently is not involved in any other material litigation or similar events.

 

Lease:

 

The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.

 

The future minimum lease payment under noncancelable operating lease with terms greater than one year as of June 30, 2023:

 

Schedule Of Future Minimum Lease Payment      
Year ended June 30, 2023 to June 2024   $ 75,000  
Year ended June 30, 2024 to December 2024     37,500  
Undiscounted cash flow     112,500  
Less imputed interest     (8,432 )
Total   $ 104,068  
   Less current portion     (75,000 )
Long term lease liability     29,068  

 

The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of June 30, 2023 were 1.58 years and 10%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.

 

XML 30 R17.htm IDEA: XBRL DOCUMENT v3.23.3
INCOME TAXES
12 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES

10.       INCOME TAXES

 

The reconciliation between the expected federal income tax benefit computed by applying the Federal statutory rate to loss before income taxes and the actual benefit for taxes on loss for the years ended June 30, 2023 and 2022 is as follows:

          
   2023   2022 
Expected income tax benefit at statutory rate  $(670,000)  $1,741,000 
State taxes, net of federal benefit   (117,000)   303,000 
Permanent differences and other   9,000    8,000 
Expiration of net operating allowances   733,000    1,229,000 
Change in valuation allowance   (45,000)   (3,281,000)
Income tax benefit  $     $   

 

The Company has net operating loss carry-forwards (“NOLs”) for tax purposes of approximately $39,500,000 as of June 30, 2023. These NOLs expire on various dates through 2042.

 

The utilization of the NOLs may be limited under Section 382 of the Internal Revenue Code.

The Company’s deferred tax assets for the years ended June 30, 2023 and 2022 are estimated as follows:

          
   2023   2022 
NOL carryforwards (Federal and State)  $8,299,000   $8,274,000 
Stock-based compensation   5,459,000    5,436,000 
Impairment   1,340,000    1,340,000 
Business interest   338,000    339,000 
Deferred compensation   1,054,000    1,054,000 
Capitalized research and development   66,000       
Gross deferred tax assets   16,148,000    16,443,000 
Valuation allowance   (16,148,000)   (16,443,000)
Net deferred tax assets  $     $   

 

The Company has provided a valuation allowance of 100% of its net deferred tax asset due to the uncertainty of generating future profits that would allow for the realization of such deferred tax assets.

 

XML 31 R18.htm IDEA: XBRL DOCUMENT v3.23.3
401(k) PLAN:
12 Months Ended
Jun. 30, 2023
Retirement Benefits [Abstract]  
401(k) PLAN:

11.       401(k) PLAN:

 

The Company has adopted the Bion Technologies, Inc. 401(k) Profit Sharing Plan and Trust (the “401(k) Plan”), a defined contribution retirement plan for the benefit of its employees. The 401(k) Plan is currently a salary deferral only plan and at this time the Company does not match employee contributions. The 401(k) is open to all employees over 21 years of age and no service requirement is necessary.

 

XML 32 R19.htm IDEA: XBRL DOCUMENT v3.23.3
SUBSEQUENT EVENTS:
12 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS:

12.        SUBSEQUENT EVENTS:

 

The Company has evaluated events that occurred subsequent to June 30, 2023 for recognition and disclosure in the financial statements and notes to the financial statements.

 

From July 1, 2023 through September 28, 2023, the Company has incurred costs of $583,870 for an aggregate of $7,431,630 for the Initial Project. 

 

From July 1, 2023 through September 28, 2023, 38,000 warrants were exercised to purchase 38,000 shares of the Company’s common stock at $0.75 per share for total proceeds of $28,500.

 

On July 7, 2023, the Company issued 7,500 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.20 per share for a total value of $9,000.

On July 21, 2023, Mr. Smith converted $49,048 of principal from his Adjusted 2020 Convertible note into 518,477 Units at a conversion rate of $.0946; each unit consisting of one share and one warrant with the exercise price of $.75 until 7/21/2026. Each of these warrants carry an exercise price adjustment provision of 75%.

 

On August 16, 2023, the Company issued 10,753 shares of the Company’s common stock to a consultant for services. The shares were issued at $1.55 per share for a total value of $16,667.

On August 28, 2023, the Company sold 28,589 units at a price of $1.60 for a total of $45,742.  

 

XML 33 R20.htm IDEA: XBRL DOCUMENT v3.23.3
SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Principles of consolidation

Principles of consolidation:

 

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its 58.9% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.

 

Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.

 

 

Cash and cash equivalents

Cash and cash equivalents:

 

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of June 30, 2023 and June 30, 2022 there are no cash equivalents.

 

Property and equipment

Property and equipment:

 

Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.

 

Patents

Patents:

 

The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.

 

Stock-based compensation

Stock-based compensation:

 

The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.

 

Derivative Financial Instruments

Derivative Financial Instruments:

 

Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.

 

Options

Options:

 

The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.

 

Warrants

Warrants:

 

The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.

 

Concentrations of credit risk

Concentrations of credit risk:

 

The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.

 

Noncontrolling interests

Noncontrolling interests:

 

In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.

 

Fair value measurements

Fair value measurements:

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.

 

Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;

 

Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and

 

Level 3 – assets and liabilities whose significant value drivers are unobservable.

 

Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.

 

The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.

 

Lease Accounting

Lease Accounting:

The Company accounts for leases under ASC 842, Leases (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.

For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.

 

Revenue Recognition

Revenue Recognition:

 

The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.

 

Income (Loss) per share

Income (Loss) per share:

 

Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the years ended June 30, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.

 

The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:

 

          
   June 30,
2023
   June 30,
2022
 
Warrants   22,543,765    20,778,635 
Options   12,006,600    11,201,600 
Convertible debt   9,922,769    10,686,065 
Convertible preferred stock            

 

The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the years ended June 30, 2023 and 2022:

 

           
   Year
ended
June 30,
2023
   Year
ended
June 30,
2022
 
Shares issued – beginning of period   43,758,820    41,315,986 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)
Shares outstanding – beginning of period   43,054,511    40,611,677 
Weighted average shares issued
    during the period
   1,983,968    1,350,625 
Diluted weighted average shares –
    end of period
   45,038,479    41,962,302 

 

 

Use of estimates

Use of estimates:

 

In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements:

 

The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.

 

XML 34 R21.htm IDEA: XBRL DOCUMENT v3.23.3
SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Schedule of anti dilutive securities
          
   June 30,
2023
   June 30,
2022
 
Warrants   22,543,765    20,778,635 
Options   12,006,600    11,201,600 
Convertible debt   9,922,769    10,686,065 
Convertible preferred stock            
Schedule of earnings per share, basic and diluted
           
   Year
ended
June 30,
2023
   Year
ended
June 30,
2022
 
Shares issued – beginning of period   43,758,820    41,315,986 
Shares held by subsidiaries (Note 7)   (704,309)   (704,309)
Shares outstanding – beginning of period   43,054,511    40,611,677 
Weighted average shares issued
    during the period
   1,983,968    1,350,625 
Diluted weighted average shares –
    end of period
   45,038,479    41,962,302 

 

XML 35 R22.htm IDEA: XBRL DOCUMENT v3.23.3
PROPERTY AND EQUIPMENT (Tables)
12 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
Schedule of property and equipment
          
   June 30,
2023
   June 30,
2022
 
Computers and office equipment   15,156    13,598 
Initial Project: construction in process   6,847,760    2,892,222 
Property and equipment, gross   6,862,916    2,905,820 
Less accumulated depreciation   (11,907)   (10,262)
 Property and equipment, net  $6,851,009   $2,895,558 
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.23.3
STOCKHOLDERS' EQUITY: (Tables)
12 Months Ended
Jun. 30, 2023
Equity [Abstract]  
Schedule of assumptions
                
   Weighted
Average,
June 30,
2023
   Range,
June 30,
2023
   Weighted
Average,
June 30,
2022
   Range,
June 30,
2022
 
Volatility   65%   64% -66%   65%   65%-69%
Dividend yield                        
Risk-free interest rate   3.83%   3.67% – 4.11    2.99%   1.71%-3.01 
Expected term (years)   3.44    2.84 to 3.95%   3.71    3.04 to 3.72%
Schedule of option activity
                                   
      Options     Weighted-
Average
Exercise
Price
    Weighted-
Average
Remaining
Contractual
Life
    Aggregate
Intrinsic
Value
 
  Outstanding at July 1, 2022       11,201,600     $ 0.80       2.7     $ 4,429,263  
    Granted       805,000                           
    Exercised                                    
    Forfeited                                    
    Expired                                    
  Outstanding at June 30, 2023       12,006,600     $ 0.85       1.83     $ 5,085,659  
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.23.3
COMMITMENTS AND CONTINGENCIES: (Tables)
12 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Schedule Of Future Minimum Lease Payment
Schedule Of Future Minimum Lease Payment      
Year ended June 30, 2023 to June 2024   $ 75,000  
Year ended June 30, 2024 to December 2024     37,500  
Undiscounted cash flow     112,500  
Less imputed interest     (8,432 )
Total   $ 104,068  
   Less current portion     (75,000 )
Long term lease liability     29,068  
XML 38 R25.htm IDEA: XBRL DOCUMENT v3.23.3
INCOME TAXES (Tables)
12 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
Schedule of effective income tax rate reconciliation
          
   2023   2022 
Expected income tax benefit at statutory rate  $(670,000)  $1,741,000 
State taxes, net of federal benefit   (117,000)   303,000 
Permanent differences and other   9,000    8,000 
Expiration of net operating allowances   733,000    1,229,000 
Change in valuation allowance   (45,000)   (3,281,000)
Income tax benefit  $     $   
Schedule of deferred tax assets and liabilities
          
   2023   2022 
NOL carryforwards (Federal and State)  $8,299,000   $8,274,000 
Stock-based compensation   5,459,000    5,436,000 
Impairment   1,340,000    1,340,000 
Business interest   338,000    339,000 
Deferred compensation   1,054,000    1,054,000 
Capitalized research and development   66,000       
Gross deferred tax assets   16,148,000    16,443,000 
Valuation allowance   (16,148,000)   (16,443,000)
Net deferred tax assets  $     $   
XML 39 R26.htm IDEA: XBRL DOCUMENT v3.23.3
ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS (Details Narrative)
12 Months Ended
Jul. 26, 2023
USD ($)
May 02, 2023
USD ($)
Apr. 24, 2023
USD ($)
Jan. 17, 2023
USD ($)
Apr. 30, 2022
USD ($)
Mar. 31, 2022
Jan. 28, 2022
USD ($)
Jun. 30, 2023
USD ($)
Decimal
Jun. 30, 2022
USD ($)
Jun. 30, 2018
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Tech wastage | Decimal               1,500    
Cattle per head | Decimal               300    
Debt instrument paid amount             $ 2,665,500      
Debt Instrument, Interest Rate During Period           25.00% 25.00%   25.00%  
Principal, interest     $ 83,275 $ 533,100     $ 666,375      
Aggregate payment   $ 2,615,500           $ 2,615,500    
Purchase order $ 50,000       $ 50,000          
Capitalized labor and interest costs               4,182,260    
Capitalized labor and interest costs paid               3,962,207    
Capitalized labor and interest costs yet to pay               $ 220,053    
Percentage of sustainable               29.50%    
Description of kreider 2 poultry project               Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA).    
Net Income (loss)               $ 3,189,000 $ 8,292,000  
Net income               10,235,000    
Gain on sale of domain               902,000    
Working Capital               968,000    
Reduction of debt               3,522,000    
Proceeds from Issuance or Sale of Equity               4,038,000 1,737,000  
Exercise of warrants               86,000 $ 19,000  
Deferred Compensation Liability, Amount Cancelled                   $ 2,404,000
Minimum [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Capital Required for Capital Adequacy               20,000,000    
Maximum [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Capital Required for Capital Adequacy               $ 80,000,000    
J V A [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Tech wastage | Decimal               15,000    
Gen 3 Tech [Member]                    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                    
Tech wastage | Decimal               15,000    
XML 40 R27.htm IDEA: XBRL DOCUMENT v3.23.3
SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) - shares
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 22,543,765 20,778,635
Share-Based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 12,006,600 11,201,600
Convertible Debt Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities 9,922,769 10,686,065
Convertible Preferred Stock Antidilutive Securities [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities
XML 41 R28.htm IDEA: XBRL DOCUMENT v3.23.3
SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) - shares
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Accounting Policies [Abstract]    
Shares issued – beginning of period 43,758,820 41,315,986
Shares held by subsidiaries (Note 7) (704,309) (704,309)
Shares outstanding – beginning of period 43,054,511 40,611,677
Weighted average shares issued     during the period 1,983,968 1,350,625
Diluted weighted average shares –     end of period 45,038,479 41,962,302
XML 42 R29.htm IDEA: XBRL DOCUMENT v3.23.3
SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
Jun. 30, 2023
Jun. 30, 2022
Cash equivalents $ 0 $ 0
Centerpoint [Member]    
Noncontrolling interest, ownership percentage by parent 58.90%  
XML 43 R30.htm IDEA: XBRL DOCUMENT v3.23.3
PROPERTY AND EQUIPMENT - Property and Equipment (Details) - USD ($)
Jun. 30, 2023
Jun. 30, 2022
Property, Plant and Equipment [Abstract]    
Computers and office equipment $ 15,156 $ 13,598
Initial Project: construction in process 6,847,760 2,892,222
Property and equipment, gross 6,862,916 2,905,820
Less accumulated depreciation (11,907) (10,262)
 Property and equipment, net $ 6,851,009 $ 2,895,558
XML 44 R31.htm IDEA: XBRL DOCUMENT v3.23.3
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Property, Plant and Equipment [Line Items]    
Capitalized interest $ 211,984  
Non cash compensation 135,648  
Depreciation expense 1,645 $ 1,161
Property Plant And Equipment Of P A 1 [Member]    
Property, Plant and Equipment [Line Items]    
Impairment of Long-Lived Assets Held-for-use $ 0  
XML 45 R32.htm IDEA: XBRL DOCUMENT v3.23.3
DEFERRED COMPENSATION (Details Narrative) - USD ($)
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Deferred compensation liability $ 864,781 $ 594,798
Interest Rate on Deferred Compensation 4.00%  
Deferred Compensation Consecutive Trading Days (Day) 10 days  
Former employee compensation $ 72,500  
Interest Expense On Deferred Compensation Obligation [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Interest Expense 19,983 16,390
Interest Expense, Related Party 17,716 15,537
Smith [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Deferred Compensation, Convertible to Common Stock 90,000  
Bassani [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Deferred compensation liability $ 527,058 437,508
Interest Rate on Deferred Compensation 0.00%  
Smith [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Deferred compensation liability $ 20,167 10,000
Interest Rate on Deferred Compensation 3.00%  
Consultants And Employee [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Deferred compensation liability $ 105,056 74,790
Bassani And Smith [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Deferred Compensation, Convertible to Common Stock $ 300,000  
Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share) $ 0.75  
Bill O Neill [Member]    
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]    
Deferred compensation liability $ 140,000 $ 20,000
Deferred compensation interest $ 0  
XML 46 R33.htm IDEA: XBRL DOCUMENT v3.23.3
LOANS PAYABLE (Details Narrative) - USD ($)
12 Months Ended
Jun. 15, 2022
Mar. 31, 2022
Jan. 28, 2022
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
Dec. 29, 2021
Sep. 30, 2021
Sep. 25, 2014
Short-Term Debt [Line Items]                  
Total assets       $ 7,593,633 $ 6,360,337     $ 297  
Total liabilities       3,361,954 7,254,916   $ 10,234,501 10,154,334  
Accounts payable and accrued liabilities       677,137 $ 1,360,644   10,009,802 9,939,148  
Accounts payable             212,263 214,235  
Accrued Liabilities, Current             $ 12,436 $ 950  
Gain on legal dissolution of subsidiary       10,234,501          
Debt Instrument, Interest Rate During Period   25.00% 25.00%   25.00%        
Loans as a liability           $ 9,868,495      
P A 1 [Member]                  
Short-Term Debt [Line Items]                  
Debt Instrument, Debt Default, Amount                 $ 8,137,117
Realized from the asset sale $ 104,725                
Pennvest Loan [Member]                  
Short-Term Debt [Line Items]                  
Construction Loan       10,010,000          
Accrued Interest and Late Charges Payable       2,255,802          
Line of Credit Facility, Maximum Borrowing Capacity       7,754,000          
Debt Instrument, Annual Principal Payment       5,886,000          
Long-Term Debt, Maturity, Year Two       846,000          
Long-Term Debt, Maturity, Year Three       873,000          
Long-Term Debt, Maturity, Year Four       $ 149,000          
Interest Expense, Debt         $ 123,444 $ 246,887      
Pennvest Loan [Member] | Years One Through Five [Member]                  
Short-Term Debt [Line Items]                  
Debt Instrument, Interest Rate During Period       2.547%          
Pennvest Loan [Member] | Years Six Through Maturity [Member]                  
Short-Term Debt [Line Items]                  
Debt Instrument, Interest Rate During Period       3.184%          
XML 47 R34.htm IDEA: XBRL DOCUMENT v3.23.3
CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) - USD ($)
12 Months Ended
Jun. 04, 2023
Mar. 31, 2023
Mar. 08, 2023
Jan. 28, 2022
Jun. 30, 2023
Jun. 30, 2022
Feb. 02, 2023
May 01, 2022
Mar. 31, 2022
Jan. 01, 2020
Convertible notes payable         $ 3,470,000          
Sell units         $ 1.00          
Convertible Notes Payable, Noncurrent         $ 1,715,970 $ 5,170,610        
Original conversion price         $ 0.50          
Debt conversion value       $ 2,665,500            
Capitalized amount         $ 179,981 32,000        
Convertible note         $ 3,520,000          
Chief Executive Officer [Member]                    
Shares issued, warrants               1,000,000    
President [Member] | Secured Promissory Note [Member]                    
Financing receivable interest rate stated percentage         4.00%          
Restricted Common Stock [Member]                    
Sell units         $ 2.40          
Common Shares [Member] | Direct Ownership [Member]                    
Shares issued, warrants         292,514          
Common Shares [Member] | Indirect Ownership [Member]                    
Shares issued, warrants         450,000          
Common Shares [Member] | Convertible Obligations 2020 [Member]                    
Convertible stock shares issued, warrants         700,000          
Warrants [Member] | Direct Ownership [Member]                    
Shares issued, warrants         116,566          
Warrants [Member] | Indirect Ownership [Member]                    
Shares issued, warrants         370,948          
Warrants [Member] | Convertible Obligations 2020 [Member]                    
Convertible stock shares issued, warrants         955,000          
September 2015 Convertible Notes [Member] | Convertible Debt [Member]                    
Conversion price per unit         $ 0.60          
Interest Expense         $ 23,318 23,796        
September 2015 Convertible Notes [Member] | Chief Executive Officer [Member]                    
Convertible Notes Payable, Noncurrent         24,645          
September 2015 Convertible Notes [Member] | Chief Executive Officer [Member] | Bassani Family Trusts [Member]                    
Convertible Notes Payable         183,628       $ 279,366  
September 2015 Convertible Notes [Member] | Chief Executive Officer [Member] | Schafer [Member]                    
Convertible Notes Payable         4,081          
September 2015 Convertible Notes [Member] | Executive Vice Chairman [Member]                    
Convertible Notes Payable, Noncurrent         4,081          
September 2015 Convertible Notes [Member] | Executive Vice Chairman [Member] | Shareholder [Member]                    
Convertible Notes Payable         $ 460,873       445,756  
September 2015 Convertible Notes [Member] | Consultants [Member] | Schafer [Member]                    
Convertible Notes Payable                 $ 20,845  
September 2015 Convertible Notes [Member] | Restricted Common Shares [Member]                    
Conversion price per unit   $ 0.115     $ 0.115          
The 2020 Convertible Obligations [Member]                    
Salary paid         $ 90,000          
The 2020 Convertible Obligations [Member] | Convertible Debt [Member]                    
Conversion price per unit         $ 0.0946         $ 0.50
Conversion of shares, value $ 36,573 $ 29,888 $ 70,000   $ 136,462          
Conversion of shares, shares 386,608 315,948 739,958   1,442,514          
Debt Instrument, Interest Rate, Stated Percentage                   4.00%
Debt Instrument, Interest Rate, Stated Percentage, Quarterly                   4.00%
Interest Expense         $ 102,478 131,718        
The 2020 Convertible Obligations [Member] | Chief Executive Officer [Member]                    
Convertible Notes Payable, Noncurrent         441,446          
The 2020 Convertible Obligations [Member] | Chief Executive Officer [Member] | Convertible Debt [Member]                    
Convertible Notes Payable, Noncurrent         361,321 2,597,329        
The 2020 Convertible Obligations [Member] | Chief Executive Officer [Member] | Smith [Member]                    
Convertible Notes Payable             $ 262,154      
The 2020 Convertible Obligations [Member] | Chief Executive Officer [Member] | Bassani Family Trusts [Member]                    
Convertible Notes Payable             434,016      
The 2020 Convertible Obligations [Member] | Chief Executive Officer [Member] | Schafer [Member]                    
Convertible Notes Payable             96,364      
The 2020 Convertible Obligations [Member] | President [Member]                    
Convertible Notes Payable, Noncurrent         130,180          
The 2020 Convertible Obligations [Member] | President [Member] | Convertible Debt [Member]                    
Convertible Notes Payable, Noncurrent         36,432 1,328,040        
The 2020 Convertible Obligations [Member] | Executive Vice Chairman [Member]                    
Convertible Notes Payable, Noncurrent         $ 98,014          
The 2020 Convertible Obligations [Member] | Executive Vice Chairman [Member] | Convertible Debt [Member]                    
Convertible Notes Payable, Noncurrent           $ 499,274        
The 2020 Convertible Obligations [Member] | Restricted Common Stock [Member]                    
Sell units         $ 0.75          
Adjusted Convertible Obligations [Member] | Convertible Debt [Member]                    
Conversion of shares, value $ 36,573 $ 29,888                
Conversion of shares, shares 386,608 315,948                
Principal [Member] | Convertible Obligations 2020 [Member]                    
Debt conversion value         $ 30,000          
Debt conversion shares, warrants         60,000          
Principal [Member] | Convertible Obligations 2020 [Member] | After Adjustment [Member]                    
Debt conversion value         $ 136,462          
Debt conversion shares, warrants         1,442,514          
Principal [Member] | Convertible Obligations 2020 [Member] | Warrants [Member]                    
Debt conversion shares, warrants         60,000          
Principal [Member] | Convertible Obligations 2020 [Member] | Warrants [Member] | After Adjustment [Member]                    
Debt conversion shares, warrants         1,442,514          
Principal [Member] | Common Shares [Member] | Convertible Obligations 2020 [Member]                    
Debt conversion shares, warrants         60,000          
Principal [Member] | Common Shares [Member] | Convertible Obligations 2020 [Member] | After Adjustment [Member]                    
Debt conversion shares, warrants         1,442,514          
Accrued Interest [Member] | Convertible Obligations 2020 [Member]                    
Debt conversion value         $ 20,000          
Debt conversion shares, warrants         40,000          
Accrued Interest [Member] | Common Shares [Member] | Convertible Obligations 2020 [Member]                    
Debt conversion shares, warrants         40,000          
Accrued Interest [Member] | Warrants [Member] | Convertible Obligations 2020 [Member]                    
Debt conversion shares, warrants         40,000          
Mark A Smith [Member]                    
Principal amount   $ 262,154     $ 1,109,649          
Conversion price per unit   $ 0.0946     $ 0.0946          
Dominic Bassani [Member]                    
Principal amount   $ 434,016     $ 1,939,670          
Conversion price per unit   $ 953     $ 0.0953          
Ed Schafer [Member]                    
Principal amount   $ 96,364     $ 424,873          
Conversion price per unit   $ 0.0953     $ 0.0953          
Ed Schafer [Member] | September 2015 Convertible Notes [Member] | Chief Executive Officer [Member]                    
Convertible Notes Payable             4,012      
Bassani [Member] | September 2015 Convertible Notes [Member] | Chief Executive Officer [Member]                    
Convertible Notes Payable             $ 24,230      
XML 48 R35.htm IDEA: XBRL DOCUMENT v3.23.3
STOCKHOLDERS' EQUITY - Assumptions (Details) - Share-Based Payment Arrangement, Option [Member]
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Dividend yield
Weighted Average [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Volatility 65.00% 65.00%
Dividend yield
Risk-free interest rate 3.83% 2.99%
Expected term (years) 3 years 5 months 8 days 3 years 8 months 15 days
Minimum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Volatility 64.00% 65.00%
Risk-free interest rate 3.67% 1.71%
Expected term (years) 2 years 10 months 2 days 3 years 14 days
Maximum [Member]    
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]    
Volatility 66.00% 69.00%
Risk-free interest rate 4.11% 3.01%
Expected term (years) 3 years 11 months 12 days 3 years 8 months 19 days
XML 49 R36.htm IDEA: XBRL DOCUMENT v3.23.3
STOCKHOLDERS' EQUITY - Stock Option Activity (Details) - USD ($)
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Equity [Abstract]    
Options outstanding, beginning (in shares) 11,201,600  
Options outstanding, beginning weighted-average exercise price $ 0.80  
Outstanding, weighted-average remaining contractual life (Year) 1 year 9 months 29 days 2 years 8 months 12 days
Outstanding, aggregate intrinsic value beginning $ 4,429,263  
Granted, options (in shares) 805,000  
Granted, weighted-average exercise price  
Exercised, options (in shares)  
Exercised, weighted-average exercise price  
Forfeited, options (in shares)  
Forfeited, weighted-average exercise price  
Expired, options (in shares)  
Expired, weighted-average exercise price  
Options outstanding, ending (in shares) 12,006,600 11,201,600
Options outstanding, ending weighted-average exercise price $ 0.85 $ 0.80
Outstanding, aggregate intrinsic value ending $ 5,085,659 $ 4,429,263
XML 50 R37.htm IDEA: XBRL DOCUMENT v3.23.3
STOCKHOLDERS' EQUITY: (Details Narrative) - USD ($)
12 Months Ended
Jun. 04, 2023
May 09, 2023
Mar. 31, 2023
Mar. 15, 2023
Mar. 08, 2023
Feb. 07, 2023
Jan. 10, 2023
Dec. 31, 2022
Jan. 28, 2022
Jun. 30, 2023
Jun. 30, 2022
Feb. 02, 2023
May 01, 2022
Jun. 30, 2021
Jan. 01, 2020
Jul. 03, 2014
Jul. 02, 2014
Class of Stock [Line Items]                                  
Convertible Notes Payable, Current                   $ 3,470,000              
Increase to additional paid in capital                   3,522,000              
Reduction of additional paid in capital                   14,051              
Redemption of convertible Preferred stock                   $ 41,000              
Shares Held by Subsidiaries                   704,309 704,309            
Share price                   $ 1.00              
Number of shares issued                   346,230              
Sale of common shares                   $ 2,000,000              
Commissions paid                   $ 86,400              
Class of Warrant or Right, Exercised During Period                   175,114              
Common Stock Shares Issued upon Exercise of Warrants                   175,114              
Warrant Exercised for Common Stock                   $ 131,335              
Debt conversion value                 $ 2,665,500                
Conversion price per share                   $ 0.50              
Warrant outstanding                   22,500,000              
Weighted average exercise price                   $ 0.85 $ 0.80            
Exercise bonus                           75.00%      
Number of shares granted                   805,000              
Share-based Compensation, Granted   500,000       275,000                      
Share-based Compensation, Granted   250,000                              
Options Held [Member]                                  
Class of Stock [Line Items]                                  
Share-based Compensation, Granted                   805,000 730,000            
Plan 2006 [Member]                                  
Class of Stock [Line Items]                                  
Number of shares granted       30,000                          
Minimum [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share                   $ 0.60              
Exercise bonus                   50.00%              
Maximum [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share                   $ 2.40              
Exercise bonus                   90.00%              
Common Stock [Member]                                  
Class of Stock [Line Items]                                  
Number of shares issued                   2,000,000              
Sale of common shares                                
Warrants exercisable per share     $ 0.75             $ 0.75              
Shares issued for consultant services                   82,259 25,000            
Warrant [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share                   $ 0.75              
Issuance of warrants                   $ 21,000              
Share-based Payment Arrangement, Plan Modification, Incremental Cost                   154,932              
Interest expenses                   72,589              
Series B Preferred Stock [Member]                                  
Class of Stock [Line Items]                                  
Preferred Stock, Shares Outstanding, Ending Balance (in shares)                                 200
Par value                                 $ 0.01
Preferred Stock, Convertible Option Per Share                               $ 2.00  
Preferred Stock, Redemption Price Per Share                                 $ 100
Dividends Payable                   21,000              
Dividends, Preferred Stock                   $ 1,000 $ 1,000            
Restricted Stock [Member]                                  
Class of Stock [Line Items]                                  
Sale of stock, shares                   2,000,000              
Share price                   $ 0.75              
Sale of common shares                   $ 346,230              
Common Stock [Member]                                  
Class of Stock [Line Items]                                  
Shares purchased, shares             1,800,000 200,000                  
Shares purchased, value                   $ 2,000,000              
Restricted Common Stock [Member]                                  
Class of Stock [Line Items]                                  
Sale of stock, shares                   975,000              
Sale of units                   $ 1.60              
Share price                   $ 2.40              
Number of shares issued                   975,000              
Sale of common shares                   $ 1,560,000              
Warrants [Member]                                  
Class of Stock [Line Items]                                  
Weighted average exercise price                   $ 0.80              
Remaining contractual life                   1 year 7 months 6 days              
Warrants [Member] | Direct Ownership [Member]                                  
Class of Stock [Line Items]                                  
Number of shares issued                   116,566              
Warrants [Member] | Indirect Ownership [Member]                                  
Class of Stock [Line Items]                                  
Number of shares issued                   370,948              
Warrants [Member] | Convertible Obligations 2020 [Member]                                  
Class of Stock [Line Items]                                  
Convertible stock shares issued, warrants                   955,000              
Common Shares [Member] | Direct Ownership [Member]                                  
Class of Stock [Line Items]                                  
Number of shares issued                   292,514              
Common Shares [Member] | Indirect Ownership [Member]                                  
Class of Stock [Line Items]                                  
Number of shares issued                   450,000              
Common Shares [Member] | Convertible Obligations 2020 [Member]                                  
Class of Stock [Line Items]                                  
Convertible stock shares issued, warrants                   700,000              
Share-Based Payment Arrangement, Option [Member]                                  
Class of Stock [Line Items]                                  
Stock options, authorized (in shares)     36,000,000                            
Share-based Payment Arrangement, Expense                   $ 249,744 $ 419,370            
Share-Based Payment Arrangement, Option [Member] | Equity Incentive Plan [Member]                                  
Class of Stock [Line Items]                                  
Stock options, authorized (in shares)     30,000,000                            
September 2015 Convertible Notes [Member] | Convertible Debt [Member]                                  
Class of Stock [Line Items]                                  
Conversion Price Per Unit (in dollars per share)                   $ 0.60              
September 2015 Convertible Notes [Member] | Restricted Common Shares [Member]                                  
Class of Stock [Line Items]                                  
Conversion Price Per Unit (in dollars per share)     $ 0.115             0.115              
The 2020 Convertible Obligations [Member] | Convertible Debt [Member]                                  
Class of Stock [Line Items]                                  
Conversion Price Per Unit (in dollars per share)                   $ 0.0946         $ 0.50    
Conversion of shares, value $ 36,573   $ 29,888   $ 70,000         $ 136,462              
Conversion of shares, shares 386,608   315,948   739,958         1,442,514              
The 2020 Convertible Obligations [Member] | Warrant [Member] | Accrued Interest [Member]                                  
Class of Stock [Line Items]                                  
Debt conversion shares                   100,000              
Conversion price per share                   $ 0.50              
The 2020 Convertible Obligations [Member] | Warrant [Member] | Convertible Debt [Member]                                  
Class of Stock [Line Items]                                  
Debt conversion shares                   100,000              
Conversion price per share                   $ 0.0946              
The 2020 Convertible Obligations [Member] | Restricted Common Stock [Member]                                  
Class of Stock [Line Items]                                  
Share price                   0.75              
The 2020 One Convertible Obligations [Member] | Warrant [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share                   $ 0.75              
The 2020 One Convertible Obligations [Member] | Warrant [Member] | Convertible Debt [Member]                                  
Class of Stock [Line Items]                                  
Debt conversion shares                   1,442,514              
Conversion price per share                   $ 0.0946              
Chief Executive Officer [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share                         $ 1.00        
Number of shares issued                         1,000,000        
Cancellation of warrants                         700,000        
Exercise bonus                         75.00%        
Consultant Service [Member]                                  
Class of Stock [Line Items]                                  
Shares issued for consultant services                   50,000              
Share price                   $ 1.60              
Total value of consultant services                   $ 80,000              
Consultant Service One [Member]                                  
Class of Stock [Line Items]                                  
Shares issued for consultant services                   32,259              
Share price                   $ 1.55              
Total value of consultant services                   $ 50,000              
Principal [Member] | The 2020 Convertible Obligations [Member] | Warrant [Member]                                  
Class of Stock [Line Items]                                  
Debt conversion value                   30,000              
Principal [Member] | The 2020 One Convertible Obligations [Member] | Warrant [Member]                                  
Class of Stock [Line Items]                                  
Debt conversion value                   136,462              
Accrued Interest [Member] | The 2020 Convertible Obligations [Member] | Warrant [Member]                                  
Class of Stock [Line Items]                                  
Debt conversion value                   $ 20,000              
Three Consultants [Member] | Warrant [Member]                                  
Class of Stock [Line Items]                                  
Class of Warrant or Right, Exercised During Period                   210,000              
Three Consultants [Member] | Warrant [Member] | Minimum [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share                   $ 1.50              
Three Consultants [Member] | Warrant [Member] | Maximum [Member]                                  
Class of Stock [Line Items]                                  
Warrants exercisable per share                   $ 1.60              
Consultants [Member] | Warrant [Member]                                  
Class of Stock [Line Items]                                  
Number of shares issued                   700,000              
Vesting period                   May 01, 2023              
Non cash compensation                   $ 41,653              
Mark A Smith [Member]                                  
Class of Stock [Line Items]                                  
Debt Instrument, Face Amount     $ 262,154             $ 1,109,649              
Conversion Price Per Unit (in dollars per share)     $ 0.0946             $ 0.0946              
Mark A Smith [Member] | Chief Operating Officer [Member]                                  
Class of Stock [Line Items]                                  
Debt Instrument, Face Amount                   $ 1,109,649              
Dominic Bassani [Member]                                  
Class of Stock [Line Items]                                  
Debt Instrument, Face Amount     $ 434,016             $ 1,939,670              
Conversion Price Per Unit (in dollars per share)     $ 953             $ 0.0953              
Dominic Bassani [Member] | Chief Operating Officer [Member]                                  
Class of Stock [Line Items]                                  
Debt Instrument, Face Amount                   $ 1,939,670              
Ed Schafer [Member]                                  
Class of Stock [Line Items]                                  
Debt Instrument, Face Amount     $ 96,364             $ 424,873              
Conversion Price Per Unit (in dollars per share)     $ 0.0953             $ 0.0953              
Ed Schafer [Member] | Chief Operating Officer [Member]                                  
Class of Stock [Line Items]                                  
Debt Instrument, Face Amount                   $ 424,873              
Ed Schafer [Member] | Chief Executive Officer [Member] | September 2015 Convertible Notes [Member]                                  
Class of Stock [Line Items]                                  
Convertible Notes Payable                       $ 4,012          
Bassani [Member]                                  
Class of Stock [Line Items]                                  
Share-based Compensation, Granted           100,000                      
Bassani [Member] | Chief Executive Officer [Member] | September 2015 Convertible Notes [Member]                                  
Class of Stock [Line Items]                                  
Convertible Notes Payable                       $ 24,230          
Northrop [Member]                                  
Class of Stock [Line Items]                                  
Share-based Compensation, Granted           25,000                      
Smith [Member]                                  
Class of Stock [Line Items]                                  
Share-based Compensation, Granted           150,000                      
Bill O Neill [Member]                                  
Class of Stock [Line Items]                                  
Share-based Compensation, Granted   250,000                              
XML 51 R38.htm IDEA: XBRL DOCUMENT v3.23.3
SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) - USD ($)
Jun. 30, 2023
Jun. 30, 2022
May 01, 2022
Secured Promissory Note [Member] | Smiths [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Financing Receivable, after Allowance for Credit Loss, Total $ 35,885    
Financing Receivable, Principal Amount $ 30,000    
Chief Executive Officer [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)     $ 1.00
Chief Executive Officer [Member] | Warrants Issused Subscription Receivable [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 5,565,000    
Chief Executive Officer [Member] | Secured Promissory Note [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Financing Receivable, after Allowance for Credit Loss, Total $ 428,250    
Notes receivable interest $ 517,553    
Former Employee [Member] | Warrants Issused Subscription Receivable [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 928,000    
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.75    
Former Employee [Member] | Secured Promissory Note [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Financing Receivable, after Allowance for Credit Loss, Total $ 56,860    
Financing Receivable, Principal Amount $ 46,400    
Financing Receivable, Interest Rate, Stated Percentage 4.00%    
President [Member] | Warrants Issused Subscription Receivable [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) 300,000 300,000  
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) $ 0.60    
President [Member] | Secured Promissory Note [Member]      
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]      
Financing Receivable, after Allowance for Credit Loss, Total $ 35,884    
Financing Receivable, Principal Amount $ 30,000    
Financing Receivable, Interest Rate, Stated Percentage 4.00%    
XML 52 R39.htm IDEA: XBRL DOCUMENT v3.23.3
COMMITMENTS AND CONTINGENCIES (Details)
Jun. 30, 2023
USD ($)
Commitments and Contingencies Disclosure [Abstract]  
Year ended June 30, 2023 to June 2024 $ 75,000
Year ended June 30, 2024 to December 2024 37,500
Undiscounted cash flow 112,500
Less imputed interest (8,432)
Total 104,068
   Less current portion (75,000)
Long term lease liability $ 29,068
XML 53 R40.htm IDEA: XBRL DOCUMENT v3.23.3
COMMITMENTS AND CONTINGENCIES: (Details Narrative) - USD ($)
12 Months Ended
Jul. 26, 2023
Jun. 23, 2023
May 02, 2023
Apr. 24, 2023
Jan. 17, 2023
Jun. 15, 2022
May 02, 2022
Apr. 30, 2022
Mar. 31, 2022
Mar. 23, 2022
Jan. 28, 2022
Aug. 01, 2018
Oct. 10, 2016
Feb. 10, 2015
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2021
May 01, 2022
Dec. 29, 2021
Sep. 30, 2021
Feb. 28, 2018
Apr. 27, 2017
Oct. 31, 2016
Sep. 25, 2014
Loss Contingencies [Line Items]                                                
Compensation increased             $ 25,000                                  
Cash compensation paid                             $ 249,744 $ 346,846                
Exercise bonus                                 75.00%              
Warrants held by trust owned                                 $ 3,000,000              
Warrants and Rights Outstanding                             18,438,339                  
Debt instrument paid amount                     $ 2,665,500                          
Debt Instrument, Interest Rate During Period                 25.00%   25.00%         25.00%                
Principal, interest       $ 83,275 $ 533,100           $ 666,375                          
Paid invoice amount     $ 83,275                                          
Aggregate payment     $ 2,615,500                       2,615,500                  
Purchase order $ 50,000             $ 50,000                                
Capitalized labor and interest costs                             4,182,260                  
Capitalized labor and interest costs paid                             3,962,207                  
Capitalized labor and interest costs yet to pay                             220,053                  
Capitalized labor and interest costs                             6,103,693                  
Sale of domain, description                   the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490.                            
Accrued interest                                     $ 2,255,802          
Total assets                             7,593,633 $ 6,360,337       $ 297        
Total liabilities                             3,361,954 7,254,916     10,234,501 10,154,334        
Accounts payable and accrued liabilities                             677,137 1,360,644     10,009,802 9,939,148        
Accounts payable                                     212,263 214,235        
Accrued Liabilities, Current                                     $ 12,436 $ 950        
Gain on legal dissolution of subsidiary                             $ 10,234,501                  
Loans as a liability                                 9,868,495              
Bank account hacked amount   $ 75,000                                            
Weighted average remaining lease term                             1 year 6 months 29 days                  
Discounted rate                             10.00%                  
P A 1 [Member]                                                
Loss Contingencies [Line Items]                                                
Debt Instrument, Debt Default, Amount                                               $ 8,137,117
Realized from the asset sale           $ 104,725                                    
Pennvest Loan [Member]                                                
Loss Contingencies [Line Items]                                                
Line of Credit Facility, Maximum Borrowing Capacity                             $ 7,754,000                  
Debt Instrument, Annual Principal Payment                             5,886,000                  
Long-Term Debt, Maturity, Year Two                             846,000                  
Long-Term Debt, Maturity, Year Three                             873,000                  
Long-Term Debt, Maturity, Year Four                             $ 149,000                  
Interest Expense, Debt                               123,444 $ 246,887              
Pennvest Loan [Member] | Years One Through Five [Member]                                                
Loss Contingencies [Line Items]                                                
Debt Instrument, Interest Rate During Period                             2.547%                  
Pennvest Loan [Member] | Years Six Through Maturity [Member]                                                
Loss Contingencies [Line Items]                                                
Debt Instrument, Interest Rate During Period                             3.184%                  
Minimum [Member]                                                
Loss Contingencies [Line Items]                                                
Warrants exercisable per share                             $ 0.60                  
Exercise bonus                             50.00%                  
Maximum [Member]                                                
Loss Contingencies [Line Items]                                                
Warrants exercisable per share                             $ 2.40                  
Exercise bonus                             90.00%                  
Smith [Member]                                                
Loss Contingencies [Line Items]                                                
Cash compensation paid                             $ 5,000                  
Cash compensation paid                             200,000 $ 130,000                
William O Neill [Member]                                                
Loss Contingencies [Line Items]                                                
Payment for cash                             $ 12,500                  
President [Member]                                                
Loss Contingencies [Line Items]                                                
Monthly Officers Cash Compensation                         $ 18,000                      
President [Member] | Extension Bonus [Member] | Fy 2016 Extension Agreement [Member]                                                
Loss Contingencies [Line Items]                                                
Deferred Compensation, Maximum Convertible Amount                                           $ 300,000 $ 125,000  
Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)                                           $ 0.75 $ 0.75  
President [Member] | Warrants Issused Subscription Receivable [Member]                                                
Loss Contingencies [Line Items]                                                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                             300,000 300,000                
Warrants exercisable per share                             $ 0.60                  
President [Member] | Warrants Issued In Connection With Sale Of Units In Exchange For Salary [Member]                                                
Loss Contingencies [Line Items]                                                
Warrants exercisable per share                             $ 0.75                  
Chief Executive Officer [Member]                                                
Loss Contingencies [Line Items]                                                
Monthly Officers Cash Compensation                           $ 31,000 $ 25,000                  
Warrants exercisable per share                                   $ 1.00            
Cash compensation paid                             5,000                  
Cash compensation paid                             150,000 $ 25,000                
Deferred Compensation, Maximum Convertible Amount                             $ 10,000                  
Exercise price adjustment provision Percentage                             75.00%                  
Exercise bonus                                   75.00%            
Number of shares issued                                   1,000,000            
Cancellation of warrants                                   700,000            
Chief Executive Officer [Member] | Secured Promissory Note Consideration For Warrants Expiring On December 312025 [Member]                                                
Loss Contingencies [Line Items]                                                
Cash compensation paid                             $ 5,000                  
Financing Receivable, after Allowance for Credit Loss, Total                             361,321                  
Repayments of Long-term Debt, Total                             $ 300,000 $ 250,000                
Chief Executive Officer [Member] | Warrants Issused Subscription Receivable [Member]                                                
Loss Contingencies [Line Items]                                                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                             5,565,000                  
Chief Executive Officer [Member] | Warrants Expiring On December 312025 [Member]                                                
Loss Contingencies [Line Items]                                                
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)                       3,000,000                        
Bassani [Member]                                                
Loss Contingencies [Line Items]                                                
Salaries and wages                                         $ 31,000      
Additional paid amount                                         $ 2,000      
Interest bearing secured promissory note                       $ 300,000                        
XML 54 R41.htm IDEA: XBRL DOCUMENT v3.23.3
INCOME TAXES (Details) - USD ($)
12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Income Tax Disclosure [Abstract]    
Expected income tax benefit at statutory rate $ (670,000) $ 1,741,000
State taxes, net of federal benefit (117,000) 303,000
Permanent differences and other 9,000 8,000
Expiration of net operating allowances 733,000 1,229,000
Change in valuation allowance (45,000) (3,281,000)
Income tax benefit
XML 55 R42.htm IDEA: XBRL DOCUMENT v3.23.3
INCOME TAXES (Details 1) - USD ($)
Jun. 30, 2023
Jun. 30, 2022
Income Tax Disclosure [Abstract]    
NOL carryforwards (Federal and State) $ 8,299,000 $ 8,274,000
Stock-based compensation 5,459,000 5,436,000
Impairment 1,340,000 1,340,000
Business interest 338,000 339,000
Deferred compensation 1,054,000 1,054,000
Capitalized research and development 66,000
Gross deferred tax assets 16,148,000 16,443,000
Valuation allowance (16,148,000) (16,443,000)
Net deferred tax assets
XML 56 R43.htm IDEA: XBRL DOCUMENT v3.23.3
INCOME TAXES (Details Narrative)
12 Months Ended
Jun. 30, 2023
USD ($)
Income Tax Disclosure [Abstract]  
Operating Loss Carryforwards, Total $ 39,500,000
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 100.00%
XML 57 R44.htm IDEA: XBRL DOCUMENT v3.23.3
SUBSEQUENT EVENTS: (Details Narrative) - USD ($)
3 Months Ended 12 Months Ended
Aug. 28, 2023
Aug. 16, 2023
Jul. 21, 2023
Jul. 07, 2023
Sep. 28, 2023
Jun. 30, 2023
Jun. 30, 2022
Subsequent Event [Line Items]              
Cost incurred           $ 179,981 $ 32,000
Number of shares exercised            
Number of shares warrants outstanding           22,500,000  
Subsequent Event [Member]              
Subsequent Event [Line Items]              
Cost incurred         $ 583,870    
Aggregate cost         $ 7,431,630    
Number of shares exercised         38,000    
Number of shares exercised         $ 38,000    
Warrants exercised   $ 1.55   $ 1.20 $ 0.75    
Total proceeds         $ 28,500    
Number of shares warrants outstanding   10,753   7,500      
Total value of consultant services $ 45,742 $ 16,667   $ 9,000      
Unreimbursed expenses     $ 49,048        
Number of shares converted     518,477        
Conversion price per unit     $ 0.0946        
Warrant exercise price     $ 0.75        
Warrants exercise price percentage     75.00%        
Slae of shares 28,589            
Slae of share price $ 1.60            
XML 58 bion_10k-063023_htm.xml IDEA: XBRL DOCUMENT 0000875729 2022-07-01 2023-06-30 0000875729 2023-06-30 0000875729 2023-08-01 0000875729 2021-07-01 2022-06-30 0000875729 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-06-30 0000875729 us-gaap:CommonStockMember 2021-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-06-30 0000875729 2021-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2022-06-30 0000875729 us-gaap:CommonStockMember 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:CommonStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2022-06-30 0000875729 bnet:SubscriptionsReceivableMember 2021-07-01 2022-06-30 0000875729 us-gaap:RetainedEarningsMember 2021-07-01 2022-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2021-07-01 2022-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2022-07-01 2023-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2022-07-01 2023-06-30 0000875729 us-gaap:CommonStockMember 2022-07-01 2023-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2023-06-30 0000875729 bnet:SubscriptionsReceivableMember 2022-07-01 2023-06-30 0000875729 us-gaap:RetainedEarningsMember 2022-07-01 2023-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2022-07-01 2023-06-30 0000875729 us-gaap:SeriesAPreferredStockMember 2023-06-30 0000875729 us-gaap:SeriesCPreferredStockMember 2023-06-30 0000875729 us-gaap:CommonStockMember 2023-06-30 0000875729 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000875729 bnet:SubscriptionsReceivableMember 2023-06-30 0000875729 us-gaap:RetainedEarningsMember 2023-06-30 0000875729 us-gaap:NoncontrollingInterestMember 2023-06-30 0000875729 bnet:JVAMember 2022-07-01 2023-06-30 0000875729 bnet:Gen3TechMember 2022-07-01 2023-06-30 0000875729 2022-01-27 2022-01-28 0000875729 2022-03-30 2022-03-31 0000875729 2023-01-16 2023-01-17 0000875729 2023-04-23 2023-04-24 0000875729 2023-07-25 2023-07-26 0000875729 2017-07-01 2018-06-30 0000875729 srt:MinimumMember 2023-06-30 0000875729 srt:MaximumMember 2023-06-30 0000875729 bnet:CenterpointMember 2023-06-30 0000875729 us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 us-gaap:WarrantMember 2021-07-01 2022-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2023-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2023-06-30 0000875729 us-gaap:ConvertibleDebtSecuritiesMember 2021-07-01 2022-06-30 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2022-07-01 2023-06-30 0000875729 bnet:ConvertiblePreferredStockAntidilutiveSecuritiesMember 2021-07-01 2022-06-30 0000875729 bnet:PropertyPlantAndEquipmentOfPA1Member 2022-07-01 2023-06-30 0000875729 bnet:BassaniMember 2023-06-30 0000875729 bnet:SmithMember 2023-06-30 0000875729 bnet:BassaniMember 2022-06-30 0000875729 bnet:SmithMember 2022-06-30 0000875729 bnet:ConsultantsAndEmployeeMember 2023-06-30 0000875729 bnet:ConsultantsAndEmployeeMember 2022-06-30 0000875729 bnet:BassaniAndSmithMember 2023-06-30 0000875729 bnet:BillONeillMember 2023-06-30 0000875729 bnet:BillONeillMember 2022-06-30 0000875729 bnet:SmithMember 2023-06-30 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2022-07-01 2023-06-30 0000875729 bnet:InterestExpenseOnDeferredCompensationObligationMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2023-06-30 0000875729 2021-09-30 0000875729 2021-12-29 0000875729 bnet:YearsOneThroughFiveMember bnet:PennvestLoanMember 2022-07-01 2023-06-30 0000875729 bnet:YearsSixThroughMaturityMember bnet:PennvestLoanMember 2022-07-01 2023-06-30 0000875729 bnet:PennvestLoanMember 2021-07-01 2022-06-30 0000875729 bnet:PennvestLoanMember 2020-07-01 2021-06-30 0000875729 bnet:PA1Member 2014-09-25 0000875729 bnet:PA1Member 2022-06-14 2022-06-15 0000875729 bnet:MarkASmithMember 2023-06-30 0000875729 bnet:DominicBassaniMember 2023-06-30 0000875729 bnet:EdSchaferMember 2023-06-30 0000875729 bnet:RestrictedCommonSharesMember bnet:September2015ConvertibleNotesMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:SmithMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:BassaniFamilyTrustsMember 2023-02-02 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember bnet:SchaferMember 2023-02-02 0000875729 bnet:BassaniMember srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2023-02-02 0000875729 bnet:EdSchaferMember srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2023-02-02 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-07-01 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-06-30 0000875729 bnet:RestrictedCommonStockMember bnet:The2020ConvertibleObligationsMember 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-07 2023-03-08 0000875729 bnet:AdjustedConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-30 2023-03-31 0000875729 bnet:AdjustedConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-06-01 2023-06-04 0000875729 bnet:CommonSharesMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-06-30 0000875729 bnet:WarrantsMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-06-30 0000875729 bnet:DirectOwnershipMember bnet:CommonSharesMember 2023-06-30 0000875729 bnet:DirectOwnershipMember bnet:WarrantsMember 2023-06-30 0000875729 bnet:IndirectOwnershipMember bnet:CommonSharesMember 2023-06-30 0000875729 bnet:IndirectOwnershipMember bnet:WarrantsMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember 2023-06-30 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember 2023-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember 2023-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2020-01-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-06-30 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-06-30 0000875729 srt:PresidentMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2022-06-30 0000875729 bnet:The2020ConvertibleObligationsMember 2022-07-01 2023-06-30 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-06-30 0000875729 bnet:CommonSharesMember bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-06-30 0000875729 bnet:PrincipalMember bnet:ConvertibleObligations2020Member bnet:WarrantsMember 2022-07-01 2023-06-30 0000875729 bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-06-30 0000875729 bnet:CommonSharesMember bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-06-30 0000875729 bnet:WarrantsMember bnet:AccruedInterestMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-06-30 0000875729 bnet:AfterAdjustmentMember bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-06-30 0000875729 bnet:AfterAdjustmentMember bnet:CommonSharesMember bnet:PrincipalMember bnet:ConvertibleObligations2020Member 2022-07-01 2023-06-30 0000875729 bnet:AfterAdjustmentMember bnet:PrincipalMember bnet:ConvertibleObligations2020Member bnet:WarrantsMember 2022-07-01 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2021-07-01 2022-06-30 0000875729 srt:PresidentMember bnet:SecuredPromissoryNoteMember 2023-06-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2023-06-30 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:September2015ConvertibleNotesMember bnet:BassaniFamilyTrustsMember 2022-03-31 0000875729 bnet:ConsultantsMember bnet:September2015ConvertibleNotesMember bnet:SchaferMember 2022-03-31 0000875729 bnet:ExecutiveViceChairmanMember bnet:September2015ConvertibleNotesMember bnet:ShareholderMember 2022-03-31 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2022-07-01 2023-06-30 0000875729 bnet:September2015ConvertibleNotesMember us-gaap:ConvertibleDebtMember 2021-07-01 2022-06-30 0000875729 bnet:MarkASmithMember srt:ChiefOperatingOfficerMember 2023-06-30 0000875729 bnet:DominicBassaniMember srt:ChiefOperatingOfficerMember 2023-06-30 0000875729 bnet:EdSchaferMember srt:ChiefOperatingOfficerMember 2023-06-30 0000875729 bnet:MarkASmithMember 2023-03-31 0000875729 bnet:DominicBassaniMember 2023-03-31 0000875729 bnet:EdSchaferMember 2023-03-31 0000875729 bnet:RestrictedCommonSharesMember bnet:September2015ConvertibleNotesMember 2023-03-31 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-02 0000875729 us-gaap:SeriesBPreferredStockMember 2014-07-03 0000875729 us-gaap:SeriesBPreferredStockMember 2023-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2022-07-01 2023-06-30 0000875729 us-gaap:SeriesBPreferredStockMember 2021-07-01 2022-06-30 0000875729 us-gaap:RestrictedStockMember 2022-07-01 2023-06-30 0000875729 us-gaap:CommonStockMember 2023-01-02 2023-01-10 0000875729 us-gaap:CommonStockMember 2022-12-30 2022-12-31 0000875729 us-gaap:CommonStockMember 2022-07-01 2023-06-30 0000875729 bnet:RestrictedCommonStockMember 2022-07-01 2023-06-30 0000875729 bnet:RestrictedCommonStockMember 2023-06-30 0000875729 us-gaap:RestrictedStockMember 2023-06-30 0000875729 bnet:ConsultantServiceMember 2022-07-01 2023-06-30 0000875729 bnet:ConsultantServiceMember 2023-06-30 0000875729 bnet:ConsultantServiceOneMember 2022-07-01 2023-06-30 0000875729 bnet:ConsultantServiceOneMember 2023-06-30 0000875729 bnet:PrincipalMember bnet:The2020ConvertibleObligationsMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 bnet:AccruedInterestMember bnet:The2020ConvertibleObligationsMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember bnet:AccruedInterestMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember bnet:AccruedInterestMember us-gaap:WarrantMember 2023-06-30 0000875729 us-gaap:WarrantMember 2023-06-30 0000875729 bnet:PrincipalMember bnet:The2020OneConvertibleObligationsMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 bnet:The2020OneConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 bnet:The2020OneConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2023-06-30 0000875729 bnet:The2020OneConvertibleObligationsMember us-gaap:WarrantMember 2023-06-30 0000875729 bnet:WarrantsMember 2023-06-30 0000875729 bnet:WarrantsMember 2022-07-01 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember us-gaap:WarrantMember 2023-06-30 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-03-30 2023-03-31 0000875729 bnet:The2020ConvertibleObligationsMember us-gaap:ConvertibleDebtMember 2023-06-01 2023-06-04 0000875729 bnet:ThreeConsultantsMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 srt:MinimumMember bnet:ThreeConsultantsMember us-gaap:WarrantMember 2023-06-30 0000875729 srt:MaximumMember bnet:ThreeConsultantsMember us-gaap:WarrantMember 2023-06-30 0000875729 us-gaap:CommonStockMember 2023-03-31 0000875729 srt:ChiefExecutiveOfficerMember 2022-05-01 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2023-06-30 0000875729 bnet:ConsultantsMember us-gaap:WarrantMember 2022-07-01 2023-06-30 0000875729 us-gaap:EmployeeStockOptionMember bnet:EquityIncentivePlanMember 2023-03-31 0000875729 us-gaap:EmployeeStockOptionMember 2023-03-31 0000875729 bnet:Plan2006Member 2023-03-14 2023-03-15 0000875729 2023-02-06 2023-02-07 0000875729 bnet:NorthropMember 2023-02-06 2023-02-07 0000875729 bnet:BassaniMember 2023-02-06 2023-02-07 0000875729 bnet:SmithMember 2023-02-06 2023-02-07 0000875729 2023-05-08 2023-05-09 0000875729 bnet:BillONeillMember 2023-05-08 2023-05-09 0000875729 us-gaap:EmployeeStockOptionMember 2022-07-01 2023-06-30 0000875729 us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 us-gaap:OptionMember 2022-07-01 2023-06-30 0000875729 us-gaap:OptionMember 2021-07-01 2022-06-30 0000875729 srt:WeightedAverageMember us-gaap:EmployeeStockOptionMember 2022-07-01 2023-06-30 0000875729 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2022-07-01 2023-06-30 0000875729 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2022-07-01 2023-06-30 0000875729 srt:WeightedAverageMember us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2021-07-01 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteMember 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-06-30 0000875729 bnet:FormerEmployeeMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-06-30 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2022-06-30 0000875729 srt:PresidentMember bnet:WarrantsIssusedSubscriptionReceivableMember 2023-06-30 0000875729 bnet:SmithsMember bnet:SecuredPromissoryNoteMember 2023-06-30 0000875729 bnet:FormerEmployeeMember bnet:SecuredPromissoryNoteMember 2023-06-30 0000875729 srt:PresidentMember 2016-10-01 2016-10-10 0000875729 srt:PresidentMember bnet:WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember 2023-06-30 0000875729 2022-04-27 2022-05-02 0000875729 bnet:SmithMember 2022-07-01 2023-06-30 0000875729 bnet:SmithMember 2021-07-01 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2015-02-03 2015-02-10 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2016-10-31 0000875729 srt:PresidentMember bnet:ExtensionBonusMember bnet:Fy2016ExtensionAgreementMember 2017-04-27 0000875729 bnet:BassaniMember 2018-02-28 0000875729 bnet:BassaniMember 2018-07-28 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:WarrantsExpiringOnDecember312025Member 2018-08-01 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2022-07-01 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember bnet:SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member 2021-07-01 2022-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2022-07-01 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2023-06-30 0000875729 bnet:WilliamONeillMember 2022-07-01 2023-06-30 0000875729 srt:ChiefExecutiveOfficerMember 2021-07-01 2022-06-30 0000875729 2020-07-01 2021-06-30 0000875729 2023-05-02 0000875729 2023-04-27 2023-05-02 0000875729 2022-04-29 2022-04-30 0000875729 2022-03-22 2022-03-23 0000875729 2023-06-22 2023-06-23 0000875729 us-gaap:SubsequentEventMember 2023-07-01 2023-09-28 0000875729 us-gaap:SubsequentEventMember 2023-07-07 0000875729 us-gaap:SubsequentEventMember 2023-07-06 2023-07-07 0000875729 us-gaap:SubsequentEventMember 2023-07-20 2023-07-21 0000875729 us-gaap:SubsequentEventMember 2023-07-21 0000875729 us-gaap:SubsequentEventMember 2023-08-16 0000875729 us-gaap:SubsequentEventMember 2023-08-15 2023-08-16 0000875729 us-gaap:SubsequentEventMember 2023-08-27 2023-08-28 0000875729 us-gaap:SubsequentEventMember 2023-08-28 iso4217:USD shares iso4217:USD shares pure bnet:Decimal 0000875729 false FY 2023 10-K true 2023-06-30 --06-30 false 000-19333 BION ENVIRONMENTAL TECHNOLOGIES, INC. CO 84-1176672 9 East Park Court Old Bethpage NY 11804 (516) 586-5643 No No Yes Yes false Non-accelerated Filer true false false 46500000 48703905 457 Eide Baily LLP 286 Haynie & Company Salt Lake City, Utah Denver, Colorado 625964 3160442 16785 157550 6000 1000 648749 3318992 93875 145787 6851009 2895558 7593633 6360337 677137 1360644 864781 594798 75000 1616916 1955442 29068 128864 1715970 5170610 3361954 7254916 0 0 250000000 250000000 48044790 43758820 47340480 43054511 131935418 123620046 504650 504650 -127236663 -124047548 4194105 -932152 37573 37573 4231678 -894579 7593633 6360337 3072163 2348324 1645 1161 82759 200691 3156567 2550176 -3156567 -2550176 5836 5625 38384 301659 902490 10234501 32548 -10840957 -3189115 8290781 -1544 -3189115 8292325 -0.07 -0.07 0.20 0.20 45038479 45038479 41962302 41962302 41315986 121399067 -504650 -132339873 39117 -11406339 2315550 1736662 1736662 66860 -18601 -18601 35424 17711 17711 25000 27500 27500 8337 8337 30000 30000 419370 419370 8292325 -1544 8290781 43758820 123620046 -504650 -124047548 37573 -894579 1321530 1906230 1906230 2000000 2000000 2000000 175114 131335 131335 82259 130000 130000 62563 62563 1542514 186462 186462 249744 249744 -86400 -86400 154932 154932 72589 72589 3507917 3507917 -3189115 -3189115 48880237 131935418 -504650 -127236663 37573 4231678 -3189115 8290781 10234501 1645 1161 38384 319523 249744 346846 130000 154932 62563 -140765 33501 5000 -879618 366629 27116 -16923 340000 289200 -2928584 -670785 3557059 2062155 -3557059 -2062155 3906230 131335 1736662 86400 18601 -41000 3951165 1677061 -2534478 -1055879 3160442 4216321 625964 3160442 3507917 186462 17711 23943 90000 190000 179984 32000 50145 220052 666375 <p id="xdx_80B_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z78UOiiqLkua" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="width: 5pt"></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_82A_zJooO5YaaGy4">ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT’S PLANS</span>:</b></span></td> </tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Organization and nature of business: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Bion Environmental Technologies, Inc.'s ("Bion," "Company," "We," "Us," or "Our") was incorporated in 1987 in the State of Colorado. Bion’s mission is to make livestock production more sustainable, profitable and transparent. We intend to accomplish this by deploying our Gen3Tech platform/business model (discussed below) in ventures focused on the ‘feeder’ space of the livestock production/value chain to provide the consumer with verifiably sustainable premium meat products (together with environmentally friendly, sustainable and/or organic co-products from the production process).  Bion believes this approach can create extraordinary value for our shareholders and employees (all of whom own securities in the Company) and for livestock/agriculture industry ‘partners’ who join us in our ventures. We anticipate pursuing the opportunity created by our third generation technology (“Gen3Tech”) and business/technology platform in conjunction with other industry practices (“Gen3Tech Platform” or “Platform”) utilizing a joint venture/strategic partner model. We believe our approach will improve the well-being of farmers, ranchers, feeders, etc. we work with and create value for our shareholders while improving the environment.  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our patented and proprietary technology provides advanced waste treatment and resource recovery for large-scale livestock production facilities (also known as “Concentrated Animal Feeding Operations” or “CAFOs"). Livestock production and its waste, particularly from CAFOs, has been identified as one of the greatest soil, air, and water quality problems in the U.S. today.  Application of our Gen3Tech”) can largely mitigate these environmental problems, while simultaneously improving operational/ resource efficiencies by recovering high-value co-products from the CAFOs’ waste stream. These waste ‘assets’ – nutrients and methane – have traditionally been wasted or underutilized and are the same ‘pollutants’ that today fuel harmful algae blooms, contaminate surface groundwater, and exacerbate climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms) (“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). To accomplish Bion’s goals, we anticipate the we will ‘partner’ with other technology companies who provide solutions for different links of the beef (and other livestock) value chain and with strategic partners up and down the supply chain<b>.</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We anticipate this will result in substantial long-term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent one of the largest enhanced revenue contributors provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s Gen3Tech was designed to capture and stabilize these assets and produce renewable energy, fertilizer products, and clean water as part of the process of raising verifiably sustainable livestock. All steps and stages in the animal raising and waste treatment process will be third-party verified, providing the basis for additional revenues, including carbon and/or renewable energy-related credits and, eventually, payment for a range of ecosystem services, including nutrient credits as described below. The same verified data will be used to substantiate the claims of a USDA-certified sustainable brand that will support premium pricing for the meat/ animal protein products that are produced in Bion facilities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"> During the first half of 2022 Bion began pre-marketing our sustainable beef to retailers, food service distributors and the meat industry in the U.S.  In general, the response has been favorable. During July 2022, Bion announced a letter of intent (“Ribbonwire LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Ribbonwire Ranch, in Dalhart, Texas (with a provision to expand to 60,000 head) (“Dalhart Project”). During January 2023 Bion announced a letter of intent (“Olson LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with the Olson Feeders and TD Angus, near North Platte, Nebraska (with a provision to expand to 45,000 head or more) (“Olson Project”). During April 2023 Bion announced a letter of intent (“DVG LOI”) to develop a large-scale commercial project - a 15,000-head sustainable beef cattle feeding operation together with Dakota Valley Growers near Bathgate, North Dakota (“DVG Project”). Based on our experience to date, we believe we will not have difficulty in securing participation in our Projects from additional feeders/cattlemen. The Olson, Dalhart and DVG Projects (and subsequent Projects) will be developed to produce blockchain-verified, sustainable beef in customized covered barns (resulting in reduced stress on cattle caused by extreme weather and temperatures and resulting higher feed/weight gain efficiency) with ongoing manure transfer (through slatted floors) to anaerobic digesters (AD) to capture nitrogen from the manure stream before loss to the atmosphere and generate renewable natural gas (RNG) for sale while remediating the environmental/carbon impacts usually associated with cattle feedlots and CAFOs. Bion’s patented Gen3Tech platform will refine the waste stream into valuable coproducts that include clean water, RNG, photovoltaic solar electricity and fertilizer (‘climate smart’ and/or organic) products. We anticipate converting these LOIs into definitive JV agreements and creating related distribution agreements with key retailers and food service distributors during the current fiscal year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Our business plan is focused on executing multiple agreements and letters of intent related to additional sustainable beef JV projects over the next twenty-four (24) months while moving forward with the Initial Project (see below) and commencing development of one or more of the Dalhart/Olson/DVG Projects (“LOI Projects”)(and/or other Gen3Tech beef JV projects) while pursuing other opportunities in the livestock industry enabled by our Gen3Tech business model.  The LOI announcements have generated significant interest within the livestock industry (among ranchers, feedlot operators, farmers and other AG industry parties) and has led to and assisted our discussions with many major of the larger agriculture/livestock industry companies (including those involved with distribution and/or sales of meat products) in the country which are ongoing at this date. We believe that this interest, combined with consumer interest in ‘sustainable products’ and growing enthusiasm among some livestock industry parties for environmental/sustainable/regenerative practices, may provide Bion (and its partners/venturers) with an opportunity to move forward with a truly sustainable solution in this industry segment at a rapid pace.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the past nine months, the Company has constructed (construction is largely completed) our 3GTech Ammonia Recovery System (‘ARS’) located near Fair Oaks, Indiana and begun operations of phase 1 of our Initial Project (our commercial scale demonstration facility) located near Fair Oaks, Indiana. We recently announced that announced the ARS has achieved and maintained controlled steady-state operations under a variety of conditions. When operated at steady state, the system produces an ammonium distillate (solution), the base of Bion’s nitrogen fertilizer products. Bion has begun optimizing the ARS’s operating parameters with the goal of meeting and/or exceeding the results needed for Bion’s economic models for large-scale commercial projects. The Company expects the current optimization phase will continue during the next quarter (or longer) and provide data required to support final design/engineering for commercial project modules. We believe this data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, distributors, retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The patented ARS is the core of Bion’s Gen3Tech platform. It recovers and upcycles problem ammonia contained in the effluent from anaerobic digestion (where methane is captured and more ammonia is released) of the livestock manure waste stream. The ARS captures the ammonia, minimizing its environmental impacts and creating low-carbon and/or organic nitrogen fertilizer products with it. Over during the next quarter, the Company intends to produce ammonium distillate at Fair Oaks in several concentrations and initiate the application process for organic certification for each concentration of liquid fertilizer product. Bion will produce a solid/granular nitrogen fertilizer product at the Initial Project (when the crystalizer module is ready for operation) which we believe will be both ‘Climate-Smart’ and ‘Water-Smart’ – a pure nitrogen fertilizer with a low carbon footprint, that is water soluble and readily available to plants. Samples of the granular product will also be utilized to support organic certification applications. See <b>Fertilizer---Organic and ‘ClimateSmart’ </b>below.<b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the next three - six/ months, the Company intends to fully complete construction of the Initial Project’s phase 1, including the crystalizer module, and continue the optimization operations. Bion expects the Initial Project data will document the effectiveness of our Gen3Tech in a commercial-scale setting during the current fiscal year and support development of the LOI Projects (and/or other Gen3Tech beef JV projects) commencing later this fiscal year.  We do not presently know the order in which these JV Projects will be developed as that decision will be made based on many factors not yet in place. We believe the Initial Project data will also provide additional potential stakeholders (cattle producers, cattle feeders, packers, food distributors and retailers and financial institutions) with the information they need to proceed with confidence in collaborating with Bion on multiple new projects (see below). </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion is now focused primarily on: i) completion of development/construction and operation of the Initial Project, our initial commercial-scale Gen3Tech installation, and optimization of its operational parameters, ii) pre-development plan of the LOI Projects (and/or other Gen3Tech beef JV projects) including steps toward distribution agreements, iii) developing applications and markets for its low carbon ‘ClimateSmart’ and organic fertilizer products (including listings/certifications of multiple liquid and solid products) and its sustainable (conventional and organic) animal protein products, and iv) discussions regarding initiation and development of agreements and joint ventures (“JVs” as discussed herein) (and related Projects) based on the augmented capabilities of our Gen3Tech business platform (in the sustainable beef and other livestock segments), while (v) continuing to pursue business opportunities related to large retrofit projects (such as the Kreider poultry project JV described below) and vi) ongoing R&amp;D activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>HISTORY, BACKGROUND AND CURRENT ACTIVITIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify">Since the Company’s inception, Bion has designed and developed advanced waste treatment systems for livestock. The first and second generations of Bion’s technology platform were biological systems, primarily focused on nutrient control. Over 30 of these systems were deployed at New York dairies, Florida food processing facilities and dairies, North Carolina hog farms, a Texas dairy and a Pennsylvania dairy (“Kreider 1 Project”). The systems were highly effective at their intended purpose: capturing nitrogen and phosphorus. They produced BionSoil as a byproduct, which was a remarkably effective soil amendment/ fertilizer product, but whose value was not enough to support a viable business model. As such, these early technology iterations were entirely dependent on either implementation of new regulations requiring waste treatment, or subsidy/ incentive programs that would provide ‘payment for ecosystem services’. By the mid-2010’s, it became apparent that neither of these options were imminent or even assured, so the Company initiated the steps to reimagine and redesign its technology.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From 2016 to 2021 fiscal years, the Company focused most of its activities and resources on developing, testing and demonstrating the third generation of its technology and technology platform (“Gen3Tech”) that was developed with an emphasis producing more valuable co-products from the waste treatment process, including renewable natural gas and ammonium bicarbonate, a low-carbon, organic ’pure’ nitrogen fertilizer product, while raising sustainable livestock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The $175 billion U.S. livestock industry is under intense scrutiny for its environmental and public health impacts – its ‘environmental sustainability’-- at the same time it is struggling with declining revenues and margins (derived in part from clinging to its historic practices and resulting limitations and impacts) which threaten its ‘economic sustainability’. Its failure to adequately respond to consumer concerns including food safety, environmental impacts, and inhumane treatment of animals have provided impetus for plant-based alternatives such as Beyond Meat and Impossible Burger (and many others) being marketed as “sustainable” alternatives for this growing consumer segment of the market (despite the lack of verifiably sustainable attributes).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes that its Gen3Tech, in addition to providing superior environmental remediation, creates opportunities for large scale production of i) verifiably sustainable-branded conventional livestock products and ii) verifiably sustainable organic-branded livestock products, both of which will command premium pricing (in part due to ongoing monitoring and third-party verification of environmental performance which will provide meaningful assurances to both consumers and regulatory agencies). Each of these two distinct market segments (which the Company intends to pursue in parallel) presents a production/marketing opportunity for Bion (but the former is far larger). Our Gen3Tech will also produce (as co-products) biogas, solar photovoltaic electricity in appropriate locations, and valuable low carbon/organic fertilizer products, which can be utilized in the production of organic grains for use as feed for raising organic livestock (some of which may be utilized in the Company’s JV projects) and/or marketed to the growing organic fertilizer market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During 2022-23, the Company entered into 3 LOIs setting forth the parties’ intention to negotiate joint venture agreement (“JVA”) and enter into joint ventures (“JV”) to develop and operate <span id="xdx_904_ecustom--TechWastage_uDecimal_c20220701__20230630__srt--CounterpartyNameAxis__custom--JVAMember_zHHKrLjNeDV4" title="Tech wastage">15,000</span> head integrated, sustainable beef facilities (with future expansion under consideration) including:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 96px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">innovative cattle barns (with slatted floors to facilitate movement of manure to the anaerobic digester and potentially solar PV generation on the rooftops which barns will improve the living conditions of the animals while increasing feeding/weight gain efficiency,</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 96px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">‘customized’ anaerobic digestion systems (including pretreatment to increase renewable natural gas (‘RNG’) production and an RNG cleaning system (which will include capture/recycling of the CO2) to allow pipeline sales and monetization of related environmental credits,</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 96px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a Bion Gen3Tech module (which will utilize the recycled CO2 to increase ammonia nitrogen/ammonium bicarbonate recovery) for the production of ammonia nitrogen fertilizer for use in organic and/or ‘ClimateSmart’ low carbon crop production (plus residual organic solids and clean water),</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 96px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">which will produce verifiably sustainable beef products with USDA certified branding.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt; text-align: justify">The opportunity presented by the LOIs to commercialize the Company’s Gen3Tech and business model matured more quickly than anticipated (reflecting strong industry and public momentum in favor of verifiably sustainable food ventures). As a result, we have shifted our plans to focus resources and make our initial <span id="xdx_90F_ecustom--TechWastage_uDecimal_c20220701__20230630__srt--CounterpartyNameAxis__custom--Gen3TechMember_zj18XDrtn4kh" title="Tech wastage">15,000</span> head operation a reality as soon as possible.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To place the LOI Projects in the context of Company’s business plan (and our prior public disclosure), if the contemplated ventures moves forward on the timelines currently contemplated, active development of the the initial LOI Project will commence during 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prior to such activity, the Company has constructed and commenced operate of the initial phase of our previously discussed Gen3Tech demonstration project near Fair Oaks, Indiana (“Initial Project”): i) to validate our existing data and modeling at commercial scale and ii) to optimize the Bion Gen3Tech module for finalization of design parameters and fabrication details of our planned 15,000 head commercial facilities (including the LOIProjects). For the purposes of this initial phase, the Company, in order to accelerate the data acquisition phase, is utilizing anaerobic digester effluent from the nearby/contiguous Fair Oaks dairy. Thereafter, the Company will evaluate what, if any, additional facilities and testing will take place at that location.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During late September 2021, Bion entered into a lease for the development site of the Initial Project, our initial commercial scale Gen3Tech project, which Initial Project will be located on approximately four (4) acres of leased land near Fair Oaks, Indiana, and a related agreement regarding disposal of certain manure effluent with the Curtis Creek Dairy unit of Fair Oaks Farms (“FOF”). Design and pre-development work commenced during August 2021 and preliminary surveying, site engineering and other work is now underway along with site-specific engineering and design work. The Initial Project was initially planned to be an environmentally sustainable beef cattle feeding facility, equipped with state-of-the-art housing and Bion’s 3G-Tech platform to provide waste treatment and resource recovery. Bion has designed the project to house and feed approximately <span id="xdx_903_ecustom--CattlePerHead_uDecimal_c20220701__20230630_ztNebFLIlAik" title="Cattle per head">300</span> head of beef cattle. If all phases of the Initial Project are constructed, the facility will include Bion’s Gen3Tech platform including: i) covered barns (possibly including roof top solar photovoltaic generation), ii) anaerobic digestion for renewable energy recovery, iii) livestock waste treatment and resource recovery technology, iv) Bion’s ammonium bicarbonate recovery and crystallization technology and iv) data collection software to document system efficiencies and environmental benefits (with the Bion Gen3Tech facilities capable of treating the waste from approximately <span id="xdx_909_ecustom--TechWastage_uDecimal_c20220701__20230630_z845oSlrA8dc" title="Tech wastage">1,500</span> head). The facility is large enough to demonstrate engineering capabilities of Bion’s Gen3Tech at commercial scale, but small enough that it can be constructed and commissioned relatively quickly. Originally, construction and onsite assembly operations were targeted to commence sometime late in 2022, however, supply chain backlogs (many pandemic-associated) delayed delivery dates for core modules of the Bion system to the site until during January 2023. Construction has been substantially completed related to Phase 1 of the Initial Project, shakedown operations undertaken and the operation is now focused on optimization of operation parameters. See Note 3 “Property and Equipment” and Note 12 “Subsequent Events” (for activities since the start of the first quarter of the 2024 fiscal year).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project is not being developed at economic commercial scale or with an expectation of profitability due to its limited scale. However, successful installation, commissioning, and operations will demonstrate scalability, determine operating parameters at scale, and provide ongoing production and engineering capabilities, all being critical steps that must be accomplished before developing large projects with JV partners.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Specifically, the Initial Project was designed/developed to provide and/or accomplish the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td style="width: 24px"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proof of Gen3Tech platform scalability</span></td></tr> </table> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px"> </td> <td style="width: 12px"><span style="font-family: Symbol; font-size: 10pt">-</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Document system efficiency and environmental benefits and enable final engineering modifications to optimize each unit process within the Bion Gen3Technology platform. </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 36px"> </td> <td style="width: 12px"><span style="font-family: Symbol; font-size: 10pt">-</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Environmental benefits will include (without limitation) renewable energy production (natural gas recovery from AD and solar electric from integrated roof top photovoltaic generation); nutrient recovery and conversion to stable organic fertilizer; pathogen destruction; water recovery and reuse; air emission reductions.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</span></td> <td style="width: 24px"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use Bion’s data collection system to support 3<sup>rd</sup> party verified system efficiency requirement to qualify for USDA Process-Verified-Program (PVP): certification of sustainable branded beef (and potentially pork) product metrics.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii.</span></td> <td style="width: 24px"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Produce sufficient ammonium bicarbonate nitrogen fertilizer (“AD Nitrogen”) in liquid and solid forms for commercial testing by potential joint venture partners and/or purchasers, for university growth trials and to provide samples (and related documentation) to support applications for organic and/or ‘ClimateSmart’ certifications.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv.</span></td> <td style="width: 24px"> </td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Produce sustainable beef products for initial test marketing efforts.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220127__20220128_zbwWboXLHQ5j" title="Debt instrument paid amount">2,665,500</span> (and made the initial <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220127__20220128_zd9vPrVtWNj5" title="Debt Instrument, Interest Rate During Period">25</span>% payment ($<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20220127__20220128_zDe8IRSlvbai" title="Principal, interest">666,375</span>) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. Subsequent agreements were executed with engineering firms, contractors and other entities related to the construction of the Initial Project. The Company received progress billing in March 2022 and June 2022 for the second and third <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220330__20220331_zuFsO9sEvm0g" title="Debt Instrument, Interest Rate During Period"><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210701__20220630_zxWF5rEsBar6" title="Debt Instrument, Interest Rate During Period">25</span></span>% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20230116__20230117_zN0Vrpt2hPLk" title="Principal, interest">533,100</span> which was paid on March 1, 2023 and on April 24,203 for $<span id="xdx_903_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20230423__20230424_zPZImABuZvs8" title="Principal, interest">83,275</span> which was paid on May 2, 2023 bringing the aggregate payments to $<span id="xdx_907_ecustom--AggregatePayment_pp0p0_c20220701__20230630_zZQvEOfThyCl" title="Aggregate payment">2,615,500</span> as of the date of this filing. There remaining $<span id="xdx_903_ecustom--PurchaseOrder_c20230725__20230726_zPrTH39qfya4" title="Purchase order">50,000</span> open on the Purchase Order has been billed on July 26,2023. In addition to the Purchase Order, the Company has incurred additional costs of $<span id="xdx_908_eus-gaap--InterestCostsIncurredCapitalized_c20220701__20230630_z3wLgYa7WLs" title="Capitalized labor and interest costs">4,182,260</span> on the Initial Project for capitalized interest and costs, non-cash compensation and consulting fees. $<span id="xdx_906_ecustom--InterestCostsCapitalizedPaid_c20220701__20230630_zWBi5rELzwU5" title="Capitalized labor and interest costs paid">3,962,207</span> has been paid and $<span id="xdx_90A_eus-gaap--InterestCostsCapitalizedAdjustment_c20220701__20230630_zqNd1yRWBDb5" title="Capitalized labor and interest costs yet to pay">220,053</span> has been billed and not yet been paid.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Initial Project will be carried out in stages with phase one focused largely on portions of items i. and iii. set forth above.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon completing the primary goals of phase 1 of the Initial Project (coupled with obtaining organic certifications(s) for our liquid and/or solid ammonium bicarbonate fertilizer product lines), Bion expects to be ready to move forward with its plans for development of much larger facilities including the LOI Projects, including final design of its Gen3Tech modules. The Company anticipates that discussions and negotiations it has begun (together with additional opportunities that will be generated over the next 12-24 months) regarding potential JVs with strategic partners in the financial, livestock and food distribution industries to develop large scale projects will continue during the optimization operations of the Initial Project with a 2024 goal of establishing multiple JV’s for large scale projects that will produce sustainable and/or sustainable-organic corn-fed beef. These products will be supported by a USDA PVP-certified sustainable brand that will, initially, highlight reductions in carbon and nutrient footprint, as well as pathogen reductions associated with foodborne illness and antibiotic resistance, along with the organic designation where appropriate. Bion has successfully navigated the USDA PVP application process previously, having received conditional approval of its 2G Tech platform (pending resubmission and final site audits), and is confident it will be successful in qualifying its Gen3Tech platform.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the basic technology start-up milestones of the Initial Project (primarily optimization and steady-state operations of the core modules of our Gen3Tech platform) have been met, the Company will determine whether to complete the entire Initial Project as originally designed at that location or the relocate the core modules to an alternative permanent location. The Company has engaged in discussion with the University of Nebraska-Lincoln to jointly develop an integrated beef facility based on Bion’s Gen3Tech and business model at its Klosterman Feedyard Innovation Center (“KFIC”) (or other mutually agreed upon location) which facility would include innovative barns, an anaerobic digester and a Bion Gen3Tech system to conduct ongoing research and development related thereto and the KFIC is a possible site for the long-term re-location of the core modules. This venture, if it moves forward, is anticipated to include joint preparation of applications for grants and other funding from the USDA (‘climate smart’ program, rural development, etc.) and other sources. The Company will also evaluate re-locating the core module of the Initial Project to Dalhart, Texas, where it might be integrated into the first phases of the Dalhart Project and/or other locations. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s initial ammonium bicarbonate liquid product completed its Organic Materials Review Institute (“OMRI”) application and review process with approval during May 2020. Applications for our first solid ammonium bicarbonate product line have been filed with OMRI, the California Department of Food &amp; Agriculture (“CDFA”) and the Iowa Organic Program (“IOP”) and are in the review processes (which is likely to require an extended period of time and multiple procedural steps, in part due to the novel nature of our Gen3Tech in the context of organic certifications). See “<b>Fertilizer– Organic and ‘ClimateSmart’</b>” below.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the Company believes there will also be opportunities to proceed with selected ‘retrofit projects’ of existing facilities (see ‘<b><span style="text-decoration: underline">Gen3Tech Kreider 2 Poultry Project’</span></b> below as an example) in the swine, dairy and poultry industries utilizing our Gen3Tech.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes that substantial unmet demand currently exists– potentially very large – for ‘real’ meat/dairy/egg products that offer the verifiable/believable sustainability consumers seek, but with the taste and texture they have come to expect from American beef and pork, dairy and poultry. Numerous studies demonstrate the U.S. consumers’ preferences for sustainability. For example, 2019 NYU Stern’s Center for Sustainable Business study found that ‘products marketed as sustainable grew 5.6 times faster than those that were not…’ and that ‘…in more than 90 percent of consumer-packaged-goods (CPG) categories, sustainability-marketed products grew faster than their conventional counterparts.’ Sales growth of plant-based alternatives, including both dairy and more recently ground meat (Beyond Meat, Impossible Foods, etc.) have shown that a large, but apparently limited, segment of consumers is choosing seemingly sustainable offering, and are also willing to pay a premium for it. Tyson Foods, in the context of launching its Brazen beef initiative, recently said, “consumers would be willing to pay at least 24 percent more for environmentally friendly, sustainable options at retail.” Numerous studies also support the consumers’ ‘willingness-to-pay’ (WTP) for sustainable choices, including a recent meta-analysis of 80 worldwide studies with results that calculate the overall WTP premium for sustainability is <span id="xdx_900_ecustom--PercentageOfSustainable_dp_c20220701__20230630_zvFx4yaqS7p3" title="Percentage of sustainable">29.5</span> percent on average.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As one of the largest contributors to some of the greatest air and water quality problems in America, it is clear that livestock waste cleanup, at scale, represents one of the greatest opportunities we have to reduce negative environmental impacts of the food supply chain on air and water quality. Bion’s Gen3Tech platform, along with its business model, will enable the cleanup of one of the ‘dirtiest’ parts of the food supply chain: animal protein production and creates the opportunity to produce and market verifiably sustainable organic and conventional ‘real meat’ products that can participate in the growth and premium pricing that appears to be readily available for the ‘right’ products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion believes that at least a premium segment of the U.S. beef industry (and potentially other livestock industry groups) is at the doorstep of a transformative opportunity to address the growing demand for sustainable food product offerings, while pushing back against today’s anti-meat messaging. At $66 billion/year (2021 wholesale/farmgate value), the beef industry is a fragmented, commodity industry whose practices date back decades. In 1935 inflation-adjusted terms, beef was 63% more expensive in 2021, while pork and chicken, which are now primarily raised in covered barns at CAFOs with highly integrated supply chains, were 12% and 62% cheaper, respectively. In recent years, the beef industry has come under increasing fire from advocacy groups, regulatory agencies, institutional investors, and ultimately, their own consumers, over concerns that include climate change, water pollution, food safety, and the treatment of animals and workers.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Advocacy groups targeting livestock and the beef industry have recently been joined by competitors that produce animal protein alternatives in seeking to exploit the industry’s environmental and economic weaknesses. Their global anti-meat messaging has had a substantial chilling effect on the relationships the beef industry has with its institutional investors; retail distributors, such as fast-food restaurants; and mostly, its consumers. Led by the United Nations Food and Agriculture Organization, a coordinated anti-meat messaging campaign has targeted consumers worldwide, primarily focused on the industry’s impacts on climate change. A 2018 NielsenIQ Homescan survey last year found that 39% of Americans are actively trying to eat more plant-based foods. Some of the recent growth in plant-based proteins results from increasing lactose intolerance and other health concerns; however, most of that growth is attributed to consumers’ growing concerns for the environmental impacts of real meat and dairy. Several large US companies that have traditionally focused on livestock production, including Cargill, ADM, Perdue Foods, and Tyson, have also recently entered the plant protein space. While meat alternatives, especially plant-based protein producers like Beyond Meat and Impossible Foods, have been heavily promoted (by themselves and the media) and enjoyed remarkable initial sales growth, recently, sales have flattened and/or declined over the past 18 months. It should be noted that these plant-based protein producers are primarily expected to be able to serve the ground/ processed meat market, which represents only about 10 percent of the overall animal protein market. Further, there has recently been pushback to these plant-based products, focusing on their highly processed nature and unproven health benefits, scalability/ pricing, and their uncertain carbon footprint---and market growth rates have substantially slowed and may have already plateaued and/or peaked. There have also been several companies recently enter the cellular and 3D-printed meat arena. While facing myriad challenges and further out on the development timeline, some people believe cellular agriculture (aka cultured, clean, lab-grown, cultivated) meat may have the potential to service a much larger percentage of the market than plant-based protein, including cuts like steaks, chops and roasts, but the likely cost remains very uncertain at this point.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In terms of changing customer preferences, ‘saving the planet’ has proven to be a more compelling argument than the traditional animal activism/ welfare pitch. To date, the primary beef ‘industry response’ to this has been grass-fed beef, which is regarded as a generally more sustainable offering than grain-fed (largely without empirical evidence). However grass-fed beef has had only limited acceptance in U.S. markets, because it is less flavorful and tougher than the traditional corn-fed beef consumers have grown to enjoy. Sustainability initiatives have been launched by large US livestock producers (including Tyson’s very recent ‘Brazen’ program), but it is not yet possible to determine the extent the attributes of such products will be substantive and verifiable rather than completely ‘modeled’ and largely public relations ‘greenwashing’.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each of these items supports Bion’s belief that there is a potentially very large opportunity to supply premium sustainable beef products that satisfy consumer concerns. We believe that the real meat/beef products that can be cost-effectively produced today using our Gen3Tech platform, both sustainable and/or organic, can provide an affordable product that satisfies the consumer’s desire for sustainability, but with the superior taste and texture those consumers have grown to prefer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sustainable Beef</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s goal is to be one of the ‘first to market’ with meaningfully verified sustainable beef products that can be produced at sufficient scale to service national market demand. The cattle produced at Bion facilities will have a substantially lower carbon footprint, dramatically reduced nutrient impacts to water, and an almost total pathogen kill in the waste stream. Further, the economics of producing these cattle (including the cost of the facility/technology upgrade) will be greatly enhanced by the revenue realized from the recovery of valuable resources, including renewable energy, high-value fertilizer products, and clean water.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A Bion sustainable beef facility will be comprised of covered barns with slotted floors (allowing the waste to pass through) which will reduce ammonia and greenhouse gas volatilization and loss, as well as odors, thereby improving animal health and human working conditions while preventing air/soil pollution. The manure will be collected and moved directly to anaerobic digestion facilities which will produce renewable natural gas (and re-cycle CO2 from the gas cleaning process). Covered barns will reduce weather impacts on the livestock and have been demonstrated to promote improved general health and weight gain in the cattle housed in them. The barns’ very large roof surface area will be utilized (in geographical locations with adequate sunshine and appropriate ‘tariffs’) for the installation of photovoltaic solar generation systems to produce electricity for the facility, as well as export to the grid. The barn roofs will also be configured to capture rainwater, which, coupled with the water recovered from the treatment process, will reduce the projects’ reliance on current water supplies.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Waste treatment and resource recovery will be provided by Bion’s advanced Gen3Tech platform, which Bion believes offers the most comprehensive solution for livestock waste available today. In addition to direct environmental benefits, every pound of nitrogen that is captured, upcycled, and returned to the agricultural nitrogen cycle as high-quality fertilizer (vs lost to contaminate downstream waters), is also a pound of nitrogen that will not have to be produced as synthetic urea or anhydrous ammonia, with their tremendous carbon cost. System performance and environmental benefits will be monitored and verified through third parties, with USDA PVP certification of the sustainable brand that Bion also believes will be the most comprehensive available in the market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Recently there have been efforts to establish sustainable brands (including USDA PVP certification) for a number of small-scale livestock producers (largely in the grass-fed beef category). To date, the reach and extent of such efforts is limited and it is difficult to determine their effectiveness. Additionally, there have been public announcements of initiatives related to beef sustainability (largely focused on the ‘cow-calf’ segment of the livestock chain) in procurement by major beef processing companies (including Tyson’s very recent ‘Brazen’ program), but a closer look finds that many have consisted largely of ‘green washing’ public proclamations in the wake of environmental and social criticism that re-package prior initiatives and lack any significant new substance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Sustainable Organic Beef</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion also believes it may also have a unique opportunity to produce, at scale, affordable corn-fed organic beef that is also certified as sustainable. In addition to the sustainable practices described above, organic-sourced beef cows would be finished on organic corn, which would be produced using the ammonium bicarbonate fertilizer captured by the Gen3Tech platform. Bion believes its meat products will meet consumer demands with respect to sustainability and safety (organic) and provide the tenderness and taste American consumers have come to expect from premium conventional American beef. Such products are largely unavailable in the market today. We believe Bion’s unique ability to produce the fertilizer needed to grow a supply of relatively low-cost organic corn, and the resulting opportunity to produce organic beef, will dramatically differentiate us from potential competitors. This organic opportunity is dependent on successfully establishing Bion’s fertilizer products as acceptable for use in organic grain production.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Today, organic beef demand is limited and mostly supplied with grass-fed cattle. While organic ground/ chopped meat has enjoyed success in U.S. markets, grass-fed steaks have seen limited acceptance, mostly resulting from consumer issues with taste and texture. In other words, it’s tough. Regardless, such steaks sell for a significant premium over conventional beef. A grain-finished organic beef product is largely unavailable in the marketplace today due to the higher costs of producing organic corn and grain. The exception is offerings that are very expensive from small ‘boutique’ beef producers. Like all plants, corn requires nitrogen to grow. Corn is especially sensitive to a late-season application of readily available nitrogen – the key to maximizing yields. With non-organic field corn, this nitrogen is supplied by an application of a low-cost synthetic fertilizer, such as urea or anhydrous ammonia. However, the cost for suitable nitrogen fertilizer that can be applied late-season in organic corn production is so high that the late-season application becomes uneconomical, resulting in substantially lower yields – a widely recognized phenomena known as the ‘yield gap’ in organic production. The yield gap results in higher costs for organic corn that, in turn, make it uneconomical to feed that corn to livestock. As is the case for sustainable but not organic beef, Bion believes there is a potentially large unmet demand for affordable beef products that are both sustainable AND organic, but with the taste and texture consumers have come to expect from American beef. Bion’s ability to produce the low-cost nitrogen fertilizer that can close the organic yield (and affordability) gap puts the Company in a unique, if not exclusive at this time, position to participate in JV’s that will benefit from this opportunity starting next year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The demonstrated willingness of consumers to purchase sustainable products (along with numerous research and marketing studies confirming consumers are seeking, and are willing to pay a premium for, sustainable products)---in combination with the threat to the livestock industry market (primarily beef and pork) posed by plant-based alternatives (heightened by pandemic conditions)--- has succeeded in focusing the large scale livestock industry on how to meet the plant-based market challenge by addressing the consumer sustainability issues. The consumer demand for sustainability appears to be a real and lasting trend, but consumers remain skeptical of generalized claims of ‘sustainability’. To date, a large portion of the industry responses to this trend have been at a superficial level or consist of ‘green washing’, a deceptive marketing practice where companies promote non-substantive initiatives. Real sustainability for the livestock industry will require implementation of advanced waste treatment technology at or near the CAFOs – where most of the negative environmental impacts take place.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Fertilizer: Organic and ‘Climate Smart’ </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has focused a large portion of its activities on developing, testing and demonstrating the 3rd generation of its technology and technology platform (“Gen3Tech”) with emphasis on increasing the efficiency of production of valuable co-products from the waste treatment process, including ammonia nitrogen in the form of low carbon and/or organically certified soluble nitrogen fertilizer products. The Company’s low concentration ammonium bicarbonate liquid product successfully completed its Organic Materials Review Institute (“OMRI”) application and review process with listing approval during May 2020. During the next 3-4 months the Company intends to file applications with OMRI and the California Department of Food &amp; Agriculture (“CDFA”) for a line of higher concentration liquid ammonium nitrogen products ( ranging from 6% up to 16% (or higher)) based on production of liquid samples during operation of the Initial Project over the next 2 months. The Company anticipates applying for and obtaining one or more listings/certifications for higher concentration products in our liquid ammonium nitrogen fertilizer line well prior to operational dates for the Company’s initial large scale JV Gen3Tech Sustainable Beef Projects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, the Company intends to explore the market potential for its fertilizer (in liquid and/or solid forms) to be a verifiably ‘ClimateSmart’ product (potentially a much larger market than the organic market) with focus on higher value specialty crops. This will require working with industry and academic entities to develop appropriate metrics and producing a ‘life cycle assessment’ (LCA) for Bion’s ammonium nitrogen fertilizer product which can be compared to conventional nitrogen fertilizer products. Bion’s processes will capture and utilize CO2 in the waste stream (including CO2 produced with the renewable natural gas (RNG) by anaerobic digestion that is usually vented to the atmosphere) as stabilizing agent thereby potentially creating carbon offsets compared to natural gas utilized as feedstock in chemical ammonia production which reduction will be reflected in the LCA. This LCA will assess environmental impacts associated with fertilizer production in support of the beef cattle supply chain for both the existing conventional approach (primarily fossil fuel-based Haber-Bosch production methods) and the largely decarbonized Bion production approach. We believe a series of coincident yet significant LCA benefits accrue from Bion’s patented fertilizer production approach including the reduced loss of ammonia to the environment via air (volatilized) and water (nitrate in groundwater) pathways, recycled/reused water, elimination of pathogens, the production of renewable natural gas, the production solar energy from photovoltaic panels on barn roofs, enhanced animal welfare practices and reduced animal husbandry risks from extreme weather events. Bion believes that current evaluations of the carbon impact from feedlot operations materially underestimate the negative impacts because existing models do not properly include significant ‘downstream’ carbon impacts of required energy intensive waste water treatment for re-deposited ammonia nitrogen. If the Company determines there is a significant ‘ClimateSmart’ opportunity for our fertilizer products, such an LCA can be completed (based in part on data from the Initial Project) and support marketing efforts well prior to operational dates for the Company’s initial large scale JV Gen3Tech projects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ammonium bicarbonate, manufactured using thermal and mechanical processes, has a long history of use as a fertilizer. In addition to liquid ammonium nitrogen fertilizer, Bion’s Gen3Tech is capable of recovering nitrogen in the form of solid ammonium bicarbonate products containing up to 18%-22% (or higher) nitrogen in a crystalline form that is easily transported (while producing liquids with various percentages of ammonium bicarbonate nitrogen during interim stages of the process). This solid product is water soluble and provides a readily available nitrogen source for crops. It will contain virtually none of the other salt, iron and mineral constituents of the livestock waste stream that often accompany other organic fertilizers. This product is being developed to fertilizer industry standards so that it that can be precision-applied to crops using existing equipment. Bion believes that this product will potentially have broad applications in the production of organic and/or ClimateSmart grains for livestock feed, row crops, horticulture, greenhouse and hydroponic production, and potentially retail lawn and garden products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ammonium bicarbonate products (liquid and solid) produced by Bion’s Gen3Tech platform will enjoy a dramatically lower carbon footprint than synthetic nitrogen fertilizers. Much of the reactive nitrogen captured and upcycled into our fertilizer products was going to be lost through volatilization and runoff, and that loss would generally need to be offset with a synthetic nitrogen fertilizer, such as anhydrous ammonia or urea. These synthetic nitrogen products are produced through the Haber-Bosch (and other) synthetic processes, which converts hydrogen and atmospheric nitrogen to ammonia, with methane from fossil fuels as the energy source. It is an extremely energy-intensive process with a carbon footprint that, while not yet fully understood, is widely accepted to by very large. While a complete Life Cycle Assessment (LCA) of carbon impacts from synthetic fertilizer production is not yet available, according to the Institute for Industrial Productivity, its production alone is responsible for approximately 1 percent of total global CO2 emissions. To the extent that Bion can capture and repurpose the nitrogen traditionally lost from livestock waste, that carbon cost will no longer need to be paid by the environment/climate.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Applications for our first solid form of concentrated ammonia, soluble nitrogen fertilizer product line were filed with OMRI (filed during May 2021) and CDFA (filed during May 2022) without success to date. After an extended review processes (which was largely opaque), the OMRI application proceeded through multiple stages without receiving a positive result. We have initiated an informal dialogue with CDFA regarding the basis for and re-consideration of its initial determination and anticipate submitting additional supporting materials to CDFA during the next 30 days. The Company’s solid product line is novel (in the context of organic certification) in part due to the fact that no formal listing category currently in the organic space for a solid form of concentrated ammonia, soluble nitrogen fertilizers and there is no clear guidance at present from internal policy manuals on how to categorize this product and the process that produces it. There is also no clear guidance at present from either the NOP or the National Organic Standards Board (“NOSB”) (which is currently involved in a related review and recommendations process regarding ‘high nitrogen liquid fertilizers’ derived from ammonia from manure). The Company and its representatives, along with a number of other organic fertilizer stakeholders, are involved in discussions regarding resolution of these matters at all three levels. The Company intends to continue efforts to obtain listing/certification for its solid nitrogen fertilizer line over the course of this fiscal year.</p> <p style="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Gen3Tech Kreider 2 Poultry Project</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_909_ecustom--DescriptionOfKreider2PoultryProject_c20220701__20230630_zckDFZRB4iZ6">Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2<sup>nd</sup> generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA).</span> Note that this Project may also be expanded in the future to treat wastes from other local and regional CAFOs (poultry and/or dairy---including the Kreider Dairy) and/or additional Kreider poultry expansion (some of which may not qualify for nutrient reduction credits). The Company anticipates if and when PA2 re-commences work on the Kreider 2 Project, it will submit a new application based on our Gen3Tech. Site specific design and engineering work for this facility have not commenced, and the Company does not yet have financing in place for the Kreider 2 Project. This opportunity is being pursued through PA2. If there are positive developments related to the market for nutrient reductions in Pennsylvania, of which there is no assurance, the Company intends to pursue development, design and construction of the Kreider 2 Project with a goal of achieving operational status for its initial modules during the following calendar year. The economics (potential revenues and profitability) of the Kreider 2 Project, despite its proposed use of Bion’s Gen3Tech for increased recovery of marketable by-products and sustainable branding, are based in material part the long-term sale of nutrient (nitrogen and/or phosphorus) reduction credits to meet the requirements of the Chesapeake Bay environmental clean-up. However, liquidity in the Pennsylvania nutrient credit market has not yet developed significant breadth and depth, which lack of liquidity has negatively impacted Bion’s business plans and will most likely delay PA2’s Kreider 2 Project and other proposed projects in Pennsylvania.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Note that while Bion believes that the Kreider 2 Project and/or subsequent Bion Projects in PA and the Chesapeake Bay Watershed will eventually generate revenue from the sale of: a) nutrient reductions (credits or in other form), b) renewable energy (and related credits), c) sales of fertilizer products, and/or d) potentially, in time, credits for the reduction of greenhouse gas emissions, plus e) license fees/premiums related to a ‘sustainable brand’, the Covid-19 pandemic has delayed legislative efforts needed to commence its development. However, the Company is currently engaged in dialogue with the regional EPA office and the Chesapeake Bay Program Office regarding the potential of the Company’s Gen3Tech Kreider2 Project (and other potential projects) to enable Pennsylvania to move forward toward meeting its Chesapeake Bay clean-up goals. We believe that the potential market is very large, but it is not possible to predict the exact timing and/or magnitude of these potential markets at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Technology Deployment: Bion Gen3Tech</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the absence of firm regulatory mandates, widespread deployment of waste treatment technology, and the sustainability it enables, is largely dependent upon generating sufficient additional revenues to offset the capital and operating costs associated with technology adoption. Bion’s Gen3Tech business platform has been developed to create opportunities for such augmented revenue streams, while providing third party verification of sustainability claims. The Gen3Tech platform has been designed to maximize the value of co-products produced during the waste treatment/recovery processes, including pipeline-quality renewable natural gas (biogas) and commercial fertilizer products approved for organic production and/or certified as ‘ClimateSmart’. All processes will be verifiable by third parties (including regulatory authorities and certifying boards) to comply with environmental regulations and trading programs and meet the requirements for: a) renewable energy and carbon credits, b) organic certification of the fertilizer coproducts and c) USDA PVP certification of an ‘Environmentally Sustainable’ brand (see discussion above and below), and d) payment for verified ecosystem services. The Company’s first patent on its Gen3Tech was issued during 2018. In August 2020, the Company received a Notice of Allowance on its third patent which significantly expands the breadth and depth of the Company’s Gen3Tech coverage. The Company has additional applications pending and/or planned.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion’s business model and technology platform can create the opportunity for joint ventures (in various contractual forms)(“JVs”) between the Company and large livestock/food/fertilizer industry participants based upon the supplemental cash flow generated by implementation of our Gen3Tech business model, which cash flows will support the costs of technology implementation (including servicing related debt). We anticipate this will result in substantial long term value for Bion. In the context of such JVs, we believe that the verifiable sustainable branding opportunities (conventional and organic) in meat will represent the single largest enhanced revenue contributor provided by Bion to the JVs (and Bion licensees). The Company believes that the largest portion of its business with be conducted through such JVs, but a material portion may involve licensing and or other approaches.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In parallel with technology development, Bion has worked (which work continues) to implement market-driven strategies designed to stimulate private-sector participation in the overall U.S. nutrient and carbon reduction strategy. These market-driven strategies can generate “payment for ecosystem services”, in which farmers or landowners are rewarded for managing their land and operations to provide environmental benefits that will generate additional revenues. Existing renewable energy credits for the production and use of biogas are an example of payment for ecosystem services. Another such strategy is nutrient trading (or water quality trading), which will potentially create markets (in Pennsylvania and other states) that will utilize taxpayer funding for the purchase of verified pollution reductions from agriculture (“nutrient credits”) by the state (or others) through competitively-bid procurement programs. Such credits can then be used as a ‘qualified offset’ by an individual state (or municipality) to meet its federal clean water mandates at significantly lower cost to the taxpayer. Market-driven strategies, including competitive procurement of verified credits, is supported by U.S. EPA, the Chesapeake Bay Commission, national livestock interests, and other key stakeholders. Legislation in Pennsylvania to establish the first such state competitive procurement program passed the Pennsylvania Senate by a bi-partisan majority during March 2019 but has not yet crossed the hurdles required for actual adoption. The Covid-19 pandemic and related financial/budgetary crises have slowed progress for this and other policy initiatives and, as a result, it is not currently possible to project the timeline for completion (or meaningful progress) of this and other similar initiatives (see discussion below).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry and its markets are already changing. With our commercial-ready technology and business model, Bion believes it has a ‘first-mover advantage’ over others that will seek to exploit the opportunities that will arise from the industry’s inevitable transformation. Bion anticipates moving forward with the development process of its initial commercial installations utilizing its Gen3Tech, during the current 2024 fiscal year. We believe that Bion’s Gen3Tech platform and business model can provide a pathway to true economic and environmental sustainability with ‘win-win’ benefits for at least a premium sector of the livestock industry, the environment, and the consumer, an opportunity which the Company intends to pursue.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">The Livestock Problem</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry is under tremendous pressure from regulatory agencies, a wide range of advocacy groups, institutional investors and the industry’s own consumers, to adopt sustainable practices. Environmental cleanup is inevitable and has already begun — and policies have already begun to change, as well. Bion’s Gen3Tech was developed for implementation on large scale livestock production facilities, where scale drives both lower treatment costs and efficient co-products production, as well as dramatic environmental improvements. We believe that scale, coupled with Bion’s verifiable treatment technology platform, will create a transformational opportunity to integrate clean production practices at (or close to) the point of production—the primary source of the industry’s environmental impacts. Bion intends to assist the forward-looking segment of the livestock industry to bring animal protein production in line with 21<sup>st</sup> Century consumer demands for meaningful sustainability.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the U.S. (according to the USDA’s 2017 agricultural census) there are over 9 million dairy cows, 90 million beef cattle, 60 million swine and more than 2 billion poultry which provides an indication of both the scope of the problem addressed by Bion’s technology, as well as the size of Bion’s opportunity. Environmental impacts from livestock production include surface and groundwater pollution, greenhouse gas emissions, ammonia, and other air pollution, excess water use, and pathogens related to foodborne illnesses and antibiotic resistance. While the most visible and immediate problems are related to nutrient runoff and its effects on water quality, the industry has recently been targeted by various stakeholder groups for its impacts on climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Estimates of total annual U.S. livestock manure waste vary widely, but start around a billion tons, between 100 and 130 times greater than human waste. However, while human waste is generally treated by septic or municipal wastewater plants, livestock waste – raw manure – is spread on our nation’s croplands for its fertilizer value. Large portions of U.S. feed crop production (and most organic crop production) are fertilized, in part, in this manner. Under current manure management practices, 80% or more of total nitrogen from manure, much of it in the form of ammonia, escapes during storage, transportation, and during and after soil application, representing both substantial lost value and environmental costs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">More than half of the nitrogen impacts from livestock waste come from airborne ammonia emissions, which are extremely volatile, reactive and mobile. Airborne ammonia nitrogen eventually settles back to the ground through atmospheric deposition — it ‘rains’ everywhere. While some of this nitrogen is captured and used by plants, most of it runs off and enters surface waters or percolates down to groundwater. It is now well-established that most of the voluntary conservation practices, such as vegetated buffers that ‘filter’ runoff (often referred to as “BMPs” or “Best Management Practices” that have traditionally been implemented to attempt to mitigate nutrient runoff), are considerably less effective than was previously believed to be the case. This is especially true with regard to addressing the volatile and mobile nitrogen from ammonia emissions, because BMPs are primarily focused on surface water runoff, directly from farm fields in current production, versus the re-deposition that takes place everywhere or groundwater flow.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Runoff from livestock waste has been identified in most of our major watersheds as a primary source of excess nutrients that fuel algae blooms in both fresh and saltwater. Over the last several years, algae blooms have become increasingly toxic to both humans and animals, such as the Red Tides on the Florida and California coasts, and the Lake Erie algae bloom that cut off the water supply to Toledo, Ohio, residents in 2014. When the nutrient runoff subsides, it leaves the algae blooms with no more ‘food’ and the blooms die. The algae’s decomposition takes oxygen from the water, leading to ‘dead zones’ in local ponds, lakes, and ultimately, the Great Lakes, as well as the Chesapeake Bay, Gulf of Mexico, and other estuary waters. Both the toxic algae blooms and the low/no-oxygen dead zones devastate marine life, from shrimp and fish to higher mammals, including dolphins and manatees. U.S. EPA already considers excess nutrients “one of America’s most widespread, costly and challenging environmental problems”. Nutrient runoff is expected to worsen dramatically in the coming decades due to rising temperatures and increasing rainstorm intensity as a result of climate change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nitrate-contaminated groundwater is of growing concern in agricultural regions nationwide, where it has been directly correlated with nutrient runoff from upstream agricultural operations using raw manure as fertilizer. Pennsylvania, Wisconsin, California and Washington, and others, now have regions where groundwater nitrate levels exceed EPA standards for safe drinking water. High levels of nitrate can cause blue baby syndrome (methemoglobinemia) in infants and affect women who are or may become pregnant, and it has been linked to thyroid disease and colon cancer. EPA has set an enforceable standard called a maximum contaminant level (MCL) in water for nitrates at 10 parts per million (ppm) (10 mg/L) and for nitrites at 1 ppm (1 mg/L). Federal regulations require expensive pretreatment for community water sources that exceed the MCL; however, private drinking water wells are not regulated, and it is the owners’ responsibility to test and treat their wells. Additionally, groundwater flows also transport this volatile nitrogen downstream where, along its way, it intermixes with surface water, further exacerbating the runoff problem. Like atmospheric deposition, the current conservation practices we rely on to reduce agricultural runoff are largely bypassed by this subsurface flow.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, in arid climates, such as California, airborne ammonia emissions from livestock manure contribute to air pollution as a precursor to PM2.5 formation, small inhalable particulate matter that is a regulated air pollutant with significant public health risks. Whether airborne or dissolved in water, ammonia can only be cost-effectively controlled and treated at the source—before it has a chance to escape into the environment where it becomes extremely expensive to ‘chase’, capture, and treat.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">High phosphorus concentrations in soils fertilized with raw manure are another growing problem. The ratio of nitrogen to phosphorus in livestock waste is fixed, and because manure application rates are calculated based on nitrogen requirements, often phosphorus is overapplied as an unintended consequence. Phosphorus accumulation in agricultural soils reduces its productivity, increases the risk of phosphorus runoff, and represents a waste of a finite resource. Decoupling the nitrogen from the phosphorus would allow them to be precision-applied, independently of each other, when and where needed.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The livestock industry has recently come under heavy fire for its impacts on climate change, which has become a rallying cry for the anti-meat campaign discussed above. Estimates of the magnitude of those impacts vary widely, but the general consensus is that globally, livestock account for 14.5 percent of greenhouse emissions. In the U.S. however, that number drops to 4.2 percent, due to the increased efficiencies of American beef production. The greatest impacts come from direct emissions of methane from enteric fermentation (belches), methane and nitrous oxide emissions from the manure, with arguably the largest being the massive carbon footprint of the synthetic nitrogen fertilizers used to grow the grains to feed the livestock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For decades the livestock industry has overlooked and/or socialized its environmental problems and costs. Today, the impacts of livestock production on public health and the environment can no longer be ignored and are coming under increasing scrutiny from environmental groups and health organizations, regulatory agencies and the courts, the media, consumers, and activist institutional investors. The result has been a significant and alarming loss of market share to plant-based protein and other alternative products. Bion’s Gen3Tech platform was designed to resolve these environmental issues and bring the industry in line with twenty-first century consumer expectations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Going concern and management’s plans:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s audited financial statements have been prepared assuming the Company will continue as a going concern. The Company has not generated significant revenues and generated/incurred a net income of $<span id="xdx_902_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_c20210701__20220630_zMBZpbb5bUHk" title="Net Income (loss)">8,292,000</span> for the year ended June 30, 2022 and a net loss of approximately $<span id="xdx_906_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_pp0p0_c20220701__20230630_zHh5c4ITWbjk" title="Net Income (loss)">3,189,000</span> during the year ended June 30, 2023. The net income for the year ended June 30, 2022 was largely due to a one-time, non-cash event of the dissolution of PA-1 resulting in a gain of approximately $<span id="xdx_903_eus-gaap--IncomeLossFromContinuingOperations_pp0p0_c20220701__20230630_zEUyt4C6lyAb" title="Net income">10,235,000</span> as well as a one-time gain of $<span id="xdx_900_ecustom--GainOnSaleOfDomainAmount_pp0p0_c20220701__20230630_zOTvtYWYSuH3" title="Gain on sale of domain">902,000</span> from the sale of the Company’s ‘biontech.com’ domain pursuant to a purchase agreement during the period. At June 30, 2023, the Company has a working deficit and a stockholders’ equity of approximately $<span id="xdx_901_ecustom--WorkingCapital_iI_c20230630_zernQ5xBGBMd" title="Working Capital">968,000</span> and $4,194,000, respectively. During the year ended June 30, 2023 the Company had debt modifications that resulted in a reduction of debt of $<span id="xdx_902_ecustom--ReductionOfDebt_pp0p0_c20220701__20230630_zxLEnnm6dtTk" title="Reduction of debt">3,522,000</span> and an increase in equity in the same amount. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. The following paragraphs describe management’s plans with regard to these conditions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continues to explore sources of additional financing (including potential agreements with strategic partners – both financial and ag-industry) to satisfy its current and future operating and capital expenditure requirements as it is not currently generating any significant revenues.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended June 30, 2023 and 2022, the Company received gross proceeds of approximately $<span id="xdx_908_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20220701__20230630_zrQAr3mOXCu6" title="Proceeds from Issuance or Sale of Equity">4,038,000</span> and $<span id="xdx_90C_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pp0p0_c20210701__20220630_zomdNwq9Kbyi" title="Proceeds from Issuance or Sale of Equity">1,737,000</span>, respectively, from the sale of its debt and equity securities. The company paid commissions on the exercise of warrants in the amount of $<span id="xdx_901_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20230630_zKzxVhd1ZF4j" title="Exercise of warrants">86,000</span> and $<span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstanding_iI_pp0p0_c20220630_z5p8Pija3Fpl" title="Exercise of warrants">19,000</span> in 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During fiscal years 2023 and 2022, the Company faced less difficulty in raising equity funding (but was subject to substantial equity dilution from the larger amounts of equity financing during the periods) than was experienced in the prior 3 years. However, this positive trend did not continue during the last quarter of the 2023 fiscal year and first quarter of the current fiscal year (to date). The Company raised only raised very limited equity funds during such periods to meet its some of its immediate needs, therefore, the Company needs to raise additional funds in the upcoming periods. The Company currently faces substantial increases in demand for capital and operating expenditures for the fiscal year 2024 to date (and we anticipate such increased demands will continue during the remainder of the 2024 fiscal year and periods thereafter) as it moves toward commercial implementation of its 3G Tech and development of JVs (including costs associated with additions of personnel to carry out the business activities of the Company) and, therefore, is likely to continue to face, significant cash flow management issues due to limited capital resources and working capital constraints which had only recently begun to be alleviated. As a result, the Company has faced, and continues to face, significant cash flow management challenges due to material working capital constraints. To partially mitigate these working capital constraints, the Company's core senior management and some key employees and consultants have been deferring most of their cash compensation and/or are accepting compensation in the form of securities of the Company (Notes 5 and 7 to Financial Statements) and members of the Company's senior management have from time to time made loans to the Company and may need to do so in future periods. Note that, to deal with earlier capital constraints, during the year ended June 30, 2018, senior management and certain core employees and consultants agreed to a one-time extinguishment of liabilities owed by the Company which in aggregate totaled $<span id="xdx_901_ecustom--DeferredCompensationLiabilityAmountCancelled_pp0p0_c20170701__20180630_zqCJ1oPyUuyk" title="Deferred Compensation Liability, Amount Cancelled">2,404,000</span>. Additionally, the Company made reductions in its personnel during the years ended June 30, 2014 and 2015 and again during the year ended June 30, 2018. As set forth in detail elsewhere herein, during the year ended June 30, 2023 senior management (and family members) who held convertible obligations of the Company adjusted the terms of their outstanding notes and agreed to debt modifications that reduced of the Company’s debt by $<span id="xdx_900_ecustom--ReductionOfDebt_pp0p0_c20220701__20230630_zeYziFslMxl4" title="Reduction of debt">3,522,000</span> and increased shareholders equity by the same amount. The constraints on available resources have had, and continue to have, negative effects on the pace and scope of the Company’s efforts to develop its business. The Company has had to delay payment of trade obligations and has had to economize in many ways that have potentially negative consequences. If the Company is able to raise needed funds during the remainder of the current fiscal year (and subsequent periods), of which there is no assurance, management will not need to consider deeper cuts (including additional personnel cuts) and/or curtailment of ongoing activities including research and development activities.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company will need to obtain additional capital to fund its operations and technology development, to satisfy existing creditors, to develop Projects (including operations at the Initial Project, JV Projects (including the Dalhart/Olson/DVG Projects), and the Kreider 2 facility) and CAFO Retrofit waste remediation systems. The Company anticipates that it will seek to raise from $<span id="xdx_90C_eus-gaap--CapitalRequiredForCapitalAdequacy_iI_pp0p0_c20230630__srt--RangeAxis__srt--MinimumMember_zcbLrm7YtZU9" title="Capital Required for Capital Adequacy">20,000,000</span> to $<span id="xdx_909_eus-gaap--CapitalRequiredForCapitalAdequacy_iI_pp0p0_c20230630__srt--RangeAxis__srt--MaximumMember_znJH7hHX5r4" title="Capital Required for Capital Adequacy">80,000,000</span> or more debt and/or equity through joint ventures, strategic partnerships and/or sale of its equity securities (common, preferred and/or hybrid) and/or debt (including convertible) securities, and/or through use of ‘rights’ and/or warrants (new and/or existing) and/or through other means during the next twelve months. However, as discussed above, there is no assurance, especially in light of the difficulties the Company has experienced in many recent years and the extremely unsettled capital markets that presently exist for small companies like us, that the Company will be able to obtain the funds that it needs to stay in business, complete its technology development or to successfully develop its business and Projects.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There is no realistic likelihood that funds required during the next twelve months (or in the periods immediately thereafter) for the Company’s basic operations, the Initial Project and/or proposed JVs and/or Projects will be generated from operations. Therefore, the Company will need to raise sufficient funds from external sources such as debt or equity financings or other potential sources. The lack of sufficient additional capital resulting from the inability to generate cash flow from operations and/or to raise capital from external sources would force the Company to substantially curtail or cease operations and would, therefore, have a material adverse effect on its business. Further, there can be no assurance that any such required funds, if available, will be available on attractive terms or that they will not have a significantly dilutive effect on the Company’s existing shareholders. All of these factors have been exacerbated by the extremely limited and unsettled credit and capital markets presently existing for small companies like Bion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Covid-19 pandemic related matters:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company faces many risks and uncertainties and factors beyond our control that have been magnified during the current Covid-19 pandemic and the unique economic, financial, governmental and health-related conditions in which the Company, the country and the entire world now reside. To date the Company has experienced direct impacts in various areas including but without limitation: i) government ordered shutdowns which have slowed the Company’s research and development projects and other initiatives, ii) shifted focus of state and federal governments which is likely to negatively impact the Company’s legislative initiatives in Pennsylvania and Washington D. C., iii) strains and uncertainties in both the equity and debt markets which have made discussion and planning of funding of the Company and its initiatives and projects with investment bankers, banks and potential strategic partners more tenuous, iv) strains and uncertainties in the agricultural sector and markets have made discussion and planning more difficult as future industry conditions are now more difficult to assess and predict, v) constraints due to problems experienced in the global industrial supply chain since the onset of the Covid-19 pandemic, which have delayed certain research and development testing and have delayed and/or increased the cost of construction of the Company’s initial 3G Tech installation as equipment/services remain difficult to acquire in a timely manner, vi) due to the age and health of our core management team, many of whom are age 70 or older and have had one or more existing health issues (including brief periods of Covid-19 infection), the Covid-19 pandemic places the Company at greater risk than was previously the case (to a higher degree than would be the case if the Company had a larger, deeper and/or younger core management team), and vii) there almost certainly will be other unanticipated consequences for the Company as a result of the current pandemic emergency and its aftermath.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 15000 15000 300 1500 2665500 0.25 666375 0.25 0.25 533100 83275 2615500 50000 4182260 3962207 220053 0.295 Bion has done extensive pre-development work related to a waste treatment/renewable energy production facility to treat the waste from KF’s approximately 6+ million chickens (planned to expand to approximately 9-10 million) (and potentially other poultry operations and/or other waste streams) (‘Kreider Renewable Energy Facility’ or ‘Kreider 2 Project’). On May 5, 2016, the Company executed a stand-alone joint venture agreement (“JVA”) with Kreider Farms covering all matters related to development and operation of Kreider 2 system to treat the waste streams from Kreider’s poultry facilities in Bion PA2 LLC (“PA2”). Now that development of the Company’s Gen3Tech is being deployed, the Company has commenced discussions with KF regarding updating and amending the JV agreement and anticipates executing an amended joint venture agreement during 2023. During May 2011 the PADEP certified a smaller version of the Kreider 2 Project (utilizing our 2nd generation technology) under the old EPA’s Chesapeake Bay model. The Company anticipates that if and when new designs are finalized utilizing our Gen3Tech, a larger Kreider 2 Project will be re-certified for a far larger number of credits (management’s current estimates are between 2-4 million (or more) nutrient reduction credits for treatment of the waste stream from Kreider’s poultry pursuant to the amended EPA Chesapeake Bay model and agreements between the EPA and PA). 8292000 3189000 10235000 902000 968000 3522000 4038000 1737000 86000 19000 2404000 3522000 20000000 80000000 <p id="xdx_804_eus-gaap--SignificantAccountingPoliciesTextBlock_zMjFiIQQra47" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2.       <span id="xdx_824_z5dEsVk6Jslb">SIGNIFICANT ACCOUNTING POLICIES </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zpplF3XRqda4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zHcNtCjhEvC">Principles of consolidation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its <span id="xdx_906_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20230630__srt--OwnershipAxis__custom--CenterpointMember_zaPPKERHd2e6" title="Noncontrolling interest, ownership percentage by parent">58.9</span>% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zNvMbzfGb9dh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zxIh0bLE2QP2">Cash and cash equivalents</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of June 30, 2023 and June 30, 2022 there are <span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20230630_zxaTj3pXgUrb" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20220630_zvJYNhP6r83f" title="Cash equivalents">no</span></span> cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSwe2C8DLiq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zVOUxDA6w9H7">Property and equipment</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zgQ7vuo1OQqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zWACcoc2UOah">Patents</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zBMrfGfHCYfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zr5q1aCMYbq5">Stock-based compensation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--DerivativesPolicyTextBlock_zyuYANo2ZyK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zoeSLAyzZKk4">Derivative Financial Instruments</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_ecustom--OptionsPolicyTextBlock_zl9i0ZQZFtwb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zeLM0J8UhLzi">Options</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_ecustom--EquityIssuancesWarrantsPolicyPolicyTextBlock_zECK2ELvdwe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zC8m77Ds6474">Warrants</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zrrdybjsh0P4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zas5Ocn712Ek">Concentrations of credit risk</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_ecustom--MinorityInterestPolicyPolicyTextBlock_zQrMGZCfV04i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zycUQokdw2fh">Noncontrolling interests</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z9eaanOWsyme" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zjPVw8aSfnX9">Fair value measurements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 – assets and liabilities whose significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--LessorLeasesPolicyTextBlock_zkypu3zUTzva" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_867_zy6p9HGk2wih">Lease Accounting</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">The Company accounts for leases under ASC 842, <i>Leases</i> (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_842_eus-gaap--RevenueRecognitionPolicyTextBlock_zC6dGCRyZd9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zWrKdtrIIIk1">Revenue Recognition</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zROml2TsBpF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zO2PijOrwXZk">Income (Loss) per share</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the years ended June 30, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIkaz1D82Jth" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_8B2_zbuzOrRLZ1zc" style="display: none">Schedule of anti dilutive securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30, <br/> 2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30, <br/> 2022</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: justify">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Antidilutive securities">22,543,765</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Antidilutive securities">20,778,635</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities">12,006,600</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities">11,201,600</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities">9,922,769</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities">10,686,065</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible preferred stock</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0720">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0722">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <p id="xdx_8A5_z3OSmDFIN7sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the years ended June 30, 2023 and 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zMqWMaaPaDt" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> <span id="xdx_8BB_z0X346bE5jn7" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_490_20220701__20230630_z5icLlvW9tyi" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_490_20210701__20220630_zumbXA2vjV18" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Year <br/> ended <br/> June 30, <br/> 2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Year <br/> ended <br/> June 30, <br/> 2022</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_ecustom--SharesIssuedBeginningOfPeriod_zrzcT887ao17" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">Shares issued – beginning of period</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">43,758,820</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">41,315,986</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--SharesHeldBySubsidiaries_zvPvuqV71rOj" style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Shares held by subsidiaries (Note 7)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(704,309</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(704,309</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_ecustom--SharesOutstandingBeginningOfPeriod_zVpy70B5bJS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Shares outstanding – beginning of period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">43,054,511</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">40,611,677</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--WeightedAverageSharesIssuedDuringPeriod_zfEznpnTDjAb" style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Weighted average shares issued <br/>     during the period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,983,968</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,350,625</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Diluted weighted average shares – <br/>     end of period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">45,038,479</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">41,962,302</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_8A9_zRdtq27v42r9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84F_eus-gaap--UseOfEstimates_zjS5DhvuK4J6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_z88B5NfuiPal">Use of estimates</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z5Bslg4adA72" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zUjGXbixlc4j">Recent Accounting Pronouncements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--ConsolidationPolicyTextBlock_zpplF3XRqda4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zHcNtCjhEvC">Principles of consolidation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Bion Integrated Projects Group, Inc., Bion Technologies, Inc., BionSoil, Inc., Bion Services, Bion PA2 LLC and Bion 3G-1 LLC (“3G1”); and its <span id="xdx_906_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_dp_c20230630__srt--OwnershipAxis__custom--CenterpointMember_zaPPKERHd2e6" title="Noncontrolling interest, ownership percentage by parent">58.9</span>% owned subsidiary, Centerpoint Corporation (“Centerpoint”). All significant intercompany accounts and transactions have been eliminated in consolidation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bion PA1 LLC was dissolved on December 29, 2021 (See Note 5). Its operating losses are included in the consolidation through December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 0.589 <p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zNvMbzfGb9dh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zxIh0bLE2QP2">Cash and cash equivalents</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash and cash equivalents. As of June 30, 2023 and June 30, 2022 there are <span id="xdx_909_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20230630_zxaTj3pXgUrb" title="Cash equivalents"><span id="xdx_900_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0p0_do_c20220630_zvJYNhP6r83f" title="Cash equivalents">no</span></span> cash equivalents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 0 0 <p id="xdx_84A_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zSwe2C8DLiq8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86F_zVOUxDA6w9H7">Property and equipment</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment are stated at cost and are depreciated, when placed into service, using the straight-line method over the estimated useful lives of the related assets, generally three to twenty years. The Company capitalizes all direct costs and all indirect incrementally identifiable costs related to the design and construction of its Integrated Projects such as consulting fees, internal salaries and benefits and interest. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized based on the amount by which the carrying value of the assets or asset group exceeds its estimated fair value, and is recognized as a loss from operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_zgQ7vuo1OQqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zWACcoc2UOah">Patents</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has elected to expense all costs and filing fees related to obtaining patents (resulting in no related asset being recognized in the Company’s consolidated balance sheets) because the Company believes such costs and fees are immaterial (in the context of the Company’s total costs/expenses) and have no direct relationship to the value of the Company’s patents.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84B_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zBMrfGfHCYfb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_865_zr5q1aCMYbq5">Stock-based compensation</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provisions of Accounting Standards Codification (“ASC”) 718, which generally requires that share-based compensation transactions be accounted and recognized in the statement of operations based upon their grant date fair values.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_842_eus-gaap--DerivativesPolicyTextBlock_zyuYANo2ZyK1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zoeSLAyzZKk4">Derivative Financial Instruments</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to ASC Topic 815 “Derivatives and Hedging” (“Topic 815”), the Company reviews all financial instruments for the existence of features which may require fair value accounting and a related mark-to-market adjustment at each reporting period end. Once determined, the Company assesses these instruments as derivative liabilities. The fair value of these instruments is adjusted to reflect the fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84C_ecustom--OptionsPolicyTextBlock_zl9i0ZQZFtwb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zeLM0J8UhLzi">Options</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued options to employees and consultants under the 2006 Plan to purchase common shares of the Company. Options are valued on the grant date using the Black-Scholes option-pricing model. The expected volatility is based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_84A_ecustom--EquityIssuancesWarrantsPolicyPolicyTextBlock_zECK2ELvdwe2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zC8m77Ds6474">Warrants</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has issued warrants to purchase common shares of the Company. Warrants are valued using a fair value based method, whereby the fair value of the warrant is determined at the warrant issue date using a market-based option valuation model based on factors including an evaluation of the Company’s value as of the date of the issuance, consideration of the Company’s limited liquid resources and business prospects, the market price of the Company’s stock in its mostly inactive public market and the historical valuations and purchases of the Company’s warrants. When warrants are issued in combination with debt or equity securities, the warrants are valued and accounted for based on the relative fair value of the warrants in relation to the total value assigned to the debt or equity securities and warrants combined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zrrdybjsh0P4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_863_zas5Ocn712Ek">Concentrations of credit risk</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company's financial instruments that are exposed to concentrations of credit risk consist of cash. The Company's cash is in demand deposit accounts placed with federally insured financial institutions and selected brokerage accounts. Such deposit accounts at times may exceed federally insured limits. The Company has not experienced any losses on such accounts.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_841_ecustom--MinorityInterestPolicyPolicyTextBlock_zQrMGZCfV04i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zycUQokdw2fh">Noncontrolling interests</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In accordance with ASC 810, “Consolidation”, the Company separately classifies noncontrolling interests within the equity section of the consolidated balance sheets and separately reports the amounts attributable to controlling and noncontrolling interests in the consolidated statements of operations. In addition, the noncontrolling interest continues to be attributed its share of losses even if that attribution results in a deficit noncontrolling interest balance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84D_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z9eaanOWsyme" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zjPVw8aSfnX9">Fair value measurements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the principal or most advantageous market. The Company uses a fair value hierarchy that has three levels of inputs, both observable and unobservable, with use of the lowest possible level of input to determine fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 – observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 – assets and liabilities whose significant value drivers are unobservable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of cash and accounts payable approximates their carrying amounts due to their short-term maturities. The fair value of the loan payable is indeterminable at this time due to the nature of the arrangement with a state agency and the fact that it is in default. The fair value of the redeemable preferred stock approximates its carrying value due to the dividends accrued on the preferred stock which are reflected as part of the redemption value. The fair value of the deferred compensation and convertible notes payable - affiliates are not practicable to estimate due to the related party nature of the underlying transactions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_848_eus-gaap--LessorLeasesPolicyTextBlock_zkypu3zUTzva" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_867_zy6p9HGk2wih">Lease Accounting</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">The Company accounts for leases under ASC 842, <i>Leases</i> (“ASC 842”). Accordingly, the Company will determine whether an arrangement contains a lease at the inception of the arrangement. If a lease is determined to exist, the term of such lease is assessed based on the date on which the underlying asset is made available for the Company’s use by the lessor. The Company’s assessment of the lease term reflects the non-cancelable term of the lease, inclusive of any rent-free periods and/or periods covered by early-termination options which the Company is reasonably certain of not exercising, as well as periods covered by renewal options which the Company is reasonably certain of exercising. The Company also determines lease classification as either operating or finance at lease commencement, which governs the pattern of expense recognition and the presentation reflected in the consolidated statements of operations over the lease term.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 11pt 0 0; text-align: justify">For leases with a term exceeding 12 months, a lease liability is recorded on the Company’s consolidated balance sheet at lease commencement reflecting the present value of its fixed minimum payment obligations over the lease term. A corresponding right-of-use (“ROU”) asset equal to the initial lease liability is also recorded, adjusted for any prepaid rent and/or initial direct costs incurred in connection with execution of the lease and reduced by any lease incentives received. For purposes of measuring the present value of its fixed payment obligations for a given lease, the Company uses its incremental borrowing rate, determined based on information available at lease commencement, as rates implicit in its leasing arrangements are typically not readily determinable. The Company's incremental borrowing rate reflects the rate it would pay to borrow on a secured basis and incorporates the term and economic environment of the associated lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_842_eus-gaap--RevenueRecognitionPolicyTextBlock_zC6dGCRyZd9c" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86E_zWrKdtrIIIk1">Revenue Recognition</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company currently does not generate revenue and if and when the Company begins to generate revenue the Company will comply with the provisions of ASC 606 “Revenue from Contracts with Customers”.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zROml2TsBpF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_861_zO2PijOrwXZk">Income (Loss) per share</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic income (loss) per share amounts are calculated using the weighted average number of shares of common stock outstanding during the period. Diluted income (loss) per share assumes the conversion, exercise or issuance of all potential common stock instruments, such as options or warrants, unless the effect is to reduce the income (loss) per share or increase the earnings per share. During the years ended June 30, 2023 and 2022, the basic and diluted income (loss) per share was the same, as the impact of potential dilutive common shares was anti-dilutive.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents the warrants and options (as if exercised) and convertible securities (as if converted) that have been excluded from the calculation of basic income (loss) per share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIkaz1D82Jth" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_8B2_zbuzOrRLZ1zc" style="display: none">Schedule of anti dilutive securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30, <br/> 2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30, <br/> 2022</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: justify">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Antidilutive securities">22,543,765</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Antidilutive securities">20,778,635</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities">12,006,600</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities">11,201,600</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities">9,922,769</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities">10,686,065</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible preferred stock</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0720">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0722">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> <p id="xdx_8A5_z3OSmDFIN7sl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a reconciliation of the denominators of the basic and diluted income (loss) per share computations for the years ended June 30, 2023 and 2022:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zMqWMaaPaDt" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> <span id="xdx_8BB_z0X346bE5jn7" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_490_20220701__20230630_z5icLlvW9tyi" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_490_20210701__20220630_zumbXA2vjV18" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Year <br/> ended <br/> June 30, <br/> 2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Year <br/> ended <br/> June 30, <br/> 2022</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_ecustom--SharesIssuedBeginningOfPeriod_zrzcT887ao17" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">Shares issued – beginning of period</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">43,758,820</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">41,315,986</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--SharesHeldBySubsidiaries_zvPvuqV71rOj" style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Shares held by subsidiaries (Note 7)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(704,309</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(704,309</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_ecustom--SharesOutstandingBeginningOfPeriod_zVpy70B5bJS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Shares outstanding – beginning of period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">43,054,511</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">40,611,677</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--WeightedAverageSharesIssuedDuringPeriod_zfEznpnTDjAb" style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Weighted average shares issued <br/>     during the period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,983,968</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,350,625</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Diluted weighted average shares – <br/>     end of period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">45,038,479</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">41,962,302</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_8A9_zRdtq27v42r9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zIkaz1D82Jth" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_8B2_zbuzOrRLZ1zc" style="display: none">Schedule of anti dilutive securities</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30, <br/> 2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30, <br/> 2022</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: justify">Warrants</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Antidilutive securities">22,543,765</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right" title="Antidilutive securities">20,778,635</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_980_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities">12,006,600</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities">11,201,600</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible debt</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities">9,922,769</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--ConvertibleDebtSecuritiesMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities">10,686,065</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Convertible preferred stock</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0720">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210701__20220630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePreferredStockAntidilutiveSecuritiesMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Antidilutive securities"><span style="-sec-ix-hidden: xdx2ixbrl0722">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> </table> 22543765 20778635 12006600 11201600 9922769 10686065 <table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zMqWMaaPaDt" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> <span id="xdx_8BB_z0X346bE5jn7" style="display: none">Schedule of earnings per share, basic and diluted</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_490_20220701__20230630_z5icLlvW9tyi" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_490_20210701__20220630_zumbXA2vjV18" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Year <br/> ended <br/> June 30, <br/> 2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">Year <br/> ended <br/> June 30, <br/> 2022</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_400_ecustom--SharesIssuedBeginningOfPeriod_zrzcT887ao17" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%">Shares issued – beginning of period</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">43,758,820</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">41,315,986</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--SharesHeldBySubsidiaries_zvPvuqV71rOj" style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Shares held by subsidiaries (Note 7)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(704,309</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(704,309</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_ecustom--SharesOutstandingBeginningOfPeriod_zVpy70B5bJS7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Shares outstanding – beginning of period</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">43,054,511</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">40,611,677</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--WeightedAverageSharesIssuedDuringPeriod_zfEznpnTDjAb" style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">Weighted average shares issued <br/>     during the period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,983,968</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,350,625</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt">Diluted weighted average shares – <br/>     end of period</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">45,038,479</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">41,962,302</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 43758820 41315986 -704309 -704309 43054511 40611677 1983968 1350625 45038479 41962302 <p id="xdx_84F_eus-gaap--UseOfEstimates_zjS5DhvuK4J6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_z88B5NfuiPal">Use of estimates</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In preparing the Company’s consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_84A_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_z5Bslg4adA72" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_869_zUjGXbixlc4j">Recent Accounting Pronouncements</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company continually assesses any new accounting pronouncements to determine their applicability. When it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequences of the change to its consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s consolidated financial statements properly reflect the change.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p id="xdx_800_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zkLJJ3r8jDD7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>3.  <span id="xdx_823_zKAfDRoUXYwi">PROPERTY AND EQUIPMENT</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Property and equipment consist of the following:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--PropertyPlantAndEquipmentTextBlock_z28VJP6PvCw3" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span id="xdx_8B2_ztQQUv0mXmof" style="display: none">Schedule of property and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49B_20230630_zhoNYfPAlBtg" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_491_20220630_zw7RBQ6yTc25" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30, <br/> 2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30, <br/> 2022</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_ecustom--ComputersAndOfficeEquipment_iI_pp0p0_maPPAEGzkIE_zojtyf4ojV43" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Computers and office equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">15,156</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">13,598</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAEGzkIE_zTQYdFNdZKE7" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Initial Project: construction in process</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,847,760</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,892,222</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGzkIE_maPPAEOzsvC_z2ZcToEFPVb6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, gross</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,862,916</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,905,820</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAEOzsvC_zo5AoKMf9tR6" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(11,907</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(10,262</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentOtherNet_iTI_pp0p0_mtPPAEOzsvC_zaofqPw3473h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,851,009</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,895,558</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 3G1 project (“Initial Project”) began in July of 2021, with a lease signed on land October 1, 2021 (Note 9). Once the lease commenced the Company moved into construction phase. The balance for the Initial Project construction in process includes $<span id="xdx_90B_eus-gaap--InterestCostsCapitalized_pp0p0_c20220701__20230630_z3R9g43mqXV9" title="Capitalized interest">211,984</span> for capitalized interest and $<span id="xdx_90D_ecustom--NonCashCompensation_pp0p0_c20220701__20230630_zsurTkWIT7y3" title="Non cash compensation">135,648</span> in non-cash compensation as of June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Management has reviewed the remaining property and equipment for impairment as of June 30, 2023 and believes that <span id="xdx_906_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20220701__20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--PropertyPlantAndEquipmentOfPA1Member_zdv5uMzfi1h8" title="Impairment of Long-Lived Assets Held-for-use">no</span> impairment exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depreciation expense was $<span id="xdx_904_eus-gaap--Depreciation_c20220701__20230630_pp0p0" title="Depreciation expense">1,645</span> and $<span id="xdx_906_eus-gaap--Depreciation_c20210701__20220630_pp0p0" title="Depreciation expense">1,161</span> for the years ended June 30, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_885_eus-gaap--PropertyPlantAndEquipmentTextBlock_z28VJP6PvCw3" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><span id="xdx_8B2_ztQQUv0mXmof" style="display: none">Schedule of property and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49B_20230630_zhoNYfPAlBtg" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_491_20220630_zw7RBQ6yTc25" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30, <br/> 2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">June 30, <br/> 2022</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_40D_ecustom--ComputersAndOfficeEquipment_iI_pp0p0_maPPAEGzkIE_zojtyf4ojV43" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: left">Computers and office equipment</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">15,156</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">13,598</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--ConstructionInProgressGross_iI_pp0p0_maPPAEGzkIE_zTQYdFNdZKE7" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Initial Project: construction in process</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,847,760</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,892,222</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--PropertyPlantAndEquipmentGross_iTI_pp0p0_mtPPAEGzkIE_maPPAEOzsvC_z2ZcToEFPVb6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Property and equipment, gross</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6,862,916</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">2,905,820</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAEOzsvC_zo5AoKMf9tR6" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt">Less accumulated depreciation</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(11,907</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(10,262</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentOtherNet_iTI_pp0p0_mtPPAEOzsvC_zaofqPw3473h" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"> Property and equipment, net</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">6,851,009</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,895,558</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 15156 13598 6847760 2892222 6862916 2905820 11907 10262 6851009 2895558 211984 135648 0 1645 1161 <p id="xdx_800_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z4H5ASJm6dte" style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><b>4.       <span id="xdx_82D_zeL4gYKy80Zk">DEFERRED COMPENSATION</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company owes deferred compensation to various employees, former employees and consultants totaling $<span id="xdx_903_eus-gaap--DeferredCompensationLiabilityCurrent_c20230630_pp0p0" title="Deferred compensation liability">864,781</span> and $<span id="xdx_900_eus-gaap--DeferredCompensationLiabilityCurrent_c20220630_pp0p0" title="Deferred compensation liability">594,798</span> as of June 30, 2023 and 2022, respectively. Included in the deferred compensation balances as of June 30, 2023, are $<span id="xdx_90E_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__custom--BassaniMember_zXDMxhMh5BT7" title="Deferred compensation liability">527,058</span> and $<span id="xdx_902_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__custom--SmithMember_zf67iOGgCsZe" title="Deferred compensation liability">20,167</span> owed Dominic Bassani (“Bassani”), the Company’s Chief Operating Officer (who was Chief Executive Officer until through April 30, 2022), and Mark A. Smith (“Smith”), the Company’s President, respectively, pursuant to extension agreements effective January 1, 2015, whereby unpaid compensation earned after January 1, 2015, accrues interest at <span id="xdx_900_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20230630_z4RGCQ7BJxia" title="Interest Rate on Deferred Compensation">4</span>% per annum and can be converted into shares of the Company’s common stock at the election of the employee during the first five calendar days of any month. The conversion price shall be the average closing price of the Company’s common stock for the last <span id="xdx_90C_ecustom--DeferredCompensationConsecutiveTradingDays_dtD_c20220701__20230630_zItgpzD94sU1" title="Deferred Compensation Consecutive Trading Days (Day)">10</span> trading days of the immediately preceding month. The deferred compensation owed Bassani and Smith as of June 30, 2022 was $<span id="xdx_90B_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__custom--BassaniMember_z6giGNirb7a9" title="Deferred compensation liability">437,508</span> and $<span id="xdx_901_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__custom--SmithMember_z697lPsoLUs4" title="Deferred compensation liability">10,000</span>, respectively. The Company also owes various consultants and an employee, pursuant to various agreements, for deferred compensation of $<span id="xdx_902_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__custom--ConsultantsAndEmployeeMember_z3B8qm1kQvU4" title="Deferred compensation liability">105,056</span> and $<span id="xdx_906_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__custom--ConsultantsAndEmployeeMember_zlI9WJaltwj8" title="Deferred compensation liability">74,790</span> as of June 30, 2023 and 2022, respectively, with similar conversion terms as those described above for Bassani and Smith, with the exception that the interest accrues at <span id="xdx_903_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20230630__srt--TitleOfIndividualAxis__custom--BassaniMember_zNT9w7PDKe1l" title="Interest Rate on Deferred Compensation">0</span>% to <span id="xdx_902_ecustom--InterestRateOnDeferredCompensation_iI_dp_c20230630__srt--TitleOfIndividualAxis__custom--SmithMember_zueAbK5RNx8c" title="Interest Rate on Deferred Compensation">3</span>% per annum. The Company also owes a former employee $<span id="xdx_903_ecustom--FormerEmployeeCompensation_c20220701__20230630_z4Nbhi0zWOk3" title="Former employee compensation">72,500</span>, which is not convertible and is non-interest bearing. Bassani and Smith have each been granted the right to convert up to $<span id="xdx_900_ecustom--DeferredCompensationConvertibleToCommonStock_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__custom--BassaniAndSmithMember_zXgTu8Ye5U95" title="Deferred Compensation, Convertible to Common Stock">300,000</span> of deferred compensation balances at a price of $<span id="xdx_906_ecustom--DeferredCompensationConvertibleToCommonStockPricePerShare_iI_c20230630__srt--TitleOfIndividualAxis__custom--BassaniAndSmithMember_zvpXscF2Vd56" title="Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share)">0.75</span> per share until June 30, 2024 into common shares (to be issued pursuant to the 2006 Plan). Smith also has the right to convert all or part of his deferred compensation balance into the Company’s securities (to be issued pursuant to the 2006 Plan) “at market” and/or on the same terms as the Company is selling or has sold its securities in its then current (or most recent if there is no current) private placement. Smith also received the right to transfer future deferred compensation to his 2020 Convertible Obligation at his election but such right is no longer in force.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Bill O’Neill has a balance of $<span id="xdx_90D_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__custom--BillONeillMember_zJXu7eMN5iI5" title="Deferred compensation liability">140,000</span> and $<span id="xdx_90D_eus-gaap--DeferredCompensationLiabilityCurrent_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__custom--BillONeillMember_z44eIZlWGUO3" title="Deferred compensation liability">20,000</span> at June 30, 2023 and 2022, respectively. There is <span id="xdx_900_ecustom--DeferredCompensationInterest_iI_pp0p0_do_c20230630__srt--TitleOfIndividualAxis__custom--BillONeillMember_zRNPnaRCvbr7" title="Deferred compensation interest">no</span> interest or conversions on the deferred balance. During the year ended June 30, 2023, Smith elected to add $<span id="xdx_905_ecustom--DeferredCompensationConvertibleToCommonStock_iI_pp0p0_c20230630__srt--CounterpartyNameAxis__custom--SmithMember_zKQr6219uNh8" title="Deferred Compensation, Convertible to Common Stock">90,000</span> of deferred compensation to his 2020 Convertible Note.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company recorded interest expense of $<span id="xdx_90A_eus-gaap--InterestExpense_c20220701__20230630__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense">19,983</span> ($<span id="xdx_90E_ecustom--InterestExpenseRelatedParties_pp0p0_c20220701__20230630__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zEH4RlQsykUd" title="Interest Expense, Related Party">17,716</span> with related parties) and $<span id="xdx_908_eus-gaap--InterestExpense_c20210701__20220630__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_pp0p0" title="Interest Expense">16,390</span> ($<span id="xdx_904_ecustom--InterestExpenseRelatedParties_pp0p0_c20210701__20220630__us-gaap--NatureOfExpenseAxis__custom--InterestExpenseOnDeferredCompensationObligationMember_zhJt8Su6hPK6" title="Interest Expense, Related Party">15,537</span> with related parties) for the years ended June 30, 2023 and 2022, respectively.</p> 864781 594798 527058 20167 0.04 P10D 437508 10000 105056 74790 0 0.03 72500 300000 0.75 140000 20000 0 90000 19983 17716 16390 15537 <p id="xdx_808_eus-gaap--DebtDisclosureTextBlock_zAhvfyApnfs4" style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b>5.       <span id="xdx_82E_zai4079LbfY4">LOANS PAYABLE</span>:</b></p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Pennvest Loan and Bion PA1 LLC (“PA1”) Dissolution</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $<span id="xdx_90B_eus-gaap--ConstructionLoan_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zk9bjJwWAmR6" title="Construction Loan">10,010,000</span> under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $<span id="xdx_90F_ecustom--AccruedInterestAndLateChargesPayable_iI_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zvLfts9Cveg4" title="Accrued Interest and Late Charges Payable">2,255,802</span> as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $<span id="xdx_90C_eus-gaap--Assets_iI_pp0p0_c20210930_zfGYhkb547Bd" title="Total assets">297</span> and its total liabilities were $<span id="xdx_90E_eus-gaap--Liabilities_iI_pp0p0_c20210930_zE7jnxooZBXj" title="Total liabilities">10,154,334</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_909_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zerlngpJjAG2" title="Accounts payable and accrued liabilities">9,939,148</span>, accounts payable of $<span id="xdx_903_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20210930_zgO1Wm18KiCh" title="Accounts payable">214,235</span> and accrued liabilities of $<span id="xdx_903_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zArL2WEXL2i9" title="Accrued Liabilities, Current">950</span>) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $<span id="xdx_909_eus-gaap--Liabilities_c20211229_pp0p0" title="Total liabilities">10,234,501</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_904_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_c20211229_pp0p0" title="Accounts payable and accrued liabilities">10,009,802</span>, accounts payable of $<span id="xdx_903_eus-gaap--AccountsPayableCurrent_c20211229_pp0p0" title="Accounts payable">212,263</span> and accrued liabilities of $<span id="xdx_906_eus-gaap--AccruedLiabilitiesCurrent_c20211229_pp0p0" title="Accrued Liabilities, Current">12,436</span>). The net amount of $<span id="xdx_90D_eus-gaap--GainOrLossOnSaleOfStockInSubsidiary_pp0p0_c20220701__20230630_zO1kTwBmZh4" title="Gain on legal dissolution of subsidiary">10,234,501</span> was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As background, the terms of the Pennvest Loan provided for funding of up to $<span id="xdx_903_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z5wSCEOMLzAk" title="Line of Credit Facility, Maximum Borrowing Capacity">7,754,000</span> which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220701__20230630__srt--StatementScenarioAxis__custom--YearsOneThroughFiveMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zEmoVHxPJUZ" title="Debt Instrument, Interest Rate During Period">2.547</span>% per annum for years 1 through 5 and <span id="xdx_902_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220701__20230630__srt--StatementScenarioAxis__custom--YearsSixThroughMaturityMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zvAliALxHqBh" title="Debt Instrument, Interest Rate During Period">3.184</span>% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $<span id="xdx_907_eus-gaap--DebtInstrumentAnnualPrincipalPayment_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zqGDakzwMxg" title="Debt Instrument, Annual Principal Payment">5,886,000</span> in fiscal years 2013 through 2021, and $<span id="xdx_904_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zVbMybvMayxh" title="Long-Term Debt, Maturity, Year Two">846,000</span> in fiscal year 2022, $<span id="xdx_904_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zTUlS7TrHf19" title="Long-Term Debt, Maturity, Year Three">873,000</span> in fiscal year 2023 and $<span id="xdx_90F_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zhCQs0sNiMY7" title="Long-Term Debt, Maturity, Year Four">149,000</span> in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $<span id="xdx_902_eus-gaap--InterestExpenseDebt_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Interest Expense, Debt">123,444</span> and $<span id="xdx_90D_eus-gaap--InterestExpenseDebt_c20200701__20210630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_pp0p0" title="Interest Expense, Debt">246,887</span> for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $<span id="xdx_90B_eus-gaap--LinesOfCreditCurrent_c20210630_pp0p0" title="Loans as a liability">9,868,495</span> despite the fact that the obligation (if any) was solely an obligation of PA1<b>. </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $<span id="xdx_909_eus-gaap--DebtDefaultLongtermDebtAmount_c20140925__dei--LegalEntityAxis__custom--PA1Member_pp0p0" title="Debt Instrument, Debt Default, Amount">8,137,117</span> (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $<span id="xdx_909_eus-gaap--GainLossOnSecuritizationOfFinancialAssets_pp0p0_c20220614__20220615__dei--LegalEntityAxis__custom--PA1Member_zTQmG9QVSYH3" title="Realized from the asset sale">104,725</span> was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest described above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception and no payment will be made to the Company or any affiliate in connection with the dissolution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.</p> <p style="font: 10pt/11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 10010000 2255802 297 10154334 9939148 214235 950 10234501 10009802 212263 12436 10234501 7754000 0.02547 0.03184 5886000 846000 873000 149000 123444 246887 9868495 8137117 104725 <p id="xdx_809_ecustom--ConvertibleDebtTextBlock_zWHNTjhyzrca" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>6.       <span id="xdx_82C_zWntD2YYilYj">CONVERTIBLE NOTES PAYABLE - AFFILIATES</span>: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes --- see below) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3_dm_c20230630_zGctQTHLFkfd" title="Convertible notes payable">3.47</span> million, in aggregate –See Note 7 below, <b>‘Debt Modification to Additional Paid in Capital’) </b>while equitably maintaining existing conversion rights.  The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__srt--CounterpartyNameAxis__custom--MarkASmithMember_zQETto2DHW5d">1,109,649</span>, $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230630__srt--CounterpartyNameAxis__custom--DominicBassaniMember_zpdfM0O7H0H2">1,939,670 </span>and $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230630__srt--CounterpartyNameAxis__custom--EdSchaferMember_ziuvciE3xns5">424,873</span>, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and the adjusted portion of the September 2015 Convertible Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units (consisting of 1 share and from one half (1/2) to one (1) warrant) at prices of $<span id="xdx_905_ecustom--ConversionPricePerUnit_iI_c20230630__srt--CounterpartyNameAxis__custom--MarkASmithMember_ztAlOnXSzQli">.0946</span>, $<span id="xdx_903_ecustom--ConversionPricePerUnit_iI_c20230630__srt--CounterpartyNameAxis__custom--DominicBassaniMember_zDFLwES3k1ik">.0953</span>, and $<span id="xdx_901_ecustom--ConversionPricePerUnit_iI_c20230630__srt--CounterpartyNameAxis__custom--EdSchaferMember_zKlZWGOgvr52">.0953</span>, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $<span id="xdx_90C_ecustom--ConversionPricePerUnit_iI_uUSDPShares_c20230630__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonSharesMember_z2L455xzUk6e">0.115 </span>per share. The adjusted conversion prices slightly reduce the securities to be issued on conversion of each instrument from the amount receivable under the unadjusted instruments. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). After the adjustment, the Company owed Smith, Bassani (and trust) and Schafer $<span id="xdx_90E_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--RelatedPartyTransactionAxis__custom--SmithMember_zQlejFzdzQd6">262,154</span>, $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--RelatedPartyTransactionAxis__custom--BassaniFamilyTrustsMember_zubgmlK7g9Si">434,016 </span>and $<span id="xdx_900_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--RelatedPartyTransactionAxis__custom--SchaferMember_zKcg2LqF6fjb">96,364</span>, respectively, of Adjusted 2020 Convertible Obligations and Bassani and Schafer, respectively, $<span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__srt--CounterpartyNameAxis__custom--BassaniMember_zUtytPlWta4j">24,230 </span>and $<span id="xdx_908_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__srt--CounterpartyNameAxis__custom--EdSchaferMember_zEzN5Q3LhH3a">4,012 </span>of Adjusted September 2015 Convertible Notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2023, Smith elected to convert $<span id="xdx_904_eus-gaap--ConversionOfStockAmountConverted1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z8Ad0XrHfyNh" title="Conversion of shares, value">136,462</span>, in aggregate, of his Adjusted 2020 Convertible Obligation into <span id="xdx_90A_eus-gaap--ConversionOfStockSharesConverted1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zNin5cB5YUKf" title="Conversion of shares, shares">1,442,514</span> units at $<span id="xdx_906_ecustom--ConversionPricePerUnit_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zZL5pC67lzyg" title="Conversion price per unit">0.0946</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_905_eus-gaap--SharePrice_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zi3rKcoEiJNh" title="Sell units">0.75</span> per share until March 2026. In more detail, effective: a) March 8, 2023, Smith converted $<span id="xdx_903_eus-gaap--ConversionOfStockAmountConverted1_c20230307__20230308__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zgD7kwSRvdp7" title="Conversion of shares, value">70,000</span> of his Adjusted 2020 Convertible Obligation into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20230307__20230308__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zlzWQsNrAgyd" title="Conversion of shares, shares">739,958</span> Units (each Unit consisting one share and one warrant); b) March 31, 2023, Smith converted $<span id="xdx_904_eus-gaap--ConversionOfStockAmountConverted1_c20230330__20230331__us-gaap--DebtInstrumentAxis__custom--AdjustedConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zCyQv6bLVWGc" title="Conversion of shares, value">29,888</span> of his Adjusted Convertible Obligation into <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_c20230330__20230331__us-gaap--DebtInstrumentAxis__custom--AdjustedConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zYhAOzZWdsQc" title="Conversion of shares, shares">315,948</span> Units (each Unit consisting one share of common stock and one warrant); and c) June 4, 2023, Smith converted $<span id="xdx_908_eus-gaap--ConversionOfStockAmountConverted1_c20230601__20230604__us-gaap--DebtInstrumentAxis__custom--AdjustedConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zyqe8lgiRD4l" title="Conversion of shares, value">36,573</span> of his Adjusted Convertible Obligation into <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20230601__20230604__us-gaap--DebtInstrumentAxis__custom--AdjustedConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zEJwE8O6WDf6" title="Conversion of shares, shares">386,608</span> Units (each Unit consisting one share of common stock and one warrant). Smith donated to charitable organizations and/or gifted to family members and others a large portion of these securities (<span id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20220701__20230630__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--CommonSharesMember_zEf4PVqqIFzj" title="Convertible stock shares issued, common shares">700,000</span> common shares and <span id="xdx_902_eus-gaap--ConversionOfStockSharesIssued1_c20220701__20230630__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--WarrantsMember_ze5hncpDkMui" title="Convertible stock shares issued, warrants">955,000</span> warrants, in aggregate) while retaining direct ownership of <span id="xdx_901_eus-gaap--SharesIssued_iI_c20230630__us-gaap--AwardTypeAxis__custom--CommonSharesMember__srt--OwnershipAxis__custom--DirectOwnershipMember_z5RLZLmRDfH4" title="Shares issued, common shares">292,514</span> common shares and <span id="xdx_902_eus-gaap--SharesIssued_iI_c20230630__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--OwnershipAxis__custom--DirectOwnershipMember_zekGsI0Hb0Nj" title="Shares issued, warrants">116,566</span> warrants and indirect ownership of <span id="xdx_904_eus-gaap--SharesIssued_iI_c20230630__us-gaap--AwardTypeAxis__custom--CommonSharesMember__srt--OwnershipAxis__custom--IndirectOwnershipMember_ztHZhSSOrQS4" title="Shares issued, common shares">450,000</span> common shares and <span id="xdx_90E_eus-gaap--SharesIssued_iI_c20230630__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--OwnershipAxis__custom--IndirectOwnershipMember_z3jeVI0KDr71" title="Shares issued, warrants">370,948</span> warrants (owned by his wife). The warrants are exercisable for three years from conversion dates. Subsequent to June 30, 2023, Smith converted additional portions of his Adjusted Convertible Obligation. See Note 12.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30 2023, the Adjusted 2020 Convertible Obligation balances, including accrued interest, owed Bassani (and his donees), Smith and Edward Schafer were $<span id="xdx_909_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_ziN4CK8lRNz9" title="Convertible Notes Payable, Noncurrent">441,446</span>, $<span id="xdx_90D_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zDj8qiYRWBg6" title="Convertible Notes Payable, Noncurrent">130,180</span> and $<span id="xdx_909_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zTHfjAsbdQye" title="Convertible Notes Payable, Noncurrent">98,014</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $<span id="xdx_90F_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_zWWsXiih9ex4" title="Convertible Notes Payable, Noncurrent">24,645</span> and $<span id="xdx_903_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20230630__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_zq8Qmbhvs0Ai" title="Convertible Notes Payable, Noncurrent">4,081</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>2020 Convertible Obligations </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2020 Convertible Obligations (which combined/replaced prior convertible instruments dating to 2017 (or earlier), which accrue interest at either <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zJED7XC1vxm8" title="Debt Instrument, Interest Rate, Stated Percentage">4</span>% per annum or <span id="xdx_906_ecustom--DebtInstrumentInterestRateStatedPercentageQuarterly_iI_dp_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zZqGwjpQHFH" title="Debt Instrument, Interest Rate, Stated Percentage, Quarterly">4</span>% compounded quarterly and effective January 1, 2020 are due and payable on July 1, 2024. The 2020 Convertible Obligations (including accrued interest, plus all future deferred compensation added subsequently), are convertible, at the sole election of the holder, into Units consisting of one share of the Company’s common stock and one half to one warrant to purchase a share of the Company’s common stock, at a price of $<span id="xdx_907_ecustom--ConversionPricePerUnit_c20200101__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_pdd" title="Conversion price per unit">0.50</span> per Unit until July 1, 2024. The original conversion price of $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_c20230630_zjkdC5K7cjP4" title="Original conversion price">0.50</span> per Unit approximated the fair value of the Units at the date of the agreements; therefore, no beneficial conversion feature exists. Management evaluated the terms and conditions of the embedded conversion features based on the guidance of ASC 815-15 “Embedded Derivatives” to determine if there was an embedded derivative requiring bifurcation. An embedded derivative instrument (such as a conversion option embedded in the deferred compensation) must be bifurcated from its host instruments and accounted for separately as a derivative instrument only if the “risks and rewards” of the embedded derivative instrument are not “clearly and closely related” to the risks and rewards of the host instrument in which it is embedded. Management concluded that the embedded conversion feature of the deferred compensation was not required to be bifurcated because the conversion feature is clearly and closely related to the host instrument, and because of the Company’s limited trading volume that indicates the feature is not readily convertible to cash in accordance with ASC 815-10, “Derivatives and Hedging”. Effective February 1, 2023, a large portion of the 2020 Convertible Obligations were adjusted as set forth herein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2023, the remaining unadjusted portion of the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts (and his donees) and Smith, were $<span id="xdx_909_eus-gaap--ConvertibleLongTermNotesPayable_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_ziAxLWmzP3xb" title="Convertible Notes Payable, Noncurrent">361,321</span> and $<span id="xdx_904_eus-gaap--ConvertibleLongTermNotesPayable_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zNgbGaZYXlxj" title="Convertible Notes Payable, Noncurrent">36,432</span>, respectively. As of June 30, 2022, the 2020 Convertible Obligation balances, including accrued interest, owed Bassani Family Trusts, Smith and Schafer were $<span id="xdx_90E_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zj8t6OpO1xZ6" title="Convertible Notes Payable, Noncurrent">2,597,329</span>, $<span id="xdx_906_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zcSgwVUcooW7" title="Convertible Notes Payable, Noncurrent">1,328,040</span> and $<span id="xdx_90B_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20220630__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zKJZT4HJYYN7" title="Convertible Notes Payable, Noncurrent">499,274</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2023 (on dates prior to the adjustment on February 1, 2023), Smith elected to add $<span id="xdx_909_eus-gaap--SalariesAndWages_pp0p0_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zpihbjfT7H83" title="Salary paid">90,000</span> of his accrued unpaid compensation/un-reimbursed expenses to his 2020 Convertible Obligations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2023 (on dates prior to the adjustment on February 1, 2023), Smith elected to convert $<span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zGFAq4fGYmid" title="Debt conversion value">30,000</span> in principal of the 2020 Convertible Obligation to <span id="xdx_90C_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zgtZSMMgOejf" title="Debt conversion shares">60,000</span> units (<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--CommonSharesMember_ztDjTwpg2GKb" title="Debt conversion shares, common shares">60,000</span> common shares and <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember_z8uv0CoBtm7d" title="Debt conversion shares, warrants">60,000</span> warrants), and $<span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--AccruedInterestMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zk1FetAlfFB1" title="Debt conversion value">20,000</span> of accrued interest of the 2020 Convertible Obligation to <span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--AccruedInterestMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_z9lokAdzCB48" title="Debt conversion shares">40,000</span> units (<span id="xdx_909_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--AccruedInterestMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--CommonSharesMember_zfj9ijJyYcFi" title="Debt conversion shares, warrants">40,000</span> common shares and <span id="xdx_90D_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230630__us-gaap--AwardTypeAxis__custom--WarrantsMember__us-gaap--DebtInstrumentAxis__custom--AccruedInterestMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member_zP6RVbugwM94" title="Debt conversion shares, warrants">40,000</span> warrants). The warrants are exercisable for three years from conversion date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2023 (on dates after the adjustment on February 1, 2023), Smith elected to convert $<span id="xdx_907_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__srt--StatementScenarioAxis__custom--AfterAdjustmentMember_zRarCSgwxE6b" title="Debt conversion value">136,462</span> in principal of the Adjusted 2020 Convertible Obligation to <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__srt--StatementScenarioAxis__custom--AfterAdjustmentMember_zdD0LezIykA3" title="Debt conversion shares">1,442,514</span> units (<span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--CommonSharesMember__srt--StatementScenarioAxis__custom--AfterAdjustmentMember_z512zH4m099a" title="Debt conversion shares, common shares">1,442,514</span> common shares and <span id="xdx_90E_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--PrincipalMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--StatementEquityComponentsAxis__custom--WarrantsMember__srt--StatementScenarioAxis__custom--AfterAdjustmentMember_z4qqa8CP7Vpa" title="Debt conversion shares, warrants">1,442,514</span> warrants). The warrants are exercisable for three years from conversion dates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_90B_eus-gaap--InterestExpense_pp0p0_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zh7JyVrr80Xb" title="Interest Expense">102,478</span> and $<span id="xdx_906_eus-gaap--InterestExpense_pp0p0_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zpSo68I1hvx7" title="Interest Expense">131,718</span> for the year ended June 30, 2023 and 2022, respectively. The Company capitalized $<span id="xdx_900_eus-gaap--CostsIncurredDevelopmentCosts_pp0p0_c20220701__20230630_z2yC04RSE5fj" title="Capitalized amount">179,981</span> and $<span id="xdx_904_eus-gaap--CostsIncurredDevelopmentCosts_pp0p0_c20210701__20220630_zB7UE3gaMqHf" title="Capitalized amount">32,000</span> related to the Initial Project for the year ended June 30, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long-term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $<span id="xdx_90C_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3_dm_c20230630_zuyRCz69ToGj">3.47</span> million, in aggregate) while equitably maintaining existing conversion rights. Because the modifications where with affiliates that are related parties, the debt modification was treated as an equity transaction. The Company recorded a deemed dividend for the reductions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__srt--CounterpartyNameAxis__custom--MarkASmithMember_zuRJZLKHT3ol">1,109,649</span>, $<span id="xdx_90B_eus-gaap--DebtInstrumentFaceAmount_pp0p0_c20230630__srt--CounterpartyNameAxis__custom--DominicBassaniMember_zSvqE2CFaVMl">1,939,670</span> and $<span id="xdx_90F_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230630__srt--CounterpartyNameAxis__custom--EdSchaferMember_zJXB194yr1Bi">424,873</span>, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations (see above and Note 7.). The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>September 2015 Convertible Notes</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2016, the Company entered into September 2015 Convertible Notes with Bassani, Schafer and a Shareholder which replaced previously issued promissory notes. The September 2015 Convertible Notes bear interest at <span id="xdx_90D_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20230630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zrnFdslyoH7i" title="Financing receivable interest rate stated percentage">4</span>% per annum, have maturity dates of July 1, 2024, and may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $<span id="xdx_909_ecustom--ConversionPricePerUnit_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zD8MzdiZIXu4" title="Conversion price per unit">0.60</span> per share. As the conversion price of $0.60 approximated the fair value of the common shares at the date of the September 2015 Convertible Notes, no beneficial conversion feature exists.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The balances of the September 2015 Convertible Notes as of June 30, 2023, including accrued interest owed Bassani, Schafer and Shareholder, are $<span id="xdx_901_eus-gaap--ConvertibleNotesPayable_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--BassaniFamilyTrustsMember_zQAAIs0pKJCa" title="Convertible Notes Payable">183,628</span>, $<span id="xdx_90A_eus-gaap--ConvertibleNotesPayable_iI_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--SchaferMember_zC9zjwcBl6Sl" title="Convertible Notes Payable">4,081</span> and $<span id="xdx_90C_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ShareholderMember_zspC3v7LEovf" title="Convertible Notes Payable">460,873</span>, respectively. The balances of the September 2015 Convertible Notes as of June 30, 2022, including accrued interest, were $<span id="xdx_90D_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20220331__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--BassaniFamilyTrustsMember_z1I3CnpIqqid" title="Convertible Notes Payable">279,366</span>, $<span id="xdx_908_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20220331__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--SchaferMember_zBA27fR0BKg5" title="Convertible Notes Payable">20,845</span> and $<span id="xdx_907_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20220331__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--RelatedPartyTransactionAxis__custom--ShareholderMember_zCTY7vcQ7N0c" title="Convertible Notes Payable">445,756</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded interest expense of $<span id="xdx_908_eus-gaap--InterestExpense_pp0p0_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zoIPbBMiKFbl" title="Interest Expense">23,318</span> and $<span id="xdx_908_eus-gaap--InterestExpense_pp0p0_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z9LVhzhj5WE" title="Interest Expense">23,796</span> for the year ended June 30, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including the September 2015 Convertible Notes owned by Bassani and Schafer) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $<span id="xdx_904_eus-gaap--ConvertibleDebt_iI_pn3n3_dm_c20230630_z4FQ9XSZIpPf" title="Convertible note">3.52</span> million, in aggregate) while equitably maintaining existing conversion rights.  Mark A. Smith (the Company’s President), Dominic Bassani (the Company’s Chief Operating Officer)(and a family Trust) and Ed Schafer (Director), adjusted/reduced the principal owed to them by $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__srt--CounterpartyNameAxis__custom--MarkASmithMember_zT65xNmuiwdj" title="Principal amount">1,109,649</span>, $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230630__srt--CounterpartyNameAxis__custom--DominicBassaniMember_zWth1oIbGKDf" title="Principal amount">1,939,670</span> and $<span id="xdx_90C_eus-gaap--DebtInstrumentFaceAmount_pp0p0_c20230630__srt--CounterpartyNameAxis__custom--EdSchaferMember_ztf6ANeSBeQ7" title="Principal amount">424,873</span>, respectively. Subsequent to the adjustment, the adjusted portion of the were renamed Adjusted September 2015 Convertible Notes. The Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $<span id="xdx_909_ecustom--ConversionPricePerUnit_iI_c20230630__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonSharesMember_zmkDud7u6hmd" title="Conversion price per unit">0.115</span> per share. As of June 30, 2023 the Adjusted September 2015 Convertible Notes balances, including accrued interest, owed Bassani Family Trusts and Schafer were $<span id="xdx_90F_eus-gaap--ConvertibleLongTermNotesPayable_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_zn4y0fXxYjnj" title="Convertible Notes Payable, Noncurrent">24,645</span> and $<span id="xdx_90A_eus-gaap--ConvertibleLongTermNotesPayable_iI_c20230630__srt--TitleOfIndividualAxis__custom--ExecutiveViceChairmanMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember_z61StpT1ov31" title="Convertible Notes Payable, Noncurrent">4,081</span>, respectively. The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties. See above.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 3470000 1109649 1939670 424873 0.0946 0.0953 0.0953 0.115 262154 434016 96364 24230 4012 136462 1442514 0.0946 0.75 70000 739958 29888 315948 36573 386608 700000 955000 292514 116566 450000 370948 441446 130180 98014 24645 4081 0.04 0.04 0.50 0.50 361321 36432 2597329 1328040 499274 90000 30000 60000 60000 60000 20000 40000 40000 40000 136462 1442514 1442514 1442514 102478 131718 179981 32000 3470000 1109649 1939670 424873 0.04 0.60 183628 4081 460873 279366 20845 445756 23318 23796 3520000 1109649 1939670 424873 0.115 24645 4081 <p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zrrbE7MNLnVg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>7.       <span id="xdx_82C_z6dfA69uG6lb">STOCKHOLDERS' EQUITY:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Debt Modification to Additional paid in capital </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective February 1, 2023, three (3) directors/officers of the Company agreed to adjust the provisions of long term convertible obligations (including most of the 2020 Convertible Obligations and September 2015 Convertible Notes --- see below) owed to them by the Company in a manner which reduced the indebtedness of the Company by 80% (approximately $<span id="xdx_90B_eus-gaap--ConvertibleNotesPayableCurrent_iI_pn3n3_dm_c20230630_z6U9l9oN6bdc">3.47</span> million, in aggregate<b>) </b>while equitably maintaining existing conversion rights. Because the modifications where with affiliates that are related parties, the debt modification was treated as an equity transaction. The Company recorded a deemed dividend for the reductions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mark A. Smith (the Company’s President)(“Smith”), Dominic Bassani (the Company’s Chief Operating Officer)(“Bassani”) and Ed Schafer (Director)(“Schafer”), adjusted/reduced the principal owed to them by $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__srt--CounterpartyNameAxis__custom--MarkASmithMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zRGJtHHzBG26">1,109,649</span>, $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__srt--CounterpartyNameAxis__custom--DominicBassaniMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zjmdkevHCTP7">1,939,670</span> and $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_c20230630__srt--CounterpartyNameAxis__custom--EdSchaferMember__srt--TitleOfIndividualAxis__srt--ChiefOperatingOfficerMember_zM4e4wqpaPM3">424,873</span>, respectively. Subsequent to the adjustment, the adjusted portion of the 2020 Convertible Obligations were renamed Adjusted 2020 Convertible Obligations and the adjusted portion of the September 2015 Convertible Notes were renamed Adjusted September 2015 Convertible Notes. The Adjusted 2020 Convertible Obligations of Smith, Bassani and Schafer are convertible into Units at prices of $<span id="xdx_90C_ecustom--ConversionPricePerUnit_iI_c20230331__srt--CounterpartyNameAxis__custom--MarkASmithMember_zqNgHRwxrzvf">.0946</span>, $<span id="xdx_903_ecustom--ConversionPricePerUnit_iI_c20230331__srt--CounterpartyNameAxis__custom--DominicBassaniMember_zuMCl2XJVix9">0953</span>, and $<span id="xdx_90B_ecustom--ConversionPricePerUnit_iI_c20230331__srt--CounterpartyNameAxis__custom--EdSchaferMember_z1qlGKI3KLN4">.0953</span>, respectively, and the Adjusted September 2015 Convertible Notes may be converted at the sole election of the noteholders into restricted common shares of the Company at a conversion price of $<span id="xdx_90F_ecustom--ConversionPricePerUnit_c20230331__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__us-gaap--AwardTypeAxis__custom--RestrictedCommonSharesMember_pdd">0.115 </span>per share. The adjusted conversion prices slightly reduce the securities to be issued on conversion of each instrument from the amount receivable under the unadjusted instruments. The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). After the adjustment, the Company owed Smith, Bassani (and trust) and Schafer $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--MarkASmithMember_zzxLJw5WI3Oe">262,154</span>, $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--DominicBassaniMember_zNH8Gkec0Ccd">434,016 </span>and $<span id="xdx_900_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20230331__srt--CounterpartyNameAxis__custom--EdSchaferMember_zYFmRHCpMaJg">96,364</span>, respectively, of Adjusted 2020 Convertible Obligations and Bassani and Schafer, respectively, $<span id="xdx_902_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__srt--CounterpartyNameAxis__custom--BassaniMember_zqsEHeY8MxCf">24,230 </span>and $<span id="xdx_908_eus-gaap--ConvertibleNotesPayable_iI_pp0p0_c20230202__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--DebtInstrumentAxis__custom--September2015ConvertibleNotesMember__srt--CounterpartyNameAxis__custom--EdSchaferMember_z8SpmMjg7GEk">4,012 </span>of Adjusted September 2015 Convertible Notes. The debt modification was treated as an equity transaction because the modifications were with affiliates that are related parties.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Adjusted 2020 Convertible Obligations and Adjusted September 2015 Convertible Notes do not accrue any interest until their maturity date (July 1, 2024). The Company treated this as an equity transaction and recorded the reduction of debt through additional paid in capital at the net present value of the modified debt agreements. This resulted in an increase to Additional Paid in Capital of $<span id="xdx_90E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalOther_c20220701__20230630_ziuPJ8O6u8df" title="Increase to additional paid in capital">3,522,000</span> at the modification date and a reduction of additional paid in capital of $<span id="xdx_904_ecustom--ReductionOfAdditionalPaidInCapital_c20220701__20230630_zhX3SiZez7Mc" title="Reduction of additional paid in capital">14,051</span> for the year ended June 30, 2023 for the adjustment to the net present value of the modified debt agreements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Series B Preferred stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since July 1, 2014, the Company had <span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Preferred Stock, Shares Outstanding, Ending Balance (in shares)">200</span> shares of Series B redeemable convertible Preferred stock outstanding with a par value of $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_pdd" title="Par value">0.01</span> per share, convertible at the option of the holder at $<span id="xdx_906_ecustom--PreferredStockConvertibleOptionPerShare_iI_c20140703__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zlNCqUVN0Ei4" title="Preferred Stock, Convertible Option Per Share">2.00</span> per share, with dividends accrued and payable at 2.5% per quarter. The Series B Preferred stock is mandatorily redeemable at $<span id="xdx_90F_eus-gaap--PreferredStockRedemptionPricePerShare_iI_c20140702__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zyHLZg3HRVoj" title="Preferred Stock, Redemption Price Per Share">100</span> per share by the Company three years after issuance and accordingly was classified as a liability. The 200 shares had reached their redemption date and the Company approved the redemption of the Series B preferred stock during the year ended June 30, 2022. The 200 shares of Series B redeemable convertible Preferred stock were redeemed for $<span id="xdx_90C_ecustom--RedemptionOfConvertiblePreferredStock_pp0p0_c20220701__20230630_z6aTRSC8h0O1" title="Redemption of convertible Preferred stock">41,000</span>, which included the $<span id="xdx_903_eus-gaap--DividendsPayableCurrentAndNoncurrent_iI_pp0p0_c20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zNJY1nCgquo1" title="Dividends Payable">21,000</span> in accrued dividend payable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended June 30, 2023, and 2022, the Company declared dividends of nil and $<span id="xdx_90D_eus-gaap--DividendsPreferredStock_pp0p0_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zFM8iBr05R8f" title="Dividends, Preferred Stock"><span id="xdx_903_eus-gaap--DividendsPreferredStock_pp0p0_c20210701__20220630__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zzjRkdUZ6kb8" title="Dividends, Preferred Stock">1,000</span></span> respectively. The dividends are classified as a component of operations as the Series B Preferred stock is presented as a liability in these financial statements. There is no liability at June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Common stock:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Holders of common stock are entitled to one vote per share on all matters to be voted on by common stockholders. In the event of liquidation, dissolution or winding up of the Company, the holders of common stock are entitled to share in all assets remaining after liabilities have been paid in full or set aside and the rights of any outstanding preferred stock have been satisfied. Common stock has no preemptive, redemption or conversion rights. The rights of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of any outstanding series of preferred stock or any series of preferred stock the Company may designate in the future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Centerpoint holds <span id="xdx_90C_ecustom--SharesHeldBySubsidiaries_iN_di_c20220701__20230630_zqHBEaBF47t2" title="Shares Held by Subsidiaries">704,309</span> shares of the Company’s common stock. These shares of the Company’s common stock held by Centerpoint are for the benefit of its shareholders without any beneficial interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2023, the Company entered into a subscription agreement to sell <span id="xdx_90F_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zF3eBjP4Wz81" title="Sale of stock, shares">2,000,000</span> shares of restricted and legended common stock of which <span id="xdx_907_eus-gaap--StockRepurchasedDuringPeriodShares_c20230102__20230110__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zBVLZDowKC49" title="Shares purchased, shares">1,800,000</span> shares were purchased on January 10, 2023 and the other <span id="xdx_900_eus-gaap--StockRepurchasedDuringPeriodShares_c20221230__20221231__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zLKn6Stbt1q4" title="Shares purchased, shares">200,000</span> shares were purchased on December 31, 2022 for total proceeds during the year ended June 30, 2023 $<span id="xdx_90B_eus-gaap--StockRepurchasedDuringPeriodValue_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--CommonStockMember_zomqjzb9fhU3" title="Shares purchased, value">2,000,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2023, the Company entered into subscription agreements to sell <span id="xdx_905_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20220701__20230630__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zt5esF95NWxa" title="Sale of stock, shares">975,000</span> units at a price of $<span id="xdx_908_ecustom--SaleOfUnitPricePerUnit_iI_c20230630__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zE4BNmNTadki" title="Sale of units">1.60</span>, with each unit consisting of one share of the Company’s restricted common stock and one half warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_906_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zdaR4OntiaL9" title="Sell units">2.40</span> per share with an expiry date of June 30, 2024, and pursuant thereto, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220701__20230630__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_z5xv5ygHZDS2" title="Number of shares issued">975,000</span> units for total proceeds of $<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220701__20230630__us-gaap--AwardTypeAxis__custom--RestrictedCommonStockMember_zKr0LJVDJJMh" title="Number of shares issued, value">1,560,000</span>, in aggregate. The Company paid commissions of $<span id="xdx_90E_eus-gaap--PaymentsForCommissions_pp0p0_c20220701__20230630_zHSBlGbfZSHj" title="Commissions paid">86,400</span> on the sale of units.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended June 30, 2023, <span id="xdx_907_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20220701__20230630_zR0G5OaZV8og" title="Class of Warrant or Right, Exercised During Period">175,114</span> warrants were exercised to purchase <span id="xdx_904_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20220701__20230630_zVZFxAqhNP0l" title="Common Stock Shares Issued upon Exercise of Warrants">175,114</span> shares of the Company’s common stock at $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyBeMstOO6c4" title="Warrants exercisable per share">0.75</span> per share for total proceeds of $<span id="xdx_90F_ecustom--WarrantsExercisedForCommonStock_pp0p0_c20220701__20230630_zJFuds4JNPif" title="Warrant Exercised for Common Stock">131,335</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2023, the Company entered into subscription agreements to sell units for $<span id="xdx_907_eus-gaap--SharePrice_iI_c20230630_zQ1qmwjCU9te" title="Share price">1.00</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90C_eus-gaap--SharePrice_iI_c20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z7lNHIAuvB55" title="Share price">0.75</span> per share with an expiry date of December 31, 2024, and pursuant thereto, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220701__20230630_zRxt5kXI2sbl" title="Number of shares issued">346,230</span> units for total proceeds of $<span id="xdx_907_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zYEn6eoWItf9" title="Sale of common shares">346,230</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended June 30, 2023, the Company issued <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220701__20230630__srt--TitleOfIndividualAxis__custom--ConsultantServiceMember_zNiiKfjXkaT7" title="Shares issued for consultant services">50,000</span> shares of the Company’s common stock to a consultant for services. The shares were issued at $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_c20230630__srt--TitleOfIndividualAxis__custom--ConsultantServiceMember_zrKxn0aNACIe" title="Share price">1.60</span> per share for a total value of $<span id="xdx_90F_ecustom--TotalValueOfConsultantService_c20220701__20230630__srt--TitleOfIndividualAxis__custom--ConsultantServiceMember_zfzkDvIaJvL8" title="Total value of consultant services">80,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the year ended June 30, 2023, the Company issued <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20220701__20230630__srt--TitleOfIndividualAxis__custom--ConsultantServiceOneMember_zvQS4YXZCad8" title="Shares issued for consultant services">32,259</span> shares of the Company’s common stock to a consultant for services. The shares were issued at $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_c20230630__srt--TitleOfIndividualAxis__custom--ConsultantServiceOneMember_zBdHBeCcfdC2" title="Share price">1.55</span> per share for a total value of $<span id="xdx_902_ecustom--TotalValueOfConsultantService_c20220701__20230630__srt--TitleOfIndividualAxis__custom--ConsultantServiceOneMember_zmiau7sZoMPf" title="Total value of consultant services">50,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2023, Smith elected to convert $<span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__srt--TitleOfIndividualAxis__custom--PrincipalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXWiVBv8toZh" title="Debt conversion value">30,000</span> in principal and $<span id="xdx_905_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20230630__srt--TitleOfIndividualAxis__custom--AccruedInterestMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zbcuhwTGDxr1" title="Debt conversion value">20,000</span> in accrued interest from the 2020 Convertible Obligation to <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__custom--AccruedInterestMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuJbvI62Qyk5" title="Debt conversion shares">100,000</span> units at $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230630__us-gaap--LongtermDebtTypeAxis__custom--AccruedInterestMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBU0c0wHBU2c" title="Conversion price per share">.50</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zU7cFilLndji" title="Warrants exercisable per share">0.75</span> per share until December 31, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2023, Smith elected to convert $<span id="xdx_901_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--The2020OneConvertibleObligationsMember__srt--TitleOfIndividualAxis__custom--PrincipalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDaKchWsW5B2" title="Debt conversion value">136,462</span> in principal of his Adjusted 2020 Convertible Obligation into <span id="xdx_90F_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--The2020OneConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaPUoTlRJb3j" title="Debt conversion shares">1,442,514</span> units at $<span id="xdx_906_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_uUSDPShares_c20230630__us-gaap--DebtInstrumentAxis__custom--The2020OneConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zDh4zELwvhY2" title="Conversion price per share">0.0946</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--The2020OneConvertibleObligationsMember_zWUAibez1PKe" title="Warrants exercisable per share">0.75</span> per share until March 2026. See above and Note 6 for more detail.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Warrants:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2023, the Company had approximately <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pn3n3_dm_c20230630_zuSFOIwKoFa" title="Warrant outstanding">22.5</span> million warrants outstanding, with exercise prices from $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__srt--RangeAxis__srt--MinimumMember_zstQ8sAJKC" title="Warrants exercise price per share">0.60</span> to $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__srt--RangeAxis__srt--MaximumMember_z57pgEX6c8Eh" title="Warrants exercise price per share">2.40</span> and expiring on various dates through November 9, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted-average exercise price for the outstanding warrants is $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_c20230630__us-gaap--AwardTypeAxis__custom--WarrantsMember_z3dm8Wu4lPea" title="Weighted average exercise price">0.80</span>, and the weighted-average remaining contractual life as of March 31, 2023 is <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220701__20230630__us-gaap--AwardTypeAxis__custom--WarrantsMember_z94WhZ15ygwe" title="Remaining contractual life">1.6</span> years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2023, Smith elected to convert $<span id="xdx_908_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__srt--TitleOfIndividualAxis__custom--PrincipalMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlcDDBLmMfh7" title="Debt conversion value">30,000</span> in principal and $<span id="xdx_902_eus-gaap--DebtConversionConvertedInstrumentAmount1_c20220701__20230630__srt--TitleOfIndividualAxis__custom--AccruedInterestMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember_zBSJyCIwFSl9" title="Debt conversion value">20,000</span> in accrued interest from the 2020 Convertible Obligation to <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhvFc3xX78M7" title="Debt conversion shares">100,000</span> units at $<span id="xdx_907_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230630__us-gaap--LongtermDebtTypeAxis__custom--AccruedInterestMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5XH8HfZMWLa" title="Conversion price per share">.50</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z3qxuXgfUv9c" title="Warrants exercisable per share">0.75</span> per share until three years after the date of conversion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2023, Smith elected to convert $<span id="xdx_904_eus-gaap--ConversionOfStockAmountConverted1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zKgKSuB4APkd" title="Conversion of shares, value">136,462</span>, in aggregate, of his Adjusted 2020 Convertible Obligation into <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20220701__20230630__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zqUq0ZSHOF1" title="Conversion of shares, shares">1,442,514</span> units at $<span id="xdx_909_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230630__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxa2w5minWqh" title="Conversion price per share">0.0946</span> per unit, with each unit consisting of one share of the Company’s restricted common stock and one warrant to purchase one share of the Company’s restricted common stock for $<span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkZOJH4oFoh1" title="Warrants exercisable per share">0.75</span> per share until March 2026. In more detail: a) effective March 8, 2023, Smith converted $<span id="xdx_90C_eus-gaap--ConversionOfStockAmountConverted1_c20230307__20230308__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_z60zPpf9kTq8" title="Conversion of shares, value">70,000</span> of his Adjusted 2020 Convertible Obligation into <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_c20230307__20230308__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zbGsWSc7zYsf" title="Conversion of shares, shares">739,958</span> Units (each Unit consisting one share and one warrant); b) effective March 31, 2023, Smith converted $<span id="xdx_90B_eus-gaap--ConversionOfStockAmountConverted1_c20230330__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zZ9Xy3rwVVDd" title="Conversion of shares, value">29,888</span> of his Adjusted Convertible Obligation into <span id="xdx_90C_eus-gaap--ConversionOfStockSharesConverted1_c20230330__20230331__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zr5pLdW1v0o8" title="Conversion of shares, shares">315,948</span> Units (each Unit consisting one share of common stock and one warrant); and c) effective June 4, 2023, Smith converted $<span id="xdx_900_eus-gaap--ConversionOfStockAmountConverted1_c20230601__20230604__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zYCxJmR5SOYj" title="Conversion of shares, value">36,573</span> of his Adjusted Convertible Obligation into <span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20230601__20230604__us-gaap--DebtInstrumentAxis__custom--The2020ConvertibleObligationsMember__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zBeg7Prl7KOd" title="Conversion of shares, shares">386,608</span> Units (each Unit consisting one share of common stock and one warrant). Smith donated to charitable organizations and/or gifted to family members and others a large portion of these securities (<span id="xdx_90A_eus-gaap--ConversionOfStockSharesIssued1_c20220701__20230630__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--CommonSharesMember_zXamSYQYr5Mj" title="Convertible stock shares issued, common shares">700,000</span> common shares and <span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20220701__20230630__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleObligations2020Member__us-gaap--AwardTypeAxis__custom--WarrantsMember_z7Evv7W3WN2g" title="Convertible stock shares issued, warrants">955,000</span> warrants, in aggregate) while retaining direct ownership of <span id="xdx_904_eus-gaap--SharesIssued_iI_c20230630__us-gaap--AwardTypeAxis__custom--CommonSharesMember__srt--OwnershipAxis__custom--DirectOwnershipMember_znvemzQQpcRh" title="Shares issued, common shares">292,514</span> common shares and <span id="xdx_90F_eus-gaap--SharesIssued_iI_c20230630__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--OwnershipAxis__custom--DirectOwnershipMember_zZWaNDCBY1Gc" title="Shares issued, warrants">116,566</span> warrants and indirect ownership of <span id="xdx_907_eus-gaap--SharesIssued_iI_c20230630__us-gaap--AwardTypeAxis__custom--CommonSharesMember__srt--OwnershipAxis__custom--IndirectOwnershipMember_zGLaKBDLw7O2" title="Shares issued, common shares">450,000</span> common shares and <span id="xdx_90B_eus-gaap--SharesIssued_iI_c20230630__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--OwnershipAxis__custom--IndirectOwnershipMember_zsObgy6fOfO4" title="Shares issued, warrants">370,948</span> warrants (owned by his wife). The warrants are exercisable for three years from conversion dates. Subsequent to June 30, 2023, Smith converted additional portions of his Adjusted Convertible Obligation. See Note 12.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the twelve months ended June 30, 2023, the Company approved the issuance of <span id="xdx_90A_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20220701__20230630__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z7LY04yyTNBi" title="Class of Warrant or Right, Exercised During Period (in shares)">210,000</span> warrants, in aggregate, to three new members of its Advisory Group for advisory and/or consulting services of $<span id="xdx_90F_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zr5jrmmyqpmb" title="Issuance of warrants">21,000</span>, in aggregate. The warrants are exercisable at $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_ze6JEC3KT708" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">1.50</span> to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__srt--TitleOfIndividualAxis__custom--ThreeConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zaPU38vY7i0a" title="Class of Warrant or Right, Exercise Price of Warrants or Rights">1.60</span> and expire in August 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">During the twelve months ended June 30, 2023, the Company approved the modification of existing warrants held by one former consultant and investors, which extended certain expiration dates. The modifications resulted in incremental non-cash compensation of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_pp0p0_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zk86H16BXtp9" title="Share-based Payment Arrangement, Plan Modification, Incremental Cost">154,932</span> and interest expenses of $<span id="xdx_90D_ecustom--InterestExpenses_pp0p0_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCdAdFZ8v22k" title="Interest expenses">72,589</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">During the twelve months ended June 30, 2023, <span id="xdx_900_ecustom--ClassOfWarrantOrRightExercisedDuringPeriod_c20220701__20230630_zOCBGqPaAbc3" title="Class of Warrant or Right, Exercised During Period">175,114</span> warrants were exercised to purchase <span id="xdx_90F_ecustom--CommonStockSharesIssuedUponExerciseOfWarrants_c20220701__20230630_z2vcTDIZL0v6" title="Common Stock Shares Issued upon Exercise of Warrants">175,114</span> shares of the Company’s common stock at $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdfei2pLBJXi" title="Warrants exercisable per share">0.75</span> per share for total proceeds of $<span id="xdx_901_ecustom--WarrantsExercisedForCommonStock_pp0p0_c20220701__20230630_zSV774OuyPy1" title="Warrant Exercised for Common Stock">131,335</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective May 1, 2022, an entity affiliated with William O’Neill (“O’Neill”) was issued <span id="xdx_900_eus-gaap--SharesIssued_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zWyax8pYpKx9" title="Number of shares issued">1,000,000</span> Incentive Warrants exercisable at $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Warrants exercisable per share">1.00</span> per share until April 30, 2026 of which up to <span id="xdx_90C_ecustom--CancellationOfWarrants_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Cancellation of warrants">700,000</span> Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. These warrants each have a <span id="xdx_904_ecustom--ExerciseBonus_iI_dp_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z3Q7RMofj6U9" title="Exercise bonus">75</span>% exercise price adjustment provision if the terms set forth therein are met. <span id="xdx_90C_eus-gaap--SharesIssued_iI_c20230630__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zzkkxveg8ym6" title="Number of shares issued">700,000</span> of the warrants are vesting through <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20220701__20230630__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zBgknhvc2a78" title="Vesting period">May 1, 2023</span> and 2024. The vesting resulted in non-cash compensation of $<span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_c20220701__20230630__srt--TitleOfIndividualAxis__custom--ConsultantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0v2nUnfQIV7" title="Non cash compensation">41,653</span> during the year ended June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Stock options: </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 7, 2022 the Company’s shareholders approved the Bion Environmental Technologies, Inc. 2021 Equity Incentive Award Plan (the “<span style="text-decoration: underline">Equity Plan</span>”). The Equity Plan provides for the issuance of options (and/or other securities) to purchase up to <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--PlanNameAxis__custom--EquityIncentivePlanMember_zK2gZOcJwERf" title="Stock options, authorized (in shares)">30,000,000</span> shares of the Company’s common stock. The Equity Plan was adopted and ratified by Board of Directors on April 8, 2022. Terms of exercise and expiration of options/securities granted under the Equity Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. No grants have been made pursuant to the Equity Plan as of the date of this report.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s 2006 Consolidated Incentive Plan, as amended during the year ended June 30, 2021 (the “2006 Plan”), provides for the issuance of options (and/or other securities) to purchase up to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20230331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1gyBaFedaGc" title="Stock options, authorized (in shares)">36,000,000</span> shares of the Company’s common stock. Terms of exercise and expiration of options/securities granted under the 2006 Plan may be established at the discretion of the Board of Directors, but no option may be exercisable for more than ten years. The 2006 Plan will be maintained to service grants already made thereunder (together with new grants, if any, to employees and consultants who already has received grants pursuant to its terms,</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 15, 2023, the Company granted <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230314__20230315__us-gaap--PlanNameAxis__custom--Plan2006Member_zC9rN5YslPFf" title="Number of shares granted">30,000</span> options under the 2006 Plan to two consultants. The options vest equally in thirds on March 20, 2023, June 20, 2023 and September 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 7, 2023, the Company granted an aggregate of <span id="xdx_902_ecustom--SharebasedCompensationGranted_c20230206__20230207_zkJ6S28M9b8" title="Share-based Compensation, Granted">275,000</span> options under the 2006 Plan to five employees/consultants/directors including: i) <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230206__20230207__srt--CounterpartyNameAxis__custom--NorthropMember_zsq0X7Rs9q0c" title="Share-based Compensation, Granted">25,000</span> options to Jon Northrop for service as director, ii) <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230206__20230207__srt--CounterpartyNameAxis__custom--BassaniMember_zXG1sNQFRCqi" title="Share-based Compensation, Granted">100,000</span> to two consultants and iii) <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230206__20230207__srt--CounterpartyNameAxis__custom--SmithMember_zsDJqfQ0B8Q6" title="Share-based Compensation, Granted">150,000</span> to employees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 9, 2023, the Company granted <span id="xdx_90D_ecustom--SharebasedCompensationGranted_c20230508__20230509_zJK2vvjhhfP3" title="Share-based Compensation, Granted">500,000</span> options under the 2006 Plan to Bill O’Neill. <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230508__20230509__srt--CounterpartyNameAxis__custom--BillONeillMember_zycAPeA5zNse" title="Share-based Compensation, Granted">250,000</span> of these options vest on June 1, 2024 and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20230508__20230509_z91p8ULuFcL7" title="Share-based Compensation, Granted">250,000</span> options vest on June 1, 2025; all options expire on June 30, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded compensation expense related to employee stock options of $<span id="xdx_900_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0p0_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5x4a2i3SqS9" title="Share-based Payment Arrangement, Expense">249,744</span> and $<span id="xdx_90F_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_pp0p0_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrYfqMhikwpj" title="Share-based Payment Arrangement, Expense">419,370</span> for the years ended June 30, 2023 and 2022, respectively. The Company granted <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220701__20230630__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zmDON83Cq7i8" title="Share-based Compensation, Granted">805,000</span> and <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210701__20220630__us-gaap--FinancialInstrumentAxis__us-gaap--OptionMember_zxKv1QKgXxx8" title="Share-based Compensation, Granted">730,000</span> options for the year ended June 30, 2023 and 2022, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of the options granted during the years ended June 30, 2023 and 2022 were estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zD3yj3nTrpI4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Assumptions (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: left"><span id="xdx_8B7_zERah8VkWGB2" style="display: none">Schedule of assumptions</span></td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: center"> </td><td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: center"> </td><td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: center"> </td><td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: center"> </td><td style="font-size: 11pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: center"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted <br/> Average, <br/> June 30, <br/> 2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Range, <br/> June 30, <br/> 2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted <br/> Average, <br/> June 30, <br/> 2022</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Range, <br/> June 30, <br/> 2022</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Volatility</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zXfDNGCr0EA6" title="Volatility">65</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zSOClOB1c41l" title="Volatility">64</span>% -<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_z4YRE4HEBv1d" title="Volatility">66</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zRI0VAjQZY9c" title="Volatility">65</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zQwBjTqUZ7E" title="Volatility">65</span>%-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zxii9ZYasw79" title="Volatility">69</span></span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zGl2UifmfhHa" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1274">—</span></span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zevqL69x3P2f" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1276">—</span></span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zCsKiWB3wWE1" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1278">—</span></span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlACz3XXW403" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1280">—</span></span>  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zHZWoWlez0we" title="Risk-free interest rate">3.83</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHgoeuM6d3C9" title="Risk-free interest rate">3.67</span>% – <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zYD3gVyj5Ajg" title="Risk-free interest rate">4.11</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zZxKMEUmiFZh" title="Risk-free interest rate">2.99</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zA4RabasMNO2" title="Risk-free interest rate">1.71</span>%-<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zONxwnsMGzy5" title="Risk-free interest rate">3.01</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_z8AqXmK1xgwe" title="Expected term (years)">3.44</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zx6GyWQr9Cf3" title="Expected term (years)">2.84</span> to <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zQ6FNeHOi7x9" title="Expected term (years)">3.95</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zAS2K1q1W718" title="Expected term (years)">3.71</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zjbO4LIuqnW7" title="Expected term (years)">3.04</span> to <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zpvu4Ti5etRa" title="Expected term (years)">3.72</span></span></td><td style="text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The expected volatility was based on the historical price volatility of the Company’s common stock. The dividend yield represents the Company’s anticipated cash dividend on common stock over the expected term of the stock options. The U.S. Treasury bill rate for the expected term of the stock options was utilized to determine the risk-free interest rate. The expected term of stock options represents the period of time the stock options granted are expected to be outstanding based upon management’s estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt">A summary of option activity under the 2006 Plan for year ended June 30, 2023 is as follows:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></p> <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_za1bgnotfg0l" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details)"> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span id="xdx_8B3_zL8e5hinAcN1" style="display: none">Schedule of option activity</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right" title="Granted, options (in shares)"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right" title="Granted, weighted-average exercise price"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td colspan="2" style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Options</b></span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Weighted- <br/> Average <br/> Exercise <br/> Price</b></span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life</b></span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Aggregate <br/> Intrinsic <br/> Value</b></span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 1%"> </td> <td style="vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at July 1, 2022</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220701__20230630_zG65Ukf85oV2" style="vertical-align: bottom; width: 14%; text-align: right" title="Options outstanding, beginning (in shares)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,201,600</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220701__20230630_zUhhXfHK38Q3" style="vertical-align: bottom; width: 14%; text-align: right" title="Options outstanding, beginning weighted-average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.80</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630_zShEaHtjB9ce" title="Outstanding, weighted-average remaining contractual life (Year)">2.7</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220701__20230630_zwX63nGgvH44" style="vertical-align: bottom; width: 14%; text-align: right" title="Outstanding, aggregate intrinsic value beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,429,263</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Granted</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630_z6a2BtkXlo3h" style="vertical-align: bottom; text-align: right" title="Granted, options (in shares)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">805,000</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230630_zwymSOAsejGb" style="vertical-align: bottom; text-align: right" title="Granted, weighted-average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1318">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Exercised</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220701__20230630_zKhKbUacPeY8" style="vertical-align: bottom; text-align: right" title="Exercised, options (in shares)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1320">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220701__20230630_z33XRiSdpHV2" style="vertical-align: bottom; text-align: right" title="Exercised, weighted-average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1322">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Forfeited</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220701__20230630_zqYaYhYXWYMa" style="vertical-align: bottom; text-align: right" title="Forfeited, options (in shares)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1324">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220701__20230630_zM27hcvxFUYg" style="vertical-align: bottom; text-align: right" title="Forfeited, weighted-average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1326">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Expired</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220701__20230630_za2xo697X08h" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Expired, options (in shares)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1328">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230630_zYJEOAQaabC8" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Expired, weighted-average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1330">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at June 30, 2023</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220701__20230630_z3UOznuJezs1" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Options outstanding, ending (in shares)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,006,600</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220701__20230630_zq8i2qcfgWP1" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Options outstanding, ending weighted-average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.85</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630_zflG0ykYaVld" title="Outstanding, weighted-average remaining contractual life (Year)">1.83</span></span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220701__20230630_zxCRJFiaSzN3" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Outstanding, aggregate intrinsic value ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,085,659</span></td> <td style="vertical-align: bottom"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total fair value of stock options that vested during both the year ended June 30, 2023 and 2022 was $249,744 and $419,370, respectively. As of June 30, 2023, the Company had no unrecognized compensation cost related to stock options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> 3470000 1109649 1939670 424873 0.0946 953 0.0953 0.115 262154 434016 96364 24230 4012 3522000 14051 200 0.01 2.00 100 41000 21000 1000 1000 -704309 2000000 1800000 200000 2000000 975000 1.60 2.40 975000 1560000 86400 175114 175114 0.75 131335 1.00 0.75 346230 346230 50000 1.60 80000 32259 1.55 50000 30000 20000 100000 0.50 0.75 136462 1442514 0.0946 0.75 22500000 0.60 2.40 0.80 P1Y7M6D 30000 20000 100000 0.50 0.75 136462 1442514 0.0946 0.75 70000 739958 29888 315948 36573 386608 700000 955000 292514 116566 450000 370948 210000 21000 1.50 1.60 154932 72589 175114 175114 0.75 131335 1000000 1.00 700000 0.75 700000 2023-05-01 41653 30000000 36000000 30000 275000 25000 100000 150000 500000 250000 250000 249744 419370 805000 730000 <table cellpadding="0" cellspacing="0" id="xdx_886_eus-gaap--ScheduleOfAssumptionsUsedTableTextBlock_zD3yj3nTrpI4" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Assumptions (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: left"><span id="xdx_8B7_zERah8VkWGB2" style="display: none">Schedule of assumptions</span></td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: center"> </td><td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: center"> </td><td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: center"> </td><td style="font-size: 11pt"> </td><td style="font-size: 11pt"> </td> <td colspan="2" style="font-size: 11pt; text-align: center"> </td><td style="font-size: 11pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: center"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted <br/> Average, <br/> June 30, <br/> 2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Range, <br/> June 30, <br/> 2023</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Weighted <br/> Average, <br/> June 30, <br/> 2022</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><span style="font-size: 8pt"><b>Range, <br/> June 30, <br/> 2022</b></span></td><td style="padding-bottom: 1pt"><span style="font-size: 8pt"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%">Volatility</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zXfDNGCr0EA6" title="Volatility">65</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zSOClOB1c41l" title="Volatility">64</span>% -<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_z4YRE4HEBv1d" title="Volatility">66</span></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zRI0VAjQZY9c" title="Volatility">65</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zQwBjTqUZ7E" title="Volatility">65</span>%-<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zxii9ZYasw79" title="Volatility">69</span></span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zGl2UifmfhHa" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1274">—</span></span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zevqL69x3P2f" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1276">—</span></span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zCsKiWB3wWE1" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1278">—</span></span>  </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zlACz3XXW403" title="Dividend yield"><span style="-sec-ix-hidden: xdx2ixbrl1280">—</span></span>  </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zHZWoWlez0we" title="Risk-free interest rate">3.83</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHgoeuM6d3C9" title="Risk-free interest rate">3.67</span>% – <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zYD3gVyj5Ajg" title="Risk-free interest rate">4.11</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zZxKMEUmiFZh" title="Risk-free interest rate">2.99</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zA4RabasMNO2" title="Risk-free interest rate">1.71</span>%-<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zONxwnsMGzy5" title="Risk-free interest rate">3.01</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_z8AqXmK1xgwe" title="Expected term (years)">3.44</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zx6GyWQr9Cf3" title="Expected term (years)">2.84</span> to <span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zQ6FNeHOi7x9" title="Expected term (years)">3.95</span></span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--WeightedAverageMember_zAS2K1q1W718" title="Expected term (years)">3.71</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zjbO4LIuqnW7" title="Expected term (years)">3.04</span> to <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210701__20220630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zpvu4Ti5etRa" title="Expected term (years)">3.72</span></span></td><td style="text-align: left">%</td></tr> </table> 0.65 0.64 0.66 0.65 0.65 0.69 0.0383 0.0367 0.0411 0.0299 0.0171 0.0301 P3Y5M8D P2Y10M2D P3Y11M12D P3Y8M15D P3Y14D P3Y8M19D <table cellpadding="0" cellspacing="0" id="xdx_888_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_za1bgnotfg0l" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details)"> <tr> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span id="xdx_8B3_zL8e5hinAcN1" style="display: none">Schedule of option activity</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right" title="Granted, options (in shares)"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right" title="Granted, weighted-average exercise price"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr> <td colspan="2" style="vertical-align: top"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Options</b></span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Weighted- <br/> Average <br/> Exercise <br/> Price</b></span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Weighted- <br/> Average <br/> Remaining <br/> Contractual <br/> Life</b></span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td colspan="2" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 8pt"><b>Aggregate <br/> Intrinsic <br/> Value</b></span></td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 1%"> </td> <td style="vertical-align: top; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at July 1, 2022</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220701__20230630_zG65Ukf85oV2" style="vertical-align: bottom; width: 14%; text-align: right" title="Options outstanding, beginning (in shares)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,201,600</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_uUSDPShares_c20220701__20230630_zUhhXfHK38Q3" style="vertical-align: bottom; width: 14%; text-align: right" title="Options outstanding, beginning weighted-average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.80</span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210701__20220630_zShEaHtjB9ce" title="Outstanding, weighted-average remaining contractual life (Year)">2.7</span></span></td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220701__20230630_zwX63nGgvH44" style="vertical-align: bottom; width: 14%; text-align: right" title="Outstanding, aggregate intrinsic value beginning"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,429,263</span></td> <td style="vertical-align: bottom; width: 1%"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Granted</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630_z6a2BtkXlo3h" style="vertical-align: bottom; text-align: right" title="Granted, options (in shares)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">805,000</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230630_zwymSOAsejGb" style="vertical-align: bottom; text-align: right" title="Granted, weighted-average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1318">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Exercised</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220701__20230630_zKhKbUacPeY8" style="vertical-align: bottom; text-align: right" title="Exercised, options (in shares)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1320">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220701__20230630_z33XRiSdpHV2" style="vertical-align: bottom; text-align: right" title="Exercised, weighted-average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1322">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Forfeited</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c20220701__20230630_zqYaYhYXWYMa" style="vertical-align: bottom; text-align: right" title="Forfeited, options (in shares)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1324">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220701__20230630_zM27hcvxFUYg" style="vertical-align: bottom; text-align: right" title="Forfeited, weighted-average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1326">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">  Expired</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20220701__20230630_za2xo697X08h" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Expired, options (in shares)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1328">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230630_zYJEOAQaabC8" style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right" title="Expired, weighted-average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1330">—</span>  </span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top"> </td> <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at June 30, 2023</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20220701__20230630_z3UOznuJezs1" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Options outstanding, ending (in shares)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,006,600</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_uUSDPShares_c20220701__20230630_zq8i2qcfgWP1" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Options outstanding, ending weighted-average exercise price"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.85</span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630_zflG0ykYaVld" title="Outstanding, weighted-average remaining contractual life (Year)">1.83</span></span></td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="border-bottom: black 2.25pt double; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220701__20230630_zxCRJFiaSzN3" style="border-bottom: black 2.25pt double; vertical-align: bottom; text-align: right" title="Outstanding, aggregate intrinsic value ending"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,085,659</span></td> <td style="vertical-align: bottom"> </td></tr> </table> 11201600 0.80 P2Y8M12D 4429263 805000 12006600 0.85 P1Y9M29D 5085659 <p id="xdx_808_ecustom--SubscriptionReceivableTextBlock_zZrVLc51sWLi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>8.       <span id="xdx_823_z1ttuoVOqaW4">SUBSCRIPTION RECEIVABLE - AFFILIATES</span>:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2023, the Company has three interest bearing, secured promissory notes with an aggregate principal amount of $<span id="xdx_90F_eus-gaap--NotesReceivableNet_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zvNw5PBNyqai" title="Financing Receivable, after Allowance for Credit Loss, Total">428,250</span> ($<span id="xdx_900_ecustom--NotesReceivableInterest_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zG8s7czNiUki" title="Notes receivable interest">517,553</span>, including interest) from Bassani which were received as consideration for purchases of warrants to purchase <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_zor7WqCIBQT" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">5,565,000</span> shares, in aggregate, of the Company’s restricted common stock, which warrants have an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230630__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_z1DGKjIwKzvj" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> (with a 75% exercise price adjustment provision) and have expiry dates ranging from December 31, 2024 to December 31, 2025 (subject to extension rights) secured by portions of Bassani Family Trust’s 2020 Convertible Obligation and Bassani Family Trust’s September 2015 Convertible Notes. The secured promissory notes are payable July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> As of June 30, 2023, the Company has an interest bearing, secured promissory note for $<span id="xdx_903_ecustom--FinancingReceivablePrincipalAmount_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zopNCC7nhNMk" title="Financing Receivable, Principal Amount">30,000</span> ($<span id="xdx_903_eus-gaap--NotesReceivableNet_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_z7nhtgScNsJh" title="Financing Receivable, after Allowance for Credit Loss, Total">35,884</span> including interest) from Smith as consideration to purchase warrants to purchase <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20220630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_zpppJjLPuCF8" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">300,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20230630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_zy6Cd9cWYMfg" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.60</span>(with a 75% exercise price adjustment provision) and have expiry dates of December 31, 2024 (subject to extension rights) The promissory note bears interest at <span id="xdx_90C_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20230630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zj435WKwiJN2" title="Financing receivable interest rate stated percentage">4</span>% per annum, and is secured by $<span id="xdx_905_ecustom--FinancingReceivablePrincipalAmount_iI_c20230630__srt--CounterpartyNameAxis__custom--SmithsMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_z1jClLJZpucg" title="Financing Receivable, Principal Amount">30,000</span> ($<span id="xdx_90D_eus-gaap--NotesReceivableNet_iI_c20230630__srt--CounterpartyNameAxis__custom--SmithsMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zdr7cuh53tR4" title="Financing Receivable, after Allowance for Credit Loss, Total">35,885</span> including interest) of Smith’s 2020 Convertible Obligations. The secured promissory note is payable on July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of June 30, 2023 the Company has two interest bearing, secured promissory notes with an aggregate principal amount of $<span id="xdx_902_ecustom--FinancingReceivablePrincipalAmount_pp0p0_c20230630__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zWIeL3SJDD8c" title="Financing Receivable, Principal Amount">46,400</span> ($<span id="xdx_90E_eus-gaap--NotesReceivableNet_pp0p0_c20230630__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zeMDI4MDPBY4" title="Financing Receivable, after Allowance for Credit Loss, Total">56,860</span> including interest) from two employee/consultants as consideration to acquire warrants to purchase <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_c20230630__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_z1MNaN8sVuqd" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">928,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_z1v1FQt7a1V1" title="Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)">0.75</span> (with a 90% exercise price adjustment provision) and have expiry dates of December 31, 2024. (The promissory notes bear interest at <span id="xdx_908_ecustom--FinancingReceivableInterestRateStatedPercentage_iI_dp_c20230630__srt--TitleOfIndividualAxis__custom--FormerEmployeeMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteMember_zgwDdEHPrCW7" title="Financing Receivable, Interest Rate, Stated Percentage">4</span>% per annum, are secured by a perfected security interest in the warrants, and are payable on July 1, 2024.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">These secured promissory notes are recorded as “Subscription receivable—affiliates” on the Company’s balance sheet pending payment.</p> 428250 517553 5565000 0.75 30000 35884 300000 0.60 0.04 30000 35885 46400 56860 928000 0.75 0.04 <p id="xdx_804_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_z2bp9EmJ9T2l" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>9.       <span id="xdx_827_zll8F6obwyoi">COMMITMENTS AND CONTINGENCIES:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Employment and consulting agreements:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Smith has held the positions of Director, Executive Chairman, President and General Counsel of Company and its subsidiaries under various agreements (and extensions) and terms since March 2003. On October 10, 2016, the Company approved a month-to-month contract extension with Smith which included provisions for i) a monthly salary of $<span id="xdx_90B_ecustom--MonthlyOfficersCashCompensation_c20161001__20161010__srt--TitleOfIndividualAxis__srt--PresidentMember_zEt65A1BnPqg" title="Monthly officers cash compensation">18,000</span> ( deferred until the Board of Directors re-instated cash payments to all employees and consultants who are deferring compensation), ii) the right to convert up to $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20230630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssusedSubscriptionReceivableMember_zQLLpwdyoCad" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">300,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20230630__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember_z9AUyEXMNKl" title="Warrants exercisable per share">0.75</span> per share, until December 31, 2024, and iii) the right to convert his deferred compensation in whole or in part, at his sole election, at any time in any amount at “market” or into securities sold in the Company’s current/most recent private offering at the price of such offering to third parties. Smith agreed effective July 29, 2018 to continue to serve the Company under the same basic terms on a month-to-month basis. On May 1, 2022 Smith’s compensation was increased to $<span id="xdx_901_ecustom--CompensationIncreased_c20220427__20220502_z4PhQUGFSKU3" title="Compensation increased">25,000</span> per month of which $5,000 per month is deferred. Currently Smith is deferring all but $<span id="xdx_90F_ecustom--CompensationConserveCash_pp0p0_c20220701__20230630__srt--CounterpartyNameAxis__custom--SmithMember_zXuLRGCkQere" title="Compensation conserve cash">5000</span> of his monthly compensation to help the Company conserve cash. For the years ended June 30, 2023 and 2022, Smith was paid $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20230630__srt--CounterpartyNameAxis__custom--SmithMember_zTvzM48J8E83" title="Cash compensation paid">200,000</span> and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_pp0p0_c20210701__20220630__srt--CounterpartyNameAxis__custom--SmithMember_zyHTk71ST948" title="Cash compensation paid">130,000</span>, respectively, of cash compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since March 31, 2005, the Company has had various agreements with Bassani (and/or Brightcap which provided his services during some of the years), now the Company’s Chief Operating Officer (‘COO’) and formerly the Company’s Chief Executive Officer (‘CEO’)(any reference to Brightcap or Bassani for all purposes are referring to the same individual). The Board appointed Bassani as the Company's CEO effective May 13, 2011. On February 10, 2015, the Company executed an Extension Agreement with Bassani pursuant to which Bassani extended the term of his service to the Company to December 31, 2017 (with the Company having an option to extend the term an additional six months.) Pursuant to the Extension Agreement, Bassani continued to defer his cash compensation ($<span id="xdx_901_ecustom--MonthlyOfficersCashCompensation_pp0p0_c20150203__20150210__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zDQW26TLkQZg" title="Monthly officers cash compensation">31,000</span> per month) until the Board of Directors re-instated cash payments to all employees and consultants who were deferring their compensation. During October 2016 Bassani was granted the right to convert up to $<span id="xdx_90F_ecustom--DeferredCompensationMaximumConvertibleAmount_iI_pp0p0_c20161031__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_zkftiL7ZDi4b" title="Deferred Compensation, Maximum Convertible Amount">125,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_908_ecustom--DeferredCompensationStockConversionPricePerShare_iI_c20161031__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_zZ1T3hMMNJqk" title="Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)">0.75</span> per share, until March 15, 2018 (which was expanded on April 27, 2017 to the right to convert up to $<span id="xdx_90B_ecustom--DeferredCompensationMaximumConvertibleAmount_iI_pp0p0_c20170427__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_z8XtMDNiSHdd" title="Deferred Compensation, Maximum Convertible Amount">300,000</span> of his deferred compensation, at his sole election, at $<span id="xdx_902_ecustom--DeferredCompensationStockConversionPricePerShare_iI_c20170427__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_zxXAjWkc4uUd" title="Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)"><span id="xdx_90C_ecustom--DeferredCompensationStockConversionPricePerShare_iI_c20170427__srt--TitleOfIndividualAxis__srt--PresidentMember__us-gaap--AwardTypeAxis__custom--ExtensionBonusMember__us-gaap--PlanNameAxis__custom--Fy2016ExtensionAgreementMember_zSqveJGmiZbh" title="Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)">0.75</span></span> per share, until June 30, 2024 (including extensions). During February 2018, the Company agreed to the material terms for a binding two-year extension agreement for Bassani’s services as CEO. Bassani’s salary remained $<span id="xdx_90C_eus-gaap--AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent_c20180228__srt--TitleOfIndividualAxis__custom--BassaniMember_pp0p0" title="Salaries and wages">31,000</span> per month, which will continue to be accrued in part during periods when the Board determines there is not adequate cash available. Additionally, the Company agreed to pay or accrue $<span id="xdx_90D_eus-gaap--OtherAdditionalCapital_c20180228__srt--TitleOfIndividualAxis__custom--BassaniMember_pp0p0" title="Additional paid amount">2,000</span> per month to be applied to life insurance premiums (which sums have been accrued as liabilities). On August 1, 2018, in the context of extending his agreement to provide services to the Company on a full-time basis through December 31, 2022) plus 2 years after that on a part-time basis, the Company received an interest bearing secured promissory note for $<span id="xdx_904_ecustom--InterestBearingSecuredPromissoryNote_pp0p0_c20180728__20180801__srt--TitleOfIndividualAxis__custom--BassaniMember_zUYSrv94p3Ta" title="Interest bearing secured promissory note">300,000</span> from Bassani as consideration to purchase warrants to purchase <span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20180801__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsExpiringOnDecember312025Member_zz1MsdalhAM6" title="Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)">3,000,000</span> shares of the Company’s restricted common stock, which warrants are exercisable at $0.60 and have expiry dates of June 30, 2025. The promissory note is secured by a portion of Bassani’s 2020 Convertible Obligations and as of June 30, 2023, the principal and accrued interest was $<span id="xdx_906_eus-gaap--NotesReceivableNet_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_zo8mpMvcgwqd" title="Financing Receivable, after Allowance for Credit Loss, Total">361,321</span>. Currently Bassani is deferring all but $<span id="xdx_900_ecustom--CompensationConserveCash_pp0p0_c20220701__20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_zZODAbiUY5j3" title="Repayments of Long-term Debt, Total">5000</span> of his monthly compensation to help the Company conserve cash. For the years ended June 30, 2023 and 2022, Brightcap was paid $<span id="xdx_905_eus-gaap--RepaymentsOfLongTermDebt_pp0p0_c20220701__20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_zpnspJ7pZdyd" title="Repayments of Long-term Debt, Total">300,000</span> and $<span id="xdx_90C_eus-gaap--RepaymentsOfLongTermDebt_pp0p0_c20210701__20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member_z3iCRNIG4i0j" title="Repayments of Long-term Debt, Total">250,000</span>, respectively, of cash compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">William O’Neill (“O’Neill”) was hired as the Company’s Chief Executive Officer (“CEO”) effective May 1, 2022.  O’Neill had previously been working with the Company as a consultant and had been employed by the Company as its CEO during 2010-2011. Bassani, CEO of the Company since 2011, assumed the position of COO while retaining existing operational management responsibilities and working with O’Neill on ‘commercialization’ of the Company’s technology and work related to JVs (and other transactions) based on the Company’s Gen3 Technology and related matters. Bassani’s compensation arrangements with the Company have not been altered in the context of the change of positions. The Company and O’Neill entered into a thirty-seven (37) month employment agreement with compensation of $<span id="xdx_90D_ecustom--MonthlyOfficersCashCompensation_pp0p0_c20220701__20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zj5vBs7IaNzd" title="Monthly Officers Cash Compensation">25,000</span> cash and $<span id="xdx_903_ecustom--DeferredCompensationMaximumConvertibleAmount_iI_pp0p0_c20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z0NukN8Zdupk" title="Deferred Compensation, Maximum Convertible Amount">10,000</span> deferred compensation per month. The cash payment is paid $<span id="xdx_904_eus-gaap--PaymentsForFees_c20220701__20230630__srt--CounterpartyNameAxis__custom--WilliamONeillMember_zaUxZ2wuFYK" title="Payment for cash">12,500</span> to O’Neill and $12,500 to an entity affiliated with O’Neill. An entity affiliated with O’Neill was issued 1,000,000 Incentive Warrants exercisable at $1.00 per share ( a <span id="xdx_90F_ecustom--ExercisePriceAdjustmentProvisionInPercentage_dp_c20220701__20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zQXPNqRSdNx6" title="Exercise price adjustment provision Percentage">75</span>% exercise price adjustment provision if the terms set forth therein are met) until April 30, 2026 of which up to 700,000 Incentive Warrants may be cancelled if O’Neill is not renewed at 13 months and/or fails to serve the entire contract term thereafter. Currently O’Neill is deferring all but $<span id="xdx_903_ecustom--CompensationConserveCash_pp0p0_c20220701__20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zHbxYIAqcfRi" title="Cash compensation paid">5000</span> of his monthly compensation to help the Company conserve cash. For the years ended June 30, 2023 and 2022, O’Neill and the entity affiliated with O’Neill was paid $<span id="xdx_90A_eus-gaap--ShareBasedCompensation_pp0p0_c20220701__20230630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zuosjdBbtyQ4" title="Cash compensation paid">150,000</span> and $<span id="xdx_907_eus-gaap--ShareBasedCompensation_pp0p0_c20210701__20220630__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zn8Ze4Lk9Ege" title="Cash compensation paid">25,000</span>, respectively, of cash compensation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Exercise Price Adjustments/Extension Rights:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of agreements the Company entered into with Bassani and Smith effective May 15, 2013, they were each granted the following: a) a 50% execution/exercise price adjustment provision (exercise bonus in the context of options) which shall be applied upon the effective date of the notice of intent to exercise (for options and warrants) or issuance event, as applicable, of any currently outstanding and/or subsequently acquired options, warrants and/or contingent stock bonuses owned by each (and/or their donees) as follows: i) in the case of exercise by payment of cash, the bonus shall take the form of reduction of the exercise price; ii) in the case of cashless exercise, the adjustment shall be applied to reduce the exercise price prior to the cashless exercise calculations; and iii) with regard to contingent stock adjustments, issuance shall be triggered upon the Company’s common stock reaching a closing price equal to 50% of currently specified price; and b) the right to extend the exercise period of all or part of the applicable options and warrants for up to five years (one year at a time) by annual payments of $.05 per option or warrant to the Company on or before a date during the three months prior to expiration of the exercise period at least three business days before the end of the expiration period. Effective January 1, 2016 such annual payments to extend warrant exercise periods were reduced to $.01 per option or warrant. These exercise adjustments were subsequently increased to 75%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2021, the Company added a <span id="xdx_909_ecustom--ExerciseBonus_iI_dp_c20210630_zMzkQEHNhHL" title="Exercise bonus">75</span>% exercise price adjustment to the terms of <span id="xdx_906_ecustom--WarrantsHeldByTrustOwned_pp0p0_c20200701__20210630_ztCG52ks2oW9" title="Warrants held by trust owned">3,000,000</span> warrants held by a trust owned by Bassani.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2023, exercise price adjustment provisions ranging from <span id="xdx_90B_ecustom--ExerciseBonus_iI_dp_c20230630__srt--RangeAxis__srt--MinimumMember_zzzxtODmXuD3" title="Exercise bonus">50</span>-<span id="xdx_901_ecustom--ExerciseBonus_iI_dp_c20230630__srt--RangeAxis__srt--MaximumMember_zkBngRTF2aHe" title="Exercise bonus">90</span>% were applicable to 11,771,600 of the Company’s outstanding options and <span id="xdx_90F_ecustom--WarrantsAndRightsOutstandings_iI_pp0p0_c20230630_zX5oJzTYkrha" title="Warrants and Rights Outstanding">18,438,339</span> of the Company’s outstanding warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Effective May 1, 2022, an entity affiliated with O’Neill was issued <span id="xdx_906_eus-gaap--SharesIssued_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_znhDNYjHHNmb" title="Number of shares issued">1,000,000</span> Incentive Warrants exercisable at $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z5Nv2ms4IKZj" title="Warrants exercisable per share">1.00</span> per share until April 30, 2026 of which up to <span id="xdx_904_ecustom--CancellationOfWarrants_iI_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zWr2qIk1mzD5" title="Cancellation of warrants">700,000</span> Incentive Warrants were cancellable if O’Neill was not renewed at 13 months (renewal has happened) and/or fails to serve the entire contract term thereafter. These warrants each have a <span id="xdx_905_ecustom--ExerciseBonus_iI_dp_c20220501__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_z19lIeV38jOd" title="Exercise bonus">75</span>% exercise price adjustments if the terms set forth therein are met.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Initial Project:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 28, 2022 Bion Environmental Technologies, Inc. (‘Bion’), on behalf of Bion 3G1 LLC (‘3G1’), a wholly-owned subsidiary, entered into a Purchase Order Agreement with Buflovak and Hebeler Process Solutions (collectively ‘Buflovak’) in the amount of $<span id="xdx_903_eus-gaap--DebtConversionConvertedInstrumentAmount1_pp0p0_c20220127__20220128_zQQPvDu39Xef" title="Debt instrument paid amount">2,665,500</span> (and made the initial <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220127__20220128_zWNDLxL07a06" title="Debt Instrument, Interest Rate During Period">25</span>% payment ($<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20220127__20220128_zVM3axvzpBtk" title="Principal, interest">666,375</span>) for the core of the ‘Bion System’ portion (without the crystallization  modules which will be ordered and fabricated pursuant to subsequent agreements) of the previously announced 3G Tech Initial Project. This Purchase Order encompasses the core of Bion’s 3G Technology. The Company received progress billing in March 2022 and June 2022 for the second and third <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210701__20220630_zLx7qn79Shde" title="Debt Instrument, Interest Rate During Period">25</span>% installments, both of which have been paid as of the filing date. On January 17, 2023 the Company received an invoice from Buflovak for $<span id="xdx_901_eus-gaap--DebtInstrumentPeriodicPayment_pp0p0_c20230116__20230117_zsJyEsxr4xWe" title="Principal, interest">533,100</span> which was paid on March 1, 2023 and on April 24, 2023 the Company received an invoice from Buflovak for $<span id="xdx_901_eus-gaap--PrepaidExpenseAndOtherAssets_iI_c20230502_zRK4lDFLdsyh" title="Paid invoice amount">83,275</span> which was paid on May 2, 2023 bringing the aggregate payments to $<span id="xdx_90A_ecustom--AggregatePayment_pp0p0_c20230427__20230502_zs3mKngPJaq1" title="Aggregate payment">2,615,500</span> as of the date of this filing. There remains $<span id="xdx_906_ecustom--PurchaseOrder_c20220429__20220430_zsa0ZH6cmpYd" title="Purchase order">50,000</span> open on the Purchase Order has been billed on July 26, 2023. In addition to the Purchase Order, through June 30, 2023 the Company has incurred additional costs of $<span id="xdx_908_eus-gaap--InterestCostsIncurredCapitalized_c20220701__20230630_zUDFh0XwhvC2" title="Capitalized labor and interest costs">4,182,260</span> on the Initial Project for capitalized interest and costs, non-cash compensation and consulting fees. $<span id="xdx_906_ecustom--InterestCostsCapitalizedPaid_c20220701__20230630_zSP0qg7IL6c9" title="Capitalized labor and interest costs paid">3,962,207</span> has been paid and $<span id="xdx_90A_eus-gaap--InterestCostsCapitalizedAdjustment_c20220701__20230630_z97rNNcIvi8" title="Capitalized labor and interest costs yet to pay">220,053</span> has been billed and not yet paid. See Note 12 <b>“Subsequent Events” </b>for expenditure after June 30, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Buflovak has worked with the Company on design and testing of its 3G Tech over several years. The basic design for the Initial Project’s Bion System is complete, fabrication and delivery of equipment from Bufflovak from the Purchase Order Agreement has been largely completed and assembly/construction is in process.  3G1 is working in concert with Integrated Engineering Services, the primary site engineering firm for the facility, on the integration of all project components/modules at the Initial Project site. Additional agreements have been entered into various professional services providers (engineers, surveyors, utilities, etc.) for work related to the Initial Project. The Company has incurred costs of $<span id="xdx_903_ecustom--InterestsCostsIncurredCapitalized_c20220701__20230630_zW60Qr3G3mKd" title="Capitalized labor and interest costs">6,103,693</span> on the Initial Project, not including capitalized labor and interest.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Litigation:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">A: Website: Domain Sale/Resolved Litigation/Hacking/Theft</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> On March 23, 2022 <span id="xdx_90A_ecustom--SaleOfDomainDescription_c20220322__20220323_zjXzJNks0sM9" title="Sale of domain, description">the Company entered into an agreement to sell domain name &lt;biontech.com&gt; and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490.</span> The Company has been using www.bionenviro.com as its primary website (and domain) since July 2021 due to the events described below. The Company has not been using biontech.com as its primary website since July 2021 so domain name &lt;biontech.com&gt; no longer represented a core asset of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As previously reported, on Saturday morning, July 17, 2021, our historical website domain – biontech.com – and email services were compromised and disabled. Research indicated that an unknown party had ‘hijacked’ the domain in a theft attempt. On September 10, 2021, the Company filed a federal lawsuit ‘in rem’ to recover the &lt;biontech.com&gt; domain and the unknown ‘John Doe’ who hacked and attempted to steal the website. The litigation was filed in the United States District Court for the Eastern District of Virginia, Alexandria Division under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and &lt;biontech.com&gt;, Defendants’ (Case No. 1:21-cv-01034), seeking recovery of the domain name and other relief as set forth therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 19, 2021, the United States District Court for the Eastern District of Virginia, Alexandria Division issued an order stating that “… ORDERED, ADJUDGED and Decreed that plaintiff Bion Environmental Technologies, Inc. (‘plaintiff) Is the lawful owner of domain name &lt;biontech.com&gt; ….” under the heading ‘Bion Environmental Technologies, Inc., Plaintiff, vs John Doe and &lt;biontech.com&gt;, Defendants’ (Case No. 1:21-cv-01034). The Company has moved the domain name &lt;biontech.com&gt; to a new registrar and reactivated it for the Company’s use (paired currently with its current bionenviro.com website).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">No shareholder, sensitive or confidential information was available to be breached which has limited damages from the hack/theft to date. However, the Company’s email operations were subjected to disruption and expenses were incurred related to the matter including legal fees.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company created ‘work-arounds’ as a result. These issues have been resolved and the Company has moved our website (and email) to a new domain: bionenviro.com. Website access is now www.bionenviro.com. To send emails to Bion personnel, one uses the same name identifier previously used, but in the address, substitute ‘bionenviro.com’ for “biontech.com’: For example cscott@biontech.com (no longer functional) is cscott@bionenviro.com and mas@biontech.com (no longer functional) is now mas@bionenviro.com.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><span style="text-decoration: underline">B: Pennvest Loan and Dissolution of Bion PA1, LLC (“PA1”)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1, the Company’s wholly-owned subsidiary, was dissolved on December 29, 2021 on which date it owed approximately $10,010,000 under the terms of the Pennvest Loan related to the construction of the Kreider 1 System including accrued interest and late charges totaling $<span id="xdx_904_eus-gaap--AccruedLiabilitiesCurrentAndNoncurrent_iI_pp0p0_c20211229_zp2xhiSGbbHe" title="Accrued interest">2,255,802</span> as of that date. Through the date of the dissolution, PA1 was a wholly-owned subsidiary of the Company and its assets and liabilities were included on the Company’s consolidated balance sheet. At September 30, 2021, PA1’s total assets were $<span id="xdx_90C_eus-gaap--Assets_iI_pp0p0_c20210930_ztVMeUQrQDSc" title="Total assets">297</span> and its total liabilities were $<span id="xdx_900_eus-gaap--Liabilities_iI_pp0p0_c20210930_zKzZwhDTL8Fl" title="Total liabilities">10,154,334</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_90B_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zCKioLNSiDm5" title="Accounts payable and accrued liabilities">9,939,148</span>, accounts payable of $<span id="xdx_906_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20210930_z5LowVsfDSR7" title="Accounts payable">214,235</span> and accrued liabilities of $<span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20210930_zhtPalniYEpj" title="Accrued Liabilities, Current">950</span>) which sums were included in the Company’s consolidated balance sheet in its Form 10-Q for the quarter ended September 30, 2021. Subsequent to the dissolution of PA1, its assets and liabilities are no longer consolidated and included in the Company’s consolidated balance sheet. As of December 29, 2021, PA1’s total assets were nil and its total liabilities were $<span id="xdx_90B_eus-gaap--Liabilities_iI_pp0p0_c20211229_zDYI224d3WVf" title="Total liabilities">10,234,501</span> (including the Pennvest Loan in the aggregate amount of $<span id="xdx_908_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_pp0p0_c20211229_zmDpKdxFhpij" title="Accounts payable and accrued liabilities">10,009,802</span>, accounts payable of $<span id="xdx_90D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_c20211229_zb293yW8v8Oa" title="Accounts payable">212,263</span> and accrued liabilities of $<span id="xdx_90F_eus-gaap--AccruedLiabilitiesCurrent_iI_pp0p0_c20211229_zG7Izyivao97" title="Accrued Liabilities, Current">12,436</span>. The net amount of $<span id="xdx_906_eus-gaap--ExtinguishmentOfDebtGainLossNetOfTax_pp0p0_c20220701__20230630_ziFqVeTzYRy6" title="Gain on legal dissolution of subsidiary">10,234,501</span> was recognized as a gain on the legal dissolution of a subsidiary in other (income) expense.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 4pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As background, the terms of the Pennvest Loan provided for funding of up to $<span id="xdx_906_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zIUyUztIOwN4" title="Line of Credit Facility, Maximum Borrowing Capacity">7,754,000</span> which was to be repaid by interest-only payments for three years, followed by an additional ten-year amortization of principal. The Pennvest Loan accrued interest at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220701__20230630__srt--StatementScenarioAxis__custom--YearsOneThroughFiveMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z548AhDLA2Bj" title="Debt Instrument, Interest Rate During Period">2.547</span>% per annum for years 1 through 5 and <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220701__20230630__srt--StatementScenarioAxis__custom--YearsSixThroughMaturityMember__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z07msIWcL8M5" title="Debt Instrument, Interest Rate During Period">3.184</span>% per annum for years 6 through maturity. The Pennvest Loan required minimum annual principal payments of approximately $<span id="xdx_905_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z2A2FzMl3oGf" title="Debt Instrument, Annual Principal Payment">5,886,000</span> in fiscal years 2013 through 2021, and $<span id="xdx_905_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_iI_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z4kOJfSVwBVg" title="Long-Term Debt, Maturity, Year Two">846,000</span> in fiscal year 2022, $<span id="xdx_900_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_iI_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zpoDMjx4qMuf" title="Long-Term Debt, Maturity, Year Three">873,000</span> in fiscal year 2023 and $<span id="xdx_90B_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_iI_pp0p0_c20230630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zjdwwrXlOSq9" title="Long-Term Debt, Maturity, Year Four">149,000</span> in fiscal year 2024. The Pennvest Loan was collateralized by PA1’s Kreider 1 System and by a pledge of all revenues generated from Kreider 1 including, but not limited to, revenues generated from nutrient reduction credit sales and by-product sales. In addition, in consideration for the excess credit risk associated with the project, Pennvest was entitled to participate in the profits from Kreider 1 calculated on a net cash flow basis, as defined. The Company has incurred interest expense related to the Pennvest Loan of $<span id="xdx_90E_eus-gaap--InterestExpenseDebt_pp0p0_c20210701__20220630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_zbDSZrnb5n44" title="Interest Expense, Debt">123,444</span> and $<span id="xdx_90F_eus-gaap--InterestExpenseDebt_pp0p0_c20200701__20210630__us-gaap--DebtInstrumentAxis__custom--PennvestLoanMember_z9bnzjdmXXYd" title="Interest Expense, Debt">246,887</span> for the years ended June 30, 2022 and 2021, respectively. Based on the limited development of the depth and breadth of the Pennsylvania nutrient reduction credit market, PA1 commenced discussions and negotiations with Pennvest related to forbearance and/or re-structuring the obligations under the Pennvest Loan during 2013. In the context of such negotiations, PA1 elected not to make interest payments to Pennvest on the Pennvest Loan since January 2013. Additionally, the PA1 did not make any principal payments, which were to begin in fiscal 2013, and, therefore, the Company classified the Pennvest Loan as a current liability through the dissolution of PA1 on December 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During August 2012, the Company provided Pennvest (and the PADEP) with data demonstrating that the Kreider 1 system met the ‘technology guaranty’ standards which were incorporated in the Pennvest financing documents and, as a result, the Pennvest Loan has been solely an obligation of PA1 since that date. Note, however, the Company’s consolidated balance sheet as of June 30, 2021 reflects the Pennvest Loan as a liability of $<span id="xdx_90C_eus-gaap--LinesOfCreditCurrent_iI_pp0p0_c20210630_zNHWD5owapE6" title="Loans as a liability">9,868,495</span> despite the fact that the obligation (if any) was solely an obligation of PA1<b>. </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2014, the Pennsylvania Infrastructure Investment Authority (“Pennvest”) exercised its right to declare the PA1’s Pennvest Loan in default, accelerated the Pennvest Loan and demanded that PA1 pay $<span id="xdx_907_eus-gaap--DebtDefaultLongtermDebtAmount_iI_pp0p0_c20140925__dei--LegalEntityAxis__custom--PA1Member_z3PvMEJtUCaf" title="Debt Instrument, Debt Default, Amount">8,137,117</span> (principal, interest plus late charges) on or before October 24, 2014. PA1 did not make the payment and did/does not have the resources to make the payments demanded by Pennvest. PA1 commenced discussions and negotiations with Pennvest concerning this matter but Pennvest rejected PA1’s proposal made during the fall of 2014. PA1 made a final proposal to Pennvest during September 2021 which proposal was also rejected by Pennvest. PA1 provided Pennvest with its financial statements (which include a description of system status) annually. During the 2021 fiscal year, Pennvest’s auditors requested a ‘corrective action plan’ and PA1 informed Pennvest that “… there is no viable corrective action plan for the Pennvest Loan (‘Loan’). The facility funded by the Loan has been shut down for many years (which has been disclosed in the annual financial reports to Pennvest and in public filings by the parent of Bion PA 1, LLC) and the technology utilized in the facility is now obsolete. The facility has not been commercially operated for approximately six years and has generated zero income. We recommend that Pennvest take appropriate steps to remove and sell the equipment.” Pennvest responded favorably to the approach of selling the equipment. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 29, 2021, the Company approved and executed a ‘Consent of the Sole Member of Bion PA 1’ (the “Consent to Dissolution”) that authorized the complete liquidation and dissolution of PA1. A Statement of Dissolution was filed by PA1 with the Colorado Secretary of State on December 29, 2021.The liquidation value of Bion PA 1’s property is substantially below the current amount outstanding under the Funding Agreement dated October 27, 2010 by and between PA1 and Pennvest, the only known secured creditor of PA1. Post-dissolution, PA1’s activities will be limited entirely to activities required to properly distribute its net assets to creditors and wind down its business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1 and Pennvest agreed to have the equipment sold by a third party auctioneer who arranged for the sale of its property and delivery of all proceeds (net of commissions and customary costs of sale) to Pennvest. The auction took place during the period of May 13-18, 2022. The Company’s personnel assisted PA1 with this process as needed at no cost to PA1. The net sum of $<span id="xdx_903_eus-gaap--GainLossOnSecuritizationOfFinancialAssets_pp0p0_c20220614__20220615__dei--LegalEntityAxis__custom--PA1Member_zbFjPqhsMW38" title="Realized from the asset sale">104,725</span> was realized from the asset sale, which sum was delivered to Pennvest on June 15, 2022. Pursuant to agreement with Pennvest and Kreider Farms, the remaining unsold assets have been transferred to Kreider Farms in order to complete the winding up of the Kreider 1 project.</p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon the complete distribution of all assets of PA1, whether by transfer or sale and distribution of net proceeds as provided above, PA1 will use commercially reasonable efforts to cause the cessation of all activities. No distributions of PA1’s assets will be made to the Company or its affiliates. The Consent to Dissolution authorized Mark A. Smith, the Company’s President and the sole manager of PA1, to cause to be delivered for filing the Statement of Dissolution, to give notice of the dissolution, and to take any other act necessary to wind up and liquidate the business.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PA1 has made no payments to vendors or other creditors in connection with the dissolution other than the payment to Pennvest set forth above. No distributions or payments of any kind have ever been made to the Company, the sole member of PA1 since inception, and no payment will be made to the Company or any affiliate in connection with the dissolution.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For more information regarding the history and background of the Pennvest Loan and PA1, please review our Form’s 10-K for the years from 2008 through 2021 including the Notes to the Financial Statements included therein.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Bank Account Hacking </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 23, 2023, an officer of the Company with personal accounts with Signature Bank was hacked and $<span id="xdx_90C_ecustom--BankAccountHackedAmount_c20230622__20230623_zorOqzK0I8m" title="Bank account hacked amount">75,000</span> was transferred from the Company’s accounts at Signature Bank to the officer’s personal accounts. The bank was notified and all Company accounts were placed on hold. Subsequently, the funds were released and transferred back to the Company prior to June 30, 2023 the end of the fiscal year and there were no losses incurred.  The Company has reviewed the authorized individuals on all accounts and further limited access after the hacking incident.  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company currently is not involved in any other material litigation or similar events.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Lease:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company entered into an agreement on September 23, 2021, to lease approximately four acres of land near Fair Oaks, Indiana, for the development site of its Initial Project.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The future minimum lease payment under noncancelable operating lease with terms greater than one year as of June 30, 2023:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock_zugU9eXnir2b" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zxd7Cr1KtX6i">Schedule Of Future Minimum Lease Payment</span></span></td> <td> </td> <td colspan="2" id="xdx_495_20230630_zU6EVRhLoQA4" style="text-align: center"> </td> <td> </td></tr> <tr id="xdx_40A_ecustom--OperatingLeasesFutureMinimumPaymentReceivableInTwoYears_iI_pp0p0_zOHeZzJSqSu9" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended June 30, 2023 to June 2024</span></td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000</span></td> <td style="width: 1%"> </td></tr> <tr id="xdx_40F_ecustom--OperatingLeasesFutureMinimumPaymentReceivableInThreeYears_iI_pp0p0_zQmKZgg0N9bc" style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended June 30, 2024 to December 2024</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,500</span></td> <td> </td></tr> <tr id="xdx_402_ecustom--UndiscountedCashFlow_iI_pp0p0_zdkybpxaw877" style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undiscounted cash flow</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,500</span></td> <td> </td></tr> <tr id="xdx_40F_ecustom--LessImputedInterest_iI_pp0p0_zKBlE0MdzbP" style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less imputed interest</span></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,432</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40A_ecustom--CapitalLeaseContingentRentalPaymentsDue_iI_pp0p0_zvAyC1qy63aj" style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104,068</span></td> <td> </td></tr> <tr id="xdx_409_ecustom--FinanceLeasesLiabilityCurrent_iNI_pp0p0_di_zGAO17KpE8n8" style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">   Less current portion</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(75,000</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtAndCapitalLeaseObligations_iI_z7fk96f6Vcb7" style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long term lease liability</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,068</span></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average remaining lease term and discounted rate related to the Company’s lease liability as of June 30, 2023 were <span id="xdx_90A_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630_zIznzm7lnCyl" title="Weighted average remaining lease term">1.58</span> years and <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_c20230630_zEFQhSwFqgT2" title="Discounted rate">10</span>%, respectively. The Company’s lease discount rate is generally based on the estimates of its incremental borrowing rate as the discount rates implicit in the Company’s lease cannot be readily determined.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> 18000 300000 0.75 25000 5000 200000 130000 31000 125000 0.75 300000 0.75 0.75 31000 2000 300000 3000000 361321 5000 300000 250000 25000 10000 12500 0.75 5000 150000 25000 0.75 3000000 0.50 0.90 18438339 1000000 1.00 700000 0.75 2665500 0.25 666375 0.25 533100 83275 2615500 50000 4182260 3962207 220053 6103693 the Company entered into an agreement to sell domain name <biontech.com> and other related assets to BioNTech SE (“BNTX”) for the sum of $950,000 (before expenses related to the transaction) which sale was closed/completed on April 2, 2022 with a one-time gain of $902,490. 2255802 297 10154334 9939148 214235 950 10234501 10009802 212263 12436 10234501 7754000 0.02547 0.03184 5886000 846000 873000 149000 123444 246887 9868495 8137117 104725 75000 <table cellpadding="0" cellspacing="0" id="xdx_88B_ecustom--ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock_zugU9eXnir2b" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - COMMITMENTS AND CONTINGENCIES (Details)"> <tr style="vertical-align: bottom"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B7_zxd7Cr1KtX6i">Schedule Of Future Minimum Lease Payment</span></span></td> <td> </td> <td colspan="2" id="xdx_495_20230630_zU6EVRhLoQA4" style="text-align: center"> </td> <td> </td></tr> <tr id="xdx_40A_ecustom--OperatingLeasesFutureMinimumPaymentReceivableInTwoYears_iI_pp0p0_zOHeZzJSqSu9" style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 84%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended June 30, 2023 to June 2024</span></td> <td style="width: 1%"> </td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="width: 13%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">75,000</span></td> <td style="width: 1%"> </td></tr> <tr id="xdx_40F_ecustom--OperatingLeasesFutureMinimumPaymentReceivableInThreeYears_iI_pp0p0_zQmKZgg0N9bc" style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Year ended June 30, 2024 to December 2024</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37,500</span></td> <td> </td></tr> <tr id="xdx_402_ecustom--UndiscountedCashFlow_iI_pp0p0_zdkybpxaw877" style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Undiscounted cash flow</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">112,500</span></td> <td> </td></tr> <tr id="xdx_40F_ecustom--LessImputedInterest_iI_pp0p0_zKBlE0MdzbP" style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less imputed interest</span></td> <td> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,432</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40A_ecustom--CapitalLeaseContingentRentalPaymentsDue_iI_pp0p0_zvAyC1qy63aj" style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td> <td> </td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104,068</span></td> <td> </td></tr> <tr id="xdx_409_ecustom--FinanceLeasesLiabilityCurrent_iNI_pp0p0_di_zGAO17KpE8n8" style="vertical-align: bottom; background-color: white"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">   Less current portion</span></td> <td> </td> <td> </td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(75,000</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40E_eus-gaap--LongTermDebtAndCapitalLeaseObligations_iI_z7fk96f6Vcb7" style="vertical-align: bottom; background-color: #CCEEFF"> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long term lease liability</span></td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,068</span></td> <td> </td></tr> </table> 75000 37500 112500 -8432 104068 75000 29068 P1Y6M29D 0.10 <p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_zZaOYOvTMfCg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>10.       <span id="xdx_828_z47OXPVS5dS9">INCOME TAXES</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The reconciliation between the expected federal income tax benefit computed by applying the Federal statutory rate to loss before income taxes and the actual benefit for taxes on loss for the years ended June 30, 2023 and 2022 is as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zLHCSQVdXBVl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_8B3_zNRCMniK8Sc6" style="display: none">Schedule of effective income tax rate reconciliation</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20220701__20230630_zjXtPVSEJ2ue" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20210701__20220630_zvTVb6OQiMGk" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maDOTEOz2es_zJUCYT6kBAUd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify">Expected income tax benefit at statutory rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(670,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,741,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maDOTEOz2es_zgZO7v1hd1sc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">State taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(117,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">303,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--IncomeTaxReconciliationPermanentDifferences_maDOTEOz2es_zJ8Bxx382Y6f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Permanent differences and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingAllowanceAmount_maDOTEOz2es_zyDA1OkqAiPd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expiration of net operating allowances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">733,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,229,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maDOTEOz2es_zULsonXs5hi6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(45,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,281,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_iT_pp0p0_mtDOTEOz2es_zFn6UYxL5TLj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Income tax benefit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1577">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1578">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has net operating loss carry-forwards (“NOLs”) for tax purposes of approximately $<span id="xdx_907_eus-gaap--OperatingLossCarryforwards_iI_pdp0_c20230630_zpmxDSoMMql5" title="Operating Loss Carryforwards, Total">39,500,000</span> as of June 30, 2023. These NOLs expire on various dates through 2042.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The utilization of the NOLs may be limited under Section 382 of the Internal Revenue Code.</p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The Company’s deferred tax assets for the years ended June 30, 2023 and 2022 are estimated as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zMtnQtc52Igg" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_8B1_zOwIOegEvrPc" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49A_20230630_zNz7l24PIL1l" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_494_20220630_zAmaQHjEhAv2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: justify">NOL carryforwards (Federal and State)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">8,299,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">8,274,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,459,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,436,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Impairment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,340,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,340,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsBusinessInterest_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Business interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">338,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">339,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Deferred compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,054,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,054,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_zlEjN1sCMPoe" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Capitalized research and development</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">66,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1600">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Gross deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,148,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,443,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zRykmHbHfkle" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16,148,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16,443,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0p0_zQcKsi0h3hO1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1608">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1609">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zxiTizDDO9xh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has provided a valuation allowance of <span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_c20220701__20230630_zXK3bMvhQkVe" title="Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent">100</span>% of its net deferred tax asset due to the uncertainty of generating future profits that would allow for the realization of such deferred tax assets.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zLHCSQVdXBVl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span id="xdx_8B3_zNRCMniK8Sc6" style="display: none">Schedule of effective income tax rate reconciliation</span></td><td> </td> <td style="text-align: left"> </td><td id="xdx_490_20220701__20230630_zjXtPVSEJ2ue" style="text-align: center"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_49E_20210701__20220630_zvTVb6OQiMGk" style="text-align: center"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt; text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_maDOTEOz2es_zJUCYT6kBAUd" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: justify">Expected income tax benefit at statutory rate</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(670,000</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,741,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--IncomeTaxReconciliationStateAndLocalIncomeTaxes_maDOTEOz2es_zgZO7v1hd1sc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">State taxes, net of federal benefit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(117,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">303,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--IncomeTaxReconciliationPermanentDifferences_maDOTEOz2es_zJ8Bxx382Y6f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Permanent differences and other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingAllowanceAmount_maDOTEOz2es_zyDA1OkqAiPd" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expiration of net operating allowances</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">733,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,229,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_maDOTEOz2es_zULsonXs5hi6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Change in valuation allowance</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(45,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,281,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_iT_pp0p0_mtDOTEOz2es_zFn6UYxL5TLj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Income tax benefit</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1577">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1578">—</span>  </td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -670000 1741000 -117000 303000 9000 8000 733000 1229000 -45000 -3281000 39500000 <table cellpadding="0" cellspacing="0" id="xdx_89C_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zMtnQtc52Igg" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"> <tr style="vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_8B1_zOwIOegEvrPc" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49A_20230630_zNz7l24PIL1l" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_494_20220630_zAmaQHjEhAv2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2023</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center">2022</td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 66%; text-align: justify">NOL carryforwards (Federal and State)</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">8,299,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">$</td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right">8,274,000</td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Stock-based compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,459,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5,436,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsPropertyPlantAndEquipment_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Impairment</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,340,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,340,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxAssetsBusinessInterest_iI_pp0p0" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Business interest</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">338,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">339,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Deferred compensation</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,054,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">1,054,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_iI_pp0p0_zlEjN1sCMPoe" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Capitalized research and development</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">66,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1600">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsGross_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Gross deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,148,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">16,443,000</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_zRykmHbHfkle" style="vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Valuation allowance</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16,148,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16,443,000</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_401_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0p0_zQcKsi0h3hO1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 2.5pt">Net deferred tax assets</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1608">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1609">—</span>  </td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 8299000 8274000 5459000 5436000 1340000 1340000 338000 339000 1054000 1054000 66000 16148000 16443000 16148000 16443000 1 <p id="xdx_807_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zzrditm8p5ol" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>11.       <span id="xdx_82F_zxvxYY2Qfqc6">401(k) PLAN:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has adopted the Bion Technologies, Inc. 401(k) Profit Sharing Plan and Trust (the “401(k) Plan”), a defined contribution retirement plan for the benefit of its employees. The 401(k) Plan is currently a salary deferral only plan and at this time the Company does not match employee contributions. The 401(k) is open to all employees over 21 years of age and no service requirement is necessary.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zjA3Az8lEZEi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>12.        <span id="xdx_82E_zNmMXKvfcTu5">SUBSEQUENT EVENTS:</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has evaluated events that occurred subsequent to June 30, 2023 for recognition and disclosure in the financial statements and notes to the financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">From July 1, 2023 through September 28, 2023, the Company has incurred costs of $<span id="xdx_90C_eus-gaap--CostsIncurredDevelopmentCosts_c20230701__20230928__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zatYKonPBCRb" title="Cost incurred">583,870 </span>for an aggregate of $<span id="xdx_903_eus-gaap--DirectCommunicationsAndUtilitiesCosts_c20230701__20230928__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zw8Ix3TnoZTf" title="Aggregate cost">7,431,630</span> for the Initial Project. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From July 1, 2023 through September 28, 2023, <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20230701__20230928__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zl0ylmcI7599" title="Number of shares exercised">38,000</span> warrants were exercised to purchase <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20230701__20230928__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zLZdaLilXWW6" title="Number of shares exercised">38,000</span> shares of the Company’s common stock at $<span id="xdx_903_ecustom--WarrantsExercised_uUSDPShares_c20230701__20230928__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8Zh1ij9nF5j" title="Warrants exercised">0.75</span> per share for total proceeds of $<span id="xdx_90A_ecustom--WarrantsExercisedForCommonStocks_pp0p0_c20230701__20230928__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zYZlWppcYJG9" title="Total proceeds">28,500</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On July 7, 2023, the Company issued <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEB2ncAxxxs9" title="Number of shares warrants outstanding">7,500</span> shares of the Company’s common stock to a consultant for services. The shares were issued at $<span id="xdx_90D_ecustom--WarrantsExercised_uUSDPShares_c20230706__20230707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOgcWV2RBBk9" title="Warrants exercised">1.20</span> per share for a total value of $<span id="xdx_90A_ecustom--TotalValueOfConsultantServices_c20230706__20230707__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zU7uBZY3Ohc8" title="Total value of consultant services">9,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 21, 2023, Mr. Smith converted $<span id="xdx_90D_ecustom--UnreimbursedExpenses_c20230720__20230721__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zCSrr4Dp09H6" title="Unreimbursed expenses">49,048</span> of principal from his Adjusted 2020 Convertible note into <span id="xdx_90A_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230720__20230721__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zvYzvFf12o04" title="Number of shares converted">518,477</span> Units at a conversion rate of $<span id="xdx_90F_ecustom--ConversionPricePerUnits_iI_c20230721__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zm8cT4RhLXq4" title="Conversion price per unit">.0946</span>; each unit consisting of one share and one warrant with the exercise price of $<span id="xdx_902_ecustom--WarrantExercisePrice_iI_c20230721__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zEPVoaDMKwHe" title="Warrant exercise price">.75</span> until 7/21/2026. Each of these warrants carry an exercise price adjustment provision of <span id="xdx_908_ecustom--WarrantsExercisePricePercentage_dp_c20230720__20230721__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z0PJaK2bZRd7" title="Warrants exercise price percentage">75</span>%.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On August 16, 2023, the Company issued <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_c20230816__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGkcJNDcnHs1" title="Number of shares warrants outstanding">10,753</span> shares of the Company’s common stock to a consultant for services. The shares were issued at $<span id="xdx_907_ecustom--WarrantsExercised_uUSDPShares_c20230815__20230816__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zOBJ0bfbKWBb" title="Warrants exercised">1.55</span> per share for a total value of $<span id="xdx_909_ecustom--TotalValueOfConsultantServices_c20230815__20230816__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8VpBSMF3cK5" title="Total value of consultant services">16,667</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 28, 2023, the Company sold <span id="xdx_900_ecustom--SaleOfStockShares_c20230827__20230828__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zoX8eZjCExbj" title="Slae of shares">28,589</span> units at a price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20230828__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zpHRBjVhO6c9" title="Slae of share price">1.60</span> for a total of $<span id="xdx_908_ecustom--TotalValueOfConsultantServices_c20230827__20230828__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztTmiJfCreO2" title="Total value of consultant services">45,742</span>.  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> 583870 7431630 38000 38000 0.75 28500 7500 1.20 9000 49048 518477 0.0946 0.75 0.75 10753 1.55 16667 28589 1.60 45742 EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 240 351 1 false 85 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://biontech.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://biontech.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://biontech.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Sheet http://biontech.com/role/ConsolidatedStatementsOfOperationsParenthetical CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) Statements 5 false false R6.htm 00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT) Statements 6 false false R7.htm 00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://biontech.com/role/ConsolidatedStatementsOfCashFlows CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 00000008 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS Sheet http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS Notes 8 false false R9.htm 00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://biontech.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 00000010 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://biontech.com/role/PropertyAndEquipment PROPERTY AND EQUIPMENT Notes 10 false false R11.htm 00000011 - Disclosure - DEFERRED COMPENSATION Sheet http://biontech.com/role/DeferredCompensation DEFERRED COMPENSATION Notes 11 false false R12.htm 00000012 - Disclosure - LOANS PAYABLE Sheet http://biontech.com/role/LoansPayable LOANS PAYABLE Notes 12 false false R13.htm 00000013 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES Notes http://biontech.com/role/ConvertibleNotesPayable-Affiliates CONVERTIBLE NOTES PAYABLE - AFFILIATES Notes 13 false false R14.htm 00000014 - Disclosure - STOCKHOLDERS' EQUITY: Sheet http://biontech.com/role/StockholdersEquity STOCKHOLDERS' EQUITY: Notes 14 false false R15.htm 00000015 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES Sheet http://biontech.com/role/SubscriptionReceivable-Affiliates SUBSCRIPTION RECEIVABLE - AFFILIATES Notes 15 false false R16.htm 00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES: Sheet http://biontech.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES: Notes 16 false false R17.htm 00000017 - Disclosure - INCOME TAXES Sheet http://biontech.com/role/IncomeTaxes INCOME TAXES Notes 17 false false R18.htm 00000018 - Disclosure - 401(k) PLAN: Sheet http://biontech.com/role/KPlan 401(k) PLAN: Notes 18 false false R19.htm 00000019 - Disclosure - SUBSEQUENT EVENTS: Sheet http://biontech.com/role/SubsequentEvents SUBSEQUENT EVENTS: Notes 19 false false R20.htm 00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://biontech.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 20 false false R21.htm 00000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://biontech.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://biontech.com/role/SignificantAccountingPolicies 21 false false R22.htm 00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://biontech.com/role/PropertyAndEquipmentTables PROPERTY AND EQUIPMENT (Tables) Tables http://biontech.com/role/PropertyAndEquipment 22 false false R23.htm 00000023 - Disclosure - STOCKHOLDERS' EQUITY: (Tables) Sheet http://biontech.com/role/StockholdersEquityTables STOCKHOLDERS' EQUITY: (Tables) Tables http://biontech.com/role/StockholdersEquity 23 false false R24.htm 00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Tables) Sheet http://biontech.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES: (Tables) Tables http://biontech.com/role/CommitmentsAndContingencies 24 false false R25.htm 00000025 - Disclosure - INCOME TAXES (Tables) Sheet http://biontech.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://biontech.com/role/IncomeTaxes 25 false false R26.htm 00000026 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Sheet http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT???S PLANS (Details Narrative) Details http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans 26 false false R27.htm 00000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) Sheet http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details) Details 27 false false R28.htm 00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) Sheet http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details) Details 28 false false R29.htm 00000029 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://biontech.com/role/SignificantAccountingPoliciesTables 29 false false R30.htm 00000030 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details) Sheet http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails PROPERTY AND EQUIPMENT - Property and Equipment (Details) Details 30 false false R31.htm 00000031 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative) Sheet http://biontech.com/role/PropertyAndEquipmentDetailsNarrative PROPERTY AND EQUIPMENT (Details Narrative) Details http://biontech.com/role/PropertyAndEquipmentTables 31 false false R32.htm 00000032 - Disclosure - DEFERRED COMPENSATION (Details Narrative) Sheet http://biontech.com/role/DeferredCompensationDetailsNarrative DEFERRED COMPENSATION (Details Narrative) Details http://biontech.com/role/DeferredCompensation 32 false false R33.htm 00000033 - Disclosure - LOANS PAYABLE (Details Narrative) Sheet http://biontech.com/role/LoansPayableDetailsNarrative LOANS PAYABLE (Details Narrative) Details http://biontech.com/role/LoansPayable 33 false false R34.htm 00000034 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) Notes http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative) Details http://biontech.com/role/ConvertibleNotesPayable-Affiliates 34 false false R35.htm 00000035 - Disclosure - STOCKHOLDERS' EQUITY - Assumptions (Details) Sheet http://biontech.com/role/StockholdersEquity-AssumptionsDetails STOCKHOLDERS' EQUITY - Assumptions (Details) Details 35 false false R36.htm 00000036 - Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details) Sheet http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails STOCKHOLDERS' EQUITY - Stock Option Activity (Details) Details 36 false false R37.htm 00000037 - Disclosure - STOCKHOLDERS' EQUITY: (Details Narrative) Sheet http://biontech.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS' EQUITY: (Details Narrative) Details http://biontech.com/role/StockholdersEquityTables 37 false false R38.htm 00000038 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) Sheet http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative) Details http://biontech.com/role/SubscriptionReceivable-Affiliates 38 false false R39.htm 00000039 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://biontech.com/role/CommitmentsAndContingenciesDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://biontech.com/role/CommitmentsAndContingenciesTables 39 false false R40.htm 00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Details Narrative) Sheet http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES: (Details Narrative) Details http://biontech.com/role/CommitmentsAndContingenciesTables 40 false false R41.htm 00000041 - Disclosure - INCOME TAXES (Details) Sheet http://biontech.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://biontech.com/role/IncomeTaxesTables 41 false false R42.htm 00000042 - Disclosure - INCOME TAXES (Details 1) Sheet http://biontech.com/role/IncomeTaxesDetails1 INCOME TAXES (Details 1) Details http://biontech.com/role/IncomeTaxesTables 42 false false R43.htm 00000043 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://biontech.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://biontech.com/role/IncomeTaxesTables 43 false false R44.htm 00000044 - Disclosure - SUBSEQUENT EVENTS: (Details Narrative) Sheet http://biontech.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS: (Details Narrative) Details http://biontech.com/role/SubsequentEvents 44 false false All Reports Book All Reports bion_10k-063023.htm bnet-20230630.xsd bnet-20230630_cal.xml bnet-20230630_def.xml bnet-20230630_lab.xml bnet-20230630_pre.xml image_001.jpg image_002.jpg image_003.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 64 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bion_10k-063023.htm": { "nsprefix": "bnet", "nsuri": "http://biontech.com/20230630", "dts": { "inline": { "local": [ "bion_10k-063023.htm" ] }, "schema": { "local": [ "bnet-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "bnet-20230630_cal.xml" ] }, "definitionLink": { "local": [ "bnet-20230630_def.xml" ] }, "labelLink": { "local": [ "bnet-20230630_lab.xml" ] }, "presentationLink": { "local": [ "bnet-20230630_pre.xml" ] } }, "keyStandard": 244, "keyCustom": 107, "axisStandard": 20, "axisCustom": 0, "memberStandard": 20, "memberCustom": 54, "hidden": { "total": 178, "http://fasb.org/us-gaap/2023": 85, "http://biontech.com/20230630": 89, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 240, "entityCount": 1, "segmentCount": 85, "elementCount": 545, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 619, "http://xbrl.sec.gov/dei/2023": 36 }, "report": { "R1": { "role": "http://biontech.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R2": { "role": "http://biontech.com/role/ConsolidatedBalanceSheets", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R3": { "role": "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R4": { "role": "http://biontech.com/role/ConsolidatedStatementsOfOperations", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:GeneralAndAdministrativeExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R5": { "role": "http://biontech.com/role/ConsolidatedStatementsOfOperationsParenthetical", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:EarningsPerShareBasic", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R6": { "role": "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R7": { "role": "http://biontech.com/role/ConsolidatedStatementsOfCashFlows", "longName": "00000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2021-07-012022-06-30", "name": "bnet:GainOnLegalDissolutionsOfSubsidiary", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "unique": true } }, "R8": { "role": "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans", "longName": "00000008 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS", "shortName": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R9": { "role": "http://biontech.com/role/SignificantAccountingPolicies", "longName": "00000009 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R10": { "role": "http://biontech.com/role/PropertyAndEquipment", "longName": "00000010 - Disclosure - PROPERTY AND EQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R11": { "role": "http://biontech.com/role/DeferredCompensation", "longName": "00000011 - Disclosure - DEFERRED COMPENSATION", "shortName": "DEFERRED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R12": { "role": "http://biontech.com/role/LoansPayable", "longName": "00000012 - Disclosure - LOANS PAYABLE", "shortName": "LOANS PAYABLE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R13": { "role": "http://biontech.com/role/ConvertibleNotesPayable-Affiliates", "longName": "00000013 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES", "shortName": "CONVERTIBLE NOTES PAYABLE - AFFILIATES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "bnet:ConvertibleDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "bnet:ConvertibleDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R14": { "role": "http://biontech.com/role/StockholdersEquity", "longName": "00000014 - Disclosure - STOCKHOLDERS' EQUITY:", "shortName": "STOCKHOLDERS' EQUITY:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R15": { "role": "http://biontech.com/role/SubscriptionReceivable-Affiliates", "longName": "00000015 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES", "shortName": "SUBSCRIPTION RECEIVABLE - AFFILIATES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "bnet:SubscriptionReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "bnet:SubscriptionReceivableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R16": { "role": "http://biontech.com/role/CommitmentsAndContingencies", "longName": "00000016 - Disclosure - COMMITMENTS AND CONTINGENCIES:", "shortName": "COMMITMENTS AND CONTINGENCIES:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R17": { "role": "http://biontech.com/role/IncomeTaxes", "longName": "00000017 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R18": { "role": "http://biontech.com/role/KPlan", "longName": "00000018 - Disclosure - 401(k) PLAN:", "shortName": "401(k) PLAN:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R19": { "role": "http://biontech.com/role/SubsequentEvents", "longName": "00000019 - Disclosure - SUBSEQUENT EVENTS:", "shortName": "SUBSEQUENT EVENTS:", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R20": { "role": "http://biontech.com/role/SignificantAccountingPoliciesPolicies", "longName": "00000020 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "20", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R21": { "role": "http://biontech.com/role/SignificantAccountingPoliciesTables", "longName": "00000021 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "21", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R22": { "role": "http://biontech.com/role/PropertyAndEquipmentTables", "longName": "00000022 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R23": { "role": "http://biontech.com/role/StockholdersEquityTables", "longName": "00000023 - Disclosure - STOCKHOLDERS' EQUITY: (Tables)", "shortName": "STOCKHOLDERS' EQUITY: (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R24": { "role": "http://biontech.com/role/CommitmentsAndContingenciesTables", "longName": "00000024 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Tables)", "shortName": "COMMITMENTS AND CONTINGENCIES: (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "bnet:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "bnet:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R25": { "role": "http://biontech.com/role/IncomeTaxesTables", "longName": "00000025 - Disclosure - INCOME TAXES (Tables)", "shortName": "INCOME TAXES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R26": { "role": "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "longName": "00000026 - Disclosure - ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "shortName": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "bnet:TechWastage", "unitRef": "Decimal", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "bnet:TechWastage", "unitRef": "Decimal", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R27": { "role": "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "longName": "00000027 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2022-07-012023-06-30_us-gaap_WarrantMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-012023-06-30_us-gaap_WarrantMember", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R28": { "role": "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails", "longName": "00000028 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES - Earnings Per Share, Basic and Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "bnet:SharesIssuedBeginningOfPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "bnet:SharesIssuedBeginningOfPeriod", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R29": { "role": "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative", "longName": "00000029 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:CashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R30": { "role": "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails", "longName": "00000030 - Disclosure - PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "shortName": "PROPERTY AND EQUIPMENT - Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "bnet:ComputersAndOfficeEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "bnet:ComputersAndOfficeEquipment", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R31": { "role": "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative", "longName": "00000031 - Disclosure - PROPERTY AND EQUIPMENT (Details Narrative)", "shortName": "PROPERTY AND EQUIPMENT (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:InterestCostsCapitalized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:InterestCostsCapitalized", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R32": { "role": "http://biontech.com/role/DeferredCompensationDetailsNarrative", "longName": "00000032 - Disclosure - DEFERRED COMPENSATION (Details Narrative)", "shortName": "DEFERRED COMPENSATION (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:DeferredCompensationLiabilityCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "bnet:InterestRateOnDeferredCompensation", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "unique": true } }, "R33": { "role": "http://biontech.com/role/LoansPayableDetailsNarrative", "longName": "00000033 - Disclosure - LOANS PAYABLE (Details Narrative)", "shortName": "LOANS PAYABLE (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:Assets", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:GainOrLossOnSaleOfStockInSubsidiary", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "unique": true } }, "R34": { "role": "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "longName": "00000034 - Disclosure - CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative)", "shortName": "CONVERTIBLE NOTES PAYABLE - AFFILIATES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bnet:ConvertibleDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:ConvertibleDebt", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bnet:ConvertibleDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "unique": true } }, "R35": { "role": "http://biontech.com/role/StockholdersEquity-AssumptionsDetails", "longName": "00000035 - Disclosure - STOCKHOLDERS' EQUITY - Assumptions (Details)", "shortName": "STOCKHOLDERS' EQUITY - Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "From2022-07-012023-06-30_us-gaap_EmployeeStockOptionMember_srt_WeightedAverageMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-012023-06-30_us-gaap_EmployeeStockOptionMember_srt_WeightedAverageMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R36": { "role": "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails", "longName": "00000036 - Disclosure - STOCKHOLDERS' EQUITY - Stock Option Activity (Details)", "shortName": "STOCKHOLDERS' EQUITY - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "AsOf2022-06-30", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "unique": true } }, "R37": { "role": "http://biontech.com/role/StockholdersEquityDetailsNarrative", "longName": "00000037 - Disclosure - STOCKHOLDERS' EQUITY: (Details Narrative)", "shortName": "STOCKHOLDERS' EQUITY: (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bnet:ConvertibleDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalOther", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "unique": true } }, "R38": { "role": "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative", "longName": "00000038 - Disclosure - SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative)", "shortName": "SUBSCRIPTION RECEIVABLE - AFFILIATES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "AsOf2023-06-30_custom_SmithsMember_custom_SecuredPromissoryNoteMember", "name": "us-gaap:NotesReceivableNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30_custom_SmithsMember_custom_SecuredPromissoryNoteMember", "name": "us-gaap:NotesReceivableNet", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "bnet:SubscriptionReceivableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R39": { "role": "http://biontech.com/role/CommitmentsAndContingenciesDetails", "longName": "00000039 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "bnet:OperatingLeasesFutureMinimumPaymentReceivableInTwoYears", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "bnet:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "bnet:OperatingLeasesFutureMinimumPaymentReceivableInTwoYears", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "bnet:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R40": { "role": "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "00000040 - Disclosure - COMMITMENTS AND CONTINGENCIES: (Details Narrative)", "shortName": "COMMITMENTS AND CONTINGENCIES: (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "From2022-04-272022-05-02", "name": "bnet:CompensationIncreased", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-04-272022-05-02", "name": "bnet:CompensationIncreased", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R41": { "role": "http://biontech.com/role/IncomeTaxesDetails", "longName": "00000041 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R42": { "role": "http://biontech.com/role/IncomeTaxesDetails1", "longName": "00000042 - Disclosure - INCOME TAXES (Details 1)", "shortName": "INCOME TAXES (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R43": { "role": "http://biontech.com/role/IncomeTaxesDetailsNarrative", "longName": "00000043 - Disclosure - INCOME TAXES (Details Narrative)", "shortName": "INCOME TAXES (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:OperatingLossCarryforwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true, "unique": true } }, "R44": { "role": "http://biontech.com/role/SubsequentEventsDetailsNarrative", "longName": "00000044 - Disclosure - SUBSEQUENT EVENTS: (Details Narrative)", "shortName": "SUBSEQUENT EVENTS: (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "From2022-07-01to2023-06-30", "name": "us-gaap:CostsIncurredDevelopmentCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "bnet:ConvertibleDebtTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-012023-09-28_us-gaap_SubsequentEventMember", "name": "us-gaap:CostsIncurredDevelopmentCosts", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bion_10k-063023.htm", "unique": true } } }, "tag": { "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r47", "r48", "r49", "r51", "r52", "r53", "r55", "r118", "r119", "r120", "r158", "r159", "r160", "r217", "r325", "r326", "r327", "r329", "r332", "r337", "r339", "r522", "r523", "r524", "r525", "r638", "r683", "r705" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r398", "r399", "r400", "r530", "r708", "r709", "r710", "r760", "r781" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r16" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "crdr": "credit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Increase to additional paid in capital", "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC)." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r24", "r150", "r165", "r166", "r167", "r186", "r187", "r188", "r190", "r196", "r198", "r216", "r266", "r267", "r341", "r398", "r399", "r400", "r414", "r415", "r428", "r429", "r430", "r431", "r432", "r433", "r436", "r440", "r441", "r442", "r443", "r444", "r445", "r453", "r514", "r515", "r516", "r530", "r595" ] }, "bnet_DebtInstrumentInterestRateStatedPercentageQuarterly": { "xbrltype": "percentItemType", "nsuri": "http://biontech.com/20230630", "localname": "DebtInstrumentInterestRateStatedPercentageQuarterly", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage, Quarterly" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance or Sale of Equity", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r1", "r522" ] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://biontech.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "INCOME TAXES", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r181", "r407", "r409", "r410", "r413", "r416", "r417", "r418", "r419", "r527" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r150", "r186", "r187", "r188", "r190", "r196", "r198", "r266", "r267", "r398", "r399", "r400", "r414", "r415", "r428", "r430", "r431", "r433", "r436", "r514", "r516", "r530", "r781" ] }, "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes", "crdr": "debit", "calculation": { "http://biontech.com/role/IncomeTaxesDetails": { "parentTag": "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "State taxes, net of federal benefit", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [ "r755" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r663" ] }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "crdr": "debit", "calculation": { "http://biontech.com/role/IncomeTaxesDetails": { "parentTag": "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://biontech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Change in valuation allowance", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r755" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r149", "r158", "r159", "r160", "r180", "r203", "r204", "r211", "r213", "r217", "r218", "r265", "r287", "r289", "r290", "r291", "r294", "r295", "r325", "r326", "r329", "r332", "r339", "r439", "r522", "r523", "r524", "r525", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r542", "r552", "r576", "r595", "r611", "r612", "r613", "r614", "r615", "r683", "r705", "r712" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r111", "r155", "r507" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total Bion's stockholders\u2019 equity (deficit)", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r91", "r94", "r95", "r109", "r554", "r573", "r596", "r597", "r647", "r661", "r707", "r719", "r761", "r781" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost", "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification." } } }, "auth_ref": [ "r396" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net (Note 3)", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r494", "r507", "r647" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r676" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r150", "r165", "r166", "r167", "r186", "r187", "r188", "r190", "r196", "r198", "r216", "r266", "r267", "r341", "r398", "r399", "r400", "r414", "r415", "r428", "r429", "r430", "r431", "r432", "r433", "r436", "r440", "r441", "r442", "r443", "r444", "r445", "r453", "r514", "r515", "r516", "r530", "r595" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r666" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r171", "r174", "r175" ] }, "us-gaap_IncreaseDecreaseInDeferredCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDeferredCompensation", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase in deferred compensation", "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future." } } }, "auth_ref": [ "r4" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r4" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r667" ] }, "bnet_AccruedInterestAndLateChargesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "AccruedInterestAndLateChargesPayable", "crdr": "credit", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued Interest and Late Charges Payable" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Property and equipment", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r6", "r141", "r147", "r505" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock options, authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r642" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r108", "r177" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r671" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Expired, options (in shares)", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r375" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Forfeited, options (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r374" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Granted, options (in shares)", "verboseLabel": "Number of shares granted", "documentation": "Net number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r736" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r664" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Outstanding, aggregate intrinsic value beginning", "periodEndLabel": "Outstanding, aggregate intrinsic value ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r59" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, beginning (in shares)", "periodEndLabel": "Options outstanding, ending (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r368", "r369" ] }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "crdr": "debit", "calculation": { "http://biontech.com/role/IncomeTaxesDetails": { "parentTag": "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Expected income tax benefit at statutory rate", "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r408" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "periodStartLabel": "Options outstanding, beginning weighted-average exercise price", "periodEndLabel": "Options outstanding, ending weighted-average exercise price", "label": "Weighted average exercise price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r368", "r369" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r173" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://biontech.com/role/StockholdersEquity-AssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r389" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r173" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://biontech.com/role/StockholdersEquity-AssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r390" ] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://biontech.com/role/StockholdersEquity-AssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r619", "r620", "r766", "r768", "r771" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r675" ] }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued interest", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities." } } }, "auth_ref": [ "r78" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of shares, shares", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r32", "r33", "r34" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair value measurements", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r129", "r157", "r180", "r219", "r225", "r229", "r265", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r422", "r426", "r439", "r497", "r567", "r647", "r661", "r724", "r725", "r764" ] }, "us-gaap_AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableUnderwritersPromotersAndEmployeesOtherThanSalariesAndWagesCurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Salaries and wages", "documentation": "Amount of obligation to underwriters, promoters, and employees excluding salaries, wages and amount to related party, classified as current." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r680" ] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion of shares, value", "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r32", "r33", "r34" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ReceivableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivableTypeDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates." } } }, "auth_ref": [ "r25" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share price", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "bnet_YearsOneThroughFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "YearsOneThroughFiveMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Years One Through Five [Member]" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "auth_ref": [ "r199", "r359", "r684", "r711" ] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentAmount1", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt instrument paid amount", "verboseLabel": "Debt conversion value", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r32", "r34" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r214" ] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of earnings per share, basic and diluted", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r713" ] }, "us-gaap_DividendsPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividends Payable", "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding." } } }, "auth_ref": [ "r88", "r89", "r131", "r657", "r775" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "bnet_YearsSixThroughMaturityMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "YearsSixThroughMaturityMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Years Six Through Maturity [Member]" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r664" ] }, "bnet_PA1Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "PA1Member", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "P A 1 [Member]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Securities [Member]", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r728" ] }, "us-gaap_ConversionOfStockSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesIssued1", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible stock shares issued, warrants", "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r32", "r33", "r34" ] }, "bnet_MarkASmithMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "MarkASmithMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Mark A Smith [Member]" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r19" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercised, options (in shares)", "verboseLabel": "Number of shares exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r90", "r91", "r120", "r373" ] }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOperating", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest income", "label": "Interest Income, Operating", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": [ "r98", "r577", "r609", "r610", "r658", "r659", "r783" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r104" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Conversion of debt and liabilities, shares", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r9", "r23", "r51", "r120", "r313" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r664" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r35" ] }, "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentSharesIssued1", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt conversion shares, warrants", "verboseLabel": "Debt conversion shares", "terseLabel": "Number of shares converted", "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period." } } }, "auth_ref": [ "r32", "r34" ] }, "bnet_DominicBassaniMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "DominicBassaniMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dominic Bassani [Member]" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r664" ] }, "bnet_September2015ConvertibleNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "September2015ConvertibleNotesMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "September 2015 Convertible Notes [Member]" } } }, "auth_ref": [] }, "bnet_EdSchaferMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "EdSchaferMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ed Schafer [Member]" } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r664" ] }, "bnet_RestrictedCommonSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "RestrictedCommonSharesMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Common Shares [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]", "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability." } } }, "auth_ref": [ "r56", "r122" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of anti dilutive securities", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r35" ] }, "bnet_The2020ConvertibleObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "The2020ConvertibleObligationsMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "The 2020 Convertible Obligations [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r35" ] }, "bnet_BassaniFamilyTrustsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "BassaniFamilyTrustsMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bassani Family Trusts [Member]" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r682" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r38", "r39", "r40", "r138", "r139", "r142", "r143" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income (Loss) per share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r35", "r36" ] }, "bnet_RestrictedCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "RestrictedCommonStockMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Common Stock [Member]" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "bnet_SchaferMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "SchaferMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Schafer [Member]" } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14", "r647" ] }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "crdr": "debit", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Impairment of Long-Lived Assets Held-for-use", "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)." } } }, "auth_ref": [ "r5", "r41", "r112" ] }, "bnet_AdjustedConvertibleObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "AdjustedConvertibleObligationsMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Adjusted Convertible Obligations [Member]" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercisable per share", "verboseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r340" ] }, "bnet_ConvertibleObligations2020Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "ConvertibleObligations2020Member", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Obligations 2020 [Member]" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "verboseLabel": "Accounts payable and accrued liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r17" ] }, "bnet_CommonSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "CommonSharesMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Shares [Member]" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "bnet_IndirectOwnershipMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "IndirectOwnershipMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Indirect Ownership [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r186", "r187", "r188", "r216", "r491", "r521", "r542", "r545", "r546", "r547", "r548", "r549", "r550", "r552", "r555", "r556", "r557", "r558", "r559", "r563", "r564", "r565", "r566", "r568", "r569", "r570", "r571", "r572", "r574", "r578", "r579", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r595", "r652" ] }, "bnet_DirectOwnershipMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "DirectOwnershipMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Direct Ownership [Member]" } } }, "auth_ref": [] }, "bnet_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "WarrantsMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "http://biontech.com/role/StockholdersEquity-AssumptionsDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesTable", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Table]", "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations." } } }, "auth_ref": [ "r281", "r282", "r283", "r286", "r722", "r723" ] }, "bnet_MinorityInterestPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biontech.com/20230630", "localname": "MinorityInterestPolicyPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Noncontrolling interests" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible note", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r13", "r132", "r776" ] }, "bnet_EquityIssuancesWarrantsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biontech.com/20230630", "localname": "EquityIssuancesWarrantsPolicyPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Warrants" } } }, "auth_ref": [] }, "us-gaap_InterestCostsCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestCostsCapitalized", "crdr": "debit", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capitalized interest", "documentation": "Amount of interest capitalized during the period." } } }, "auth_ref": [ "r73" ] }, "bnet_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biontech.com/20230630", "localname": "ScheduleOfFutureMinimumLeasePaymentsForCapitalLeaseTableTextBlock", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule Of Future Minimum Lease Payment" } } }, "auth_ref": [] }, "bnet_ModificationOfWarrantsInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "ModificationOfWarrantsInterest", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Modification of warrants - interest" } } }, "auth_ref": [] }, "bnet_VestingOfOptionsForEmployeesAndServices": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "VestingOfOptionsForEmployeesAndServices", "crdr": "debit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Vesting of options for employees and services" } } }, "auth_ref": [] }, "bnet_StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "StockIssuedDuringPeriodValueCommissionsOnSaleOfUnits", "crdr": "debit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Commissions on sale of units" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAssumptionsUsedTableTextBlock", "presentation": [ "http://biontech.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of assumptions", "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate." } } }, "auth_ref": [ "r348" ] }, "bnet_ModificationOfWarrantsNoncashComp": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "ModificationOfWarrantsNoncashComp", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Modification of warrants - non-cash comp" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpense", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in prepaid expenses", "label": "Increase (Decrease) in Prepaid Expense", "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods." } } }, "auth_ref": [ "r4" ] }, "bnet_DebtModification": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "DebtModification", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Debt modification" } } }, "auth_ref": [] }, "us-gaap_InterestCostsIncurredCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestCostsIncurredCapitalized", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capitalized labor and interest costs", "documentation": "Amount of interest capitalized, including amount of allowance for funds used during construction." } } }, "auth_ref": [ "r81" ] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Decrease (increase) in operating lease assets and liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r686", "r703" ] }, "bnet_GainOnLegalDissolutionsOfSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "GainOnLegalDissolutionsOfSubsidiary", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on legal dissolution of subsidiary", "label": "GainOnLegalDissolutionsOfSubsidiary" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r22", "r44" ] }, "bnet_ModificationOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "ModificationOfWarrants", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Modification of warrants", "label": "ModificationOfWarrants" } } }, "auth_ref": [] }, "bnet_ProceedsFromSaleOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "ProceedsFromSaleOfUnits", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of units" } } }, "auth_ref": [] }, "us-gaap_SeriesCPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesCPreferredStockMember", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Series C Preferred Stock [Member]", "documentation": "Series C preferred stock." } } }, "auth_ref": [ "r695", "r696", "r727" ] }, "bnet_InterestExpenseRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "InterestExpenseRelatedParties", "crdr": "debit", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Related Party" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based Compensation, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r372" ] }, "bnet_CommissionsOnSaleOfUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "CommissionsOnSaleOfUnits", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Commissions on sale of units", "label": "CommissionsOnSaleOfUnits" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of warrants", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r9", "r45", "r120" ] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series B Preferred Stock [Member]", "documentation": "Series B preferred stock." } } }, "auth_ref": [ "r695", "r696", "r727" ] }, "bnet_CapitalizedInterestInPropertyAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "CapitalizedInterestInPropertyAndEquipment", "crdr": "debit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Capitalized interest in property and equipment" } } }, "auth_ref": [] }, "bnet_RedemptionOfPreferredSeriesBSharesAndInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "RedemptionOfPreferredSeriesBSharesAndInterest", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Redemption of Preferred Series B shares and interest" } } }, "auth_ref": [] }, "bnet_AdjustmentForDebtModification": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "AdjustmentForDebtModification", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustment for debt modification" } } }, "auth_ref": [] }, "bnet_ConversionOfDebtAndLiabilitiesIntoCommonUnits": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "ConversionOfDebtAndLiabilitiesIntoCommonUnits", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of debt and liabilities into common units" } } }, "auth_ref": [] }, "bnet_ConversionOfDebtAndLiabilitiesIntoNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "ConversionOfDebtAndLiabilitiesIntoNotesPayable", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of debt and liabilities into notes payable" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "bnet_ConversionOfDeferredCompensationToNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "ConversionOfDeferredCompensationToNotesPayable", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Conversion of deferred compensation to notes payable" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://biontech.com/role/StockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r11", "r12", "r60" ] }, "bnet_SharesIssuedForWarrantExerciseCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "SharesIssuedForWarrantExerciseCommissions", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Shares issued for warrant exercise commissions" } } }, "auth_ref": [] }, "bnet_PurchaseOfPropertyAndEquipmentForAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "PurchaseOfPropertyAndEquipmentForAccountsPayable", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Purchase of property and equipment for accounts payable" } } }, "auth_ref": [] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing transactions:" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseDiscountRate", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Discounted rate", "documentation": "Discount rate used by lessee to determine present value of operating lease payments." } } }, "auth_ref": [ "r645" ] }, "bnet_DisclosureConvertibleNotesPayableAffiliatesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biontech.com/20230630", "localname": "DisclosureConvertibleNotesPayableAffiliatesAbstract", "lang": { "en-us": { "role": { "label": "Convertible Notes Payable - Affiliates" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from sale of warrants", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r702" ] }, "bnet_ConvertibleDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biontech.com/20230630", "localname": "ConvertibleDebtTextBlock", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-Affiliates" ], "lang": { "en-us": { "role": { "label": "CONVERTIBLE NOTES PAYABLE - AFFILIATES" } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "bnet_OptionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biontech.com/20230630", "localname": "OptionsPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Options" } } }, "auth_ref": [] }, "us-gaap_SeriesAPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesAPreferredStockMember", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Series A Preferred Stock [Member]", "documentation": "Series A preferred stock." } } }, "auth_ref": [ "r695", "r696", "r727" ] }, "bnet_DisclosureSubscriptionReceivableAffiliatesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biontech.com/20230630", "localname": "DisclosureSubscriptionReceivableAffiliatesAbstract", "lang": { "en-us": { "role": { "label": "Subscription Receivable - Affiliates" } } }, "auth_ref": [] }, "bnet_SubscriptionReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biontech.com/20230630", "localname": "SubscriptionReceivableTextBlock", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-Affiliates" ], "lang": { "en-us": { "role": { "label": "SUBSCRIPTION RECEIVABLE - AFFILIATES" } } }, "auth_ref": [] }, "bnet_DeferredCompensationConvertibleToCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "DeferredCompensationConvertibleToCommonStock", "crdr": "credit", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation, Convertible to Common Stock" } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r186", "r187", "r188", "r216", "r491", "r521", "r542", "r545", "r546", "r547", "r548", "r549", "r550", "r552", "r555", "r556", "r557", "r558", "r559", "r563", "r564", "r565", "r566", "r568", "r569", "r570", "r571", "r572", "r574", "r578", "r579", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r595", "r652" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r35" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r105" ] }, "bnet_TechWastage": { "xbrltype": "decimalItemType", "nsuri": "http://biontech.com/20230630", "localname": "TechWastage", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Tech wastage" } } }, "auth_ref": [] }, "us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockShareSubscribedButUnissuedSubscriptionsReceivable", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "negatedLabel": "Subscription receivable - affiliates (Note 8)", "label": "Common Stock, Share Subscribed but Unissued, Subscriptions Receivable", "documentation": "Amount of subscription receivable from investors who have been allocated common stock." } } }, "auth_ref": [ "r91", "r561", "r600" ] }, "bnet_DeferredCompensationConvertibleToCommonStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://biontech.com/20230630", "localname": "DeferredCompensationConvertibleToCommonStockPricePerShare", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation, Convertible to Common Stock, Price Per Share (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_SalariesAndWages": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalariesAndWages", "crdr": "debit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Salary paid", "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold." } } }, "auth_ref": [ "r699" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash at beginning of year", "periodEndLabel": "Cash at end of year", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r30", "r105", "r176" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r91" ] }, "bnet_DeferredCompensationInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "DeferredCompensationInterest", "crdr": "credit", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred compensation interest" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "bnet_CattlePerHead": { "xbrltype": "decimalItemType", "nsuri": "http://biontech.com/20230630", "localname": "CattlePerHead", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cattle per head" } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r664" ] }, "bnet_AggregatePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "AggregatePayment", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate payment" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting period", "documentation": "Date the equity-based award expires, in YYYY-MM-DD format." } } }, "auth_ref": [ "r730" ] }, "bnet_TotalValueOfConsultantService": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "TotalValueOfConsultantService", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total value of consultant services" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "us-gaap_LessorLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LessorLeasesPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lease Accounting", "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor." } } }, "auth_ref": [ "r144", "r145", "r146", "r452" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, no par value, 250,000,000 shares authorized, 48,044,790 and 43,758,820 shares issued, respectively; 47,340,480 and 43,054,511 shares outstanding, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r91", "r500", "r647" ] }, "bnet_InterestCostsCapitalizedPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "InterestCostsCapitalizedPaid", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capitalized labor and interest costs paid" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liability, current (Note 9)", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r450" ] }, "bnet_InterestExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "InterestExpenses", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest expenses" } } }, "auth_ref": [] }, "bnet_PurchaseOrder": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "PurchaseOrder", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Purchase order" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://biontech.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENCIES:", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r113", "r279", "r280", "r618", "r721" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r668" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, authorized (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r91", "r552" ] }, "bnet_FormerEmployeeCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "FormerEmployeeCompensation", "crdr": "debit", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Former employee compensation" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r91", "r552", "r573", "r781", "r782" ] }, "bnet_CancellationOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20230630", "localname": "CancellationOfWarrants", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cancellation of warrants" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "bnet_PercentageOfSustainable": { "xbrltype": "percentItemType", "nsuri": "http://biontech.com/20230630", "localname": "PercentageOfSustainable", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Percentage of sustainable" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r669" ] }, "bnet_SharebasedCompensationGranted": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20230630", "localname": "SharebasedCompensationGranted", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation, Granted" } } }, "auth_ref": [] }, "bnet_ExerciseBonus": { "xbrltype": "percentItemType", "nsuri": "http://biontech.com/20230630", "localname": "ExerciseBonus", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise bonus" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "bnet_DescriptionOfKreider2PoultryProject": { "xbrltype": "stringItemType", "nsuri": "http://biontech.com/20230630", "localname": "DescriptionOfKreider2PoultryProject", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of kreider 2 poultry project" } } }, "auth_ref": [] }, "bnet_GainOnSaleOfDomainAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "GainOnSaleOfDomainAmount", "crdr": "debit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gain on sale of domain" } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations", "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Depreciation", "verboseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r5", "r42" ] }, "bnet_PreferredStockConvertibleOptionPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://biontech.com/20230630", "localname": "PreferredStockConvertibleOptionPerShare", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Convertible Option Per Share" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease liability, long term (Note 9)", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r450" ] }, "bnet_ReductionOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "ReductionOfDebt", "crdr": "debit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reduction of debt" } } }, "auth_ref": [] }, "bnet_NotesReceivableInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "NotesReceivableInterest", "crdr": "debit", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Notes receivable interest" } } }, "auth_ref": [] }, "bnet_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "WorkingCapital", "crdr": "debit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working Capital" } } }, "auth_ref": [] }, "us-gaap_PaymentsForCommissions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForCommissions", "crdr": "credit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Commissions paid", "documentation": "The amount of cash paid for commissions during the current period." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "bnet_UndiscountedCashFlow": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "UndiscountedCashFlow", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Undiscounted cash flow" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r670" ] }, "bnet_FinancingReceivablePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "FinancingReceivablePrincipalAmount", "crdr": "debit", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Financing Receivable, Principal Amount" } } }, "auth_ref": [] }, "bnet_OperatingLeasesFutureMinimumPaymentReceivableInTwoYears": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "OperatingLeasesFutureMinimumPaymentReceivableInTwoYears", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Year ended June 30, 2023 to June 2024" } } }, "auth_ref": [] }, "bnet_DeferredCompensationLiabilityAmountCancelled": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "DeferredCompensationLiabilityAmountCancelled", "crdr": "debit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Liability, Amount Cancelled" } } }, "auth_ref": [] }, "bnet_SharesIssuedBeginningOfPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20230630", "localname": "SharesIssuedBeginningOfPeriod", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "lang": { "en-us": { "role": { "label": "Shares issued \u2013 beginning of period" } } }, "auth_ref": [] }, "bnet_OperatingLeasesFutureMinimumPaymentReceivableInThreeYears": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "OperatingLeasesFutureMinimumPaymentReceivableInThreeYears", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Year ended June 30, 2024 to December 2024" } } }, "auth_ref": [] }, "bnet_SharesHeldBySubsidiaries": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20230630", "localname": "SharesHeldBySubsidiaries", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares held by subsidiaries (Note 7)", "negatedLabel": "Shares Held by Subsidiaries" } } }, "auth_ref": [] }, "us-gaap_DividendsPreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DividendsPreferredStock", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Dividends, Preferred Stock", "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)." } } }, "auth_ref": [ "r2", "r120" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares issued, warrants", "verboseLabel": "Number of shares issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r9" ] }, "bnet_LessImputedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "LessImputedInterest", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Less imputed interest" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashExpense", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accrued interest on loans payable, deferred compensation and other", "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other." } } }, "auth_ref": [ "r107" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "auth_ref": [] }, "bnet_SharesOutstandingBeginningOfPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20230630", "localname": "SharesOutstandingBeginningOfPeriod", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "lang": { "en-us": { "role": { "label": "Shares outstanding \u2013 beginning of period" } } }, "auth_ref": [] }, "bnet_CompensationConserveCash": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "CompensationConserveCash", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash compensation paid" } } }, "auth_ref": [] }, "bnet_WeightedAverageSharesIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20230630", "localname": "WeightedAverageSharesIssuedDuringPeriod", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average shares issued \u00a0\u00a0\u00a0\u00a0during the period" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r673", "r675", "r676" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "bnet_CapitalLeaseContingentRentalPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "CapitalLeaseContingentRentalPaymentsDue", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Total" } } }, "auth_ref": [] }, "bnet_ComputersAndOfficeEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "ComputersAndOfficeEquipment", "crdr": "debit", "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computers and office equipment" } } }, "auth_ref": [] }, "us-gaap_NotesReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesReceivableNet", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Financing Receivable, after Allowance for Credit Loss, Total", "documentation": "Amortized cost, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement and net investment in lease." } } }, "auth_ref": [ "r234", "r273", "r562" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "bnet_FinanceLeasesLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "FinanceLeasesLiabilityCurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less current portion", "label": "FinanceLeasesLiabilityCurrent" } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expense", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r674" ] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 }, "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows", "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss)", "label": "Net income (loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r97", "r107", "r135", "r152", "r163", "r164", "r167", "r180", "r189", "r191", "r192", "r193", "r194", "r197", "r198", "r209", "r219", "r224", "r228", "r230", "r265", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r438", "r439", "r510", "r575", "r593", "r594", "r630", "r659", "r724" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r672" ] }, "bnet_NonCashCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "NonCashCompensation", "crdr": "debit", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Non cash compensation" } } }, "auth_ref": [] }, "bnet_MonthlyOfficersCashCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "MonthlyOfficersCashCompensation", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Monthly Officers Cash Compensation" } } }, "auth_ref": [] }, "us-gaap_PaymentsForFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForFees", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Payment for cash", "documentation": "Amount of cash outflow for fees classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net income (loss) applicable to Bion's common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r170", "r191", "r192", "r193", "r194", "r200", "r201", "r210", "r213", "r219", "r224", "r228", "r230", "r630" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation for services", "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims." } } }, "auth_ref": [ "r5" ] }, "bnet_DeferredCompensationConsecutiveTradingDays": { "xbrltype": "durationItemType", "nsuri": "http://biontech.com/20230630", "localname": "DeferredCompensationConsecutiveTradingDays", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Consecutive Trading Days (Day)" } } }, "auth_ref": [] }, "bnet_InterestRateOnDeferredCompensation": { "xbrltype": "percentItemType", "nsuri": "http://biontech.com/20230630", "localname": "InterestRateOnDeferredCompensation", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest Rate on Deferred Compensation" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r321", "r337", "r434", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r511", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r715", "r716", "r717", "r718" ] }, "bnet_CompensationIncreased": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "CompensationIncreased", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Compensation increased" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSecuritizationOfFinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSecuritizationOfFinancialAssets", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Realized from the asset sale", "documentation": "A gain (loss) realized on a transfer, accounted for as a sale, of all or a portion of financial assets in which the transferor surrenders control and receives consideration other than a beneficial interest in the assets transferred. Reflects the amount of sales proceeds in excess of, or deficient from, the sum of the carrying amounts of transferred financial assets plus transaction costs." } } }, "auth_ref": [ "r462", "r700", "r701", "r704", "r774" ] }, "us-gaap_CostsIncurredDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsIncurredDevelopmentCosts", "crdr": "debit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capitalized amount", "verboseLabel": "Cost incurred", "documentation": "Development costs incurred, including capitalized costs and costs charged to expense, in oil and gas activities." } } }, "auth_ref": [ "r77" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r677" ] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of stock, shares", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r105", "r106", "r107" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Granted, weighted-average exercise price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r372" ] }, "bnet_FinancingReceivableInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://biontech.com/20230630", "localname": "FinancingReceivableInterestRateStatedPercentage", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Financing receivable interest rate stated percentage", "verboseLabel": "Financing Receivable, Interest Rate, Stated Percentage" } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES" } } }, "auth_ref": [] }, "bnet_RedemptionOfConvertiblePreferredStock": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "RedemptionOfConvertiblePreferredStock", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Redemption of convertible Preferred stock" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationLiabilityCurrent", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred compensation (Note 4)", "verboseLabel": "Deferred compensation liability", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date." } } }, "auth_ref": [ "r57", "r121" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Patents", "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined." } } }, "auth_ref": [ "r8" ] }, "bnet_ExercisePriceAdjustmentProvisionInPercentage": { "xbrltype": "percentItemType", "nsuri": "http://biontech.com/20230630", "localname": "ExercisePriceAdjustmentProvisionInPercentage", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise price adjustment provision Percentage" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Exercised, weighted-average exercise price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r373" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r451", "r646" ] }, "bnet_DeferredCompensationMaximumConvertibleAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "DeferredCompensationMaximumConvertibleAmount", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation, Maximum Convertible Amount" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Expired, weighted-average exercise price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r375" ] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Slae of share price", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r675" ] }, "us-gaap_PrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssets", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Paid invoice amount", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets." } } }, "auth_ref": [] }, "bnet_DeferredCompensationStockConversionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://biontech.com/20230630", "localname": "DeferredCompensationStockConversionPricePerShare", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation, Stock Conversion, Price Per Share (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Forfeited, weighted-average exercise price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r374" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r220", "r221", "r223", "r226", "r227", "r231", "r232", "r233", "r342", "r343", "r491" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r185", "r314" ] }, "bnet_CommonStockSharesIssuedUponExerciseOfWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20230630", "localname": "CommonStockSharesIssuedUponExerciseOfWarrants", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock Shares Issued upon Exercise of Warrants" } } }, "auth_ref": [] }, "bnet_InterestBearingSecuredPromissoryNote": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "InterestBearingSecuredPromissoryNote", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest bearing secured promissory note" } } }, "auth_ref": [] }, "bnet_WarrantsHeldByTrustOwned": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "WarrantsHeldByTrustOwned", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants held by trust owned" } } }, "auth_ref": [] }, "us-gaap_AdjustmentOfWarrantsGrantedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentOfWarrantsGrantedForServices", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Warrants issued for compensation for services", "documentation": "Adjustment for noncash service expenses paid for by granting of warrants." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document financial statement error correction", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r673", "r675", "r676", "r678" ] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and administrative (including stock-based compensation)", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r101", "r579" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r679" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r185", "r314" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r7", "r185", "r314" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r675" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r18", "r180", "r265", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r423", "r426", "r427", "r439", "r551", "r629", "r661", "r724", "r764", "r765" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Noncontrolling interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r27", "r133", "r180", "r265", "r287", "r289", "r290", "r291", "r294", "r295", "r439", "r503", "r554" ] }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "presentation": [ "http://biontech.com/role/KPlan" ], "lang": { "en-us": { "role": { "label": "401(k) PLAN:", "documentation": "The entire disclosure for retirement benefits." } } }, "auth_ref": [ "r344", "r345", "r346", "r347", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r639" ] }, "bnet_WarrantsAndRightsOutstandings": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "WarrantsAndRightsOutstandings", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Non cash compensation", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r393", "r405" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r90", "r552", "r573", "r781", "r782" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r662" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "bnet_InterestsCostsIncurredCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "InterestsCostsIncurredCapitalized", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Capitalized labor and interest costs", "label": "InterestsCostsIncurredCapitalized" } } }, "auth_ref": [] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "auth_ref": [ "r714" ] }, "bnet_SaleOfDomainDescription": { "xbrltype": "stringItemType", "nsuri": "http://biontech.com/20230630", "localname": "SaleOfDomainDescription", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sale of domain, description" } } }, "auth_ref": [] }, "us-gaap_DirectCommunicationsAndUtilitiesCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DirectCommunicationsAndUtilitiesCosts", "crdr": "debit", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate cost", "documentation": "The aggregate costs of direct communications and utilities incurred during the reporting period." } } }, "auth_ref": [ "r100" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock- based compensation", "verboseLabel": "Cash compensation paid", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r4" ] }, "bnet_BankAccountHackedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "BankAccountHackedAmount", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bank account hacked amount" } } }, "auth_ref": [] }, "srt_ChiefOperatingOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefOperatingOfficerMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Chief Operating Officer [Member]" } } }, "auth_ref": [ "r714", "r762" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentrations of credit risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r80", "r140" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r90", "r325" ] }, "bnet_SaleOfStockShares": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20230630", "localname": "SaleOfStockShares", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Slae of shares" } } }, "auth_ref": [] }, "bnet_WarrantsExercised": { "xbrltype": "perShareItemType", "nsuri": "http://biontech.com/20230630", "localname": "WarrantsExercised", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercised" } } }, "auth_ref": [] }, "bnet_IncomeTaxReconciliationPermanentDifferences": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "IncomeTaxReconciliationPermanentDifferences", "crdr": "debit", "calculation": { "http://biontech.com/role/IncomeTaxesDetails": { "parentTag": "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Permanent differences and other", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)." } } }, "auth_ref": [] }, "bnet_ConversionPricePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://biontech.com/20230630", "localname": "ConversionPricePerUnit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Conversion price per unit", "verboseLabel": "Conversion Price Per Unit (in dollars per share)" } } }, "auth_ref": [] }, "bnet_EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingAllowanceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "EffectiveIncomeTaxRateReconciliationExpirationOfNetOperatingAllowanceAmount", "crdr": "debit", "calculation": { "http://biontech.com/role/IncomeTaxesDetails": { "parentTag": "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biontech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Expiration of net operating allowances", "documentation": "Amount of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to expiration of net operating allowance." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r96", "r134", "r504", "r647", "r707", "r719", "r761" ] }, "bnet_DeferredTaxAssetsBusinessInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "DeferredTaxAssetsBusinessInterest", "crdr": "debit", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Business interest", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from business interest." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Noncontrolling interest, ownership percentage by parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "bnet_ReductionOfAdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "ReductionOfAdditionalPaidInCapital", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Reduction of additional paid in capital" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "LIABILITIES AND EQUITY (DEFICIT)" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r93", "r120", "r502", "r517", "r518", "r526", "r553", "r647" ] }, "bnet_WarrantsExercisedForCommonStocks": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "WarrantsExercisedForCommonStocks", "crdr": "credit", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total proceeds" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r449" ] }, "bnet_TotalValueOfConsultantServices": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "TotalValueOfConsultantServices", "crdr": "debit", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Total value of consultant services", "label": "TotalValueOfConsultantServices" } } }, "auth_ref": [] }, "srt_PresidentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "PresidentMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "President [Member]" } } }, "auth_ref": [ "r714" ] }, "us-gaap_IncomeLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperations", "crdr": "credit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net income", "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent." } } }, "auth_ref": [ "r65", "r99", "r107", "r191", "r192", "r193", "r194", "r209", "r213" ] }, "bnet_UnreimbursedExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "UnreimbursedExpenses", "crdr": "debit", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unreimbursed expenses" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r676" ] }, "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Receivable Type [Axis]", "documentation": "Information by type of receivable." } } }, "auth_ref": [ "r25" ] }, "bnet_ClassOfWarrantOrRightExercisedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20230630", "localname": "ClassOfWarrantOrRightExercisedDuringPeriod", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercised During Period" } } }, "auth_ref": [] }, "us-gaap_DebtDefaultLongtermDebtAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDefaultLongtermDebtAmount", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Debt Default, Amount", "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured." } } }, "auth_ref": [ "r178" ] }, "us-gaap_InterestCostsCapitalizedAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestCostsCapitalizedAdjustment", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capitalized labor and interest costs yet to pay", "documentation": "Amount of interest costs capitalized disclosed as an adjusting item to interest costs incurred." } } }, "auth_ref": [] }, "bnet_ConversionPricePerUnits": { "xbrltype": "perShareItemType", "nsuri": "http://biontech.com/20230630", "localname": "ConversionPricePerUnits", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Conversion price per unit", "label": "ConversionPricePerUnits" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r676" ] }, "us-gaap_ConstructionInProgressGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressGross", "crdr": "debit", "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Initial Project: construction in process", "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [ "r111" ] }, "bnet_WarrantExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://biontech.com/20230630", "localname": "WarrantExercisePrice", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant exercise price" } } }, "auth_ref": [] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingenciesLineItems", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r281", "r282", "r283", "r286", "r722", "r723" ] }, "bnet_WarrantsExercisePricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://biontech.com/20230630", "localname": "WarrantsExercisePricePercentage", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants exercise price percentage" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r675" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://biontech.com/role/StockholdersEquity-AssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r391" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r92", "r647", "r779" ] }, "bnet_VestingOfOptionsForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "VestingOfOptionsForServices", "crdr": "debit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Vesting of options for services" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquity-AssumptionsDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r388", "r389", "r390", "r391", "r392" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r161", "r277", "r278", "r622" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r20", "r154", "r180", "r265", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r423", "r426", "r427", "r439", "r647", "r724", "r764", "r765" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other (income) expense:" } } }, "auth_ref": [] }, "bnet_WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "WarrantsIssuedInConnectionWithSaleOfUnitsInExchangeForSalaryMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants Issued In Connection With Sale Of Units In Exchange For Salary [Member]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://biontech.com/role/StockholdersEquity-AssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r361", "r362", "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r388", "r389", "r390", "r391", "r392" ] }, "bnet_SmithsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "SmithsMember", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Smiths [Member]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://biontech.com/role/StockholdersEquity-AssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r361", "r362", "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r388", "r389", "r390", "r391", "r392" ] }, "bnet_ExtensionBonusMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "ExtensionBonusMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Extension Bonus [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "auth_ref": [] }, "bnet_Fy2016ExtensionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "Fy2016ExtensionAgreementMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fy 2016 Extension Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Original conversion price", "verboseLabel": "Conversion price per share", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r116", "r299" ] }, "bnet_WarrantsExpiringOnDecember312025Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "WarrantsExpiringOnDecember312025Member", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants Expiring On December 312025 [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total other expense", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r103" ] }, "bnet_SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "SecuredPromissoryNoteConsiderationForWarrantsExpiringOnDecember312025Member", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Secured Promissory Note Consideration For Warrants Expiring On December 312025 [Member]" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r665" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development (including stock-based compensation)", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r82", "r406", "r772" ] }, "bnet_WilliamONeillMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "WilliamONeillMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "William O Neill [Member]" } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipAxis", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r664" ] }, "bnet_InterestsExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "InterestsExpense", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest expense" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of property and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "bnet_DeficitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biontech.com/20230630", "localname": "DeficitAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity (deficit):" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "bnet_GainOnSaleOfDomains": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "GainOnSaleOfDomains", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on sale of domain", "label": "GainOnSaleOfDomains" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r360", "r367", "r386", "r387", "r388", "r389", "r392", "r401", "r402", "r403", "r404" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "OwnershipDomain", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "auth_ref": [] }, "bnet_IssuanceOfWarrantsForWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "IssuanceOfWarrantsForWarrants", "crdr": "debit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of warrants" } } }, "auth_ref": [] }, "us-gaap_GainOrLossOnSaleOfStockInSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainOrLossOnSaleOfStockInSubsidiary", "crdr": "credit", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gain on legal dissolution of subsidiary", "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries." } } }, "auth_ref": [ "r700", "r701", "r704", "r773" ] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r75", "r136", "r168", "r222", "r447", "r580", "r659", "r780" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r454", "r455", "r763" ] }, "bnet_GainOnLegalDissolutionOfSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "GainOnLegalDissolutionOfSubsidiary", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on legal dissolution of subsidiary", "label": "GainOnLegalDissolutionOfSubsidiary" } } }, "auth_ref": [] }, "bnet_SaleOfUnitsValue": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "SaleOfUnitsValue", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Sale of units" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r137", "r499", "r541", "r560", "r647", "r661", "r694" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sales of common stock", "verboseLabel": "Sale of common shares", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r90", "r91", "r120", "r530", "r595", "r612", "r660" ] }, "us-gaap_ExtinguishmentOfDebtGainLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExtinguishmentOfDebtGainLossNetOfTax", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Gain on legal dissolution of subsidiary", "label": "Extinguishment of Debt, Gain (Loss), Net of Tax", "documentation": "The difference between the reacquisition price and the net carrying amount of the extinguished debt recognized currently as a component of income in the period of extinguishment, net of tax." } } }, "auth_ref": [ "r46" ] }, "bnet_SaleOfUnitsShares": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20230630", "localname": "SaleOfUnitsShares", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Sale of units, shares" } } }, "auth_ref": [] }, "bnet_AdjustmentToAdditionalPaidInCapitalModificationOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "AdjustmentToAdditionalPaidInCapitalModificationOfWarrants", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Modification of warrants" } } }, "auth_ref": [] }, "bnet_WarrantsExercisedForCommonShares": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "WarrantsExercisedForCommonShares", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Warrants exercised for common shares" } } }, "auth_ref": [] }, "bnet_WarrantsExercisedForCommonSharesShares": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20230630", "localname": "WarrantsExercisedForCommonSharesShares", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Warrants exercised for common shares , shares" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "presentation": [ "http://biontech.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r755", "r758" ] }, "bnet_IssuanceOfWarrantsForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "IssuanceOfWarrantsForServices", "crdr": "debit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of warrants for services" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of shares exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r9", "r24", "r120" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Conversion of debt and liabilities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r9", "r24", "r120" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Derivative Financial Instruments", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r10", "r69", "r70", "r71", "r72", "r184" ] }, "bnet_WarrantsExercisedForCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "WarrantsExercisedForCommonStock", "crdr": "credit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant Exercised for Common Stock" } } }, "auth_ref": [] }, "bnet_CommissionsOnWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://biontech.com/20230630", "localname": "CommissionsOnWarrantExercises", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Commissions on warrant exercises" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "per basic common share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r169", "r191", "r192", "r193", "r194", "r195", "r200", "r203", "r211", "r212", "r213", "r215", "r437", "r438", "r492", "r512", "r628" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r102", "r316", "r323", "r636", "r637" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sales of common stock, shares", "verboseLabel": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r90", "r91", "r120", "r522", "r595", "r612" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r649", "r650", "r653", "r654", "r655", "r656" ] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "bnet_CommissionsOnWarrantExercisesShares": { "xbrltype": "sharesItemType", "nsuri": "http://biontech.com/20230630", "localname": "CommissionsOnWarrantExercisesShares", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Commissions on warrant exercises , shares" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAnnualPrincipalPayment", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Annual Principal Payment", "documentation": "Amount of the total principal payments made during the annual reporting period." } } }, "auth_ref": [ "r13" ] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Loans as a liability", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r87", "r130" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r340" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://biontech.com/role/StockholdersEquity" ], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY:", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r117", "r179", "r324", "r326", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r338", "r341", "r435", "r598", "r599", "r617" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754" ] }, "bnet_WarrantsIssusedSubscriptionReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "WarrantsIssusedSubscriptionReceivableMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants Issused Subscription Receivable [Member]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Cash equivalents", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r694", "r777" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant outstanding", "verboseLabel": "Number of shares warrants outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r58" ] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Repayments of Long-term Debt, Total", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r29", "r525" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "auth_ref": [ "r182", "r183", "r300", "r327", "r456", "r624", "r625" ] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate During Period", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": [ "r21", "r74", "r315" ] }, "bnet_ExecutiveViceChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "ExecutiveViceChairmanMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Executive Vice Chairman [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r446", "r458" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r729", "r730", "r731", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r739", "r740", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754" ] }, "bnet_AccruedInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "AccruedInterestMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Accrued Interest [Member]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "crdr": "debit", "calculation": { "http://biontech.com/role/IncomeTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biontech.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income tax benefit", "label": "Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation", "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation." } } }, "auth_ref": [ "r84", "r85", "r86", "r759" ] }, "bnet_PrincipalMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "PrincipalMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r21", "r298" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r91" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r63", "r341", "r708", "r709", "r710", "r781" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquity-AssumptionsDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r364", "r365", "r366", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r388", "r389", "r390", "r391", "r392" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r446", "r458" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r446", "r458" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r649", "r650", "r651", "r653", "r654", "r655", "r656", "r708", "r709", "r760", "r778", "r781" ] }, "bnet_AfterAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "AfterAdjustmentMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "After Adjustment [Member]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity (deficit)", "periodStartLabel": "Beginning balance, value", "periodEndLabel": "Ending balance, value", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r63", "r64", "r67", "r150", "r151", "r166", "r186", "r187", "r188", "r190", "r196", "r266", "r267", "r341", "r398", "r399", "r400", "r414", "r415", "r428", "r429", "r430", "r431", "r432", "r433", "r436", "r440", "r441", "r445", "r453", "r515", "r516", "r528", "r554", "r573", "r596", "r597", "r616", "r660", "r707", "r719", "r761", "r781" ] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Long term lease liability", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": [ "r13", "r498" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://biontech.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS:", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r457", "r459" ] }, "bnet_SubscriptionsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "SubscriptionsReceivableMember", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Subscriptions Receivable [Member]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingAssets", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Increase (decrease) in deposits in other assets", "label": "Increase (Decrease) in Other Operating Assets", "documentation": "Amount of increase (decrease) in operating assets classified as other." } } }, "auth_ref": [ "r4" ] }, "bnet_SecuredPromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "SecuredPromissoryNoteMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Secured Promissory Note [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r446", "r458" ] }, "us-gaap_DebtInstrumentPeriodicPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentPeriodicPayment", "crdr": "debit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal, interest", "documentation": "Amount of the required periodic payments including both interest and principal payments." } } }, "auth_ref": [ "r22", "r79" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorLocation", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r673", "r675", "r676" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorName", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r673", "r675", "r676" ] }, "bnet_ShareholderMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "ShareholderMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shareholder [Member]" } } }, "auth_ref": [] }, "bnet_PennvestLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "PennvestLoanMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Pennvest Loan [Member]" } } }, "auth_ref": [] }, "bnet_InterestExpenseOnDeferredCompensationObligationMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "InterestExpenseOnDeferredCompensationObligationMember", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest Expense On Deferred Compensation Obligation [Member]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfWarrants", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Commissions on sale of warrants", "label": "Payments for Repurchase of Warrants", "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt." } } }, "auth_ref": [ "r28" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principal amount", "verboseLabel": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r74", "r76", "r297", "r448", "r634", "r635" ] }, "bnet_ConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "ConsultantsMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultants [Member]" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r22", "r185", "r297", "r298", "r299", "r300", "r301", "r303", "r308", "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r448", "r633", "r634", "r635", "r636", "r637", "r706" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditorFirmId", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r673", "r675", "r676" ] }, "bnet_Gen3TechMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "Gen3TechMember", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Gen 3 Tech [Member]" } } }, "auth_ref": [] }, "bnet_JVAMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "JVAMember", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "J V A [Member]" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentOtherNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r43", "r156", "r506" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://biontech.com/role/PropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "PROPERTY AND EQUIPMENT", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r110", "r141", "r147", "r148" ] }, "bnet_ConsultantServiceMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "ConsultantServiceMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultant Service [Member]" } } }, "auth_ref": [] }, "bnet_CenterpointMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "CenterpointMember", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Centerpoint [Member]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://biontech.com/role/SubsequentEventsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r446", "r458" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperationsParenthetical", "http://biontech.com/role/SignificantAccountingPolicies-EarningsPerShareBasicAndDilutedDetails" ], "lang": { "en-us": { "role": { "label": "Weighted-average number of common shares outstanding, diluted", "verboseLabel": "Diluted weighted average shares \u2013 \u00a0\u00a0\u00a0\u00a0end of period", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r202", "r213" ] }, "bnet_ConsultantServiceOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "ConsultantServiceOneMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultant Service One [Member]" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r15" ] }, "bnet_ConvertiblePreferredStockAntidilutiveSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "ConvertiblePreferredStockAntidilutiveSecuritiesMember", "presentation": [ "http://biontech.com/role/SignificantAccountingPolicies-AntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Preferred Stock Antidilutive Securities [Member]" } } }, "auth_ref": [] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "bnet_PropertyPlantAndEquipmentOfPA1Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "PropertyPlantAndEquipmentOfPA1Member", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment Of P A 1 [Member]" } } }, "auth_ref": [] }, "bnet_The2020OneConvertibleObligationsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "The2020OneConvertibleObligationsMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "The 2020 One Convertible Obligations [Member]" } } }, "auth_ref": [] }, "bnet_BassaniMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "BassaniMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bassani [Member]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "Weighted-average number of common shares outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r200", "r213" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Sell units", "verboseLabel": "Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "bnet_ThreeConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "ThreeConsultantsMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Three Consultants [Member]" } } }, "auth_ref": [] }, "bnet_SmithMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "SmithMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Smith [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r6" ] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://biontech.com/role/LoansPayable" ], "lang": { "en-us": { "role": { "label": "LOANS PAYABLE", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r114", "r178", "r296", "r302", "r303", "r304", "r305", "r306", "r307", "r312", "r319", "r320", "r322" ] }, "bnet_ConsultantsAndEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "ConsultantsAndEmployeeMember", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Consultants And Employee [Member]" } } }, "auth_ref": [] }, "us-gaap_ConstructionLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionLoan", "crdr": "credit", "presentation": [ "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Construction Loan", "documentation": "This element represents the carrying value of a short-term real estate loan to finance building costs. The funds are disbursed as needed or in accordance with a prearranged plan; generally, a portion of the funds is disbursed at inception and the remainder as construction progresses. The money is repaid on completion of the project, usually from the proceeds of a mortgage loan. The rate is normally higher than the prime rate, and there is usually an origination fee. The effective yield on these loans tends to be high, and the lender has a security interest in the real property. Note that there are separate concepts for the current and noncurrent portions of long-term construction loans." } } }, "auth_ref": [ "r87" ] }, "bnet_EquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "EquityIncentivePlanMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Incentive Plan [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r111" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r714", "r762" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r158", "r159", "r160", "r217", "r325", "r326", "r327", "r329", "r332", "r337", "r339", "r522", "r523", "r524", "r525", "r638", "r683", "r705" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r22" ] }, "bnet_FormerEmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "FormerEmployeeMember", "presentation": [ "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Former Employee [Member]" } } }, "auth_ref": [] }, "bnet_BassaniAndSmithMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "BassaniAndSmithMember", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bassani And Smith [Member]" } } }, "auth_ref": [] }, "bnet_NorthropMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "NorthropMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Northrop [Member]" } } }, "auth_ref": [] }, "us-gaap_PreferredStockRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockRedemptionPricePerShare", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Redemption Price Per Share", "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer." } } }, "auth_ref": [ "r50", "r51", "r54" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r13", "r87", "r88", "r130", "r132", "r185", "r297", "r298", "r299", "r300", "r301", "r303", "r308", "r309", "r310", "r311", "r313", "r314", "r315", "r316", "r317", "r318", "r448", "r633", "r634", "r635", "r636", "r637", "r706" ] }, "bnet_Plan2006Member": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "Plan2006Member", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan 2006 [Member]" } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r268", "r269", "r270", "r271", "r272", "r274", "r275", "r276", "r321", "r337", "r434", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r511", "r632", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r715", "r716", "r717", "r718" ] }, "bnet_BillONeillMember": { "xbrltype": "domainItemType", "nsuri": "http://biontech.com/20230630", "localname": "BillONeillMember", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Bill O Neill [Member]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://biontech.com/role/PropertyAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r13", "r132", "r776" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r578", "r621", "r627" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares purchased, value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r9", "r90", "r91", "r120", "r530", "r595", "r614", "r660" ] }, "us-gaap_OtherAdditionalCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAdditionalCapital", "crdr": "credit", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Additional paid amount", "documentation": "Amount of additional paid-in capital (APIC) classified as other." } } }, "auth_ref": [ "r26", "r501" ] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deposits and other assets", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": [ "r697" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://biontech.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards, Total", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r61" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r115", "r297", "r298", "r308", "r309", "r310", "r314", "r315", "r316", "r317", "r318", "r633", "r634", "r635", "r636", "r637" ] }, "us-gaap_NatureOfExpenseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfExpenseAxis", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Nature of Expense [Axis]", "documentation": "Information by type of cost or expense." } } }, "auth_ref": [ "r37" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Remaining contractual life", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r123" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r681" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r219", "r224", "r228", "r230", "r630" ] }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Impairment", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment." } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible notes payable", "verboseLabel": "Convertible Notes Payable, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r19" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperationsParenthetical" ], "lang": { "en-us": { "role": { "label": "per Diluted common share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r169", "r191", "r192", "r193", "r194", "r195", "r203", "r211", "r212", "r213", "r215", "r437", "r438", "r492", "r512", "r628" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r152", "r163", "r164", "r172", "r180", "r189", "r197", "r198", "r219", "r224", "r228", "r230", "r265", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r421", "r424", "r425", "r438", "r439", "r493", "r508", "r529", "r575", "r593", "r594", "r630", "r643", "r644", "r660", "r698", "r724" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_OptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OptionMember", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options Held [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)." } } }, "auth_ref": [ "r128", "r563", "r568", "r583", "r589", "r605", "r606", "r607", "r649", "r650" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r149", "r158", "r159", "r160", "r180", "r203", "r204", "r211", "r213", "r217", "r218", "r265", "r287", "r289", "r290", "r291", "r294", "r295", "r325", "r326", "r329", "r332", "r339", "r439", "r522", "r523", "r524", "r525", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r542", "r552", "r576", "r595", "r611", "r612", "r613", "r614", "r615", "r683", "r705", "r712" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://biontech.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of deferred tax assets and liabilities", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r125" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation", "crdr": "debit", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Deferred compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation." } } }, "auth_ref": [ "r62", "r757" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Gross deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r411" ] }, "us-gaap_ConvertibleLongTermNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleLongTermNotesPayable", "crdr": "credit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Convertible notes payable - affiliates (Note 6)", "verboseLabel": "Convertible Notes Payable, Noncurrent", "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://biontech.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of effective income tax rate reconciliation", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r124" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Issuance of units for services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r420" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Issuance of units for services, shares", "verboseLabel": "Shares issued for consultant services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock-based compensation", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r62", "r757" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r420" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss attributable to the noncontrolling interest", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r68", "r127", "r163", "r164", "r197", "r198", "r509", "r698" ] }, "bnet_SaleOfUnitPricePerUnit": { "xbrltype": "perShareItemType", "nsuri": "http://biontech.com/20230630", "localname": "SaleOfUnitPricePerUnit", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Sale of units", "label": "SaleOfUnitPricePerUnit" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted-average number of common shares outstanding:" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://biontech.com/role/DeferredCompensation" ], "lang": { "en-us": { "role": { "label": "DEFERRED COMPENSATION", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r360", "r363", "r394", "r395", "r397", "r641" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Shares purchased, shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r9", "r90", "r91", "r120", "r525", "r595", "r614" ] }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsLiabilitiesNet", "crdr": "debit", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Net deferred tax assets", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting." } } }, "auth_ref": [ "r756" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquity-AssumptionsDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r345", "r358", "r389", "r390", "r391", "r466", "r490", "r513", "r543", "r544", "r601", "r602", "r603", "r604", "r608", "r619", "r620", "r631", "r638", "r640", "r648", "r651", "r720", "r726", "r767", "r768", "r769", "r770", "r771" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://biontech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment", "crdr": "debit", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "Capitalized research and development", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination." } } }, "auth_ref": [ "r62", "r757" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net Income (loss)", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r170", "r202", "r205", "r206", "r207", "r208", "r210", "r213" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlans" ], "lang": { "en-us": { "role": { "label": "ORGANIZATION, NATURE OF BUSINESS, GOING CONCERN AND MANAGEMENT\u2019S PLANS", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r83", "r126", "r519", "r520" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://biontech.com/role/StockholdersEquity-StockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Outstanding, weighted-average remaining contractual life (Year)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r123" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r153", "r162", "r180", "r265", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r422", "r426", "r439", "r647", "r724", "r725", "r764" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://biontech.com/role/StockholdersEquity-AssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected term (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r388" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquity-AssumptionsDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r358", "r490", "r513", "r543", "r544", "r601", "r602", "r603", "r604", "r608", "r619", "r620", "r631", "r638", "r640", "r648", "r726", "r766", "r767", "r768", "r769", "r770", "r771" ] }, "us-gaap_CapitalRequiredForCapitalAdequacy": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CapitalRequiredForCapitalAdequacy", "crdr": "credit", "presentation": [ "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capital Required for Capital Adequacy", "documentation": "Amount of minimum total risk-based capital required for capital adequacy as defined by regulatory framework." } } }, "auth_ref": [ "r495", "r496" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://biontech.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Principles of consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r66", "r626" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquity-AssumptionsDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "auth_ref": [ "r282", "r283", "r284", "r285", "r345", "r358", "r389", "r390", "r391", "r466", "r490", "r513", "r543", "r544", "r601", "r602", "r603", "r604", "r608", "r619", "r620", "r631", "r638", "r640", "r648", "r651", "r720", "r726", "r767", "r768", "r769", "r770", "r771" ] }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterimPeriodCostsNotAllocableDomain", "presentation": [ "http://biontech.com/role/DeferredCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred." } } }, "auth_ref": [ "r37" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "label": "NOL carryforwards (Federal and State)", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r62", "r757" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquity-AssumptionsDetails", "http://biontech.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r358", "r490", "r513", "r543", "r544", "r601", "r602", "r603", "r604", "r608", "r619", "r620", "r631", "r638", "r640", "r648", "r726", "r766", "r767", "r768", "r769", "r770", "r771" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://biontech.com/role/ConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentOtherNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentOtherNet", "crdr": "debit", "calculation": { "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biontech.com/role/PropertyAndEquipment-PropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Other, Net", "documentation": "Amount after depreciation of long-lived, physical assets used to produce goods and services and not intended for resale, classified as other." } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r199", "r359", "r684", "r685", "r711" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "presentation": [ "http://biontech.com/role/IncomeTaxesDetails1" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r412" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/ConvertibleNotesPayable-AffiliatesDetailsNarrative", "http://biontech.com/role/DeferredCompensationDetailsNarrative", "http://biontech.com/role/OrganizationNatureOfBusinessGoingConcernAndManagementsPlansDetailsNarrative", "http://biontech.com/role/StockholdersEquityDetailsNarrative", "http://biontech.com/role/SubscriptionReceivable-AffiliatesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r182", "r183", "r300", "r327", "r456", "r623", "r625" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://biontech.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://biontech.com/role/LoansPayableDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://biontech.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biontech.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation expense", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r5", "r42" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "270", "SubTopic": "10", "Section": "45", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-8" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-11" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "25", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "710", "SubTopic": "10", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "932", "SubTopic": "235", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-18" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "980", "SubTopic": "835", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482064/980-835-45-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.13)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-9" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "12", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "83", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480647/815-10-15-83" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-14" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3A" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//715/tableOfContent" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(o)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(p)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(q)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(r)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480696/942-505-50-1B" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r683": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10" }, "r685": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r686": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r687": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r688": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r689": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r690": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r691": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r692": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r693": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r694": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r695": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r696": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r697": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r698": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r699": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r700": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r701": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r702": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r703": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r704": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r705": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r706": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r707": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r708": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r709": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r710": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r711": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r712": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r713": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r714": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r715": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r716": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r717": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r718": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r719": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r720": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r721": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r722": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r723": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r724": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r725": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r726": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r727": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r728": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r729": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r730": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r731": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r732": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r733": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r734": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r735": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r736": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r737": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r738": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r739": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r740": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r741": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r742": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(g))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 65 0001079973-23-001327-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-23-001327-xbrl.zip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�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end

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